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ABSTRACT 
New synthetic routes to 1,2- and 2,3-fused indoles with seven- or eight-membered rings 
have been developed in this project, with the longer term aim of assessing their biological 
activity. Approaches to such fused indole derivatives were accessed via free radical 
cyclisation from 1- or 2-substituted indole derivatives with haloacetamide precursors. 
Using 1-substituted indole derivatives with haloacetamide functionalites, free radical 
cyclisation reactions gave fair yields of the indole- and dihydroindole-fused eight 
membered ring derivatives. Using 2-substituted indole derivatives with haloacetamide 
functionalities, prepared in turn by a palladium-mediated cyclisation of N-substituted 
indoles followed by hydrolysis and subsequent decarboxylation, free radical cyclisation 
afforded the 7,12-dihydro-indolo[3,2-d]benzazepin-6(5H)-one (Paullone) system in fair 
yields.  
A novel synthetic approach to a bis-indole fused seven-membered ring system was 
developed based on an N-substituted spirooxindole rearrangement. The spiro-indolinols 
obtained from partial amide reduction underwent rearrangement to give the bis-indole fused 
seven-membered ring derivatives 270 and 271 under acidic conditions.   
Antimicrobial activity of the indole fused eight-membered ring systems was evaluated. The 
compound 5,14-dihydro-10-methoxy-5-methoxy-5-methyindolo[2,1-d][1,5]benzodiazocin-
6-one 186c showed by far the most potent antibacterial activity (against Staphylococcus 
aureus), while 5,14-dihydro-5-(4-methoxybenzyl)indolo[2,1-d][1,5]benzodiazocine-6-one 
186d showed good in vitro antimalarial activity against both drug resistant and drug 
sensitive strains of Plasmodium falciparum. These two compounds represent novel 
structural leads for such activities. 
 xxi
ACKNOWLEDGEMENTS 
 
I would like to thank all those who have helped me throughout my study, especially thanks 
to my supervisor, Prof. John B. Bremner for his guidance and support during the course of 
this study. Thank you to the Royal Thai Government for the provision for my scholarship.  
I am grateful for the help of the following people who extended their aid in completing this 
work: Dr. John Korth, Larry Hick and Roger Kanitz for their help in performing mass 
spec., Sandra Chapman, Ellen Manning, Yoke Berry and Wilford Lie for their assistance in 
using the NMR spectrometer.  
Thanks to Dr. David Perkins, not only for the chemistry knowledge but also for the help 
and support and his warm friendship during my works in the lab. Thanks to my best friends 
in the Bremner research group, Collete, Jane, Joe, Johana, Hadi, Susan, Siritron and 
Yasmin for their help and friendship which lightened my day and did not make me feel 
alone in a foreign country.   
Lastly, thanks to my family for their unconditional love and support. 
   
 
 
 
 
 
 
 
 1
1 Introduction 
1.1 Introduction to indoles 
 Indole derivatives have been a topic of substantial research interest and continue to 
be one of the most active areas of heterocyclic chemistry, particularly due to their natural 
occurrence and pharmacological activities.1 A large number of indole derivatives are at the 
fore as pharmacologically active lead compounds for drug development. Indole derivatives 
also occur widely in many natural products such as those from plants,2 fungi3 and marine 
organisms.4 The isolation, biological evaluation and chemical properties of natural products 
have attracted the attention of organic chemists, medicinal chemists, biologists and 
pharmacists. Chemical and biological research has also presented a great challenge to 
synthesise and optimise highly efficient and economical synthetic routes to novel 
biologically active substances. 
At present, there are approximately 1500 indole alkaloids described,5 which includes 
simple and more complexly functionalised indole derivatives. The simple indole derivatives 
are comprised of a pyrrole ring fused with a benzene ring such as in the essential amino 
acid, tryptophan 1 as well as tryptamine 2 and serotonin 3. More complex indole 
derivatives usually contain an additional fused ring, and in most cases a six membered ring 
such as in carbazole 4 and β-carboline 5.         
 2
N
H
R2
NH2
H
R1
1 R1= CO2H, R2= H
2 R1= R2= H
3 R1= H, R2= OH
N
H
N
H
N
4 Carbazole 5 β−Carboline
 
1.1.1 Bioactive indoles 
There are several thousand indole derivatives known and many of these have 
important pharmacological activity. Some natural product based bioactive indoles are 
discussed here and are classified in terms of the number of indole rings present and the 
presence or absence of indole ring fusions. 
1.1.1.1 Mono indoles 
The medicinal uses of the simple tryptamine alkaloids are relatively few. Serotonin 3 
is one of the key neurotransmitters in animals. Many indole derivatives found in plants 
have been noted to have hallucinogenic activity in humans, for example bufotenine 6, and 
5-methoxy-N-methyltryptamine.  
N
H
R2
N
6 R1= Me, R2= OH
7 R1= H, R2= OMe
Me
R1
 
  Some simple indole alkaloid derivatives have also been isolated from marine 
sources.  For example, methyl-(E)-3-(6-bromo-3-indolyl)-3-propenoate 8, a known sponge 
metabolite has been isolated from a number of sponges.6-8 Further examples of simple 
bioactive indole alkaloids from marine natural products are compounds 9 and 10. The 
 3
alkaloid (±)-chelonin A 9, isolated from a marine sponge of the Chenolaplysilla sp.,9 
showed potent antimicrobial and anti-inflammatory activities. Discodermindol 10, was 
discovered in Discodermia polydiscus and showed moderate cytotoxic activity.10 
N
H
Br
COOMe
N
NHO
H
Me
Ar
N
H
N
H
N NH2
Br
Br
8 9 10  
1.1.1.2 Bis-indoles 
Bis-indole alkaloids are an important structural class due to their high degree of 
biological activity. For example, the nortopsentins A-C11 11a-c, exhibit in vitro cytotoxicity 
against P388 cells with IC50 (inhibitory concentration) values of 7.6, 7.8, and 1.7 µg/mL, 
respectively. These alkaloids were isolated from the deep water marine sponge 
Spongsorities ruetzleri. On the basis of these lead compounds, the imidazole moieties of 
nortopsentins were replaced with a thiazole, pyrazinone or pyazine ring.12,13  
N
H
N
H
N
H
N
Nortopsentin A 11a R1= R2= Br
Nortopsentin B 11b R1= Br, R2= H
Notopsentin C  11c R1= H, R2= Br
R1 R2
 
The 2,4-bis(3΄-indolyl)thiazoles 12 exhibited selective cytotoxicity against certain 
leukemia cell lines with GI50 (growth inhibition) values in the low micromolar range. The 
 4
2,4-bis(3΄-indolyl)pyranzinone 13 and the 2,4-bis(3΄-indolyl)pyrazine 14 also displayed a 
broad spectrum of cytotoxic activity, particularly compound 14, which possessed very 
strong inhibitory activity against all cell lines with  GI50 values in some cases less than 10 
µM.  
N
H
N
H
N
S
R1 R2 N
H
N
H
N
H
NO
N N
N
N
OMe OMe
12 R1, R2= Br, OMe 13
14
N
H
N
H
N
NH O
O
R X
Rhopaladin B 15a R= OH, X= H
Rhopaladin C  15b R= H, X= Br
 
Isolation of compounds from extracts of the Okinawan tunicate, Phopalawa spp.,   
afforded four bis-indole alkaloids,14 of which two possessed very interesting biological 
activity. Rhopaladin B 15a exhibited inhibitory activity against cyclin dependent kinase 4 
and c-erbB-2 kinase (IC50 values of 12.5 and 7.4 µg/mL, respectively) and rhopaladin C 
15b showed antibacterial activity against Sacina lutea and Corynebacterium xerosis (MIC; 
minimum inhibitory concentration; 16 µg/mL). Structural variety in the bis-indole series is 
further exemplified by the fungal metabolite, demethylasterriquinone B1 16, which is a 
selective activator for the insulin receptor.15 
 5
N
H
H
N
HO
O
O
OH
16  
1.1.1.3 Annelated indoles 
  Increased structural complexity in indole-based products is seen with fusion of the 
indolic moiety to other rings. For example a number of dimeric indole alkaloids with a 
fused six-, seven-, or eight-membered ring between the two indole rings are known with 
many of them also being biologically active. For instance, the indolo[3,2-a]carbazole16 17, 
with a bis-annelated six-membered ring, displayed antitumour properties and, in particular, 
inhibition of protein kinase C, while the slime mold alkaloid arcyriacyanin A17 (18), with a 
seven-membered ring, is known to inhibit protein kinase C and protein tyrosine kinase. As 
a result, 18 exhibited a unique inhibitory profile against a panel of human cancer cell lines.   
NH HN
H
NO
17 18
N
H
H
N OO
N
H
H
N
COOMe
MeOOC
19
NH
 
The bis-indole fused derivative with an eight membered ring, the caulerpin 19, was 
isolated from the green alga Caulerpa racemosa. This alkaloid showed weak in vitro 
antitumour activity18 together with plant growth regulatory activity.19 The structural motif 
 6
of two indoles fused to a seven-membered ring occurs in the novel iheyamine pigments 20 
and 21,20 which were isolated from a colonial ascidian Polycitorella sp.. Both compounds 
exhibited moderate cytotoxicity.  
N
N
NH
MeO
N
N
HN
MeO
CH3
O
CH3
O
20 21  
Related to the annelated bis-indole derivatives are a number of other derivatives 
which possess one annelated indole or modified indole skeleton. Valuable members of this 
group are vinblastine 22a and its analogue vincristine 22b, which are alkaloids isolated 
from Catharanthus roseus (Apocynaceae). These two alkaloids are currently used 
clinically2 to treat Hodgkin’s disease and other lymphomas, testicular cancer, and a variety 
of solid neoplasms. They are also used to treat patients with neuroblastoma, 
choriocarcinoma, and Kaposi’s sarcoma.  
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N
OO
NH
23 Strychnine
N
H
N
OH
O
O
H3C NH3CO
R
N
H
OH
OCOCH3
H
COOCH3
22a Vinblastine, R= CH3
22b Vincristine,  R= CHO
N
H
N
R1 R2
CH3
24a E llipticine, R1= CH3, R2= H
24b Olivacine, R1= H, R2= CH3
N
H
N
H
H3CO2C
O
H
H
OCH3
O
OCH3
OCH3
OCH3H3CO
25 Reserpine
H
H
 
 Other examples of bioactive alkaloids with one fused indolic moiety include 
strychnine, ellipticine, olivacine and reserpine. Strychnine 23 was once used to control 
rodents, but it has been replaced by poisons which are less toxic to man. Currently, 
strychnine is used in patients with eye disorders and optic nerve atrophy.2 Ellipticine 24a 
and olivacine 24b, which contain a pyrido[4,3-b]carbazole nucleus,21 have remarkable 
antitumour activity but unfortunately have not progressed to clinical use. Reserpine 252 was 
a key drug in the treatment of hypertensive, nervous and mental disorders. 
 
1.2 Indole synthesis 
 Most generally applicable synthetic methods for the indole moiety involve ring 
closure to form the pyrrole ring of indole. Substituents are often introduced prior to the 
synthesis of the ring system. The classical Fischer method has maintained its prominent 
role as the most common synthetic route to indole derivatives for more than a century. 
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Other cyclisation reactions have been reported including the Bischler synthesis, palladium-
catalysed cyclisation, photocyclisation and radical cyclisation. These and other indole 
cyclisation reactions have been reviewed elsewhere.1,22,23  
 An example of Fischer indolisation is in the synthesis of the marine alkaloid 
eudistomidin-A24 and other fused indoles which have been synthesised using the Fischer 
indole strategy.25  
Indole derivatives can also be accessed by further functionalisation of the indole 
nucleus. For example, the indolic NH which is weakly acidic, upon treatment with a strong 
base, can form the indolide anion which is capable of subsequent reaction with 
electrophiles at either the nitrogen atom or at the 3-position of the indole.26 Nitrogen 
substitution is favoured by the use of more ionic sodium and potassium salts with strong 
electrophiles and also by the use of dipolar aprotic solvents. This type of N-substitution is 
important for the introduction of protecting groups.27 Lithiation of N-substituted indoles is 
selective for C-2 because of the influence of the heteroatom,1 and therefore this is useful for 
preparing C-2 substituted indoles by reaction with electrophiles (Scheme 1-1). 
N EN
R R
Li
E+
 
Scheme 1-1. Lithiation of N-substituted indoles. 
 Indolic derivatives can also be elaborated upon using cycloaddition reactions to 
construct indole fused rings. For example, cycloaddition using Diels-Alder reactions of 2- 
and 3-vinylindoles with dienophlies results in partially hydrogenated carbazoles.1 2-
Vinylindole derivatives have also been used in the synthesis of both aspidosperma and 
iboga alkaloids28 (Scheme 1-2) from dehydrosecodine.      
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H
N
CO2CH3
dehydrosecodine
N
H
N
H3CO2C
iboga
N
H
N
CO2CH3
aspidosperma
 
Scheme 1-2. Example of Diels- Alder reaction of 2-vinylindole.  
1.3 Indole fused seven- or eight-membered ring systems  
As a result of the chemical and pharmacological importance of indole derivatives, a 
wide range of indoles and derivatives including fused- and non fused-indoles have been 
prepared. However, only a limited number of indole fused seven- or eight membered rings 
have been reported. In order to assess this more accurately and to provide a contextual 
framework for the work described in this thesis, a survey was undertaken of the relevant 
literature (SciFinder Scholar) restricted mainly to indole fused seven- or eight-membered 
ring compounds with one, two, and three nitrogens in the medium sized ring and based on 
the 1,2-fused systems 26 and the 3,4-fused systems 27. The results are discussed in the 
following Sections 1.3.1 and 1.3.2.  
N N
H
X
X
X
X
7,8
7,8
26 27  
1.3.1 Synthesis of indole-1,2-fused seven or eight membered ring systems 
A variety of synthetic methodologies for 1,2-fused indole systems have been 
developed. These include intramolecular C-C bond formation, eletrophilic cyclisations, 
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additions to carbonyl groups, radical cyclisations and coupling reactions. The direct ring 
expansion of a smaller ring to a seven- or eight-membered ring has also been used to 
synthesise such fused indole derivatives. The methodologies used to form indole-fused 
seven- and eight-membered rings at the 1,2 position are classified according to the 
substrates utilised and the bond formed in the ring-closing step. 
1.3.1.1 Bond formation to C-2; ring closure via N-substituted indoles 
Indolo[2,1-d][1,5]diazocinone derivatives29,30 29 and 31 have been synthesised by 
photocyclisation of the chloroacetamides 28 and 30, respectively (Scheme 1-3). However, 
a number of by-products were produced and low yields of the desired products were 
obtained.  
N
NH
O
Me
N
NH
O
N
NH
Me
O
C l
N
NH
O C l
R R
R= H, OMe, F
hν
hν
CH3CN
28 29
30 31  
Scheme 1-3. Photochemical cyclisation of chloroacetamides. 
 Intramolecular nitrile oxide-olefin cycloaddition of an N-substituted indole 3231 in 
the presence of phenyl isocyanate at 20 oC, via 33, led to a fused 7-membered ring 
derivative 34 in 20% yield (Scheme 1-4). This ring fusion involved the heterocyclic double 
bond in the cycloaddition.  
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Radical cyclisation of the 1-(ω-iodoalkyl)indole-3-carbaldehydes 35 with tributyltin 
hydride and AIBN resulted in the formation of the 1,2-fused indole 36 (Scheme 1-5).32,33 
However, the 7-membered ring analogue was obtained in significantly lower yield than the 
corresponding 5- and 6-membered ring analogues.33 
 
N N
N
O
N
NO-C-NHPh
NO2
PhN=C=O, Et3N
Benzene
32 33
34
N
C
N O
O
 
Scheme 1-4. Intramolecular nitrile oxide-olefin cycloaddition. 
N
(CH2)nCH2I
R1
R Bu3SnH, AIBN
toluene, reflux N
R1
R
(CH2)n
35 36
n= 3
 
Scheme 1-5. Radical cyclisation of alkylhalides.  
 Cyclodehydration via a Bischler Napieralski type reaction of acetyl and benzoyl 
derivatives 38 (R= H, Me, OMe, OEt, R1= Me, Ph, R2= Me, Ph), prepared from acylation 
of 3-aminopropyl derivatives 37, resulted in indolo-diazepine derivatives 39 (Scheme 
1-6).34 Compounds 37 and 39 were tested for antiserotonin activity, with 39 (R= H, R1= Ph, 
R2= Me) showing high activity and 37 (R= R1= Me) moderate activity.  
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N
NH2
R1R
N
N
R1R
H
R2
O
N
N
R2
R1R
37 38 39
POC l3
benzene
 
Scheme 1-6. Cyclodehydration via a Bischler Napieralski type reaction. 
 The 1,4-diazepino[1,2-a]indoles 40,35 which are closely related in structure to the 
compounds 39, have been synthesised by the Mannich condensation of the amine 37 with 
acetaldehyde or benzaldehyde. The resulting Mannich bases underwent intramolecular 
cyclisation to give the fused seven-membered ring derivatives 40 (R1= H,  R= CH2-1-
benzotriazole).  
N
NH2
Me
N
N
R
Me
37 40
R1
 
Also, the condensation of 37 (R= H, R1= Me) with (1-hydroxymethyl)benzotriazole gave 
1,4-diazepino[1,2-a]indole 40 (R= H, R1= CH2-1-benzotriazole) in 51% yield.36 
Elimination of the benzotriazole group can then give compounds of type  40 in good yield.  
  
1.3.1.2 Bond formation to N-1; ring closure via 2-substituted indoles  
Gelmi et al.37 reported the intramolecular condensation of 3-benzoylamino-6-(indol-
2-yl)-pyran-2-ones 41 upon treatment with K2CO3 in refluxing acetonitrile to afford the 
corresponding azepino[1,2-a]indol-6-ones 42. The mechanism involved the deprotonation 
of the benzoylamino group which subsequently rearranged to the indolide anion. The 
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intramolecular condensation of the indolide anion, with the near by electrophilic pyran-2-
one moiety, gave compounds 42 in 50-80% yields.  
N
42
O
CO2Et
R2
R1
R
BzHN
HO
R= H, OMe, F
R1= H, OMe
R2= H, OMe, C l
N
H
R2
R1
R
O O
EtO2C NHBz
41  
A patent by Gadient38 described the synthesis of a variety of diazepinoindoles and 
their pharmaceutical use. 2,3,4,5-Tetrahydro-1H-[1,4]diazepino[1,7-a]indole 45 (R= Ph, 
R1= Me) and its derivatives were synthesised from 43 via indolide anion formation prior to 
ring closure. The compounds of type 45 are effective psychotropics, especially 
antipressants, by standard in vivo and in vitro tests;38 other authors also reported useful 
CNS activity with these compounds.39 
N
H
R
N
R1
OC l
NaH, DMF
heat N
N
O R1
R
N
N
R1
R
LiAlH4
43 44 45  
The Strychnos alkaloid analogues of caracurine V are among the most potent known 
allosteric modulators of the muscarinic M2 receptor.40 Reduction of the caracurine V 
skeleton gave the bioactive pentacyclic derivative 46 (R= CH3). This novel ring system 
could become a new lead structure in the search for active muscarinic compounds.41 The 
synthesis of the new bis-indole fused skeleton was also achieved starting from the known 
[3-(2-dibenzylaminoethyl)indol-2-yl]acetic acid methyl ester 47 (R= CH2Ph).42 The 
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compound 46 (R= CH2Ph) was then obtained in 3 steps by employing a double alkylation 
strategy.41     
N
H
N
R
R
N
N
N
R
R
N
R
R
47
46
N
O
N
N
O
N
caracurine V
CO2Me
3 steps
reduction
 
 
1.3.1.3 Medium ring formation via 1,2-disubstituted indoles 
  The synthesis of 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indoles 45 have been 
discussed previously based on 2-substituted indoles, but an alternative route to a specific 
derivative 45a was reported from the N-substituted dihydroindol-2-yl acetate 48. Treatment 
of 48 with ammonia-saturated methanol at 50 oC generated the lactam 49. Reduction of 49 
with borane-dimethylsulfide to 50 and subsequent oxidation with DDQ then generated 
2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole 45a.43  
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N
CO2Et
Br
N
NH
O
NH3, MeOH N
NH
BH3-SMe2
48 49 50
N
NH45a
DDQ
 
 A cyclisation route to the indolo-1,5-benzodiazocine 53 has also been reported, 
starting from the 1,2-disubstituted indole 51.44 Hydrolysis of 51 gave the corresponding 
acid, which was then cyclised to 52. N-Methylation of 52 followed by reduction by LiAlH4 
gave 53 which showed potential activity in the CNS.                                                                         
N
N
O
Ph
H
52
N
Ph
H2NNC
51
N
N
Ph
Me
53
1. methylation
2. reduction
1. hydrolysis
2. cyclisation
 
In a report from Bit et al., 45 the synthesis of the tetrahydroazepino[1,2-a]indole 55 
was described based on a Dieckmann/ring expansion reaction after treatment of the indole 
54 with potassium tert-butoxide (Me3COK). This approach was claimed to allow the 
synthesis of a large variety of substituted systems required for the preparation of a series of 
potent and selective inhibitors of protein kinase C. 
N
55
O
CO2Et
N CO2Et
(CH2)nCO2Et
54  
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The cyclisation of N-Mannich bases of 2-substituted indoles46 also gave the 
indolobenzazepines 56 and indolobenzazocine 57 in good yields. 
NN
COOMe COOMe
OMe
R3
R3
R3= H, OMe
56 57  
Seven membered ring formation via intramolecular Pauson-Khand reactions gave 
good yields of the enynoindoles 5847 via carbon-carbon bond formation (Scheme 1-7). The 
addition of molecular sieves to the reaction medium promoted the cyclisation product, 
probably due to the adsorption of the enyne and stabilisation of a pretransition state; ligand 
exchange may also be promoted.48  
N
N
R
H
O
R
58 59
Co2(CO)8
 Mol. S ieves
 
Scheme 1-7. Cyclisation via intramolecular Pauson-Khand reactions. 
The 5-hydroxytryptamine antagonists 61 were prepared by intramolecular 
cyclisation of 1,2-disubstituted indoles 60 (R3= CO2Et, R4= CN). Catalytic hydrogenation 
of 60 (R3= CO2Et, R4= CN) using Raney-nickel gave 60 (R3= CO2Et, R4= CH2NH2). Ring 
closure using sodium hydride in xylene followed by reduction with LiAlH4 then gave the 
2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indoles 61 in good yields (Scheme 1-8).49,50 
Reduction of 60 (R3= CO2Et, R4= CN) with LiAlH4 gave 62, however, attempted 
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cyclodehydration of 62 was unsuccessful. The biological testing for 5-HT antagonistic 
activity revealed that the potency of most of these compounds was less than that of 
cyproheptadiene, a standard anti-5-HT drug.50  
N
R1 R2
R3 N
NH
R1 R2
N
NH
R1 R2
LiAlH4O
60 61
R4
steps
 
Scheme 1-8. Preparation of 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indoles. 
N
NH2
R2
CH2OH
62
N CO2Et
O2N
N
NH
O
6463  
A similar method to that described in Scheme 1-8 was employed to prepare the 
indolo[2,1-c][1,4]benzodiazepinone 64 from the alkylated nitro compound 63 followed by 
hydrogenation and thermal cyclisation. The alkylamino derivatives 68 were prepared from 
the lactam 64 via two methods (Scheme 1-9).51 The first method involved the conversion of 
64 to the thiolactam 65 by reaction with phosphorus pentasulfide, followed by alkylation 
with dimethyl sulfate. The resulting methyl thioester 66 was then reacted with various 
amines to give the amidines 68. The other method involved the reaction of lactam 64 with 
triethyloxonium tetrafluoroborate to give the imino ester 67, which was then reacted with 
amines in the presence of a catalytic amount of glacial acetic acid to give the amidines 68.  
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N
NH
S
65
N
N
OEt
67
N
N
68
N
N
SCH3
66
N
R1
R2R1R2NH
amines
(CH3)2SO2
KOH
64
P2S5
Et3O+BF4-
 
Scheme 1-9. Preparation of indolo[2,1-c][1,4]benzodiazepine derivatives. 
A biological study of the cyclic alkylamino derivatives 69 showed that they 
possessed antithistamine and antiserotonin activities as well as the ability to inhibit 
mediator release. These agents thus have potential for the treatment of a variety of allergic 
conditions.    
N
N
69
N
X
 
The indole fused eight-membered ring 71 was synthesised via the ring-closing 
methathesis of N-allyl-1-allyl-1H-indole-2-carboxamide derivative 70.52 Ring closure 
utilising Grubbs’ catalyst afforded the eight membered ring, although only in low yield 
(13%). 
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N
70
O
Boc
N
N
71
N N MesMes
Ru
C6H5
PCy3
C l
C l
(Grubbs' cat.)
NBoc
O
 
1.3.1.4 Indole ring formation  
      A quite different alternative approach to indole fused ring systems is via formation of 
the indole ring itself. This is illustrated by the synthesis of the indolo[1,2-
a][3]benzazocines53 73 and 74 in 43 and 8% yields, respectively, by treatment of the 
benzazepine 72 with dimsylsodium in DMSO. The mechanism involves the attack by the 
MeSOCH2 anion at C-1, followed by a ring closure-ring cleavage process. 
N
OMe
OMe
Br
MeO
MeO
N
OMe
OMe
CH2
MeO
MeO
N
OMe
OMe
CH3
MeO
MeO
+
73 7472
1
MeSOCH2-
 
1.3.2 Synthesis of indole-2,3-fused seven or eight membered ring systems 
Construction of indole fused rings at the 2,3-position may involve the use of indole 
substitution at either the 2- or 3-position, or at both the 2- and 3-positions followed by 
cyclisaton reactions or substitution reactions and then cyclisations. The following 
examples of indole 2,3-fused ring systems are classified according to the substitutent 
position on the indole ring starting materials. 
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1.3.2.1 Ring closure at C-3 via 2-substituted indoles 
 Suzuki et al.54  reported the cyclisation at C-3 of N-(2-indolecarbonyl)-β-alanine 75 
with polyphosphoric acid (PPA) to give the fused seven-membered ring derivative 76 as 
the major product.  
N
H
NH
O
O
76
N
H
H
N
O
CO2H
PPA
75  
 A set of related 5-substituted azepinoindoles 78 have been prepared starting from 
compounnd 77, a derivative of 76, via reaction with trifluoromethanesulfonic anhydride 
followed by functionalisation at the 5-position via palladium catalysed reactions with 
commercially available stannanes. Compound 78, with R= H and R1= 2-thienyl, was 
evaluated for growth inhibitory activity against murine leukemia L1210 cell lines;55 
weak in vitro cytotoxicity was observed (IC50> 10 µM).  
N N
O
O
Me R
77
N N
O
F3CO2SO
Me R
N N
O
R1
Me R
78
Tf2O Pd(PPh3)4
 
 Reactivity studies on 76 revealed that electrophilic attack at the α-position to the 
ketone in the azepino ring was feasible,55 and in this way the dibromo derivative 79 was 
achieved by direct bromination of 76. Elimination of HBr followed by palladium-mediated 
cross-coupling reactions then gave the 4-substituted azepinones 80.56 
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Br
N N
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O
Me R
Br
N N
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O
Me R
R1
80
DBU Pd(PPh3)4
R1X
 
Hiremath et al.57 described a nitrene-based route to the preparation of the 
diazepino[5,6-b]indole-1,5-diones 82 from the azides 81 in refluxing diphenyl ether. The 
antibacterial activity again E. coli and S. aureus showed that amongst the 
[1,3]diazepinoindoles tested, compound 82 (R= R1= Cl) was moderately active against both 
bacterial species. 
N
HR1
R
CONHCH2CON3 NH
NH
NHR
R1 O
O
81 82
∆
 
Free radical reactions have also been used to prepare indole-2,3-fused 7-membered 
rings. For example, radical addition then cyclisation reactions of 83 with reactive alkenes 
(Z= CN or CO2Me) resulted in the formation of cyclohepta[b]indoles 84 as the predominant 
products.58 
N
Me
Z
Z
N
Me
SePh
O
Z
n-Bu6Sn2,hν
C6H6 O
83 84  
The oxazocinoindoles 86, which are useful as antihypoxics and antiarrhythmics and 
contain an indole fused 8-membered ring, were readily accessed via reaction of the 
indolecarboxamides 85 with aldehydes.59 
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R2CHO
85 86  
1.3.2.2. Ring closure via 3-substituted indoles 
In an analogous reaction sequence to that described for 83, the 3-indolylacyl radical 
derived from the selenol ether 87 added to electron rich alkenes to give the 
cyclohepta[b]indole derivative 88, together with the five-membered ring fused product 
from the incorporation of one vinyl acetate unit.60  
N
Me
SePh
O
OAc
n-Bu6Sn2,hν
C 6H6
N
Me
OAc
OAc
O
87 88  
The racemic reduced azepino[4,5-b]indoles 91 were prepared by acid-catalysed 
electrophilic cyclisation with polyphosphoric acid from the precursors 90, which were 
obtained in turn from reduction of the amides 89.61  
N
R
NH
O
HO
CH3 NR
NH
HO
CH3 N
R
NH
CH3
LiAlH4 PPA
89 90 91  
The synthesis and evaluation of in vitro cytotoxic activities of N-substituted 
benzo[5,6]cyclohepta[b]indole derivatives 94 have also been reported. Wittig coupling 
provided access to the intermediates 93 from 92, and the former were then cyclised to C-2 
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by reaction with PPA. The cytotoxic activities against L1210 murine leukemia and HT29 
cell lines showed that compounds 94 have potent antitumour activity in L1210 cell lines.62 
N
OR
94
N
SO
O
Ph
MeO2C
N
CHO
SO Ph
O
9392
PPA
 
1.3.2.3 Ring closure via 2,3-disubstituted indoles 
A new family of benzazepinones, the paullones 96, exhibit potent, ATP-
competitive, inhibition of cell cycle regulating cyclin-dependent kinases (CDKs);63 one 
such paullone, 9-nitro-7,12-dihydro[3,2-d][1]benzazepin-6(5H)-one 96 (R= NO2, R΄= H) 
has progressed to clinical trials. Approximately forty paullones have been studied and 
features for activity determined. These paullones can be made by cyclisation of a 2,3-
disubstituted indole. For example, the paullone 96 (R, R΄= H) was prepared by cyclisation 
of 95 (prepared in turn by borylation/Suzuki coupling technology) under basic conditions.64  
N
H
NH
O
R
R'
96
N
H
CN
H2N
NaOH (10 equiv)
MeOH/H2O (2/1)
∆, 3.5 h
95
R
R'
 
The new bis-indole bearing a functionalised seven-membered ring between the two 
indole moieties, caulersin65 97, was isolated from the alga Caulerpa serrulata from the 
Xisha Islands in the South China Sea. The synthesis of caulersin 97 has been described66 
and the construction of the seven-membered ring was based on a Michael-type addition 
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of 2,3΄-bis(indolyl)ketone to methylvinylketone followed by an intramolecular 
nucleophilic substitution and oxidation.  
 
N
H
HNO
O Me
97
N
O H
N
C l
MOM
N
O H
N
C l
MOM
OMe
methylvinylketone t-BuOK
t-BuOH
∆
2,3'-bis(indolyl)ketone methylvinylketone
 
 Structures containing azepino[3,4-b]indole moieties are of considerable chemical 
and pharmaceutical importance. A concise approach to these systems (eg. 99) has been 
described, based on an intramolecular palladium-mediated cross-coupling reaction.67 
N N
OBoc Boc
99
CO2Et
N
I
Boc
N
O
Boc
CO2Et
Pb(OAc)2, PPh3
Ag2CO3, THF
       60 oC
98  
While reports on indole 2,3-fused eight-membered ring systems are less common in 
the literature, the diazocino[6,7-b]indoles 101 (and the diazepinoindoles 104) have been 
accessed via the aldehyde indole esters 100.68 Reaction of 100 with o-phenylenediamine in 
glacial acetic acid resulted in the fused diazocinoindole system 101. However, the reaction 
outcome was not satisfactory and only a low yield of 101 was obtained. Condensation of 
100 with an excess of the nitroalkane, followed by reductive hydrolysis of the resulting 
nitrovinylindoles 102, gave the substituted indoles 103, which after treatment with 
hydrazine then gave the diazepinoindoles 10468,69 in satisfactory yields. In the biological 
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assay of compounds 104 for toxicity using male wistar mice other activities were noted 
which showed that these compounds could be of interest as potential tranquilising drugs.69   
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 Various substituted indolo[3,2-b][1,4]benzodiazepines 10757 have also been made 
by cyclisation of the substituted indoles 106, obtained from the Ullmann reaction of 105 
with substituted anilines followed by thermally induced cyclisation of the carbamates 106 
to afford compounds of type 107. 
N
H
Br
NHCO2Et
R1
R
N
H
HN
NHCO2Et
R1
R CH3
N
HR1
R
N
H
H
N
O
105 106
107
CH3
H2N CH31.
2. pyr, K2CO3
3. Cu2O3
diphenyl ether
           ∆
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In the continuing search for antitumour drugs, 6,7-dihydrobenzo[4,5]- 
cyclohepta[1,2-b]indol-12(5H)-one 109,70 a compound with potent antitumour activity, 
was prepared from the electrophilic cyclisation of indole 3-carboxylate 108 in the 
presence of trifluoroacetic anhydride and boron trifluoride diethyl etherate. Preparation of 
the related substituted derivatives 110-112 by functionalisation of the ketone 109 has also 
been reported.71,72 Unfortunately, the cytotoxicity of these derivatives was significantly 
less than  the reference compound adriamycin. 
N
N
CH3
111
N
CH3
110
N
N
O
CH3
112
R
R
 
1.3.2.4 Ring expansion routes to fused indoles 
 A novel ring expansion reaction has been described to prepare the diazepinoindoles 
115. Using N-methyl-O-tosyl-hydroxylamine, the carbolines 113 were transformed into the 
diazepinoindoles 115 via the N-methylammonium salts 114 in good yields using potassium 
carbonate in refluxing ethanol.73  
N
OC2H5
O
H
α
β
N
O
CH3
108 109
1. LDA, THF
2. CH3I
3. NaOH, MeOH
4. (CF3CO)2O, BF3.E t2O
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A related thermal Meisenheimer rearrangement of N-oxide has been extended to the 
preparation of fused oxazepine and oxazocine derivatives. For example, the 
oxazepinoindole 117 was synthesised in good yield by melt pyrolysis, or pyrolysis in 
ethanenitrile, of the corresponding N-oxide from 116.74 
N
H
N
Me
Ph
N
H
O
N
Ph
Me
MCPBA
∆
116 117  
Similarly, the 5-amino-3,6-epoxyhexahydroazocino[5,4-b]indole 119 was 
synthesised from the 2-ethylazetopyridoindole 118 via a Meisenheimer rearrangement of 
the intermediate N-oxide.75 
N
Me
N N
Me
N
CO2Me
H
O
CO2MeH
MCPBA
118 119
∆
 
 The indole fused seven-membered ring derivative 122 has been synthesised using a 
microwave-assisted [6+4]-cycloaddition between 6-aminofulvene 121 and the pyrone 
120 followed by CO2 extrusion. This compound 122 displayed good activity against a 
number of cancer cell lines with average IC50 values ranging between 2.2 and 5.4 µM.76  
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1.3.2.5 Indole ring formation 
The synthesis of the paullones 96 (Section 1.3.2.3) can also be achieved by the 
Fischer indolisation approach from a pre-formed benzazepinedione.77  
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H2NHN R'
 
Iprindole, a cyclooct[b]indole 123 (R= H, R1= (CH2)3NMe2) is a typical tricyclic anti-
depressant currently in clinical use,78 and at high doses it also possesses anti-arrhythmic 
activity. A series of functionalised iprindole were synthesised in order to examine their 
potential anti-arrhythmic activity and, with 123 (R= 1-NHCO2(CH2)2NEt2 and R1= 
(CH2)3NMe2), greater anti-arrhythmic activity was observed than that of iprindole.79  
 
N
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 Further eight-membered ring fused analogues include the oxazole fused compounds 
of type 126. These compounds have also been synthesised via Fischer indolisation in the 
key initial step to afford 125 from 124. A further two steps (reactions with hydroxylamine 
hydrochloride and acetyl chloride) were then necessary to access the oxazole.80  
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   Another related series that has been described includes the bis-indole fused 
derivatives 127 incorporating an eight-membered ring. Fischer indolisation of 125 with 
phenyl hydrazine in acetic acid afforded 127 in good yield.81 
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1.4 Aims of the project 
From the survey of the literature on 1,2- and 2,3-fused indoles with seven- or eight-
membered rings, it was apparent that considerable further scope existed for new synthetic 
methodology development, particularly with regard to indole fused eight-membered ring 
systems. It was also clear that any novel derivatives produced could be of significant 
interest in terms of bioactivity. The overall aim of this project was to examine new 
approaches to such systems based on cyclisation onto the indole ring from a 1- or 2-
substituted indole derivative. The use of haloacetamide chemistry was to be a key 
underlying theme. Biologically, we were also interested in examining the antibacterial and 
antimalarial activities of some of the new compounds.  
Therefore, the specific aims of this project were: 
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•  To develop efficient new synthetic routes to the indole-fused eight (29) and 
seven membered (96) ring systems by C-C bond formation from the indolic 
precursors. The carbon-carbon bonds which were to be formed are indicated 
by bonds (i) and (ii) for 29 and 96, respectively. 
R
R"
N
O
N
O
R1
N
96 Paullones
(i) (ii)
29
R1
N
H
R
 
•  To synthesise iheyamine A 20, a novel bis-indole fused seven-membered 
ring compound from the colonial ascidian Polycitorella sp., by a direct and 
efficient route which would allow the synthesis of new analogues with 
various substitutents.   
N
N
NH
MeO
20  
•  To assess the antibacterial and antimalarial properties of the new compounds 
produced. 
 
1.5 Thesis outline 
The synthesis of the indole fused eight-membered ring derivatives is discussed in 
Chapter 2. The synthesis of indole fused seven-membered rings using free radical 
cyclisation from iodoacetamide precursors is discussed in Chapter 3. Chapter 4 describes 
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the synthetic approach to iheyamine A, utilising a new rearrangement of a spirocyclic 
intermediate. Chapter 5 is concerned with the antimicrobial assay results for some of the 
novel compounds synthesised, while Chapter 6 presents conclusions and future 
directions. Chapter 7 covers all the experimental details.      
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2 Indole-fused eight membered ring heterocycles 
2.1 Introduction 
As part of a wider program to identify structurally novel antibacterial compounds 
with, hopefully, new modes of action to combat resistance problems, we became interested 
in the indolo[2,1-d][1,5]benzodiazocinones 29, with an indole fused eight-membered ring 
system. Previous studies in our laboratory had revealed that this system could be accessed 
in low yields, together with indolo-benzodiazonine and pyrrolo-indoloquinazolines, by 
photolysis of the chloroacetamides 28 (Scheme 2-1).30  
NHCOCH2C lN
R
N
NH
O
R
HN
N
O
R
N N O
H
H
R
CH3CN/H2O
+
+
hυ
16W Hg lamp, N2
a 39%
b 43%
c 28%
a 16%
b 14%
c 14%
a 18%
b 22%
c 13%
             R
a           H
b        OCH3
c           F
28 29
 
Scheme 2-1. Photolysis of chloroacetamides.30 
 The mechanism leading to the cyclisation products involes photo-induced single 
electron transfer (S.E.T.) with subsequent loss of the chloride ion. The resonance stabilised 
intermediate may then undergo cyclisation via three pathways as shown in Scheme 2-2. 
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Scheme 2-2. Mechanism of photocyclisation. 
In an effort to develop a viable regioselective route to the indolo-benzodiazocines 
29, free radical cyclisation was of considerable interest. It would be closely related to the 
photocyclisation, however, only a radical from the precursor 1-indolyl haloacetamides 
would be involved. This carbon radical from C-X bond cleavage could then undergo 
cyclisation via  an 8-exo-trig process to give preferentially the indolo-benzodiazocines 29 
through attack at C-2. Alternative attack at C-7 would involve disruption of the benzene 
ring aromaticity and would thus be less favoured.  
 
2.2 Free radical cyclisation  
Free radical cyclisation is now an increasingly employed and well established 
methodology in heterocyclic chemistry.82-84 The more successful intramolecular radical 
cyclisations proceed to form five membered rings,85-87 and these are more general than 
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those forming six-membered88 or seven-membered33,89,90 rings. However, cyclisation 
leading to indole fused eight-membered rings is less well investigated.  
The reaction conditions generally involve the use of excess of tributyltin hydride 
(Bu3SnH) with a small equivalent (10-25 mol %) of a radical initiator, most commonly 
2,2΄-azobisisobutyronitrile (AIBN) because of its high decomposition ability and stability. 
A variety of solvents can be used but aromatic solvents such as benzene or toluene are the 
most common.91 When heating begins, AIBN is decomposed to the (CH3)2C·CN radical and 
nitrogen (Scheme 2-3), which then leads to abstraction of a hydrogen atom from the weak 
tin-hydrogen bond of Bu3SnH. 
NC
H3C
H3C CH3
CN
CH3N N
CH3
CN
CH32 N2
AIBN
∆
 
Scheme 2-3. Decomposition of AIBN on heating. 
Once the tributyltin radical (Bu3Sn·) is formed, it can react rapidly with a wide 
range of organic compounds including selenides, sulfides, xanthates and  most importantly 
alkyl halides.92 N-Haloamides have also been widely used  for the syntheses of a variety of 
the nitrogen-containing heterocycles.85,93-95 Abstracting a halogen atom by Bu3Sn· is 
straightforward, leading to the formation of carbon-centred radical 128 (Scheme 2-4). The 
cyclisation of the carbon-centred radical onto the double bond leads to new carbon-carbon 
bond formation followed by production of a new carbon-centred radical 129 and then the 
desired cyclised product 130.  
However, an important competitive process is the simple reduction of the carbon-
centred radical 128 with Bu3SnH leading to the unwanted compound 131. To avoid this, it 
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is usually carried out by controlling the concentration of the Bu3SnH (slow addition of tin 
hydride and/or use highly dilute solution of Bu3SnH).88,91 
Bu3Sn
.
Bu3SnX
H
cyclisation
simple reduction
Bu3SnH Bu3Sn
.
H
X
128129
130
131
Bu3SnH
 
Scheme 2-4. Transformation of unsaturated halides to cyclic products using Bu3SnH.92 
 Most radical cyclisations used for the syntheses of heterocycles proceed by 5-exo-
trig regioselectivity, especially the pyrrolidinones 133. Cyclisations of a variety of 
secondary haloamides 132 often give excellent yields when using a large bulky nitrogen 
protecting group (P).96  
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O
N
P
NO
P
N
CH3
O
P
132 133  
Scheme 2-5. Radical cyclisation via 5-exo-trig regioselectivity. 
  However, the radical cyclisation via the disfavoured 5-endo-trig process of N-
vinylic α-chloroacetamides 134 has also been achieved to give the five-membered ring 
lactams 135 in good yields (Scheme 2-6).97  
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Scheme 2-6. Radical cyclisation of α-chloroacetamides 134. 
Cyclisations involving indole ring systems have also proved to be useful 
synthetically. The terminal vinyl radicals, generated from vinyl halides 136 using Bu3SnH, 
have been cyclised onto the indole 2-position to yield dihydroindoles 137 in fair yields 
(Scheme 2-7).98 No evidence was reported for the C-7 cyclisation.  
N N
X
R
R1 R1
R n-Bu3SnH, AIBN
toluene, reflux
136 137  
Scheme 2-7. Cyclisation of vinyl radicals onto indole rings. 
 Another useful method for cyclisation at the 2-position of indoles involved the use 
of the N-alkenyl-2-bromoindole precusor 13899 and Bu3SnH. The indol-2-yl radicals 
generated undergo 5-exo (n= 1) and 6-exo (n= 2) cyclisation to yield the corresponding 
cyclised indole derivatives 139. 
N N
n-Bu3SnH, AIBN
toluene, reflux
138 139
n
n
Br
 
Also, (N-bromo and N-iodoalkyl)indoles, substituted in the 2-position by 
benzenesulfanyl, benzenesulfinyl and 4-(methylphenyl)sulfonyl groups 140, undergo ipso 
aromatic homolytic substitution to yield fused [1,2-a]indoles 141.100,101 The cyclisation of 
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N-alkyl radicals onto the 2-position of the indoles afforded the intermediate indole π-radical 
which then rearomatised with expulsion of the benzenesulfenyl, benzenesulfinyl or 4-
(methylphenyl)sulfonyl groups.   
N N
(CH2)nCH2(n)X
n-Bu3SnH, AIBN
toluene, reflux
140 X= Br, I
       Z= SO2Tol, SPh, SOPh
141
Z
 
Moody et al.33 have described an alternative route to the systems above by 
cyclisation of 1-(ω-iodoalkyl)indole-3-carbaldehydes 142. This procedure involved the 
generation of alkyl radicals from iodoalkylindoles 142 which then cyclised onto the 2-
position of the indole ring. The intermediate radicals produced are stabilised by the 3-
carbaldehyde, and are then aromatised by an oxidative process.33 
N N
(CH2)nCH2(n)I
CHO CHO
n-Bu3SnH, AIBN
toluene, reflux
142 143
n= 1 (64%)
n= 2 (75%)
n= 3 (43%)
 
The sucessful production of fused [1,2-a]indoles via radical cyclisation onto indole 
rings suggested that amidylmethyl radicals, generated from haloacetamides, would be of 
value in the cyclisation onto the indole ring to give indole fused eight-membered ring 
compounds. 
The initial goal of the work described here was to investigate the cyclisation of 
haloacetamides 28 via  an 8-exo-trig process to give only the indolo-benzodiazocines 29. 
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2.2.1 Proposed synthetic approach to indole fused eight-membered rings 
The synthetic approach involved an intramolecular free radical cyclisation reaction 
of N-substituted haloacetamides (Scheme 2-8). The haloacetamides could be prepared as 
described by Bremner et al.30 by haloacetylation of  a secondary amine, N-substituted with 
an alkyl or acyl group (R1). The N-substitutents were required to ensure conformational 
control for cyclisation. After cyclisation, removal of this substituent group (R΄) was 
planned to afford the secondary lactam derivatives. 
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Scheme 2-8. Proposed synthetic approach to indole fused eight-membered ring compounds. 
2.2.2 Preparation of amine starting materials (145) 
The precursors for the cyclisation were prepared following the method used in 
Bremner et al,30 starting from the 1H-indoles 146. These indoles were N-alkylated using 2-
nitro benzylbromide 147 followed by nitro group reduction to yield the respective anilines 
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149 (Scheme 2-9). These compounds were identified by MS and 1H NMR and by 
comparison30 with the literature data. Alkylation or acylation of the anilines 149a-c was 
then investigated.   
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Scheme 2-9. Preparation of aniline starting materials 149. 
2.2.3 N-methylation of primary amines   
N-Methylation of the anilines 149a-c was conducted using the direct approach of 
reacting the amines with methyl iodide at room temperature (Scheme 2-10). Both mono- 
and di-methylated products were obtained from this reaction, but the two could be 
separated. The resultes are shown in Table 2-1. 
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Scheme 2-10. N-methylation reaction. 
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Treatment of 1-[(2-aminophenyl)methyl]1H-indole 149a with 1.1 equivalents of 
methyl iodide gave a fair yield of the monomethylated product 150a, but with a 
considerable amount of starting material remaining. On increasing the amount of methyl 
iodide to 1.5 equivalents, the yield of the monomethylation product 150a was increased to 
42%, however, the dimethyl amine 151a was also then observed. On treatment with a large 
excess of 149a, the yield of 150a increased to 90% with respect to methyl iodide, however, 
a large amount of starting material was also recovered.  
The N-methylation of 149b gave 71% of the monomethylated product 150b and 36% 
of the starting material together with some comtaminants (determined by 1H NMR 
spectroscopy) when using 1.1 equivalents of methyl iodide. When the equivalents of the 
methyl iodide increased, the yield of the monoalkylation product did not improve, and the 
dimethyl derivative 151b was also obtained. Even when the large excess of the aniline was 
used, the yield of the monomethylated product dropped to 40% with respect to methyl 
iodide. In the case of the N-methylation of 149c, only dimethylated product 151c was 
obtained when using 1.1 equivalents of methyl iodide. 
 The structural elucidations of the methylation products were based on spectroscopic 
data. The 1H NMR spectra of the mono-methylated products 150a-b showed a singlet 
integrating for three protons ascribed to the methyl group at about 2.74 ppm and a broad 
singlet signal ascribed to the NH proton at about 3.51 ppm. Evidence for the dimethylated 
products 151a-c was also observed in the 1H NMR spectra, with a singlet of six protons 
ascribed to the two methyl groups at about 2.74 ppm as well as the absence of the broad 
singlet for the NH proton.  
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Table 2-1. N-methylation of anilines 149 with methyl iodide 
Substrate Yields (%) 
Entry 
149 (eq.) 
MeI (eq.) 
150 151 
Unreacted 
149 (%) 
1 1 1.1 31 - 48 
2 1 1.5 42 27 16 
3 
a 
5 1 90a - 79 
4 1 1.1 71 - 36b 
5 1 1.5 19 23 37 
6 
b 
5 1 40a - 66 
7 c 1 1.1 - 100 - 
a calculated with respect to methyl iodide b not pure 
While direct N-alkylation of primary amines with alkyl haildes is the most common 
and straightforward route to substituted amines, this method is limited due to the possibility 
of multiple alkylation giving rise to mixtures of primary, secondary, and tertiary amines as 
well as quaternary ammonium salts.102 Once the amine has been alkylated to the monoalkyl 
derivative (step II), the molecule is more susceptible to further alkylation, and thus the 
dialkyl derivative is formed much faster than the remaining primary amine is alkylated 
(Figure 2-1). With an excess of the starting material, the monoalkylation products are 
predominantly obtained.102-104 
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Figure 2-1. Mechanism of direct N-alkylation. 
2.2.4 N-benzylation of primary amines  
When the amines 149a-c were alkylated with 4-methoxybenzyl bromide or benzyl 
bromide (1:1 equivalents), no dialkylated products were observed (Scheme 2-11). The 1H 
NMR spectrum of the reaction mixture of 152 showed a singlet at 3.86 ppm ascribed to the 
amine NH and a 3-proton singlet at 3.88 ppm, ascribed to the methoxy group. The presence 
of a singlet resonating at 4.26 ppm was seen for the benzylic protons, together with four 
extra protons in the aromatic region, indicated the addition of the p-methoxybenzyl group 
onto the starting material. Similarly, the 1H NMR spectrum of the reaction mixture for 153 
showed singlets at 3.93 and 4.32 ppm ascribed to the amine NH and benzylic protons, 
respectively, together with signals consistent with some starting material being present. 
After purification by flash chromatography, the pure products were obtained in 71% and 
66% yield for 152 and 153, respectively.  The lack of N,N-dialkylation in these cases is 
probably due to steric hinderance in the second alkylation step with the more bulky 
alkylating agents. The same results were obtained in the preparation of 1-[(2-
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aminophenyl)methyl]-5-methoxy-1H-indole 154 and 1-[(2-aminophenyl)methyl]-5-fluoro-
1H-indole 155; these N-benzylated products were isolated in 58% and 48% yield 
respectively, and no dialkylation products were observed (Scheme 2-11). 
N
N
H R1
152 R= H,      R1= OMe, 71%
153 R= H,      R1= H,      66%
154 R= OMe, R1= H,      58%
155 R= F,       R1= H,     48%
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Scheme 2-11. N-benzylation of primary amine. 
2.2.5 Reductive amination 
 An alternative to N-alkylation using the reductive amination method was also 
investigated in this stage of the work. With sodium cyanoborohydride as a reducing 
agent,105 it has been shown that reductive amination of aldehydes and unhinderded ketones 
with  ammonia, primary and secondary amines, provides efficient access to N-alkylamines. 
This procedure was then applied to the condensation of amines 149a-c with various 
aldehydes to give the iminium salt, which was then reduced in situ by sodium 
cyanoborohydride  to give the N-alkylamines (Scheme 2-12). The results are shown in 
Table 2-2. 
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Scheme 2-12. Reductive amination of primary amines. 
Table 2-2. Reduction amination of the amines 149a-c using NaBH3CN in methanol. 
Product (yield, %) 
Entry Aniline
Aldehyde or Ketone 
(equivalents) Monoalkylation Dialkylation 
1 149a 
H H
O
  
(1) 150a (44) 151a (25) 
2 149a H
O
  
(1) 153 (66) - 
3 149b H
O
  
(1) 154 (28) - 
4 149c H
O
  
(1) 155 (21) - 
5 149a H3C
O
 
(0.2) 
156 (74) 
(R= H, R1= CH3, R2= 
Ph) 
- 
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Even using reductive amination for the N-methylation of 1-[(2-aminophenyl)methyl]-
1H-indole 149a, some dimethylated product 151a (25%) was still obtained from further 
reaction of 150a with formaldehyde. When 1-[(2-aminophenyl)methyl]-1H-indole 149a 
was treated with 1 equivalent of benzaldehyde in the presence of NaBH3CN, 153 was 
obtained in 66% yield and no dialkylated product was observed. The yield of 153 was 
similar to that obtained from the direct N-alkylation approach. However, reductive 
amination of 1-[(2-aminophenyl)methyl]-5-methoxy-1H-indole 149b or 1-[(2-
aminophenyl)methyl]-5-fluoro-1H-indole 149c using the same reaction conditions as for 
149a, gave only 28% and 21% of the {1-[(2-N-benzylaminophenyl)methyl]}-5-methoxy-
1H-indole 154 and {1-[(2-N-benzylaminophenyl)methyl]}-5-fluoro-1H-indole 155, 
respectively. The lower yields are difficult to explain but may be associated with  the larger 
scale of the reactions compared with the analogous reactions with 149a. 
Treatment of 149a with 0.2 equivalents of acetophenone in the presence of 
NaBH3CN, gave a product which on analytical TLC showed two components with similar 
Rf values. However, mass spectrometry showed only an ion peak at m/z 327 [MH]+ 
corresponding to 1-{[2-N-(phenylethyl)aminophenyl]methyl}-1H-indole 156. The 1H NMR 
spectrum indicated a 3:1 amide rotamer mixture.   
Borch et al.106 noted that when the reductive amination reactions are run using a 
fivefold excess of the amine, this improves the initial equilibrium to yield the iminiun ion 
intermediate and also minimises the reaction of product amine with the carbonyl 
compound. However, with the amines 149a-c, the molecules are hindred for further 
reaction with another aldehydes or ketones, therefore, the excess use of the amines might be 
unnecessary.  
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2.2.6 N-acylation of primary amine 
 The most common method for the preparation of N-substituted amines is via 
treatment of a primary amine with acylating agents.103 Acid chlorides and acid anhydrides 
are highly reactive acylating agents and react very rapidly with amines. Typically, this 
reaction is conducted under basic conditions, using bases such as potassium carbonate or 
sodium hydroxide to generate the free amine base (if required), and deprotonation of the 
amine nitrogen using a strong base such as sodium hydride.  
Trifluoroacetic anhydride was of interest as the reaction is rapid and the N-
deprotection can occur under mildly basic conditions.107 However, the trifluoroacetyl group 
is susceptible to nucleophilic attack and the indole ring is sufficiently reactive at the 3-
position to be substituted by electrophiles. Thus, treatment108 of amine 149a with 1.5 
equivalents of trifluoroacetic anhydride in dichloromethane at 0 oC gave the N-{2-[3-
trifluoroacetyl-1-(1H-indolyl)methyl]phenyl}trifluoroacetamide 157 in 66% yield. The 1H 
NMR spectrum of 157 revealed the absence of a singlet proton that could be ascribed to the 
hydrogen at the 2-position on the indole ring and a broad singlet integrating for one proton, 
which was assigned to the NH proton at 8.04 ppm. Evidence for the trifluoroacetyl groups 
was also observed in the 13C NMR spectrum. The signals ascribed to the trifluoroacetyl 
carbonyl groups resonated at 156.4 and 157.3 ppm. The HREI-MS of 157 gave a peak at 
m/z 414.0780 (M+) consistent with the molecular formula C19H12N2O2F6.  
 Treatment of 149 with 1.1 equivalents of trifluoroacetic anhydride in pyridine gave 
only the N-acylated product 158 in 92% yield. The 1H NMR spectrum clearly showed the 
presence of ten aromatic protons (6.60-7.64 ppm), which suggested that no 
trifluoroacetylation of the aromatic core had occurred. The broad signal formerly indicative 
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of the amine hydrogens was not present in the 1H NMR spectrum, and the 13C spectrum 
revealed the presence of a signal assigned to the quaternary CF3 group at 115.5 ppm and the 
carbonyl group at 155.5 ppm. In addition, HREI-MS showed a molecular ion at m/z 
318.0990 consistent with the molecular formula C17H13N2OF3 and in line with the 
substitution of a trifluoroacetyl group in the starting material. This suggested that the 
trifluoroacetyl group was incorporated in the amine nitrogen first, then the excess 
trifluoroacetic anhydride resulted in electrophilic aromatic substitution at the 3-position of 
the indolic ring (Scheme 2-13). 
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Scheme 2-13. Preparation of trifluoroacetamides 157 and 158. 
Many carbamates (such as ethyl, methyl, t-butyl and benzyl carbamate), have been 
used as nitrogen protecting groups. Ethyl carbamate was chosen in this case as it can be 
readily prepared and deprotected.109 The carbamate protected indole derivatives were 
prepared using sodium hydride and ethyl chloroformate (Scheme 2-14). The 1-[(2-N-
ethylcarbamoylaminophenyl)methyl]-1H-indole 159 was obtained in near quantitative 
yield. The structure was identified by NMR and mass spectrometic analysis. The 1H NMR 
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spectrum showed a 3-proton triplet at 1.28 ppm, which was ascribed to the methyl      
group, as well as a quartet attributed to the CH2 at 4.20 ppm and a broad singlet integrating                   
for one proton indicative of the NH proton at 6.36 ppm. HRCI-MS gave a peak at m/z 
295.1446 (MH+) consistent with the molecular formula C18H18N2O2, which supported the 
structure assigned to 159.  
N NH2 N
N
H
O
O
CH3
NaH, THF
C lCOOCH2CH3
149 159  
Scheme 2-14. Preparation of N-ethylcarbamate 159. 
The Boc protecting group is one of the most useful nitrogen protecting groups as it 
is relatively easy to remove under mild acidic conditions. It was also investigated in this 
study. Treatment of amine 149 with sodium hydride and Boc anhydride gave the Boc 
protected compound 160 in 100% yield as orange crystals (Scheme 2-15). The HREI-MS 
gave a molecular ion at m/z 322.1697 consistent with the molecular formula C20H22N2O2. 
The 1H NMR spectrum of 160 showed a singlet at 1.47 ppm, representative of the t-butyl 
group, and a broad singlet at 6.20 ppm consistent with the NH proton. The 13C NMR 
spectrum showed a resonance at 28.6 ppm ascribed to the methyl carbon, a resonance at 
81.0 ppm ascribed to the quaternary carbon of the t-butyl group and a resonance at 153.5 
ppm ascribed to the carbonyl carbon.  
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Scheme 2-15. Preparation of  N-Boc compound 160. 
2.2.7 Preparation of chloroacetamides 
A general method for preparing the chloroacetamide derivatives was based on the 
method described by Bremner et al.30 Amines 149a and 149c were reacted with 
chloroacetyl chloride in DCM to give the chloroacetamindes 161 and 162 in 84% and 86% 
yield respectively (Scheme 2-16). The 1H NMR and 13C spectra of 161 and 162 were 
identical to those previously reported in the literature.30 The 1H NMR spectra of  both 161 
and 162 showed characteristic singlet signals ascribed to the methylene protons of the 
chloroacetyl moiety at 4.03 ppm and 4.06, respectively. Signals assigned to the 
corresponding methylene carbons were also observed in the 13C NMR spectra at 42.7 ppm 
and 43.1 ppm for 161 and 162, respectively. 
N
N
H
N
R1R1
K2CO3, DCM
C lCOCH2C l
149a R1= H
149c R1= F
161 R1= H
162 R1= F
NH2
O
C l
 
Scheme 2-16. Preparation of N-unsubstituted chloroacetamides. 
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This general procedure was also used for the acetylation of the N-alkylamines 150a 
and 150b to afford the N-methylchloroacetamides 163 and 164 in 57% and 58% yields, 
respectively (Scheme 2-17). The products were identified by their ascribed methylene 
signals in both the 1H NMR and 13C NMR spectra as well as via LRMS and HRMS. In the 
1H NMR spectra, the methylene protons of the chloroacetyl moiety were ascribed to two 
sets of doublets at 3.56 ppm (J= 12.6 Hz) and 3.66 ppm (J= 12.6 Hz) and the benzylic 
methylene protons were ascribed to a doublet at around 5.25 ppm. The splitting patterns of 
the methylene protons suggested hindered rotation around the amide bond in these 
molecules 163 and 164. The 13C NMR spectra indicated the presence of the methylene 
carbon at 41.2 ppm. A signal ascribed to the carbonyl carbon in each case was also 
observed at 164.6 and 166.8 ppm for 163 and 164, respectively.   
N
N
CH3
C l
ON
N
CH3
H
R1R1
K2CO3, DCM
C lCOCH2C l
150a R1= H
150b R1= OMe
163 R1= H
164 R1= OMe  
Scheme 2-17. Preparation of N-methylchloroacetamides. 
In the preparation of the N-benzylchloroacetamides 165-168 (Scheme 2-18), 
deprotonation of the amine nitrogen was achieved utilising a strong base, sodium hydride 
(NaH), followed by acylation using chloroacetyl chloride to give 165-168 in generally good 
yields (75-93%). These products were identified by the characteristic signals ascribed to the 
chloroacetyl methylene signals in both the 1H NMR and 13C NMR spectra as well as via 
LRMS and HRMS.  
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N
N
C l
ON
N
H
R1R1
NaH, THF
C lCOCH2C l
152 R1= H,      R2= OMe
153 R1= H,      R2= H
154 R1= OMe, R2= H
155 R1= F,       R2= H
R2
R2
165 R1= H,      R2= OMe   93%
166 R1= H,      R2= H        81%
167 R1= OMe, R2= H        58%
168 R1= F,       R2= H       76%  
Scheme 2-18. Preparation of N-benzylchloroacetamides. 
However, treatment of the N-phenylethyl amine 156 with NaH and then 
chloroacetyl chloride gave none of the expected amide product 169, which was possibly 
due to the bulky phenylethyl group. The chloroacetamide 169 was obtained in 33% yield 
when 4-dimethylaminopyridine (DMAP) was used as a acylation catalyst (Scheme 2-19).94  
N
N
C l
ON
N
H
C lCOCH2C l
CH3
H
CH3
H
Et3N,DMAP, DCM
156 169  
Scheme 2-19. Synthesis of N-ethylbenzylchloroacetamide 169. 
The dimethylamino moiety in DMAP acts as an electron donor substituent, 
increasing both the nucleophilicity and basicity of the pyridine nitrogen. This pyridine 
nitrogen is involved in the initial reaction with chloroacetyl chloride to afford an acyl 
pyridinium ion intermediate, which is a powerful acylating agent and reacts more rapidly 
with  the  amine than chloroacetyl chloride alone. Thus, using  DMAP  in   acylations   with  
 
 52
chloroacetyl chloride may increase the acylation rate by up to four orders of magnitude and 
permits sucessful acylation of hindered amines.103 With the addition of large groups to the 
amide nitrogen, the molecule became very bulky and free rotation was reduced. This 
hindered rotation was confirmed by the 1H NMR and 13C NMR spectra, which showed two 
rotamers in a ratio of 2:1 (determined by 1H spectroscopy). The 1H NMR spectrum was 
complicated in the aromatic region. However, two sets of singlet signals were seen at 1.58 
ppm and 1.64 ppm and these were ascribed to the methyl group for the minor rotamer and 
the major rotamer, respectively, as well as four sets of doublet signals, each set being 
ascribed to the benzylic methylene protons. The HRCI-MS gave a peak at m/z 403.1559 
(MH+) consistent with the molecular formula C25H24N2OCl and the addition of the 
phenylethyl group to the starting material.  
The attempted preparation of the amide 170 by chloroacetylation using potassium 
carbonate in DCM or NaH in THF (Scheme 2-20) was unsucessful, possibly due to the 
ready hydrolysis of the trifluoroacetyl in 170. Further investigation of this reaction was not 
pursued.  
N
N CF3
H
O
N
N CF3
O
O
C l
158 170
(i)/ (ii)
(i) K 2CO3, DCM, ClCH2COCl; (ii) NaH, THF, ClCH2COCl  
Scheme 2-20. Attempted synthesis of N-trifluoroacetylchloroacetamide 170. 
An alternative approach to the preparation of compound 170 starting from the 
chloroacetamide 161 was then investigated (Scheme 2-21). Chloroacetamide 161 was 
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treated with sodium hydride followed by trifluoroacetic anhydride. While purification of 
the crude reaction mixture was attemped by preparative thin layer chromatography (PTLC) 
by dissolving it in a minimal volume of DCM, the solution formed a gel after leaving it for 
several minutes. The solution that remained  was subjected to PTLC, and showed five UV-
absorbing bands. Mass spectrometric analysis (CI+) of the major band (lowest Rf) showed a 
parent ion at m/z 395 (MH+), which confirmed that the COCF3 group had been added to the 
molecule. However, the 1H NMR spectrum revealed the presence of a broad singlet 
ascribed to the NH proton at 8.13 ppm together with a singlet ascribed to the indolic H-2 at 
7.92 ppm. Also the expected indole C-3 (110.4 ppm) signal was absent in the DEPT 
spectrum. The 13C NMR spectrum indicated the presence of a signal for the quaternary CF3 
group at 117.2 ppm (J= 285 Hz, 13C-19F).  From the NMR analysis, the 3-trifluoroacetyl 
derivative 171 was proposed as the structure of the major product. This would result from 
electrophilic aromatic substitution at the activated indolic 3-position. Therefore, this 
attempted synthesis of N-trifluoroacetylchloroacetamide 170 was also unsucessful. 
N
N
H
O
N
H
N
O
(CF3CO)2O, pyr
DCM
C l C l
O
CF3
161 171  
Scheme 2-21. Formation of N-{2-[1-(3-trifluoroacetyl)-1H-indolyl)methyl]phenyl}chloroacetamide 171. 
Chloroacetylation of  the carbamate 159 was unsuccessful using both potassium 
carbonate or sodium hydride as a base (Scheme 2-22). Using potassium carbonate, the 
starting material was recovered even after increasing the molar equivalents of potassium 
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carbonate and chloroacetyl chloride. Use of a stronger base, such as sodium hydride, 
followed by addition of chloroacetyl chloride, failed to give 172 or show any addition of 
the chloroacetyl group at any position in the starting material. It appeared that the bulky 
steric properties of the carbamate could have obstructed the addition. Therefore, direct 
acylation was investigated starting with chloroacetamide 161 (Scheme 2-23).  
N
N
H
O
O
CH3
N
N O
O
CH3
O
C l
(i) or (ii)
Reagents: (i) K2CO3, C lCH2COC l, DCM; (ii) NaH, C lCH2COC l, THF
159 172
 
Scheme 2-22. Attempted synthesis of  N-carbamoylchloroacetamide. 
 The chloroacetamide 161 was treated with sodium hydride in DMF and then ethyl 
chloroformate was added. After work up, the reaction mixture had changed colour from 
orange to yellow and then green. The mixture was purified using column chromatography 
to give compound 172 in 32% yield together with some starting material (10%). The 
changes in colour indicated other possible pathways taking place thus accounting for the 
low yield of the required product 172. 
N
N
H
O
C l
NaH, DMF
EtCOOC l
N
N
O
C l
O
O
CH3
161 172  
Scheme 2-23. Preparation of N-carbamoylchloroacetamide 172. 
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The HREI-MS of 172 gave a molecular ion at m/z 370.1094 consistent with the molecular 
formula C20H19N2O3Cl and the addition of a carbamate group to the starting material. In the 
1H NMR spectrum of 172, a signal for the methyl group was ascribed to a triplet at 1.09 
ppm, and the methylene protons were observed as two sets of doublets at 3.92 ppm and 
4.08 ppm. Likewise, in the 13C NMR spectrum a signal for the methyl carbon was apparent 
at 14.3 ppm and for the methine carbon at 64.2 ppm. 
 Attempted synthesis of N-Boc-chloroacetamide 173 involved reaction of 160 with 
sodium hydride followed by chloroacetyl chloride (Scheme 2-24). After 16 hours, there 
was no evidence for successful acylation on the basis of 1H NMR and MS analysis. Even 
when the N-Boc compound 160 was treated with triethylamine and a catalytic amount of 
DMAP followed by chloroacetyl chloride, there was no evidence for acylation, with mostly 
starting material being obtained and a small amount of the N-chloroacetamide 161 (Scheme 
2-25). 
N
N
H
O
O
CH3
N
N O
O
CH3
O
C l
NaH, THF
H3C
CH3
H3C
CH3C lCOCH2C l
160 173  
Scheme 2-24. Attempted synthesis of N-Boc-chloroacetamide 173. 
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CH3
H3C
CH3
N
N
H
O
C l
Et3N, DMAP
C lCOCH2C l, DCM
160 161  
Scheme 2-25. Chloroacetylation of 160 in the presence of DMAP.  
2.2.8 Preparation of iodoacetamides 
Organoiodides are the most reactive precursors for atom transfer addition reactions 
and thus have been useful for radical addition reactions. A successful atom transfer reaction 
requires a suitably weak bond between carbon and the heteroatom allowing initiation to 
occur thermally in the presence of initiators such as AIBN or a photochemical initiator.110 
The bond dissociation energy (BDE) of a carbon-iodine bond is significantly lower than 
that of a carbon-chlorine bond (BDE: CH3-I, 57 kcal/mol; CH3-Cl, 83 kcal/mol).87 
Therefore, the use of an iodine atom as a leaving group usually results in the cyclised 
products, on the other hand the use of a chlorine atom frequently yields uncyclised 
reduction products. 
Based on the fact that the iodine is a better leaving group than chlorine, the 
iodoacetamides 176-184 were prepared as the precursors for the cyclisation step. Iodide 
exchange of the chloroacetamide was readily achieved using sodium iodide in acetonitrile33 
(Scheme 2-26). Table 2-3 shows the yields, MS and formulae for the iodoacetamides. 
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N
N
R1
C l
O
R
NaI, CH3CN N
N
R1
I
O
R
174-182  
Scheme 2-26. General method for preparation of iodoacetamide. 
 The only exception was the formation of iodoacetamide 183 which was prepared by 
direct alkylation of the chloroacetamide 162 with methyl iodide in DMF after amide anion 
formation. The iodide anion, which is generated in situ, was then exchanged with the 
chlorine atom to afford the iodoacetamide in 66% yield (Scheme 2-27). The HREI-MS of 
this compound gave a molecular ion at m/z 423.0336, consistent with the molecular 
formula C18H17N2OIF and the addition of a methyl group and the replacement of the 
chlorine with an iodine. 
N
N
H
O
C l
F
NaH, DMF
CH3I
N
N
CH3
F
O
I
183162  
Scheme 2-27. Preparation of N-methyliodoacetamide by direct alkylation. 
The 1H NMR of the iodoacetamides in general showed that the two sets of doublets 
ascribed to the CH2-I protons had moved upfield compared to the chloroacetamides and the 
13C NMR of the iodoacetamides showed the signal for the CH2I carbon at between (-1) – (-
3) ppm.87 Otherwise, the 1H and 13C NMR spectra were similar to those of the precursor 
chloroacetamides. 
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Table 2-3. Results of the preparation of iodoacetamides. 
Products  Yield (%) HRMS Formula 
N
N
H
O
I
 
174 87 
390.0232 
[M]+ 
C17H15N2OI 
N
N
CH3
O
I
 
175 93 
404.0396 
[M]+ 
C18H17N2OI 
N
N
CH3
O
I
MeO
 
176 70 
434.0476 
[M]+ 
C19H19N2O2I 
N
N
I
O
OMe
 
177 70 
510.0810 
[M]+ 
C25H23N2O2I 
N
N
I
O
 
178 96 
480.0689 
[M]+ 
C24H21N2OI 
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Product  Yield (%) HRMS Formula 
N
N
I
O
MeO
179 73 
511.0868 
[MH]+ 
C25H24N2O2I 
N
N
I
O
F
 
180 89 
498.0600 
[M]+ 
C24H20N2OI 
N
N
I
O
CH3
H
 
181 82 
495.0926 
[MH]+ 
C25H24N2OI 
N
N O
O
CH3
O
I
 
   182 
 
66 
462.0445 
[M]+ 
C20H19N2O3I 
 
2.2.9 Preparation of bromoacetamides 
The bromoacetamides 184-185 were prepared using a similar approach to the 
preparation of the chloroacetamides, except bromoacetyl chloride was used as the acylating 
agent instead of chloroacetyl chloride.  
Treatment of the N-methyl amine 150b with bromoacetyl chloride in the presence of 
anhydrous potassium carbonate afforded the N-methylbromoacetamide 184 in 54% yield 
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(Scheme 2-28). The product gave the expected M+ ion at m/z 386.0624, consistent with the 
formula C19H19N2O2Br. The presence of the bromoacetyl group was evident from the 1H 
NMR spectrum with a signal for the methylene protons ascribed to two sets of doublets at 
3.53 ppm (J= 12.6 Hz) and 3.63 ppm (J= 12.6 Hz). Likewise, the 13C NMR and DEPT 
spectra showed the methylene carbon signal at 41.2 ppm and the carbonyl carbon at 166.8 
ppm.      
N
N
Me
Br
O
MeO
N
H
N
Me
MeO
K2CO3, DCM
C lCOCH2Br
150b 184  
Scheme 2-28. Preparation of N-methylbromoacetamide derivative. 
Bromoacetylation of N-benzyl amine 153 was achieved in 68% yield by treatment of 
the amine with sodium hydride and bromoacetyl chloride (Scheme 2-29). The product was 
fully characterised by spectroscopic means. In the EI-MS, the product 185 gave the 
expected M+ species at m/z 432.0851, supportive of the formula C24H21N2OBr and the 
addition of a bromoacetyl group to the starting material. The absence of the NH proton was 
apparent from the 1H NMR spectrum. In addition, the presence of a doublet signal ascribed 
to the CH2-Br protons was observed at 3.43 ppm. The bromoacetyl group was evident in 
the 13C and DEPT spectra from the signals of the methylene carbon at 42.3 ppm and the 
quaternary carbonyl group at 166.8 ppm.  
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N
Br
ON
N
H NaH, THF
C lCOCH2Br
153 185  
Scheme 2-29. Preparation of N-benzylbromoacetamide derivative. 
2.2.10 Synthesis of benzodiazocinone derivatives using free radical 
cyclisation 
Free radical cyclisation reactions of the haloacetamides 161, 163, and 174-185 were 
induced by a slow addition of a 40 mM solution of tributyltin hydride (Bu3SnH) (2.0 eq.) in 
the presence of azobisisobutyronitrile (AIBN) (1.0 eq.) in various solvents at reflux.  
Slow addition of tributyltin hydride to a boiling toluene solution of the 
haloacetamides gave the indole fused eight-membered ring compounds 186-187 in fair 
yields, and also the simple reduced compound 188 (Scheme 2-30, Table 2-4). 
Dehydrogenation of 187a was achieved in a separate aromatisation reaction with Pd/C in 
boiling toluene to give 186a in 50% yield (Scheme 2-31).  
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186 187 188  
Scheme 2-30. Free radical cyclisation reactions. 
N
N
CH3
O
10% Pd/C
toluene, reflux
N
N
CH3
O
50%
187a 186a  
Scheme 2-31. Dehydrogenation reaction of 187a. 
In the 1H NMR spectra of compounds 186, the H-8 proton appeared as a singlet 
signal at about δ 6.28-6.37, which was clearly separated from the other signals. In contrast, 
the signal attributed to the H-8 protons in compounds 187 appeared as a multiplet around δ 
2.40-2.50 due to coupling with H-7a. In the 1H NMR spectra of the acetamides 188, a 
diagnostic singlet signal integrating for three protons ascribed to the acetyl group was 
apparent at around δ 1.80.  
186-188       R          R΄ 
a         H             H 
b                    H             Me 
c                    OMe        Me 
d                    H             CH2C6H4-p-OMe 
e                    H             CH2Ph 
f                     OMe       CH2Ph 
g                    F              CH2Ph 
h                    H             CH(CH3)Ph 
i                     H             COOEt 
j                     F              Me 
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An increase in the cyclisation product yields was generally observed as the steric 
bulk of the protecting group on the haloacetamide nitrogen was increased.93,111 When the 
unsubstituted haloacetamides (Entries 1 and 3, Table 2-4) were reacted, the products of 
simple reduction were also obtained. However, when a sufficiently large group (R΄) was 
employed as a substituent on the amide nitrogen, the indole fused eight-membered ring 
cyclisation products were formed with the bromo or iodoacetamide precursors (eg. Entries 
7 and 13, Table 2-4). In the case of the carbamate analogue 182 (Entry 10, Table 2-4), the 
simple reduced product was obtained together with the amine product 149a.  
Table 2-4. Radical cyclisation of haloacetamides using Bu3SnH/AIBN in boiling toluene 
Yield (%) Entry Substate R R′ X mmol 
186 187 188 
1 161 H H Cl 0.16 - - 82 
2 163 H Me Cl 0.20 - - 83 
3 174 H H I 0.21 - - 85 
4 175 H Me I 0.13 20 60 20 
5 176 OMe Me I 0.19 50 - 20 
6 177 H CH2C2H4-p-OMe I 0.33 13 11 7 
7 178 H CH2Ph I 0.08 25 43 10 
8 179 OMe CH2Ph I 0.12 25 - <1 
9 181 H CH(CH3)Ph I 0.07 22        26a  
10 182b H COOEt I 0.06 - - 37 
11 183 F Me I 0.14 35 - 17 
12 184 OMe Me Br 0.12 24 - 33 
13 185 H CH2Ph Br 0.10 54        20b  
amixture of 187 : 188 in a ratio of ca 1: 1 (determined by 1H NMR); bmixture of 187 : 188 in a ratio of ca 2 : 1 
(determined by 1H NMR) b 34% yield of 149a also obtained.  
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It is conceivable that in this particular case, that the intermediate radical (A, Scheme 
2-32) could undergo a hydrogen abstraction from Bu3SnH to afford a simple reduced amide 
188e or lose ketene to give an intermediate (B), which could then afford the radical (C) 
(with loss of ethylene and carbon dioxide) and finally 149a after hydrogen abstraction from 
Bu3SnH.  
N
N O
O
CH3
O
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-CO2
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Scheme 2-32.  Possible reaction of 182 with Bu3SnH.  
Ishibashi et al.87 also observed halogen-dependent differences in radical cyclisation 
versus radical reduction with other N-benzylhaloacetamides. In their case, the 
chloroacetamide afforded cyclisation from the cisoid amide rotamer, while the 
iodoacetamide gave predominately the non-cyclised product from the favoured transoid 
rotamer. Clearly amide conformational preferences will be influenced by the nature of both 
the N-substituents and the nature of the haloacetamide. 
The very bulky indolylmethyl substituent, together with the methyl or benzylic 
substitutent would induce a preference for the cisoid bromo and iodoacetamide rotamer (B) 
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(Scheme 2-33) which can cyclise to give the indole fused eight-membered ring precursor 
(C) after amide radical formation. On the other hand, the radical from the transoid rotamer 
(A) cannot cyclise but would give uncyclised reduction product instead.  
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Scheme 2-33.  Proposed mechanism of radical cyclisation. 
A temperature-dependence study of the cyclisation revealed increasing yields with 
higher boiling point solvents (Table 2-5). 
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Table 2-5. Radical cyclisation of haloacetamides using Bu3SnH/AIBN in various solvents. 
Yield (%) 
Entry Substrate Solvent 
186 187 188 
1 175 Mesitylene 44 - - 
2a 178 Toluene 25 43 10 
3 178 Xylenes 57 - - 
4 178 Mesitylene 70 - - 
5 178 (CH3)3CC6H5 46 - 9 
6 179 Mesitylene 29 - - 
7a 179 Toluene 25 - <1 
8 180 Mesitylene 23 - 15 
a From Table 2-4 
Cyclisations in high boiling point solvents eg. xylenes and mesitylene, increased the 
yields of 186 and neither the dihydroindole fused products 187 nor acetamides 188 were 
isolated when 175 or 178 was the substrate (Table 2-5). No products from radical attack on 
the aromatic hydrocarbon solvents were observed.112 The increased yield of cyclisation 
products and the diminished formation of uncyclised reduction products in high boiling 
point aromatic solvents suggests that the amide rotamer (B) required for cyclisation after 
radical formation is increased in concentration in the equilibrium at higher temperatures 
relative to rotamer A.87 Also, with radical attack on the heteroaromatic ring likely to be 
slow,86 the increased temperature would be favourable for this reaction. 
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 A 8-exo-trig addition of the amidylmethyl radical gives the indole radical (C) and 
then an oxidation step to give the product 186 (Scheme 2-33); the exact details of this latter 
step in other cyclisations has been the subject of much discussion, but it now seems likely 
that two possible pathways include hydrogen abstraction by the (CH3)2C·CN radical, plus 
reaction with AIBN.113 In this connection, it is of interest to note that in a larger scale 
reaction involving 178, some of the radical trapped adduct 189 was isolated. 
N
N
O
H3C
CH3
CN
N
N
O
(CH3)2C
.
CN
189(C )  
Scheme 2-34.  The radical trapped adduct 189. 
Although Bu3SnH has been used successfully in the formation of carbon-carbon bonds, 
either inter- or intramolecularly, several problems are associated with the use of this reagent 
including toxicity, instability to moisture and difficulty to remove the tin halide by-product 
from the desired products.92 Alternative reagents have thus been investigated, including 
phosphites which contain a weak phosphorus-hydrogen bond, and can generate a 
phosphorus-centred radical on heating with AIBN.92 Recently 1-ethylpiperidinium 
hypophosphite (EPHP) has been used for radical carbon-carbon bond formation.114,115 
Tris(trimethylsilyl)silane ((TMS)3SiH) has also been used in radical reactions.116 The Si-H 
bond strength (~350 kJmol-1) is slightly stronger than the Sn-H bond (~ 310 kJmol-1), 
which means that hydrogen atom abstraction from (TMS)3SiH is around 10 times slower 
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than from Bu3SnH.92 Unfortunately (TMS)3SiH is more expensive than Bu3SnH and is also 
air-sensitive, requiring handling under argon. 
 An investigation of the uses of EPHP and (TMS)3SiH as radical reagents in the 
intramolecular cyclisation of iodoacetamides was undertaken in this study and the results 
are reported in Table 2-6. Heating iodoacetamide 175 with EPHP (10 equiv.) and AIBN in 
benzene at reflux afforded the cyclised product 186b (9%) and the simple reduced product 
188b (33%). The low yield of the cyclisation product is probably due to the lower reactivity 
of EPHP compared with tributyltin hydride (Entry 4, Table 2-4) and the low boiling point 
solvent (benzene) used. The same results were obtained when using (TMS)3SiH as the 
radical reagent. The yields of cyclisation products obtained were less than those from 
tributyltin hydride, and also more of the unwanted simple reduced products were obtained. 
Moreover, using a high boiling point solvent decreased the yield of cyclised product. This 
result, in contrast to the Bu3SnH reaction, indicated that (TMS)3SiH might decompose at 
the higher temperature or it might react with the mesitylene.    
Table 2-6.  Results of the cyclisation reaction of iodoacetamides using EPHP and (TMS)3SiH. 
Product (%) 
Entry Substrate Radical reagent Solvent 
186 187 188 
1 175 EPHP Benzene 9 - 33 
2 176 (TMS)3SiH Toluene 10 - 36 
3 178 (TMS)3SiH Toluene 31 - 54 
4 178 (TMS)3SiH Xylenes 9 - 43 
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2.2.11 Debenzylation of N-benzyl substituted indolo[2,1-d][1,5] 
benzodiazocine-6-ones   
With a view to ultimately providing access to other N-substituted indolo[2,1-
d][1,5]benzodiazocine-6-ones, a chemoselective means of removal of the N-benzyl group in 
186e was investigated. Deprotection of N-benzylamides is not straightforward and they can 
be difficult to cleave by typical catalytic hydrogenolysis.117 Thus, harsher deprotecting 
methods, such as aqueous HBr and sodium in liquid ammonia have been used to remove 
the benzyl group. Debenzylation was achieved, using metallic sodium in liquid ammonia118 
to afford 29a in 35% yield (Scheme 2-35). There was no unreacted 186e, but some 
unidentified baseline material was observed in the PTLC of the reaction mixture. 
N
NH
O
N
N
O
Na, liq. NH3
186e 29a  
Scheme 2-35. Debenzylation using Na in liquid ammonia. 
 Selective addition of a solvated electron was expected at the less-electron rich 
aromatic ring of the benzyl protecting group. However, the reaction time was crucial to 
ensure a reasonable yield of the product. The most suitable time for the cleavage of the 
benzyl protecting group was 6 to 8 minutes. If the reaction mixure was left longer both the 
protecting group and the eight-membered ring were cleaved to give adduct 190.   
N
H
N
H
O
H3C
190  
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2.3 Attempted metal-mediated cyclisation  
Metal-mediated reactions have gained increasing popularity in organic synthesis over 
the past decade119 since the reagent Bu3SnH (for radical generation) has toxicity problems 
and there are difficulties associated with complete removal of tin species from the reaction 
mixture.92 Therefore, metal-mediated reations are of considerable interest as tools in 
cyclisation reactions.  
2.3.1 Silver-mediated cyclisations 
Silver salts have been used to induce intramolecular cyclisations in indole-based 
haloacetamides. Thus reaction of the α-bromoacetamide 191 with AgBF4 resulted in 
cyclisation to the C-3 position of the indole ring (Scheme 2-36),120 while the closure of the 
E ring was achieved in 193 by treatment of the haloacetamide with silver triflate121 
(Scheme 2-37). Thus we decided to investigate the cyclisation of iodoacetamide 178 to 
construct the indolodiazocinone 186.  
N
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reflux, 50%
191 192  
Scheme 2-36. Cyclisation of bromoacetamide 191 using AgBF4. 
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Scheme 2-37. Cyclisation of chloroacetamide 193 using Ag(OTf). 
Reaction of 178 with AgBF4 in 1,2-dimethoxyethane at reflux120 gave a variety of 
unidentified products, however no evidence for the cyclised product 186e (Scheme 2-38) 
was observed from analytical TLC and LR-MS analysis. The failture to achieve silver-
mediated cyclisation could be due to an unfavourable amide rotamer population at the 
temperature of the attempted cyclisations. When AgOTf was used in place of AgBF4, the 
reaction mixture formed a gel after work up. No organic solvents could dissolve this gel 
and no cyclisation product could be indentified.  
N
N
I
O N
N
178 186e
O
AgBF4, or Ag(OTf)
DME, ∆
 
Scheme 2-38. Attempted silver-mediated cyclisation. 
2.3.2 Palladium-mediated cyclisation  
Palladium-mediated carbon-carbon bond formation has emerged as one of the most 
important methods in organic synthesis.122 Oxidative addition of Pd(0) to alkenes, alkynes, 
and aryl halides forms the C-Pd bond which can then be inserted in adjacent double or 
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triple bonds (Scheme 2-39). Recently, many applications of this methodology have been 
used in the syntheses of various polycyclic frameworks via intramolecular cyclisations.  
Pd (0) + X-Y x-Pd(II)-Y
oxidative addition
A B
X Pd Y
A B
X Pd Y
insertion
 
Scheme 2-39. General scheme for palladium-mediated carbon-carbon bond formation. 
Intramolecular cyclisations via Pd coupling reactions mostly involve aryl halides. 
Oxidative addition of Pd to the aryl bromide is then followed by addition to double or triple 
bonds. For example, intramolecular arylation using Pd(PPh3)4 of indole derivatives 195 and 
197 occurred at C-2 to give 196 when the C-3 position was substituted and 198 when C-3 
was unsubstituted.  
N
Br
Oi-P r2N
N
Oi-P r2N
Pd(PPh3)4, AcOK
DMA, 160 oC
81%
195 196  
N Br N
Pd(PPh3)4
KOAc, DMF, 130 oC
10 h, 86%
197 198  
A study by Mori et al.123 suggested that α-haloamides having an internal double 
bond could be cyclised to various five and six membered lactams in fair yields using 
Pd(PPh3)4. For example, cyclisation of iodoacetamide 199 with an equimolar amount of 
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Pd(PPh3)4 resulted in 200 in 37% yield; a σ-allylmetal complex is presumably involved as 
an intermediate.  
(CH2)nN
H2C
O
I
n= 1,  2
N (CH2)n
O
H
H
199 200
Pd(PPh3)4
DMF
 
However, cyclisation with the divalent palladium complex Pd(OAc)2 or a catalytic 
amount of Pd(OAc)2-PPh3, was not successful.123 Lactam 200 was obtained in 0% and 4% 
yield when using a catalytic amount of Pd(OAc)2 and Pd(OAc)2-PPh3, respectively. As the 
results from 199, cyclisations using Pd(OAc)2 and Pd(OAc)2-PPh3 were not investigated, 
howver, in a current study, an attempt to cyclise the iodoacetamide 178 with Pd(PPh3)4 was 
also unsuccessful. 
N
N
O
I
N
N
O
Pd(PPh3)4, KOAc
178 186e
DMF, reflux
 
Scheme 2-40. Attempted cyclisation using Pd(PPh3)4. 
2.3.3 Indium-mediated cyclisation 
 Indium-mediated carbon-carbon bond formation in aqueous media has developed 
as a powerful method in organic synthesis. Since the first ionisation potential of indium 
(5.8 eV) is close to that of alkali metals such as sodium (5.1 eV), indium promotes SET 
(single electron transfer) processes with relative ease.124 Therefore many useful indium-
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mediated carbon-carbon bond formation reactions using indium as a single-electron-
transfer radical initiator have been reported.125-127 Naito et al.125 reported that indium-
mediated radical addition to an electron-deficient carbon-carbon double bond provided a 
convenient method for preparing new carbon-carbon bonds. On the basis of this, the radical 
addition to the indole ring using indium as a radical initiator was investigated in the current 
study. A mixture of 178 and indium (3.25 equiv.) was reacted in H2O-MeOH at room 
temperature for 2 days. However, there was no evidence for any cyclised product being 
formed, only the simple reduced product 188 (3%), accompanied by the starting material 
(9%), and some unidentified baseline material were obtained.  This was thought to be 
because of the slower reaction of indium-mediated cyclisation compared with the 
reduction. At the same time, the reaction did not go to completion, probably due to 
aggregation of the indium powder in the aqueous media, a phenomenon also observed by 
Naito et al.126 
N
N
I
O N
N
178 188e
In
H2O-MeOH
O
CH3
 
Scheme 2-41. Reaction of iodoacetamide with In powder. 
  
2.3.4 Zinc-silver couple mediated cyclisation 
Zinc-silver couple has been used for various synthetic applications including the 
reduction of carbon-halogen bonds,128 and the reduction of  β-halo-α,β-unsaturated 
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esters.129 Furthermore, Meyers et al.130 described the intramolecular cyclisation of a 
bromobutanamide 201 using zinc-silver couple. However, there have been no reports of 
Zn(Ag)-mediated cyclisation of haloacetamides on to an indolic 2,3-double bond. 
N
N
MeO
O
NH2
N
N
MeO Br
O
NC
H H
Zn(Ag)
))))
201 202  
To determine if this might be possible, the potential cyclisation of the iodoacetamide 
178 using a zinc-silver couple was investigated. The zinc-silver couple was prepared as 
described by Taschner.128 However, reaction of the zinc-silver couple with N-
benzyliodoacetamide 178 in THF in a sealed tube at reflux with stirring for 5 hours, 
together with periodic sonication, did not give any cyclised products. Two products were 
obtained from this reaction, the major product being 203 which was obtained in 48% yield, 
and the minor product 204, obtained in 35% yield (Scheme 2-42). Both structures were 
indentified on spectroscopic grounds. In the HREI-MS of 203, the M+ ion was present at 
m/z 480.0701, consistent with the formula C24H21N2OI, which is the same formula as that 
for the starting material 178. The 1H NMR spectrum of 203 was different from the starting 
material however; the spectrum indicated the presence of an acetyl group from the new 
singlet signal at 1.83 ppm and the absence of the characteristic signal for the indole proton 
at C-3. The 13C NMR spectrum of 203 also indicated the loss of the CH at the 3-position, 
with the presence of a new quaternary carbon signal at 56.8 ppm,131 consistent with a 3-
iodo substituent. Also the presence of the acetyl group was consistent with the carbonyl 
signal at 170.4 ppm, and the methyl signal at 22.5 ppm. The formation of 203 suggests 
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either iodine atom or iodonium ion formation in the reaction, with subsequent attack at the 
indolic 3-position. 
N
N
I
O Zn(Ag)
))))
N
N
CH3
O
I
178 203 204
N
O
CH3
NO
O
H2O-MeOH
 
Scheme 2-42. Reaction of iodoacetamide 178 with Zinc-Silver couple.  
 In the 1H NMR spectrum of 204, the characteristic signals for the indole protons at 
C-2 and C-3 were not present, which indicated that there were substituents in both of these 
positions. A doublet signal resonating at 6.15 ppm was ascribed to the indole H-7 proton. 
The 13C NMR spectrum of 204 showed quaternary carbon signals at 158.4 and 183.6 ppm 
and which were ascribed to the carbonyl carbons at C-2 and C-3 of an indole-2,3-dione132 
respectively, together with a quaternary signal at 170.8 ppm ascribed to the amide carbonyl 
carbon. The HRCI-MS of this compound gave a peak at m/z 385.1615 (MH+), consistent 
with the molecular formula C24H21N2O3. The formula supported the oxidation of the indole 
to afford the indole-2,3-dione derivative.133  
 
 2.4 Summary and Conclusions 
It has been shown that, in contrast to photo-initiated reactions, an indole-fused eight-
membered ring system can be accessed in fair yield by a thermal free radical cyclisation 
route from 1-substituted indole derivatives with appropriately positioned haloacetamide 
functionalities. The cyclisation depended on a favourable amide rotamer population prior to 
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radical formation. The introduction of a sterically bulky protecting group on the 
haloacetamide nitrogen increased the concentration in the equilibrium of the required cisoid 
amide conformation for cyclisation. Cyclisations in high boiling point solvents such as 
xylenes and mesitylene also increased the yield of cyclised products. Selective deprotection 
of the benzyl protecting group was achieved in reasonable yield, providing potential access 
to other N-substituted indolo[2,1-d][1,5]benzodiazocine-6-ones.  
Attempted metal-mediated cyclisations to form 8-membered ring fused indole 
derivatives were unsuccessful.  
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3 Indole seven membered ring heterocycles 
3.1 Introduction 
Among the indole fused seven membered ring heterocycles, the indolo[3,2-
d][1]benzazepinone (paullone) systems have been of interest as a novel class which 
possesses potent cyclin dependent kinase (CDK)134,135 and glycogen synthase kinase 3136 
inhibitory activity. CDK inhibitors are useful for treating diseases of cellular proliferation, 
abnormal protein phosphorylation and infectious diseases, such as cancer, atherosclerosis, 
Alzheimer’s disease, and malaria.137 Structure-CDK inhibitory activity relationships of 
paullone derivatives have been undertaken in order to discover the most potent analogues 
with antitumour activity. The most active paullone derivatives are kenpaullone and 
alsterpaullone (Figure 3-1). Alsterpaullone was reported138 to be in preclinical development 
as a potential anti-tumour agent; kenpaullone is in clinical trials.139  
 
 
 
Name Substitution 
IC50 
(µM) 
Name Substitution 
IC50 
(µM) 
Alsterpaullone 9-NO2 0.035 10-bromo-paullone 10-Br 1.3 
Kenpaullone 9-Br 0.4 11-chloro-paullone 11-Cl 1.4 
9-chloro-paullone 9-Cl 0.6 Paullone None 7.0 
Figure 3-1. General chemical structure and CDK1/cyclin B inhibition values for several paullones135,140 
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Previous approaches to the synthesis of the paullone system have been based on two 
strategies. The first strategy involves a preformed 7-membered ring and elaboration of the 
fused indole moiety by Fischer indolisation with phenylhydrazines. The second strategy 
relies on a 2,3-disubstituted indole precursor and completion of the 7-membered ring by N-
C bond formation. Examples of the first paullone synthesis strategy include the preparation 
of the benzazepinediones 205 in a three step synthesis followed by Fischer indolisation 
with phenylhydrazines. Kunick et al77 employed a  Fischer indolisation of the 1H-
[1]benzazepine-2,5(3H,4H)-diones 205 and phenylhydrazines in the synthesis of the 
substituted paullones 96. The annulated azepinones 205 were obtained by 
dealkoxycarbonylation of the fused azepinecarboxylic esters 207, which were prepared via 
a Dieckmann reaction with KH from diester 206.141  
N
H
NH
O
R
H
N
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O
R'
R '
NHNH2
R
205 96
HOAc, H2SO4
 
Scheme 3-1.  Synthesis of the paullone system using Fischer indolisation. 
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Scheme 3-2. The synthesis of  the key intermediate 1H -[1]benzazepine-2,5(3H,4H)-diones 205. 
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 A synthesis of the parent paullone 96 (R= R΄= H) has also been published by the 
Kozikowski group.142 This method involved the Fischer indolisation of the α-keto lactam 
205 giving the desired product in an  overall yield of 75%. The α-keto lactam 205 (R΄= H) 
was obtained by reaction of naphthoquinone 208 with sodium azide in sulphuric acid 
followed by catalytic hydrogenation.  
O
O
N
H
O
O
2 steps
N
H
NH
O
96
PhNHNH2
ZnC l2
205208
R
R'
R '
 
Scheme 3-3.  The synthesis of paullone described by Kozikowski et al.142 
  A similar method was described by Kunick et al.,143 and began with the reaction of 
7-methoxytetralone 209 with sodium azide and sulphuric acid in glacial acetic acid to give 
210, which was oxidised by KMnO4 to the methoxy benzodiazepinedione. Fischer indole 
synthesis with 4-bromophenylhydrazine then furnished the substituted paullone (Scheme 
3-4).  
O H
NMeO
O HN
O
O
N
H
NH
O
BrPhNHNH2
Br
OMe
MeO MeO
209 210
NaN3 KMnO4
H2SO4, AcOH
 
Scheme 3-4. The synthesis of paullone derivative described by Kunick et al.143 
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Examples of the second strategy involve the cyclisation of 2-arylindole precursors 
(Scheme 3-5). The key intermediate lactam 211 was obtained in eleven steps as an 
intermediate in a sequence directed towards the synthesis of iboga alkaloid selenium 
dehydrogenation products. Ring closure with HBr/AcOH initiated by cleavage of the tosyl 
group in the lactam precursor gave the paullone shown (Scheme 3-5).144 
N
H
HO2C
NH
Ts
N
H
NH
O
CH3
CH3
CH3
H3C
HBr/AcOH
211  
Scheme 3-5.  Synthesis of a paullone via cyclisation of a 2-arylindole using HBr/AcOH. 
 As described in Chapter 1, Baudoin et al.64 reported an alternative strategy using 
palladium-catalysed borylation/Suzuki coupling technology, under basic conditions, to 
obtain the intermediate 95. Direct base-catalysed hydrolysis of 95 with alcoholic sodium 
hydroxide gave paullone 96  (R= R΄= H) cleanly in 51% yield. 
N
H
NH
O
96
N
H
CN
H2N
NaOH (10 equiv)
MeOH/H2O (2/1)
reflux, 3.5 h
95
R
R'
 
Scheme 3-6. Synthesis of the paullone via borylation/Suzuki coupling strategy. 64 
There are thus the two general synthetic methods for preparing paullones, one 
involving penultimate lactam formation to complete the 7-membered ring and the other 
involving indole elaboration from a pre-formed benzazepinedione. There has been no 
previous work done on using C-C bond formation in the last step to complete the 7-
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membered ring. Intramolecular free radical cyclisation of an iodoacetamide was considered 
as a possible way to achieve this bond formation and the seven-membered ring fusion to the 
indole ring. This approach required the development of an efficient synthesis of the 
appropriate indole-fused iodoacetamide derivatives. 
3.2 Proposed synthetic approach to indole fused seven 
membered rings 
The synthetic approach to the desired indole fused seven-membered rings in the 
paullones involved intramolecular free radical cyclisation of a haloacetamide using the 
synthetic strategies described in Chapter 2 to afford the ring closure of the radical 
intermediate onto the indole ring. The proposed synthetic approach is shown in Scheme 
3-7. Thus, monoalkylation of the 2-aminophenylindole 212 was expected to result in the 
formation of the secondary amine 213, which could then be acylated to obtain the key 
precursor  N-substituted haloacetamides 214 for the free radical cyclisation step.    
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Scheme 3-7. Proposed new synthetic scheme to the paullones. 
3.3 Preparation of 2-(2΄-aminophenyl)indoles 212 
N
H
NH2
212a R= H
212b R=OMe
212c R= F
R
 
2-(2΄-Aminophenyl)indole 212a was commercially available and was obtained from 
Sigma-Aldrich Ltd. The other derivatives 212b-c can be prepared via many methods. Most 
of the literature on the syntheses of compounds of type 212 involve the formation of indole 
rings. For example, Cava used the Fischer indole cyclisation of phenylhydrazone and 
aminoacetophenone 215 to form 212a (Scheme 3-8) as an intermediate in the synthesis of 
the marine alkaloid hinckdetine A.145 
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212a
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CH3
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NHNH2
1. E tOH/HOAc
2. CH3SO3H/P2O5
215  
Scheme 3-8. Synthesis of  2-(2΄-aminophenyl)indole using Fischer idolisation 
 Indole ring formation via the intramolecular Wittig reaction of 2-
aminobenzyltriphenylphosphnium salts 216 and 2-nitrobenzoyl chlorides resulted in 2-(2΄-
nitrophenyl)indoles 217 which, after reduction with hydrogen and palladium on charcoal, 
resulted in the appropriately substituted 2-(2΄-aminophenyl)indoles (Scheme 3-9).146,147 
The preparation of 2-aryl substituted indoles can also be achieved by direct 
arylation of the pre-formed indole via lithiation at the C-2 position and then, after 
conversion to a stannane, a zinc or a boric acid derivative, can undergo palladium catalysed 
coupling with substituted benzene derivatives (Scheme 3-10).148,149 An example of this 
strategy includes the palladium(0)-catalysed coupling of 2-tributylstanyl-N-protected 
indoles with 2-halonitrobenzene to give the 2-(ortho-nitrophenyl)indole 217. Conversion of 
217 via reduction gave the desired 2-(2΄-aminophenyl)indole 212.150  
O
C lH2N
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Scheme 3-9. Preparation of 2-aryl substituted indoles via intramolecular Wittig reaction.  
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Pd(PPh3)4
I
O2N
R1
217 R1= NO2
212 R1= NH2H2, Pd/C  
Scheme 3-10.  Direct C-2 arylation reaction. 
In the current study, an alternative new approach to obtain substituted 2-(2΄-
aminophenyl)indoles from pre-formed indoles was developed through N-acylation of 5-
substituted-1H-indole, followed by palladium-induced cyclisation, hydrolysis of the urea 
and subsequent decarboxylation, as proposed in Scheme 3-11.   
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Scheme 3-11. General scheme for the preparation of 2-(2΄-aminophenyl)indoles  
3.3.1 Acylation of 1H-indoles with isocyanates 
As established by Papadopoulos and Bedrosian,151 acylation of indolylpotassium or 
indolylmagnesium bromide with phenyl isocyanate in THF gave only 1-
indolecarboxanilides 218 in 56% yield, with no acylation being observated at the C-3 
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position (from the charge delocalisation of the anion). Some adaptions were made to this 
reaction in the current work. 
N
K (MgBr+)
1. PhNCO
2. H3O+ N
N
H
O
218  
Scheme 3-12. Preparation of 1-indolecarboxanilides 218. 
The change of reaction conditions to a sodium salt in DMF is far more favourable 
for reaction on nitrogen as it promotes greater ionic character of the deprotonated indole. 
Therefore, treatment of 5-methoxy-1H-indole using sodium hydride provided the initial 
deprotonation of the indolic NH. Nucleophilic attack by phenyl isocyanate in DMF yielded 
only the 1-indolecarboxanilide 219 in 95% yield. 
N
H
2. PhNCO
1. NaH, DMF
N
N
H
O
MeO MeO
219  
 In the CIMS, the product 219 gave an ion for the expected MH+ species at m/z 
267.1124, consistent with the formula C16H15N2O2. The presence of extra aromatic protons 
was apparent from the 1H NMR spectrum. The signal ascribed to the urea NH was observed 
at 7.32 ppm. A signal attributable to the H-7 proton was observed further downfield than 
for the respective signal in the starting material at 8.02 ppm. This can be explained by the 
deshielding effect of the urea carbonyl oxygen. Evidence for the urea carbonyl carbon was 
observed in the 13C NMR spectrum with a signal resonating at 156.1 ppm.   
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Acylation of 1H-indoles using the same conditions with 2-bromophenyl isocyanate 
resulted in a drop in the yields of 220a-c to 43-56%. The lower yield may have been due to 
the bulk of the o-bromo substituent in the isocyanate hindering nucleophilic addition. The 
products were identified by their ascribed characteristic urea signals observed in both the 
1H-NMR and 13C NMR spectra as well as via LRMS and HRMS. 
N
H
2. 2-BrPhNCO
1. NaH, DMF
N
N
H
O
R R
220a    43%
220b    56%
220c    53%
Bra R= H 
b R= OMe
c R= F
 
The 1H NMR spectrum of 220a revealed four extra aromatic protons which were 
not present in the 1H NMR of the starting material as well as a broad signal ascribed to the 
urea NH resonating at 8.00 ppm. A downfield shift of the doublet signal at 8.25 ppm 
representative of the H-7 proton indicated that acylation had occurred at the indole 
nitrogen. The corresponding urea carbonyl carbon was also observed in the 13C NMR 
spectrum at 148.9 ppm. This data suggested successful acylation of the NH indole had 
occurred and there was further confirmation of this from the HRCI-MS, which showed a 
peak for the MH+ ion at m/z 315.0091, consistent with the formula C15H12N2O79Br.  
The 1H NMR and 13C NMR spectra of 220b and 220c also showed the characteristic 
signals for the urea groups similar to that of 220a. The structures were also confirmed by 
HRCI-MS with MH+ ions at m/z 347.0204 and 335.0006 which correlate with the 
molecular weights and molecular formulae of the desired products 220b and 220c, 
respectively.  
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3.3.2 N-alkylation reactions of ureas 
The urea 219 was alkylated to its N-methyl derivative using the method described in 
Thal et al.120 Reaction of 219 with potassium hydroxide and methyl iodide in DMSO gave 
the methylated product 221 in 43% yield. This reaction was optimised by using sodium 
hydride in THF for deprotonation of the urea, which improved the yield of 221 to 76%. The 
improved yield might be due to the need for a stronger base to deprotonate the urea NH. 
Moreover, potassium hydroxide is generally known to hydrolyse ureas.  
N
N
H
O
MeO
N
NO
MeO
Base
MeI
Me219 221  
Scheme 3-13. General synthetic route for alkylation of urea. 
Alkylations of 220a-c using sodium hydride in THF with methyl iodide or benzyl 
bromide yielded the urea derivatives 222 and 223. The resulting yields are shown in Table 
3-1.    
N
N
H
O
R
220
Br
N
NO
R
222 R1= Me
223 R1= Bn
Br
NaH, THF
R1X
R1
R= H, OMe, F
 
The 1H NMR spectra of 221 and 222 revealed the absence of the amide NH proton 
and contained a singlet signal in the range of 3.40-350 ppm, which was indicative of the 
methyl protons. The 13C NMR spectra showed a resonance at about 39.0 ppm ascribed to 
the methyl carbon, while the 1H NMR spectrum of 223 showed two broad singlets in the 
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range of 4.60-5.40 ppm, representative of the benzylic protons and the five extra aromatic 
protons which were not present in the starting material. The broadening phenomenon of the 
benzylic protons may be explained by steric hindrance of rotation about the benzyl group 
and the o-bromophenyl urea moiety. The 13C NMR spectra showed a resonance in the 
region of 54.0 ppm ascribed to the benzylic carbons.  
Table 3-1.  N-alkylation of ureas 220a-c 
Yield (%) 
220 
222 223 
        a (R= H) 76 62 
b (R= OMe) 88 81 
        c (R= F) 70 91 
 
3.3.3 Palladium cyclisation of ureas 
An initial attempt using palladium-induced oxidative cyclisation of 219 followed 
the method described by Itahara.152 The method involved carbopalladation using Pd (II) 
species in glacial acetic acid at reflux for 8 hours. However work up and purification of the 
reaction did not result in the desired cyclised product 224 (R= OMe) (Scheme 3-14).    
N
NO
MeO
R1
N
NO
MeO
R1
Pd(OAc)2
224 R1= H
225b R1= Me
219 R1= H
221 R1= Me
1
12
9
 
Scheme 3-14. General precedure for oxidative palladium coupling cyclisation 
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The cyclisation reaction was re-attempted using the N-methyl derivative of 219, 
compound 221. After reaction under the same conditions as previously mentioned, 
analytical TLC showed only starting material. The reaction was continued at reflux for a 
further 2 days and after this time TLC analysis showed a new band at almost the same Rf as 
the starting material. The crude product was purified by flash column chromatography 
yielding the cyclised product 225b in 20% yield as a white solid together with the starting 
material (9%) (Scheme 3-14). Evidence for the cyclised product was apparent from NMR 
spectroscopy and mass spectral analysis. The 1H NMR spectrum of 225b showed the 
presence of a singlet signal integrating for one proton at 6.99 ppm indicative of H-12. This 
signal appreared as a doublet in the starting material 221. The DEPT spectrum comfirmed 
the loss of the C-2 and C-2΄ (or C-6΄) methine carbons. The apprearance of two more 
signals assigned to quaternary carbons in the 13C NMR spectrum was consistent with 
oxidation cyclisation to the desired indolic C-2 position. The HRCI-MS displayed a peak at 
m/z 279.1122 (MH+), consistent with the molecular formula C17H15N2O2 of the desired 
cyclised product.    
The low yield of the cyclised product was probably due to an unfavourable 
conformation of the urea group for cyclisation. Thus an optimisation was attempted using 
propanoic acid as a higher temperature solvent to induce the molecule into the required 
conformation. However, mainly starting material (33%) was obtained in this reaction. 
Although two new bands at higher Rf values than that of the starting material 221 were 
observed, the separation using PTLC with multiple development failed to give any 
products. The unsucessful cyclisation using propanoic acid compared to acetic acid may be 
because propanoic acid might not be as good a solvent as acetic acid to protonate the 
acetate ligand. This protonation makes the Pd(II) species more electrophilic thus increasing 
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the rate of electrophilic palladation of the indole ring.153 As this reaction was time 
consuming and low yielding, a change to another palladium catalysed cyclisation based on 
the Heck reaction120 was attempted in the current work.   
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Scheme 3-15.  Cyclisation via a Heck coupling reaction. 
The initial cyclisation using a Heck coupling reaction was attempted with 220a.  
Reaction with a catalytic amount of Pd(OAc)2 with triphenylphosphine as a ligand and 
potassium carbonate as a base in DMF under refluxing conditions showed none of the 
starting material present after heating at reflux for 3 hours; the crude reaction mixture 
showed no trace of the expected cyclised product 224a on the basis of CI-MS analysis.   
Using the same conditions as noted above, the N-alkylated ureas 222 and 223 were 
then reacted. After work up of these reactions, analytical TLC clearly showed only one 
band in each reaction which had a very similar Rf to that of the starting material. 
Observation of these bands under a UV lamp did not indicate any difference, however, after 
staining the TLC plate with I2 vapour, a colour difference between the starting materials 
and the corresponding products was observed. The results are shown in Table 3-2. NMR 
spectroscopy and mass spectrometric analysis were used to identify these compounds. The 
absence of the bromine atom and the indolic H-2 proton of the starting material were noted 
as well as a singlet signal ascribed to the H-12 proton, which in the gHMBC spectrum 
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showed a correlation to the carbonyl carbon. The HREI-MS of each product also confirmed 
the loss of the bromine atom and gave molecular formulae consistent with the 
corresponding cyclised products.    
Thus, the Heck coupling reactions gave clean cyclisation products from the N-(2-
bromophenyl)-N-alkyl-1-carboxamides in good yields.  
Table 3-2. The Heck coupling reaction of N-(2-bromophenyl)-N-alkyl-1-carboxamides 
Product (%)  Product (%) Starting material 
           222 225 
Starting material 
223 226 
a (R= H) 87 
 
a (R= H) 66 
b (R= OMe) 55  b (R= OMe) 88 
c (R= F) 76  c (R= F) 69 
 
3.4 Preparation of chloroacetamides 
Preparation of the chloroacetamides from the cyclised products required a two step 
synthesis; firstly a hydrolytic ring opening to give the 2-(2΄-aminophenyl)indole derivative 
227 was necessary followed by acetylation with chloroacetyl chloride to afford the desired 
chloroacetamide intermediates 228 and 229 (Scheme 3-16). 
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Scheme 3-16. General scheme for preparation of the chloroacetamides. 
3.4.1 Hydrolytic ring opening of the cyclised products 
Hydrolysis of ureas and subsequent decarboxylation can be achieved with hot 
concentrated sodium hydroxide solutions.154 Thus urea 225a was heated under reflux with 
25% NaOH in EtOH for 24 hours to afford the ring opened product N-methyl-2-(2΄-
aminophenyl)indole 227 (R= H, R1= Me) in quantitative yield (Scheme 3-16). The EI-MS 
of 227 (R= H, R1= Me) gave an ion at m/z 222, consistent with the loss of a carbonyl group 
from the starting material. The 1H NMR spectrum of 227 (R= H, R1= Me) showed the 
presence of two broadened singlets which were ascribed to the indole NH proton and the 
amine NH proton at 8.30 ppm and 5.10 ppm, respectively. This indicated cleavage of the 
two CO-N bonds in the urea had occurred. However, 227 changed colour from yellow to 
blue after coming in contact with air, and thus is was chloroacetylated directly. 
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3.4.2 Chloroacetylation  
Due to the instability of N-methyl-2-(2΄-aminophenyl)indole 227 (R= H, R1= Me), 
acylation without further purification was conducted using chloroacetyl chloride and 
K2CO3 in THF to give the chloroacetamide 228a in 70% yield.  
Formation of chloroacetamide 228a was confirmed by the presence of signals at 
3.81 ppm and 3.87 ppm in the 1H NMR spectrum and by the apprearance in the 13C NMR 
spectrum of a signal at 41.9 ppm supportive of the acetamide functionality. The absence of 
a signal corresponding to the amine NH proton (at 5.10 ppm) indicated acylation had 
sucessfully occurred at this amine nitrogen. The HRCI-MS of 228a displayed a peak at m/z 
299.0945 (MH+), consistent with the molecular formula C17H16N2O2Cl.     
Analytical TLC of the reaction mixture during hydrolytic ring opening of the ureas 
225b and 225c using the aforementioned method showed no starting material 225c 
remained after 24 hours. However, about 50% of the starting material remained in the 
hydrolysis of 225b after the same time. The reaction was continued for a further 48 hours, 
however, the reaction mixture still showed a small amount of starting material 225b 
remaining (determination by TLC analysis) and a new compound which had a similar Rf 
but a different colour when stained with I2 vapour compared to that from 225b. Extended 
reaction at reflux for longer than 48 hours resulted in the break down of both starting 
material and product. The harsh reaction conditions needed for the hydrolysis of the 5-
methoxy urea derivative 225b may be due to the electron donating properties of the 
methoxy group affecting the susceptibility of the urea carbonyl group to nucleophilic attack 
by the hydroxide ion. The fluoro derivative 225c with the electron withdrawing fluoro 
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group would make the carbonyl group more susceptible to such attack, and hence this 
reaction proceeded more rapidly.  
Chloroacetylation of the crude products from both reactions with chloroacetyl 
chloride gave 228b and 228c in 64% and 79% yield, respectively after purification. The 
HR-MS of 228b and 228c were supportive of the molecular formulae which would be 
expected for the required chloroacetamide products. The 1H NMR and 13C NMR spectra of 
both compounds showed the characteristic signals for the haloamide groups.  
    Similar results were obtained when the ureas 226a-c were hydrolysed with 
sodium hydroxide. After 24 hours, no urea starting materials were observed in the reactions 
of 226a and 226c which were then worked up, but reaction of 226b was allowed to 
continue at reflux for a further 24 hours. Acylation of 227a, 227b and 227c with 
chloroacetyl chloride afforded chloroacetamides 229a, 229b and 229c in 79%, 71% and 
82% yield, respectively. The structures were identified by NMR spectroscopy and mass 
spectrometric analysis. In the 1H NMR spectra of 229a-c, the methylene protons of the 
chloroacetyl groups were ascribed to two doublet signals at 3.70-3.77 ppm and 3.82-3.88 
ppm. The indolic NH protons were observed at 7.86 ppm for 229a, 8.17 ppm for 229b and 
7.77 ppm for 229c. The chloroacetyl groups were evident in the 13C NMR spectra by 
signals for the methylene carbons at 42.4 ppm for 229a, 42.3 ppm for 229b and 42.5 ppm 
for 229c. The HREI-MS of all compounds were matched with the required molecular 
formulae of these products.  
Acylation of 227a with trichloroacetyl chloride yielded the desired 
trichloroacetamide in 21% yield and the urea 226a in 17% yield. The low yield of the 
trichloroacetamide 230 was probably be due to the moisture sensitivity of  trichloroacetyl 
chloride and the bulk of the trichloromethyl group which would hinder acylation. 
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Moreover, the trichloroacetyl group is a good leaving group, therefore, nucleophilic attack 
by the indolic nitrogen on the carbonyl carbon could result in cyclisation back to the urea 
starting material 226a (Scheme 3-17).  
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Scheme 3-17. Mechanism for the ring cyclisation of 230.  
   In the 1H NMR spectrum of 230, the benzylic protons were ascribed to two broad 
signals at 3.95 ppm and 5.70 ppm. This is due to a slow interconversion of the bulky 
trichloroacetamide rotamers. The absence of the amine NH proton also verified the addition 
of the trichloroacetyl group to the 2-(N-benzylaminophenyl)-1H-indole. In the 13C NMR 
spectrum of 230, a signal assigned to the CCl3 carbon was observed at 103.0 ppm and a 
signal assigned to the carbonyl carbon was observed at 160.9 ppm. The HREI-MS gave a 
molecular ion at m/z 442.0405 consistent with the molecular formula C23H17N2O35Cl3.      
A separate reaction for prepration of the chloroacetamide 229a was attempted by 
chloroacetylation of 227a, which was prepared in turn in 45% yield by the direct 
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benzylation of commercially available 2-(2΄-aminopheyl)-1H-indole 212a (Scheme 3-18). 
The chloroacetamide 229a was obtained in 79% yield after purification.   
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Scheme 3-18. Preparation of chloroacetamide 229a from the amine 212a.  
The HRCI-MS of 229a gave a peak at m/z 375.1267 (MH+) consistent with the 
molecular formula C23H20N2O35Cl  and corresponding to the addition of a chloroacetyl 
group to the starting material. The chloroacetyl methylene protons were obvious in the 1H 
NMR spectrum of the product, by two doublet signals at 3.74 ppm and 3.87 ppm with a 
coupling constant of 13.2 Hz. In the 13C NMR spectrum signals at 42.4 ppm and the 
carbonyl carbon at 166.8 ppm were ascribed to the methylene carbon and carbonyl group 
respectively of the chloroacetamide functionality.  
Even though this reaction was a shorter route to the chloroacetamide, a large 
amount of 2-(2΄-aminophenyl)-1H-indole 212a remained in the initial reaction mixture due 
to the need to ensure monoalkylation predominated. Also it should be noted that only 212a 
is commercially available, and a range of substituted 2-(2΄-aminophenyl)-1H-indoles were 
required in this study.  
 
3.4.3 Preparation of iodoacetamides 
As discussed previously in Chapter 2, iodine is a better group than chlorine and a 
better group for the free radical cyclisation of haloacetamides. In this research, we were 
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interested in the construction of various N-substituted paullone derivatives, therefore, the 
N-benzylchloroacetamides 229a-c were converted to the N-benzyliodoacetamides 231a-c. 
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Scheme 3-19. General procedure for the preparation of iodoacetamides. 
Synthesis of the N-benzyliodoacetamide 231a by stirring with NaI in CH3CN at room 
temperature94 for 12 hours gave the desired product in 92% yield. The reaction was quite 
clean and the product was purified by passing through a short silica column. The HRCI-MS 
of 231a gave a peak at m/z 467.0612 (MH+) consistent with the molecular formula 
C23H20N2OI. The 1H NMR spectrum of 231a showed the presence of two doublet signals at 
3.49 ppm and 3.59 ppm ascribed to the methylene protons, which moved upfield relative to 
those in the starting material. In the DEPT spectrum, a new signal was observed at -1.9 
ppm87 which was assigned to the iodoacetyl methylene carbon. The signal ascribed to the 
methylene carbon moved dramatically upfield from those in the starting chloroacetamide 
(42.4 ppm) indicating that the iodide exchange was successful.  
The reaction of both iodoacetamide 231b and 231c were conducted using the same 
methodology as that for 231a and resulted in clean reactions with only the desried 
iodoacetamide products being obtained. The products were identified by their characteristic 
signals ascribed to the methylene group in both the 1H NMR and 13C NMR spectra.  
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3.5 Radical cyclisations 
As part of our interest in the formation of indole fused seven membered ring systems, 
the iodocetamides 231a-c were treated with Bu3SnH and AIBN to undergo free radical 
cyclisation, leading to the paullone derivatives 96 (Scheme 3-20). The results are shown in 
Table 3-3. 
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Scheme 3-20. Radical cyclisation of iodoacetamides 231a-c. 
Table 3-3. Radical cyclisation of 231a with Bu3SnH, AIBN in boiling solvents. 
Yield (%) 
Entry mmol Solvent 
96a 232a 
1 0.13 Toluene 25 - 
2 0.15 Toluene 8 13 
3 0.36 Toluene - 10 
4 0.13 Mesitylene 52 - 
 
The initial reaction of 231a with Bu3SnH and AIBN in boiling toluene afforded the 
indole fused seven-membered ring compounds 96a in 25% yield and some other 
unidentified compounds. The HRCI-MS of 96a gave a peak at m/z 339.1498 (MH+) 
consistent with the molecular formula C23H19N2O which indicated the loss of a hydrogen 
 100
and iodine atom from the starting material. The 1H NMR spectrum of 96a indicated the loss 
of the indolic H-3 proton and the presence of two doublet signals ascribed to the methylene 
protons (H-7) at 3.37 ppm and 3.73 ppm. The gHSQC spectrum confirmed the methylene 
signal for C-7 at 35.5 ppm. In the gHMBC spectrum, H-7 gave cross peaks with the indole 
carbons, which confirmed the cyclisation onto the indole ring.  
In an attempt to optimise the yield of 96a, the reaction was repeated using the same 
conditions, but using de-gassed toluene as a solvent. The yield of 96a was reduced from 
25% to 8%, however, and a new spiro compound 232a was obtained in 13% yield. The 
structure of the spiro compound 232a was comfirmed by NMR spectroscopy and mass 
spectroscopic analysis. In the 1H NMR spectrum, two doublet signals were observed at 2.89 
ppm and 3.09 ppm which were ascribed to the methylene protons (H-7). In addition, 
another group of signals, apart from those for the benzylic protons, were observed as two 
doublets at 3.03 ppm and 3.31 ppm and were ascribed to the methylene protons (H-13) on 
the indoline ring system. A broad singlet at 3.95 ppm, which was ascribed to the NH 
proton, indicated that the aromaticity of the pyrrole ring component in the indole had been 
destroyed. The DEPT, gHSQC and gHMBC experiments enabled the 13C NMR spectrum 
assignment. The DEPT spectrum of 232a indicated the presence of methylene carbons 
ascribed to C-3 and C-3΄ at 42.4 ppm and 46.3 ppm, respectively. The position of H-3 was 
confirmed from the gHMBC spectrum. The methylene H-3 protons have a cross peak with 
the carbonyl carbon while the H-3΄ protons did not have a cross peak with the carbonyl 
carbon.    
Possible mechanisms for the formation of the spiro compound 232a and the 
paullone 96a are outlined in Scheme 3-21. The carbon-centred radical intermediate (A) 
from the iodoacetamide and Bu3Sn˙ could undergo cyclisation via two different pathways.  
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Scheme 3-21. Proposed mechanism for the formation of the paullone 96a and the spiro compound 232a 
Addition of the carbon-centred radical at the indolic C-3 position via pathway a, a 
7-endo-trig process, would give the seven membered ring fusion and a new carbon centred 
radical intermediate (B) at C-2. Alternatively, radical cyclisation at the indolic C-2 position 
(pathway b), a favoured 5-exo-trig process, would give the six membered ring spiro radical 
intermediate (C). Rearrangement of the radical could also afford the fused radical species 
(B); migration of the acyl alkyl group rather than the aryl group might be expected in this 
rearrangement process as a result of benzylic stabilisation of the incipient tertiary radical. It 
should be noted however that at ordinary temperatures alkyl groups do not normally 
undergo 1,2-free radical rearrangements. However, in this case a relatively higher 
temperature is involved (mesitylene; b.p. 163-165 °C), and the alkyl-acyl moiety may also 
tautomerise to an enol which then rearranges; 1,2-migration of vinylic groups is known to 
occur readily in acyclic systems.155 
The fact that no 232a was observed when the reaction was conducted at a higher 
temperature in boiling mesitylene is consistent with a significant activation energy barrier 
for this rearrangement. At lower temperatures (boiling toluene), hydrogen abstraction by 
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(C) from Bu3SnH to afford the spiro compound 232a could be competitive with the 
rearrangement. The lack of formation of any spiro compound 232a from the first reaction 
attempted in toluene is difficult to explain. The possible reason for the observation of 232a 
in de-gassed toluene (Table 3-3, entry 2) may be that the hydrogen abstraction step from 
(C) does not have to compete with the reaction of (C) with oxygen, and also more (C) 
would be produced as any reaction of (A) with oxygen would be minimised. 
  In an attempt to increase the yield of 96a and 232a, and in order to investigate the 
effect of temperature on the rearrangement of the spiro compound to the paullone 
derivative, a larger scale reaction of 231a was attempted in boiling toluene. However, only 
a 10% yield of the spiro compound 232a was obtained together with a number of 
unidentified products; the cyclised seven membered ring product 96a was not observed in 
the 1H NMR of the mixture. The decrease in yield of the cyclised product was probably due 
to a competing reaction with oxygen in this case. 
 The spiro compound 232a is representative of a new heterocyclic ring system. A 
related 5-exo-trig spirocyclisation of a carbon centred radical onto the C-2 position of 
indole, resulting in dearomatization after hydrogen abstraction, has been reported 
recently.156  
The cyclisation reactions of iodoacetamides 231b and 231c with Bu3SnH and AIBN 
in boiling mesitylene were then investigated. Using the same conditions as for 231a, the 
reaction of 231c gave a fair yield of the paullone derivative 96c (45%). The reaction of 
231b gave a low yield the paullone derivative 96b (25%), but cyclisation onto the indole 
nitrogen was also observed in this case with the indolo[1,2-d][1,4]benzodiazepin-6-one, 
compound 233 being obtained in 30% yield (Scheme 3-22).  
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Scheme 3-22. Intramolecular cyclisation of iodoacetamide 231b 
The structures of products 96b and 96c were elucidated on the basis of the signals 
characteristic of the two methylene groups in each case, and the absence of signals which 
could be ascribed to an indolic 3-CH group in both the 1H NMR and 13C NMR spectra. The 
HREI-MS of 233 gave a peak at m/z 368.1529 (M+), consistent with the molecular formula 
of 96b. In the 1H NMR spectrum of 233, two doublet signals ascribed to the methylene 
group in the 7-membered ring appeared at 5.01 ppm and 5.10 ppm, significantly downfield 
compared with the corresponding methylene group signals at about 3.30-3.90 ppm in 96b. 
The absence of a broad signal which could be ascribed to the indole NH proton indicated 
that the downfield shift of the signals ascribed to the methylene protons was due to the 
formation of a new C-N bond to the indolic introgen.  
The indolo-benzodiazepines of type 223 have been reported previously157 via the 
reaction of the corresponding chloroacetamides and sodium hydride. However, in the work 
in this thesis, no base was necessary probably due to the electron donating properties of the 
methoxy substituent. 
 In an effort to access more highly functionalised paullone derivatives, cyclisation of 
the trichloroacetamide 230 was also investigated using the same conditions as for 231a by 
treatment with Bu3SnH and AIBN in mesitylene at reflux for 16 hours. However, EI-MS 
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analysis of the crude reaction product showed no trace of a signal at m/z 406 which would 
be expected for the cyclised product  234.  
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Scheme 3-23. Radical cyclisation of the trichloroacetamide 230. 
Purification of the reaction products by column chromatography gave two major 
fractions. The first fraction was obtained in 11% yield and the HRCI-MS spectrum gave a 
peak at m/z 329.1643 (MH+). The second fraction was also obtained in 11% yield and the 
EI-MS spectrum gave a peak at m/z 324 (M+), which was consistent with the loss of the 
CCl3 group from the starting material. The 1H NMR spectrum indicated this latter product 
was 226a. 
 A tentative structure of 235 was assigned to the other product from the reaction as 
shown in Scheme 3-23. Since only a small amount of coumpound 235 was obtained, the 
tentative structure of 235 was assigned based on only HRCI-MS and nanoprobe NMR 
spectroscopy. The HRCI-MS indicated the formula C22H21N2O and the structure was 
determined by NMR spectroscopic experiments. In the 1H NMR (CD3CN) spectrum of 235, 
two doublet signals, apart from those for the benzylic protons, were observed at 3.60 ppm 
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and 3.93 ppm and were ascribed to the methylene protons (H-2). Broad signals at 4.18 ppm 
and 5.01 ppm were ascribed to the OH and NH groups, respectively. The upfield shift of 
the NH proton indicated the loss of the aromaticity of the pyrrole ring component in the 
indole. A singlet signal ascribed to the methine proton in the 3΄-position appeared at 6.48 
ppm, significantly downfield from the corresponding indoline proton singals at about 3.0-
4.0 ppm. The gCOSY, gHSQC, gHMBC experiments enabled the 13C NMR spectrum 
assignments. There was no carbonyl signal observed in the 13C NMR. The gHSQC 
spectrum of 235 indicated the presence of the methylene protons ascribed to C-2 at 33.0 
ppm, while the methine proton was connected to a carbon signal at 71.6 ppm. A signal at 
65.9 ppm, which had no cross peaks with any protons, was assigned as the quaternary 
carbon at C-2΄ from the gHMBC long range carbon coupling experiment. Mechanistically it 
is not clear however how 235 may be formed and the structure remains a tentative one. 
 
3.6 Debenzylation 
In order to access the paullone system itself in which the lactam moiety is not N-
substituted, the feasibility of chemoselective N-debenzylation with sodium in liquid 
ammonia was investigated. The debenzylation reaction was performed by the general 
method described in Lizos et al.118 Paullone derivative 96a was treated with metallic 
sodium in liquid ammonia for 10 minutes to afford the known77 paullone 96 in 40% yield. 
There were no signals observed for the benzylic protons in the 1H NMR spectrum of 96, 
while the other signals observed were consistent with the debenzylated structure and were 
identical to those reported by Kunick.77 
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3.7 Summary and Conclusions 
It has been shown that free radical cyclisation of indolyl iodoacetamide derivatives 
is a viable new approach to the pharmacologically significant paullone ring system. New 
palladium-mediated methodology for the construction of 2-(2΄-aminoaryl)indoles has also 
been developed as part of this work. Both this methodology and free radical cyclisation 
have the potential for synthesis of a variety of new paullone analogues and derivatives. 
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4 Synthetic approach to the marine natural 
product iheyamine A 
4.1 Introduction 
Marine natural products have emerged over the past 25 years as one of the richest 
sources of bioactive secondary metabolites.4 In 2002, 677 new compounds were isolated 
and characterised from marine sources, together with their relevant bioactivities including 
indications of possible utility as anticancer, antibacterial, or cardio-vascular agents.158 A 
significant number of marine natural products are currently in preclinical and clinical trials, 
and many of these are anti-cancer agents.159 Such compounds that are in drug development 
programs included bryostatin 1 (236), a macrocyclic metabolite isolated from a Japanese 
bryozoan, Bugula neritina.160 Bryostatin 1 inhibits protein kinase C and has been developed 
to treat melanoma, non-Hodgkins lymphoma, and renal cancer and is currently in phase 2 
clinical trails.159 Ecteinascidin 743 (237) is an isoquinoline derivative from the ascidian 
Ecteinascidia turbinate161,162 and is undergoing human clinical trials as an antitumour 
agent; it is predicted to be approved as a novel drug soon.163  
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As many marine organisms are soft bodied, they have evolved the ability to 
synthesise toxic compounds in order to protect themselves from predators or to paralyse 
their prey. Such biologically active compounds might be useful for humans for the 
treatment of many human diseases, although, many marine organisms have so far only been 
explored to a very limited extent.163,164 Therefore, a continued search of marine organisms 
for their biological diversity is expected to give rise to potential drugs with greater potency 
and efficiency.     
Recently, the isolation of novel compounds from the ascidian, Polycitorella sp. 
(Figure 4-1), collected from the island of Iheya, Okinawa, Japan, has been reported.20 These 
compounds were iheyamine A (21) and B (22), which have a new polycyclic 
heteroaromatic system containing a bis-indole fused azepine system. Both compounds 
exhibited moderate cytotoxic activity against P388, A549 and HT29 cell lines.20  
 
Figure 4-1. A colonial ascidian, Polycitorella sp. (purple) 
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The yields of these iheyamines obtained from the ascidian were low, and in order to 
provide enough material to perform further biological studies, a synthetic route to the 
iheyamines was considered. In particular, this study focussed on approaches to iheyamine 
A and a demethoxylated analogue.  
  
4.2 Proposed synthetic routes 
Two methods for the synthesis of iheyamine A were proposed. The first approach 
involved an intramolecular free radical cyclisation of the key haloacetamide intermediate 
239 to form the bis-indole fused seven-membered ring 240 (Scheme 4-1). The key 
intermediate 239 could be prepared by a palladium catalysed cross coupling reaction of a 2-
iodoindole and indole. The resulting bis-indole 238 could then undergo chloroacetylation to 
give the haloacetamide 239. Partial amide reduction followed by oxidation might then be 
expected to provide access to iheyamine A.  
 110
N
H
I NH HN NH HN
HN
C lO
N
H
HN
H
N
O
N
H
N
N
1. amide
    reduction
acylation
free radical
cyclisation
NH2
2. PdC l2(PPh3)2
NH2
1. indole
Iheyamine A
238 239
240
MeO
MeO MeO
MeO
MeO
2. oxidation
 
Scheme 4-1. Proposed synthetic route to iheyamine A via radical cyclisation. 
The second approach proposed involved the acid-catalysed rearrangement (together with 
elimination) of the spiro intermediate 241 to afford the required fused seven-membered 
ring system 242a or 242b (Scheme 4-2). The spiro intermediate 241 could be prepared by 
the condensation of the appropiate isatin and tryptamine, possibly mimicking part of the 
iheyamine biosynthetic pathway. Rearrangement of 241 might be expected to give 
compound 242a, which could then undergo oxidation and deprotection to give the desired 
iheyamine A or its demethoxylated analogue. Partial amide reduction of 241 followed by 
rearrangement might also be expected to provide iheyamine A or its demethoxylated 
derivative.  
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Scheme 4-2. Proposed synthetic route to iheyamine A via spiro rearrangement. 
The second approach seemed to be the most feasible method in terms of the 
availability of starting materials and the direct and straightforward nature of the route. 
Therefore, the approach to the synthesis of iheyamine A concentrated on this second 
approach.  
 
4.3 Synthesis of N-substituted isatins 
Many methods have been devised for the N-alkylation of isatins. These derivatives 
are commonly synthesised from the reaction of the sodium or potassium salt of the isatin 
with alkyl halides or sulfates.165 Various methods for the preparation of this salt have been 
reported, and these include the reaction of isatin with sodium hydride in DMF166 or the use 
of potassium carbonate in either DMF (with microwave irradiation)132 or in acetone.167 In 
the latter case, an aldol reaction of the solvent also occurs with a carbonyl group of the 
isatin derivative. 
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In the preparation of 1-methylisatin, literature167,168 reports suggested that only 
moderate yields were obtained. However, 1-methylisatin can be obtained commercially 
from Sigma-Aldrich Ltd. at a reasonable price.   
 In the research described in this thesis, the 5-methoxyisatins were reacted with 
alkyl halides in the presence of anhydrous K2CO3 in DMF at reflux for 10 hours and the N-
alkylated products were obtained in moderate to high yields (Scheme 4-3).  
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Scheme 4-3. Reaction of isatins with alkyl halides. 
  The reaction of 5-methoxyisatin and methyl iodide in the presence of anhydrous 
K2CO3 afforded the desired N-methylated product 243a in 67% yield. In a similar manner, 
the alkyaltion of 5-methoxyisatin with allyl bromide afforded 1-allyl-5-methoxyisatin 243b 
in high yield (99%). The N-allyl group was introduced as a potential alternative nitrogen 
protecting group in the synthesis. Evidence for the successful N-alkylation in each case  
was obtained from NMR spectroscopy and mass spectrometric analysis of the products. 
The 1H NMR spectrum of 243a revealed the absence of a broad signal expected for the 
isatin NH and the presence of a signal resonating at 3.21 ppm ascribed to the N-methyl 
protons. The corresponding methyl carbon signal was also observed in the 13C NMR 
spectrum at 26.5 ppm. This data suggested that successful methylation of the isatin NH had 
occurred and there was further confirmation from HREI-MS, which showed a molecular 
ion at m/z 191.0583, consistent with the formula C10H9NO3 which correlated with the 
desired product.  
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 Similarly in the 1H NMR spectrum of 243b no signal for the indolic NH proton was 
present, but a doublet signal at 4.34 ppm, two doublet signals at 5.29 (J= 11.5 Hz) and 5.32 
(J= 11.0 Hz) ppm and a multiplet at 5.84 ppm were indicative of the presence of the allylic 
group. The 13C NMR spectrum also showed resonances at 42.7 and 112.2 ppm ascribed to 
the methylene carbons and a resonance at 130.8 ppm ascribed to a methine carbon 
consistent with this group. The structure of 243b was also confirmed by the HREI-MS. The 
mass spectrum gave a molecular ion at m/z 217.0739, which was consistent with the 
molecular formula C12H11NO3 of the N-allylated product.      
 
4.4 Synthesis of spiro compounds 
Isatin and its derivatives can undergo nucleophilic attack at the C-2 and/or C-3 
position. The chemoselectivity of these reactions depends on the nature of the nucleophiles, 
on the nature of the substituents attached to the isatin nucleus and especially on those 
bonded to the nitrogen atom, as well the solvent and temperature employed.169 Nucleophilic 
substitution at the C-3 position may be followed by a spiro-annelation process at position 
C-3 if a second nucleophilic group is present to give a spiro compound.170,171 This process 
may also involve the addition of a separate nucleophile followed by cyclisation with 
elimination. As an illustration of this spiro ring approach, condensation of isatin with 
aromatic amines in toluene afforded the intermediate isatin-3-anils 244, which cyclised in 
situ with acetyl chloride in the presence of base to give (Scheme 4-4) the fungicidal 1΄-
phenylspiro[indole-3,4΄-azetidine]-2-(3H),2΄-diones 245.172 
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Scheme 4-4. Formation of the 1΄-phenylspiro[indole-3,4΄-azetidine]-2-(3H),2΄-diones 245. 
A similar approach (Scheme 4-5) was also used to synthesise the spiro[indoline-3,2΄-
[1,3]thiazinane]-2,4΄-diones 246.173  
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Scheme 4-5. Synthesis of the spiro[indoline-3,2΄-[1,3]thiazinane]-2,4΄-diones 246. 
 The construction of the spiro ring system may also involve the second nucleophilic 
group from the same molecule. Examples of this approach include the formation of the 
spiro compounds 247,174 which were obtained as the sole products and none of the 2,3-
condensation products or ring opening products were observed (Scheme 4-6), as well as the 
cyclisation of the Schiff base from 2-(3,4-dimethoxyphenyl)-ethylamine to afford the spiro 
compound 248175 (Scheme 4-7).  
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Scheme 4-6. A spiro-annelation formation. 
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Scheme 4-7. Reaction between isatin and 2-(3,4-dimethoxyphenyl)-ethylamine. 
The condensation of tryptophan derivatives with isatin has also been reported to 
form the spiro compounds 249 (Scheme 4-18).176,177 Spiro compounds of type 249 are 
similar to the ones required for the proposed rearrangement reaction in the current study. 
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Scheme 4-8. Condensation of isatin with functionalised tryptophan derivatives. 
Thus, the condensation of isatins and 1-alkylisatins with tryptamine in ethanol with 
glacial acetic acid as catalyst gave the corresponding imine derivatives which underwent 
further internal nucleophilic attack at C-3 to afford the spiro derivatives 250 (Scheme 4-9). 
A high yield (89%) was obtained when using N-unsubstituted isatin but when using N-
methylisatins, the yields were reduced to around 55% (Table 4-1). The electron releasing 
methyl group may possibly help to stabilise the vinylogous amide-type resonance 
contributing structure involving the C-3 carbonyl group, thus making it less susceptible to 
nucleophilic attack.  
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Scheme 4-9. Mechanism for the syntheses of spiro derivatives. 
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Table 4-1. Spiro product yields from reactions of various isatins with tryptamine.  
Compound number    R              R΄  Yield (%) 
250a H H 89 
250b H CH3 54 
250c OMe CH3 56 
  
 The spiro products 250 were identified by their characteristic NMR signals and 
mass spectra, and by comparison of their spectra with those of the 3΄-methoxycarbonyl 
analogue (compound 249, R= Me, R΄= H) which was described by Levy et al.176 and Bizot-
Espiard et al.177  
In the 1H NMR spectra of 250a-c, the absence of any signal which could be 
attributed to an indolic H-2 proton was confirmatory evidence for spiro cyclisation 
involving this position. The 13C NMR spectra of 250a-c exhibited quaternary signals at 
61.7-62.3 ppm which were ascribed to the carbon atom in the spiro centre in each case, as 
well as signals characteristic of those expected for the carbonyl carbons at 176.8-179.6 
ppm. The HRMS of each product also supported the formation of the spiro moieties and 
gave a molecular formula consistent with the corresponding product in each case.  
The attempted synthesis of the N-allyl spiro derivative 250d was unsuccessful. 
Analytical TLC of the crude reaction mixture, unlike that from the reaction of the N-
methylisatin, showed the presence of several products. This might due to competing 
reactions involving attack by the intermediate iminium ion on both the indole 
(intramolecularly) and the allyl group (intermolecularly) (Scheme 4-10). Purification by 
column chromatography was difficult and the mixture could not be successfully separated.  
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Scheme 4-10. Possible reactions in the synthesis of N-allyl spiro compound 250d. 
 
4.5 Attempted acid mediated rearrangement 
  Rearrangement of a spiro bicyclic molecule via migrating a bond from one atom to 
the adjacent atom can lead to a ring enlargement. Activation is required for this process to 
occur. For example, the rearrangement of the β-lactone 251 to the lactone 252 was achieved 
via the treatment of 251 with freshly prepared MgBr2.178 The ring transformation depends 
on both the relative stability of the two intermediate carbocations involved and the ability 
of the migrating bonds to achieve an antiperiplanar relationship with respect to one another 
to effect γ-lactone formation.  
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Scheme 4-11. The rearrangement of the β-lactone 251. 
While rearrangement with ring enlargement of spiro compounds of type 250 has not 
been described previously, it was reasoned that a Lewis acid mediated process may be 
possible. Complexation of a Lewis acid to the lactam carbonyl group could provide the 
initial stimulus for such a rearrangement. However, there are two possibilities for this ring 
transformation depending on which bond adjacent to the spiro centre undergoes 
rearrangement to give the intermediate 253 (via pathway a) or 254 (via pathway b) 
(Scheme 4-12). Transformation via pathway a would ultimately give the required 
iheyamine A core nucleus, while migration of bond b would give an isomeric bis-indole 
fused azepine system. A preference for migration of bond a might be expected on the basis 
of extra charge stabilisation by the adjacent nitrogen (in 253).  
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Scheme 4-12. Two possible pathways of the spirooxindole rearrangement. 
In an attempt to give effect to the proposed transformation, reaction of the spirooxindoles 
250b-c with various Lewis acids including MgBr2, BF3.Et2O, In(OTf)3, and Ti(OiPr)4 were 
investigated, as well as a reaction with the Brönsted acid, trifluoroacetic acid (TFA). 
Unfortunately, in all cases no rearrangement products were obtained and mainly unreacted 
starting material was recovered. Clearly complexing to the carbonyl oxygen of the 
spirooxindoles 250b-c was insufficient to induce the spiro-rearrangement. In view of this, 
indoline intermediates were investigated.  
 
4.6 Rearrangement of spirocyclic oxindoles 
The literature on the migration of 3,3-disubstituted indolenines to 2,3-disubstituted 
indoles indicated they are readily rearranged under acidic conditions and the substituent 
migration depended on relative migratory aptitudes.179,180 Such a rearrangement of a 
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spiroindolenine is a central step in the formation of 1,2,3,4-tetrahydro-β-carbolines in the 
Pictet-Spengler reaction. Although a direct pathway involving electrophilic attack at 
position 2 of the indole ring system has been postulated, in general, the spiroindolenine 
intermediate was rearranged to the β-carbolines under mildly acidic conditions (Scheme 
4-13).181 A separate reaction using acid-catalysed rearrangement of the spiro[3H]indole was 
also investigated.182 The spiro[3H]indoles 255, obtained from the phenylhydrazones of the 
aldehydes by the Fischer method, were carefully treated with a sulfuric acid catalyst to 
obtain the cycloalkano[b]indoles 256 (Scheme 4-14). Thermal rearrangement of the 
spiro[3H]indole 255 (n= 2) in ethylene glycol to the cycloalkano[b]indole 256 (n= 2) in 
good yield (73%) was also observed. Ethylene glycol seems to behave as a mild protic acid 
catalyst in the reaction and the rearrangement can be rationalised by a similar mechanism to 
that shown in Scheme 4-14. 
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Scheme 4-13. The formation of β-carbolines via spiroindolenine intermediates. 
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Scheme 4-14. The rearrangement mechanism of the spiro[3H]indoles 255.182 
The presence of an aminal such as 257 (ie. –OH at C2 of a dihydroindole) was found 
to have a profound effect on the ease of migration of substituent groups on the indole 
ring.180 The rearrangement of indolinol 257 was initiated by the departure of a leaving 
group at C-2 by heating with concentrated hydrochloric acid or polyphosphoric acid to give 
the tetrahydrocarbazole 258 via the iminium ion intermediate.183  
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Scheme 4-15. Rearrangement of indolinol 257. 
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4.6.1 Preparation and rearrangement of carbinolamines 
The conversion of oxindoles to indolinols (carbinolamines) can be achieved by 
partial reduction of tertiary amides. Lithium aluminum hydride (LAH) has proved to be 
very sensitive to amide groups; the use of excess of LAH generally yields the 
corresponding tertiary amine.184 The partial reduction of the spirooxindole 259 with the 
calculated quantity of LAH gave indolinol 260 which, when treated with hydrochloric acid, 
afforded the β-carboline 261.185  
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The conversion of the spirooxindole 262 to the β-carboline 264 fits into the same pattern of 
reactivity of rearrangement.  Treatment of spirooxindole 262 with 0.5 equiv. LAH in ether 
gave the carbinolamine 263 in 51% yield.179 The formation of the rearranged product 264 
was achieved in cold 6 M HCl. 
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O N
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NHPh Ph
PhMe Me Me
LiAlH4
262 263 264  
Although LAH has proved to be useful for the partial reduction of tertiary amides, it is 
sensitive toward air and is hazardous in large scale preparations because of its high 
flammablility and strong reducing properties.186 The introduction of alkoxy substituents 
into the aluminium hydride moiety provides more selective reagents than LAH. For 
example, sodium bis(2-methoxyethoxy)aluminum hydride in toluene, known commercially 
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as Red-Al®, is stable to oxygen and is highly soluble in a variety of solvents; reactions are 
also easy to work up. It is a mild and safe reducing agent, especially for large scale 
reductions.187 Recently, Red-Al® has been widely used, especially for the selective 
reduction of a number of tertiary amides.188,189 Thus, Waldvogel et al.188  reduced amide 
265 with 1.2 equiv. of Red-Al® to obtain a mixture of two aminal (carbinolamine) 
diastereoisomers 266 in a ratio of 2:1.  
N
O
N
OH
Red-Al
265 266  
The reaction of Red-Al® with oxindole 267 reduced it stereoselectively to give the 
carbinolamine 268 in good yield.189     
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In view of these literature precedents, it was decided to investigate the reduction of the 
oxindoles 250a-c to the carbinolamines 269a-b and then assess their rearrangement under 
acidic conditions. Initially, reduction of oxindole 250a with 0.5 equiv. of LAH in refluxing 
diethyl ether for 1 hour was attempted but this was unsuccessful (Scheme 4-16). Refluxing 
for 2-4 hours in this solvent was also unsuccessful. After work up of the reactions, only 
starting materials were recovered. The insolubility of oxindole 250a in diethyl ether might 
be partly responsible for the lack of success. The addition of a small amount of THF to the 
reaction mixture in order to help solubility did not make any difference in the overall result. 
In addition, increasing the molar equivalence of LAH to 1.0 equiv. was also ineffective in 
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reducing the amides. An excess of LAH would be expected to fully reduce the oxindole 
250a to the indoline 270.    
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Scheme 4-16. Attempted partial reduction of oxindoles 250a-b using LiAlH4. 
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Reduction of oxindole 250a with Red-Al® was then attempted (Scheme 4-17), based on a 
similar reaction described in the literature.189 Analytical TLC monitoring of the reaction 
mixture over time showed only starting material present at each sampling point. No 
evidence for the desired product 269a was detected in the LRMS of the reaction mixture, 
which would be expected to show a molecular ion signal at m/z 291 if successful partial 
reduction had occurred.   
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Scheme 4-17. Attemped partial reduction of N-unsubstituted spirooxindole 250a 
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 The partial reduction was reattempted using the N-methyl substituted oxindoles 250b-c as 
starting materials. TLC analysis of each reaction indicated a new compound had formed 
which had a higher Rf than the respective starting material. Significant difficulty was 
experienced in purification of the reaction mixtures due to the instability of the products. 
However, relatively clean products were obtained eventually and they were analysed by 1H 
NMR spectroscopy. 
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Scheme 4-18. Partial reduction of spirooxindoles 250b-c. 
The 1H-NMR spectra of these products showed singlet signals ascribed to the indolic H-2 
protons at 4.88-4.96 ppm. The singlet signals ascribed to the methyl group resonated at 
2.89-2.92 ppm, upfield of the corresponding signals in the starting materials. Such an 
upfield shift is consistent with reduction of the carbonyl group. For example, as shown in 
Figure 4-2, the 1H NMR spectrum of 269b revealed a singlet signal ascribed to the methyl 
group at 2.92 ppm, which had shifted upfield from 3.20 ppm in the starting material. The 
presence of a singlet signal ascribed to the indolic H-2 at 4.96 ppm was further 
confirmatory evidence for the partial reduction of the carbonyl group. The EI-MS spectra 
gave peaks at m/z 305 and 355  (M+) for 269b and 269c, respectively, which indicated the 
reduction with Red-Al® had given the desired carbinolamine products. 
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Figure 4-2. 1H NMR spectrum of the carbinolamine 269b. 
 
4.6.2 Rearrangement 
The initial rearrangement involved the treatment of the carbinolamine 269b with 
warm 5M HCl (Scheme 4-19). A precipitate was formed after basification with 25% KOH. 
Purification by column chromatography gave the rearrangement product 270 (17% yield 
over 2 steps from 250b) along with unidentified baseline materials. An interesting feature 
of this product in the 1H NMR spectrum was that all proton signals appeared in the 
aromatic region with the exception of the methyl group. This indicated that full 
aromatisation had also occurred while warming in hydrochloric acid (or on basification) 
since the reaction mixture was exposed to air.  
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Scheme 4-19. Rearrangement of carbinolamines to fused indole seven membered rings. 
The 1H NMR spectrum of 270 as shown in Figure 4-3 revealed the absence of a singlet 
signal which could be ascribed to the indolic H-2 proton and the absence of a broad signal 
normally seen for the indolic NH; in the starting material 269b, this signal appears at 7.72 
ppm. The gHSQC spectrum confirmed the correlation of H-1 (doublet at 8.97 ppm, J= 6.3 
Hz), with C-1 at 132.2 ppm, and also the correlation of H-2 (doublet at 8.39 ppm, J= 5.7 
Hz) with C-2 at 120.1 ppm. The gCOSY spectrum confirmed that H-1 gave a cross peak 
only with H-2. The DEPT spectrum indicated no signals for methylene carbons in this 
molecule. In the gHMBC spectrum, a quaternary carbon resonating at 139.8 ppm showed 
cross peaks at δ 128.7 (C-13), δ 127.2 (C-16) and δ 28.7 (CH3), consistent with the 
quaternary carbon being C-11. This data suggested that the rearrangement and 
aromatisation of the carbinolamine had occurred and there was further confirmation from 
the HRCI-MS data, which showed a molecular ion at m/z 284.1178, consistent with the 
formula C19H14N3. It should be noted however that the isomeric structure 254a (R= H) 
cannot be excluded on the basis of the spectroscopic evidence, although on mechanistic 
grounds (Scheme 4-12), structure 270 is predicted to be favoured. 
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Figure 4-3. 1H NMR spectrum of bis-indole fused seven membered rings 270. 
The rearrangement was also attempted using the 5-methoxy carbinolamine 
derivative 269c and the result indicated that the rearrangement product was obtained in 
10% yield (over 2 steps). The structure was identified by the characteristic signals in the 
NMR spectrum and by comparison (Table 4-2) of the spectroscopic data (in CDCl3) with 
those of iheyamine A as described by Higa et al.20 The HREI-MS of this product also 
supported the formation of 271 and gave a molecular ion peak at m/z 313.1210, consistent 
with the formula C20H15N3O which correlated with the desired product.  
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Table 4-2. Comparison of  1H NMR spectra of iheyamine A and 271  
No. 1H NMR [mult. J (Hz)] δ 
Iheyamine A20                                     271         
1 9.04 (d, 6.4) 8.96 (d, 5.4) 
2 
5 
8.55 (d, 6.4) 
8.37 (brd, 7.9) 
8.50 (d, 6.0) 
8.35 (d, 7.5) 
6 7.52 (brdd, 7.9, 7.0) 7.52 (brdd, 7.5, 6.6) 
7 7.74 (brdd, 7.9, 7.0) 7.80 (brdd, 8.1, 7.5) 
8 7.86 (brd, 7.9) 8.14 (d, 8.4) 
13 7.70 (d, 8.9) 7.58 (d, 8.7) 
14 7.37 (dd, 8.9, 2.4) 7.37 (dd, 8.7, 2.4) 
16 8.01 (d, 2.4) 7.98 (d, 2.4) 
NMe                     - 5.00 (s) 
OMe 4.02 (s) 4.04 (s) 
 
 Compound 270 was also converted into its trifluoroacetate salt by treatment with 
trifluoroacetic acid. The 1H NMR spectrum of the salt form of 270 showed two isomers 
were formed in a ratio of 2:1, on the basis of two singlet signals observed at 3.93 ppm and 
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4.01 ppm for the N-methyl groups. This suggested that protonation had occurred at one or 
both imine nitrogens. Recrystallisation of the mixture from ethanol gave no suitable 
trifluoroacetate salt crystals for X-ray crystallography.   
   
4.7 Attempted N-demethylation 
In order to complete the synthesis of iheyamine A, it was necessary to remove the 
N-methyl group from 271. N-methyl groups exhibit good stability toward many kinds of 
reaction conditions, and the removal of the N-methyl protecting group often requires harsh 
reaction conditions resulting in less chemoselectivity.190 The standard method employs 
chloroformates which is successful in the N-demethylation of aliphatic amines such as the 
demethylation of morphine.191,192 Not unexpectedly perhaps, an initial attempt at 
demethylation of 270 using 2,2,2΄-trichloroethylchloroformate was unsuccessful, due to the 
low nucleophilicity of the indolic nitrogen. TLC analysis of the reaction mixture over time 
showed only starting material present at each sampling point. No evidence for the 
demethylated product was detected by LR-MS analysis.      
  The demethylation was then attempted on 271 using thiophenol in the presence of 
boron trifluoride diethyl etherate (BF3.Et2O). The BF3.Et2O was expected to complex with 
an imine nitrogen and thus assist demethylation by the thiophenol to give ultimately 
iheyamine A (Scheme 4-20).  
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Scheme 4-20. Attempted N-demethylation 271 using BF3/thiophenol. 
Exposure of 271 to BF3.Et2O (1.5 eg) followed by PhSH (excess) in dry THF  and heating 
at reflux for 3 days then resulted in reaction of all the starting material. However 
purification of the reaction product by preparative layer chromatography gave none of the 
desired product, iheyamine A, but some unidentified compounds were obtained. The 1H 
NMR spectra of the unidentified compounds showed only signals in the aliphatic region 
which indicated the break down of the molecule under these reaction conditions. 
Time constrains prevented further investigation of the N-demethylation step or the 
assessment of other N-protecting groups. 
  
4.8 Summary and Conclusions 
Progress was made towards the synthesis of the marine natural product iheyamine 
A. A route to the preparation of new spirooxindoles was developed based on condensation 
of commercially available tryptamine and isatins. These spirooxindoles were then reduced 
to unstable indolinols, which were then converted to the key bis-indole fused seven 
membered ring system of the iheyamine skeleton when treated with acid.  
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5 Antimicrobial Assay 
5.1 Introduction 
The emergence and spread of antimicrobial resistance has become one of the most 
serious public health concerns across the world. Antimicrobial resistance refers to micro-
organisms that have developed the ability to inactivate, exclude or block the inhibitory or 
lethal mechanism of the antimicrobial agents.193 The incidence of antimicrobial resistance 
has been increasing over the past few decades. Data from the World Health Organization 
indicated that between 50-90% of microbially caused conditions in India and Sri Lanka 
are resistant to commonly used antimicrobial drugs.194 In the US, about 70% of hospital 
acquired infections were found be resistant.195 Increasing reports of outbreaks of 
antimicrobial resistant bacteria have heightened the concerns of the international public 
and animal health communities, medical and veterinary clinicians and the general public. 
Despite the use of new antimicrobial agents, the microorganisms have developed 
mechanisms to overcome the effects of these potent drugs. Experts believe the only 
solution is to continue to develop new drugs to replace those that are losing their 
effectiveness.195 
5.2 Resistance to antibacterial agents 
Since the discovery of penicillin G, many new antibiotics have reached the market. 
However, bacterial resistance occurred only a year after the penicillins were introduced. 
All strains of the human pathogen Staphylococcus aureus (Golden Staph; Figure 5-1) are 
capable of destroying penicillin by the β-lactamase enzymes. Improvement of the activity 
spectrum is required to overcome this resistance phenomena. A semi-synthetic penicillin, 
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named methicillin, has been rendered ineffective due to the emergence of a methicillin-
resistant S. aureus (MRSA) strain which is a major problem worldwide, especially in 
hospitals. Vancomycin, the antibacterial drug of last resort, is also losing its effectiveness. 
In 1986, vancomycin-resistance was reported. Then in 1997, partially vancomycin-
resistant strains of Staphylococcus aureus were discovered and a few years later the first 
fully resistant case of vancomycin-resistant S. aureus were reported.196,195,197 The great 
success in developing new antibacterial drugs, along with the widespread and sometimes 
inappropriate use of antimicrobials, has resulted in increasing numbers of resistant 
strains. 
 
Figure 5-1. Staphylococcus aureus bacteria (Golden Staph). 
 Bacterial resistance results from chromosomal mutation, inductive expression of a 
later chromosomal gene or by exchange of genetic material through transformation, 
transproduction, or conjugation by plasmids.198 For example, resistance to quinolones and 
streptomycin arises from a chromosomal mutation in a single DNA base resulting in the 
production of proteins that can not bind antibiotics but can still function normally. 
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5.3 Resistance to antimalarial agents 
Malaria is one of the world’s most important diseases, killing 1-3 million people 
and causing disease in 300-500 million people each year.199 Malaria is caused by the 
protozoan parasite Plasmodium. There are four different species of plasmodium which 
cause the disease in humans, namely P. falciparum, P. vivax, P. ovale, and P. malariae. P. 
falciparum is by far the most dangerous species and can be found throughout tropical 
Africa, Asia and Latin America. The other species are often found in Central and South 
America and in some parts of Asia.200 Malaria is transmitted by the bite of a mosquito 
carrying the plasmodium parasite. The malarial parasites have a life cycle which is split 
between a vertebrate host (human) and an insect vector (Anopheles mosquito). When the 
mosquito bites a human, the parasites enter the human blood circulation and arrive in the 
liver where they multiply. A few days later, they return to the bloodstream and invade the 
red blood cells. If disease develops, the parasite density in the blood may obstruct the blood 
vessels. This may lead to damage to the organ supplied by these blood vessels. The most 
severe condition is obstruction of small blood vessels in the brain. This is known as 
cerebral malaria and may cause serious damage or death.  
A number of antimalarial drugs have been introduced to combat this disease such as 
chloroquine, sulphadoxine-pyrimethamine and artermisinin. However, eradication of this 
disease is difficult since the incidence of this disease is increasing dramatically, mainly due 
to malaria parasites becoming resistant to antimalarial drugs.201  Resistance to chloroquine, 
the most widely used and highly effective drug used to treat malaria, has now emerged in 
most parts of the world. However, in spite of the prevalence of chloroquine-resistant P. 
falciparum, this drug is still currently used because it is cheap, time tested and a safe 
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antimalarial agent. Sulphadoxine-pyrimethamine is the other widely used inexpensive 
antimalarial drug combination but resistance has emerged in many areas in Asia, South 
America, and Africa.202 
As malaria is a serious disease and with resistance of the parasite such a problem, 
the search for new antimalarial drugs (hopefully with new modes of action) has focussed on 
rapid efficacy, minimal toxicity and low cost. The in vitro screening of compounds from 
natural products, semi-synthetic natural products or synthetic compounds for their 
antimalarial activity is a critical path for antimalarial drug discovery. 
Most antimicrobial agents have been discovered from naturally occurring sources. 
However, most current antimicrobial drug candidates that are in advanced clinical trials 
are semi-synthetic derivatives of natural products.203  
 
5.4 Antimicrobial assays  
Once lead compounds are discovered, one of the key steps in the development of 
novel drug candidates is the microbiological assay. Antimicrobial assays are used to 
determine the potentcy or activity of the antimicrobial compounds. Most antimicrobial 
assay methods204 use an inoculum of the test organism which is added to a solution of the 
chemical, then, after a period of time, the proportion of surviving cells is determined. 
Alternatively, the culture medium is present together with the chemical, then after a period 
of time, the degree of inhibition of the test organism is measured, compared to that of a 
reference standard. The minimum inhibitory concentration (MIC), which is the minimun 
amount of compound required to inhibit the growth of a particular organism, is a 
fundamental measure of the intrinsic antimicrobial activity (potency) of a compound. IC50 
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is also commonly used, and is defined as the concentration of chemical at which 50% of the 
organism growth has been inhibited. The MIC and IC50 values are usually expressed in 
terms of µg/mL or µM.  
The indolo-benzodiazocine derivatives synthesised in this project contain a 
framework (Figure 5-2) incorporating a H, OMe and F in the C-10 position (R in Figure 
5-2) and a substituent at N-5 (R΄ in Figure 5-2). A number of these compounds were sent 
for antibacterial testing. 
N
N
O
R
R'
 
Figure 5-2. The generic indolo-benzodiazocine structure. 
 The assay was undertaken to determine antibacterial activity against 
Staphylococcus aureus strain ATCC 6538P and VRE strains 243, 449, 820 and 987 
(vancomycin-resistant and vancomycin-sensitive Enterococcus faecium) at the Avexa 
(formally Amrad) Corporation laboratories, Melbourne, using the antibacterial screening 
methodology described in Appendix 1.1. All samples were prepared in DMSO (2.5%) 
solution.  
Selected indolo-benzodiazocine derivatives, namely compounds 186d, 187d and 
186e, were sent for in vitro antimalarial testing against the K1 strain (antifolate resistant 
strain) and TM4 strain (antifolate sensitive strain) of Plasmodium falciparum at the Protein-
Ligand Engineering and Biotechnology laboratory, National Science and Technology 
Development Agency in Bangkok, Thailand. The tests were done by Dr. Sumalee 
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Kamchonwongpaisan and Miss Roonglawan Rattanajak using a Microdilution 
Radioisotopes Technique. Details of this method are described in Appendix 1.3. 
 
5.5 Results of the antibacterial testing 
The antibacterial testing results are shown in Table 5-1. The indolo-benzodiazocine 
derivatives with no substitutent on the nitrogen (N-5) showed no activity against S. aureus 
and vancomycin-resistant and vancomycin sensitive Enterococcus faecium (E. faecium). 
The indolo-benzodiazocine derivatives with a methyl,  p-methoxybenzyl or benzyl 
substituent at N-5 were also essentially inactive against all strains, with MIC values greater 
than 125 µg/mL. The same result was also obtained from the testing of 5-benzyl-10-fluoro-
indolo-benzodiazocine 186g, which had MIC values greater than 125 µg/mL against S. 
aureus and the VRE strains. Some antibacterial activity was observed for the 5-substituted-
10-methoxy-indolo-benzodiazocines. The 5-methyl derivative 186c showed good activity 
against S. aureus with an MIC value of 7.8 µg/mL, while the activity against vancomycin-
resistant and vancomycin sensitive E. faecium was weak with MIC values at 125 µg/mL. 
However, the 5-benzyl derivative 186f showed a dramatic drop in activity with an MIC 
value of 125 µg/mL against S. aureas and no activity against the VRE strains. A tetrahydro-
indolo-benzodiazocine analogue 187e was also evaluated for its antibacterial activity. With 
the 5-benzyl substituent, the activity against S. aureus was weak with an MIC value of 125 
µg/mL. 
From the anitbacterial test results, it is clear that the indolo-benzodiazocine 
derivative containing a methoxy substituent at the C-10 position exhibited antibacterial 
activity while the potency depended on the group attached to the amide nitrogen. The size 
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of the amide substituent might be important to the antibacterial activity. Increasing of the 
size from a hydrogen to a methyl group also raised the activity markedly, however, when 
the size was increased to a benzyl group, the activity dropped significantly. Thus, the 
groups which have a size between methyl and benzyl group would be of interest to test 
against S. aureus and the VRE strains. Furthermore, the compounds containing a methoxy 
at the 10-position on the tetrahydro-indolo-benzodiazine scaffold would also be of interest 
as a lead compound for the indole-fused eight-membered ring antibacterial agents.  
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Table 5-1. Results of antibacterial testing. MIC values in µg/mL. 
VRE strains (MIC) 
Compounds  
S.aureus 
(MIC) 243 449 820 987 
          
         29a >125 >125 >125 >125 >125 
N
NH
O
MeO
 
29b >125 >125 >125 >125 >125 
 
           186b >125 >125 >125 >125 >125 
N
N
Me
O
MeO
 
186c 7.8 (25) 125 125 125 125 
 
186d >125 >125 >125 >125 >125 
 
 
N
NH
O
N
N
Me
O
N
N
O OMe
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VRE strains (MIC) Compounds 
 
S.aureus 
(MIC) 243 449 820 987 
 
 186e >125 >125 >125 >125 >125 
 
 187e 125 (353) >125 >125 >125 >125 
N
N
O
MeO
186f 125 (327) >125 >125 >125 >125 
N
N
O
F
 
186g >125 >125 >125 >125 >125 
Vancomycin (Standard)  2.5 
<9.80, 
1.95 
62.5 >125 <0.98 
MIC-Minimum inhibitory concentration. Values in brackets are µM.  
 
N
N
O
N
N
O
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5.6 Results of antimalarial testing 
Some indolo-benzodiazocine derivatives were tested against two particular strains 
(K1 and TM4) of the protozoan Plasmodium falciparum in vitro. The  results showed that 
the p-methoxybenzyl derivative 186d had good activity against P. falciparum for both the 
K1 and TM4 strains with IC50 values of 4.57 µM and 4.26 µM, respectively. With a benzyl 
substituent at N-5, compound 186e showed an activity greater than 10 µM and thus only 
weakly active against the K1 and TM4 strains of the parasite.  
The test against both strains of P. falciparum of the 5-p-methoxybenzyl-tetrahydro 
derivative 187d also showed weak activity, with IC50 values for both strains greater than 10 
µM. Thus, this suggested that both the p-methoxy group in the benzyl group and the double 
bond of the pyrrole ring are of importance for antimalarial activity. This methoxy group 
may bind to a hydrophobic region in the biological target or act as a hydrogen acceptor 
group. While the mechanism of action remains unknown, compound 186d provides a very 
interesting, structually different anti-malarial lead compound for further development.    
 
N
N
O OMe
186d  
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Table 5-2. Results of antimalarial testing. 
P. falciparum (IC50, µM) 
Compounds  
K1 strain TM4 strain 
 
186d 4.57±0.41 4.26±0.90 
N
N
O OMe
 
187d >10 >10 
 
186e >10 >10 
              IC50 – concentration for 50% inhibition 
 
 
 
 
 
 
 
N
N
O OMe
N
N
O
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6     Conclusions and Future Directions 
6.1 Conclusions 
 Successful syntheses of 1,2- and 2,3-fused indoles with seven- or eight-membered 
rings were developed via thermal free radical cyclisation of iodo- or bromoacetamide 
precursors. Using 1-substituted indole derivatives with haloacetamide funtionalities, the 
cyclisation products depended on the protecting group on the haloacetamide nitrogen. 
When a sufficiently large protecting group (for example a benzyl group) was employed the 
indole fused eight-membered ring cyclisation products, the indolo-benzodiazocines, were 
formed. Cyclisation in high boiling point solvents such as xylenes and mesitylene increased 
the yields of the cyclisation product. The temperature effect was rationalised in terms of the 
increase in the concentration of the cisoid amide rotamer required for cyclisation. A search 
for alternative means to access the free radical intermediates revealed that although 1-
ethylpiperidinium hypophosphite (EPHP) and tris(trimethylsilyl)silane ((TMS)3SiH) could 
be used, the yields of cyclisation products were lower compared to those from the reaction 
with tributyltin hydride (Bu3SnH). Selective deprotection of the benzyl protecting group in 
one of the 8-membered ring compounds was achieved in 35% yield when reacted with Na 
in liquid ammonia over a short peroid of time.  
 Free radical cyclisation of haloacetamide intermediates was also developed for the 
synthesis of 2,3-fused indoles, in particular the indolo[3,2-d][1]benzazepinone (paullone) 
systems. 2-Substituted indole derivatives with haloacetamide funtionalities were prepared 
as the key intermediates in this cyclisation. The results obtained in this work showed that 
both cyclisation to the paullone and/or spiro compound formation occurred in this reaction 
when using toluene as a solvent. Use of a high boiling point solvent such as mesitylene 
 145
increased the yield of the cyclisation product and none of the spiro compound was isolated. 
This result also supported the idea that increased temperature resulted in an increase in the 
concentration of the cisiod amide rotamer required for cyclisation. Deprotection of the N-
benzyl protecting group present was also achieved using Na in liquid ammonia, affording 
access to the N-unsubstituted derivative 29a.  
 The bis-indole fused seven-membered ring system present in the cytotoxic marine 
natural product, iheyamine A, was synthesised via a short 3-step route involving the 
condensation of tryptamine and N-substituted isatins. Partial reduction of the N-substituted 
spirooxidoles produced in the first step was successful when using Red-Al® in toluene as a 
reducing agent. The spiro-indolinols obtained from the partial reduction underwent 
rearrangement to what is believed to be the 12H-azepino[3,2-b:4,5-b΄]diindole ring system 
under acidic conditions, as in the synthesis of 270 and 271.  
 Antimicrobial assays of a selection of the new compounds prepared showed that 
compound 186c, 5,14-dihydro-10-methoxy-5-methylindolo[2,1-d][1,5]benzodiazocin-6-
one, exhibited by far the most potent antibacterial property in this series with an MIC of 7.8 
µM against the Gram-positive pathogen, Staphylococcus aureus, while compound 186d, 
5,14-dihydro-5-(4-methoxybenzyl)indolo[2,1-d][1,5]benzodiazocin-6-one, showed good 
activity against the malarial parasite Plasmodium falciparum for the K1 and TM4 strains 
with IC50 values of 4.57 µM and 4.26 µM, respectively. Thus these indole fused eight-
membered ring compounds are of interest as new drug leads as both antibacterials and 
antimalarials.  
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6.2 Future Directions 
Structural verification of the bis-indole fused seven membered ring compounds 270 
and 271 should be sought by attempting to obtain suitable crystals for X-ray 
crystallographic analysis. Preparation of other N-substituted spirooxindoles should be 
investigated with a view to selective removal of the N-substituent after rearrangement and 
completion of the synthesis of the natural product, iheyamine A. 
 It would also be of interest to synthesise, especially via tin-free radical 
cyclisation,205 a number of analogues of the indole fused seven- or eight-membered ring 
systems with a variety of N-substituents (in the 7- or 8-membered ring) and to evaluate 
their antimicrobial activities. After removal of the N-benzyl protecting group, introduction 
of substituents which have a larger size than methyl group but smaller size than benzyl 
group on the nitrogen, such as ethyl, propyl, i-propyl, allyl and methylcyclopropyl groups, 
could be investigated and tested for their antimicrobial activity.  
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7     Experimental 
7.1 General procedure 
Melting points were determined using a Reichert hot-stage melting point 
apparatus and are uncorrected.  
300 MHz 1H NMR spectra and 75 MHz 13C NMR spectra were recorded on a 
Varian Mecury 300 Fourier transform NMR spectrometer. 500 MHz 1H NMR spectra 
and 125 MHz 13C NMR spectra were recorded on a Varain Unity Inova spectrometer. 
Unless otherwise stated, the spectra were obtained from solutions in CDCl3 and 
referenced to TMS (proton) and chloroform mid-line (77 ppm) (carbon). Chemical 
shifts were reported in parts per million (δ). Where an aromatic proton signal appeared 
as a triplet of doublets (td) in the 1H NMR, the first coupling constant given is for both 
identical ortho couplings. 
Low resolution chemical ionisation (CI+) and electron impact (EI) were obtained 
using a Shimadzu QP-5000 spectrometer. High resolution mass spectra (HRMS) were 
obtained using a Fisons/VG Autospec-TOF spectrometer.  
IR spectra were recorded with a BOMEM MB-100 FTIR using a KBr disc. The 
UV spectra (solvent corrected) were recorded on a Shimadzu 2401-PC UV-VIS 
spectrophotometer. 
TLC and preparative thin layer chromatography was performed using Merck 
silica gel 60 F254. All chromatographic solvent proportions are volume for volume. 
Column chromatography was performed using Merck Kieselgel 60 (0.063-0.200 nm 
particle size) silica gel.  
All solvents used were AR grade, except DCM and hexane, which were distilled 
prior to use. Tetrahydrofuran (THF) was dried over sodium metal/benzophenone and 
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distilled under nitrogen. Solvents were removed under reduced pressure with a rotary 
evaporator, and organic solvent extracts were dried with anhydrous Na2SO4. Solvent 
mixtures are volume for volume. Petroleum spirit (Pet. spirit) refers to the fraction of 
b.p. 40-60 °C. 
 Chemicals were purchased from Sigma-Aldrich Chemical Co. Inc. or Lancaster 
International and were used as received.   
 
7.2 Experimental for Chapter 2 
7.2.1 N-alkylation of indoles 
Synthesis of 1-[(2-nitrophenyl)methyl]-1H-indole (148a) 
A stirred suspension of sodium hydride (ca 50% dispersion in 
mineral oil, 2.6 g, 50 mmol) in dry DMF (50 mL) under a N2 
atmosphere was cooled to 0 oC and 1H-indole (5.8 g, 54.2 mmol) 
in DMF solution (150 mL) was added dropwise, with stirring over 
30 min. Stirring was continued with cooling for a further 30 min and then at r.t. for 2 h. 
At this point excess DMF (120 mL) was added to the solution and then cooled to -60 oC 
in a dry ice/acetone bath. To the cold reaction mixture, a solution of 2-nitrobenzyl 
bromide (13.7 g, 64 mmol) in DMF (50 mL) was added dropwise and the deep red 
mixture allowed to stir overnight with warming to r.t.. DMF was removed under high 
vacuum and a mixture of water and ice (400 mL) was added to the residue with 
vigorous stirring for 4 h.  The yellow solid precipitated was suction filtered, washed 
with cold water and air dried to give the title compound 148a. Recrystallisation from 
ethanol gave 148a (8.5 g, 62%) as yellow crystals; mp 88-90 oC (lit.30 90.5–92 oC); 1H 
NMR (CDCl3) δ 5.76 (s, 2H, CH2), 6.47 (dd, J= 9.0, 4.2 Hz, 1H, H-6΄), 6.63 (d, J=3.0 
N NO21
2
3
4
5
6
7
1'
3'
4'
5'
2'
6'
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Hz, 1H, H-3), 7.12-7.15 (m, 4H, H-2, H-6, H-5, and H-4΄), 7.35-7.41 (m, 2H, H-7 and 
H-5΄), 7.67 (d, J= 8.4 Hz, 1H, H-4), 8.16 (dd, J= 9.6, 4.5 Hz, 1H, H-3΄); CI-MS m/z 254 
([M+H]+, 100%). 
Synthesis of 5-methoxy-1-[(2-nitrophenyl)methyl]-1H-indole (148b) 
To a stirred suspension of  NaH (ca 50% dispersion in mineral 
oil, 0.70 g, 14.9 mmol) in DMF (20 mL) at 0 oC under a N2 
atmosphere was added a solution of 5-methoxyindole (2.0 g, 
13.6 mmol) in DMF (50 mL) dropwise. The suspension was 
stirred at 0 °C for 30 min and then at r.t. for 2 h. DMF (150 mL) was added and then the 
mixture cooled to -60 oC using a dry ice/acetone bath. A solution of 2-nitrobenzyl 
bromide (3.8 g, 17.4 mmol) in DMF (25 mL) was added dropwise and the mixture was 
allowed to stir overnight at r.t.. DMF was then removed under reduced pressure until the 
mixture was almost free of solvent. Ice water was then added to the residue with 
vigorous stirring. The solid was filtered through filter paper, washed with cold water 
and air dried. The solid was crystallised from ethanol to give 148b (2.45 g, 63%) as 
yellow crystals; mp 120-121 oC (lit. 30 117-119 oC); 1H NMR (CDCl3) δ  3.83 (s, 3H, 
OCH3), 5.72 (s, 2H, CH2), 6.45 (d, J= 9.0 Hz, 1H, H-6΄), 6.57 (d, J= 3.0 Hz, 1H, H-3), 
6.80 (dd, J= 9.3, 2.4 Hz, 1H, Ar), 7.00 (d, J= 9.0 Hz, 1H, Ar), 7.11-7.21 (m, 2H, H-2 
and Ar), 7-35-7.44 (m, 2H, Ar), 8.16 (d, J= 9.3 Hz, 1H, H-3΄);  CI-MS m/z 284 
([M+H]+, 100%). 
Synthesis of 5-fluoro-1-[(2-nitrophenyl)methyl]-1H-indole (148c) 
To a stirred suspension of  NaH (ca 50% dispersion in mineral oil, 
1.2 g, 24.4 mmol) in DMF (50 mL) at 0 oC under a N2 atmosphere 
was added a solution of 5-fluoroindole (3.0 g, 22.2 mmol) in DMF 
N
MeO
NO2
N
F
NO2
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(50 mL) dropwise. The suspension was stirred at 0 °C for 30 min and then at r.t. for 2 h. 
DMF (150 mL) was added and then the mixture cooled to -60oC using a  dry ice/acetone 
bath. A solution of 2-nitrobenzyl bromide (6.1 g, 28.4 mmol) in DMF (25 mL) was 
added dropwise and the mixture was allowed to stir overnight at r.t.. DMF was then 
removed under reduced pressure until the mixture was almost free of solvent. Ice water 
was then added to the residue with vigorous stirring. The solid was filtered through 
filter paper, washed with cold water and air dried. The solid was crystallised from 
ethanol to give 148c (3.76 g, 63%) as yellow crystals; mp 114-115 oC (lit.30 118-119 
oC); 1H NMR (CDCl3) δ 5.73 (s, 2H, CH2), 6.44 (dd, J= 5.7, 3.3 Hz, 1H, H-6΄), 6.57 (d, 
J= 3.0 Hz, 1H, H-3), 6.90 (td, J= 9.0, 2.4 Hz, 1H, Ar), 7.03 (dd, J= 8.7, 4.2 Hz, 1H, H-
7), 7.16 (d, J= 3.0 Hz, 1H, H-2), 7.29 (dd, J= 9.6, 2.4 Hz, 1H, Ar), 7.39-7.44 (m, 2H, 
Ar), 8.15 (d, J= 9.3 Hz, 1H, H-3΄); CI-MS m/z 271 ([M+H]+, 100%).   
 
7.2.2 Reduction procedure 
Synthesis of 1-[(2-aminophenyl)methyl]-1H-indole (149a) 
A solution of 148a (4.15 g, 16.5 mmol), 10% Pd/C (1 g), and 2 drops 
of conc. HCl in THF (100 mL) was stirred under a H2 atmosphere at 
r.t. overnight. The catalyst was removed by filtration, washed with 
DCM (5 x 10 mL), and the filtrate dried and evaporated to give an orange oil. The oil 
was taken up in a minimal volume of hot ethanol and the crystals obtained on cooling 
were suction filtered to yield the title compound 149a (1.85 g, 50%) as a tan crystalline 
solid; mp 76-77 oC (lit.30  79-80.5 oC); 1H NMR (CDCl3) δ 3.47 (s, 2H, NH2), 5.16 (s, 
2H, CH2), 6.52 (d, J= 3.0 Hz, 1H, H-3), 6.67 (d, J= 7.8 Hz, 1H, H-3΄), 6.70 (t, J= 7.2 
Hz, 1H, Ar), 6.99 (d, J= 8.1 Hz, 1H, Ar), 7.01 (d, J= 2.7 Hz, 1H, H-2), 7.08-7.23 (m, 
N NH2
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3H, H-5, H-6, and Ar), 7.39 (d, J=8.1 Hz, 1H, H-7), 7.65 (d, J=7.8 Hz, 1H, H-4); 13C 
NMR (CDCl3) δ 47.9 (CH2), 102.3 (C-3), 109.8 (C-7), 116.6, 119.2, 120.0, 121.3, 
121.3, 122.0, 127.5 (all ArC-H), 129.1 (C-3a), 129.5 (ArC-H), 130.0 (ArC-H), 136.5 
(C-7a), 145.1 (C-N); CI-MS m/z 223 ([M+H]+, 100%). 
Synthesis of 1-[(2-aminophenyl)methyl]-5-methoxy-1H-indole (149b) 
A solution of 148b (2.39 g, 8.5 mmol), 10% Pd/C (1 g), and 2 
drops of conc. HCl in THF (100 ml) was stirred under a H2 
atmosphere at r.t. overnight. The catalyst was removed by 
filtration, washed with DCM (5 x 10 mL), and the filtrate dried 
and evaporated to give an orange oil. The oil was subjected to flash column 
chromatography (silica gel, DCM) to give 149b (1.19 g, 56%) as a tan crystalline solid; 
mp 121- 124 oC (lit.30 118-120 oC); 1H NMR (CDCl3) δ 3.42 (s, 2H, NH2), 3.87 (s, 3H, 
OCH3), 5.14 (s, 2H, CH2), 6.47 (dd, J= 3.3, 0.6 Hz, 1H, H-3), 6.69 (dd, J= 7.8, 0.9 Hz, 
1H, H-3΄), 6.79 (td, J= 7.2, 0.9 Hz, 1H, H-5΄), 6.88 (dd, J= 8.7, 2.4 Hz, 1H, H-6), 6.91- 
7.01 (m, with prominent d, J= 3.3 Hz, 2H, H-2 and H-6΄), 7.13 (d, J= 2.4 Hz, 1H, H-4), 
7.17 (td, J= 7.8, 1.5 Hz, 1H, H-4΄), 7.28 (d, J= 8.7 Hz, 1H, H-7); 13C NMR (CDCl3) δ 
48.1 (CH2), 56.2 (CH3), 101.8 (C-4), 103.0 (C-3), 110.5 (C-6), 112.3 (C-7), 116.6 (C-
3΄), 119.2 (C-5΄), 121.4 (C-1΄), 128.1 (C-2), 129.4 (C-3a and C-4΄), 129.9 (C-6΄), 131.9 
(C-7a), 145.1 (C-N), 154.4 (COCH3); CI-MS m/z 253 ([MH]+, 100%). 
Synthesis of 1-[(2-aminophenyl)methyl]-5-fluoro-1H-indole (149c) 
A solution of 148c (3.24 g, 12 mmol), 10% Pd/C (1 g), and 2 
drops of conc. HCl in THF (100 ml) was stirred under a H2 
atmosphere at r.t. overnight. The catalyst was removed by 
filtration, washed with DCM (5 x 10 mL), and the filtrate dried 
N
F
NH2
N NH2
MeO
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and evaporated to give an orange oil. The oil was subjected to flash column 
chromatography (silica gel, DCM) to give 149c (1.30 g, 45%) as yellow crystalline 
solid; mp 81-82 oC (lit.30 81.0-82.5 oC); 1H-NMR (CDCl3) δ 3.48 (br.s, 2H, NH2), 5.15 
(s, 2H, CH2), 6.48 (d, J= 3.2 Hz, 1H, H-3), 6.70 (d, J= 8.1 Hz, 1H, Ar), 6.77 (ddd, J=  
7.6, 7.3, 1.0 Hz, 1H, Ar), 6.86-7.00 (m, 2H, Ar), 7.06 (d, J= 3.2 Hz, 1H, H-2), 7.17 
(ddd, J= 7.8, 7.6, 1.2 Hz, 1H, Ar), 7.23-7.31 (m, 2H, Ar); 13C-NMR (CDCl3) δ 48.2 
(CH2), 102.1 (C-7), 102.2 (C-3), 105.9 (ArC-H), 106.2 (C-6), 110.2, 110.3, 110.4, 
110.6, 116.7 (all ArC-H), 119.3 (ArC-H), 121.0 (C-3a), 129.1, 129.6, 129.9 (ArC-H), 
133.2 (C-7a), 145.0 (C-N); CI-MS m/z 241 ([MH]+, 100%) 
 
7.2.3 N-methylation of primary amines 
N-Methylation of 149a 
Method A: To a stirred solution of 149a (0.15 g, 0.71 mmol) in dry DMF (20 mL) under 
a N2 atmosphere was added anhydrous K2CO3 (98 mg, 0.71 mmol) and the suspension 
was stirred at 0-5 oC for 5 min. Methyl iodide (48 µL, 0.78 mmol) was then added and 
the reaction mixture stirred at r.t. overnight. Solvent was then removed under reduced 
pressure. Diethyl ether (20 mL) was added to the residue and the mixture was washed 
with water (5 x 20 mL). The organic layer was dried and concentrated to give a brown 
oil. 1H NMR of the oil confirmed the formation of 150a with the starting material 149a 
also present. The oil was purified by flash column chromatography (1:1 hexane/DCM) 
to give the first fraction as 1-[(2-N-methylaminophenyl)methyl]-1H-indole 150a (51 
mg, 31%) and the second fraction as starting material 149a (77 mg, 48%). 
Method B: A suspension of 149a (0.16 g, 0.71 mmol), anhydrous K2CO3 (98 mg, 0.71 
mmol) and methyl iodide (66 µL, 1.07 mmol) was treated as described above in method 
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A. The crude product was purified by column chromatography (1:1 hexane/DCM). The 
first fraction gave 1-[(2-N,N-dimethylaminophenyl)methyl]-1H-indole 151a (48 mg, 
27%), the second fraction gave 150a (70 mg, 42%) and the third fraction gave the 
starting material 149a (25 mg, 16%). 
Method C: A suspension of 149a (0.30 g, 1.40 mmol), anhydrous K2CO3 (0.20 g, 1.40 
mmol) and methyl iodide (18 µL, 0.28 mmol) was treated as described above in method 
A. The crude product was purified by column chromatography (1:1 hexane/DCM). The 
first fraction gave 150a (80 mg, 90%), while the second fraction gave the starting 
material 149a (0.24 g, 79%). 
150a was obtained as a colourless solid; mp 52-53 oC; IR (KBr) 
νmax: 3430 (NH), 2815 (N-CH3) cm-1; 1H NMR (CDCl3) δ 2.77 (s, 
3H, CH3), 3.51 (br.s, 1H, NH), 5.15 (s, 2H, CH2), 6.53 (d, J= 3.6 
Hz, 1H, H-3), 6.70 (d, J= 8.1 Hz, 1H, H-3΄), 6.75 (d, J= 7.5 Hz, 
1H, Ar), 6.99 (m, J= 8.4 Hz, 2H, H-2 and Ar), 7.13-7.33 (m, 3H, H-2΄, H-5 and H-6), 
7.42 (d, J= 8.1 Hz, 1H,H-7), 7.67 (d, J= 7.5 Hz, 1H, H-4); 13C NMR (CDCl3) δ 31.0 
(CH3), 47.7 (CH2), 102.2 (C-3), 109.7 (C-7), 110.6 (x2), 117.5, 120.0, 121.1 (C-1΄), 
121.3, 122.0, 127.4 (all ArCH), 129.8 (C-3a and ArCH), 136.5 (C-7a), 147.5 (C-2΄); CI-
MS m/z 237 ([MH]+, 97%); HRCI-MS m/z calcd for [M+H]+ C16H16N2: 236.1313, 
found: 236.1309. 
151a was obtained as a brown oil; 1H NMR (500 MHz, CDCl3) δ 
2.74 (s, 6H, 2xCH3), 5.44 (s, 2H, CH2), 6.51 (d, J= 8.0 Hz, 1H, H-
3΄), 6.56 (d, J= 3.0 Hz, 1H, H-3), 6.67 (t, J= 7.5 Hz, 1H, Ar), 6.72 
(d, J= 8.5 Hz, 1H, Ar), 6.91 (td, J= 7.5, 2.0 Hz, 1H, Ar), 7.04-7.27 
(m, 3H, Ar), 7.45 (d, J= 7.0 Hz, 1H, H-7), 7.66 (d, J= 7.0 Hz, 1H, 
H-4); 13C NMR (125 MHz, CDCl3) δ 45.2 (NCH3), 45.4 (CH2), 101.6 (C-3), 107.0 (C-
N
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7), 110.1, 117.5, 119.4, 119.6, 121.1, 121.4 (C-1΄), 123.3, 127.5, 128.4, 128.7 (C-3a), 
129.3 (ArCH), 132.8 (C-7a), 152.9 (C-2΄); EI-MS m/z 250 ([M]+, 54%); HREI-MS m/z 
calcd for [M]+ C17H18N2: 250.1470, found: 250.1461. 
N-Methylation of 149b 
Method A: To a solution of 149b (0.39 g, 1.54 mmol) in dry DMF (40 mL) under a N2 
atmosphere was added anhydrous K2CO3 (0.21 g, 1.54 mmol) and the suspension was 
stirred at 0-5 oC for 5 min. Methyl iodide (0.1 mL, 1.69 mmol) was then added and the 
reaction mixture stirred at r.t. overnight. Solvent was then removed under reduced 
pressure. Diethyl ether (30 mL) was added to the residue and the mixture was washed 
with water (5 x 25 mL). The organic layer was dried and concentrated. The crude 
material was chromatographed on a silica gel column using DCM as eluting solvent. 
The first fraction gave 1-[(2-N-methylaminophenyl)methyl]-5-methoxy-1H-indole 150b 
(0.29 g, 71%) and the second fraction gave the starting material 149b together with 
some contaminants (0.15g , 36%). 
Method B: A suspension of 149b (0.54 g, 2.14 mmol), anhydrous K2CO3 (0.30 g, 2.14 
mmol) and methyl iodide (2.0 mL, 3.21 mmol) was treated as described above in 
method A. The crude product was purified by column chromatography (DCM). The 
first fraction gave 1-[(2-N,N-dimethylaminophenyl)methyl]-5-methoxy-1H-indole 151b 
(0.14 g, 23%), the second fraction gave 150b (0.11 g, 19%) and the third fraction gave 
the starting material 149b (0.20g, 37%). 
Method C: A suspension of 149b (0.59 g, 2.34 mmol), anhydrous K2CO3 (0.32 g, 2.34 
mmol) and methyl iodide (30 µL, 0.47 mmol) was treated as described above in method 
A. The crude product was purified by column chromatography (DCM). The first 
fraction gave 150b (50 mg, 40%) and while the second fraction gave the starting 
material 149b (0.39 g, 66%). 
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150b was obtained as a yellow solid; mp 59-60 oC; IR (KBr) 
νmax: 3429 (NH), 2815 (N-CH3) cm-1; 1H NMR δ 2.74 (s, 
3H, CH3), 3.48 (br s, 1H, NH), 3.84 (s, 3H, OCH3), 5.06 (s, 
2H, CH2), 6.42 (d, J= 3.6 Hz, 1H, H-3), 6.66-6.73 (m, 2H, 
Ar), 6.86 (dd, J= 8.6, 2.1 Hz, 1H, H-7), 6.92-6.94 (m with prominent d, J= 3.3 Hz, 2H, 
H-2 and Ar), 7.11 (d, J= 2.1 Hz, 1H, H-4), 7.22-7.30 (m, 2H, Ar); 13C NMR δ 31.0 
(CH3), 48.1 (CH2), 56.2 (OCH3), 101.8 (C-4), 102.9 (C-3), 110.5, 110.6, 112.3, 117.6, 
120.7 (C-1΄), 128.2 (C-2), 129.5 (C-3a), 129.7, 131.9 (C-7a), 147.5 (C-N), 154.4 
(COCH3); CI-MS m/z 267 ([MH]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C17H18N2O: 267.1497, found: 267.1490. 
151b was obtained as a brown oil; 1H NMR (500 MHz, 
CDCl3) δ 2.75 (s, 6H, 2xCH3), 3.85 (s, 3H, OCH3), 5.39 (s, 
2H, CH2), 6.47 (d, J= 3.0 Hz, 1H, H-3), 6.70 (d, J= 7.5 Hz, 
1H, H-3΄),  6.82 (dd, J= 9.0, 2.5 Hz, 1H, H-6), 6.92 (td, J= 
7.5, 1.5 Hz, 1H, Ar), 7.11-7.15 (m, 3H, H-2, H-4 and Ar), 7.18 (dd, J= 8.5, 1.5 Hz, 1H, 
H-6΄), 7.22 (d, J= 7.5 Hz, 1H, H-7); 13C NMR (125 MHz, CDCl3) δ 45.4 (NCH3), 48.0 
(CH2), 55.9 (OCH3), 102.0 (C-4), 102.7 (C-3), 109.7, 112.0, 114.3, 119.6, 121.0 (C-1΄), 
123.9, 124.5, 128.1, 129.3 (C-3a), 130.1, 132.4 (C-7a), 147.5 (C-2΄), 155.8 (COCH3); 
EI-MS m/z 280 ([M]+, 47%); HREI-MS m/z calcd for [M]+ C18H20N2O: 280.1576, 
found: 280.1582. 
Synthesis of  5-fluoro-1-[(2-N,N-dimethylaminophenyl)methyl]- 1H-indole (151c) 
To a solution of 149c (0.14 g, 0.60 mmol) in dry DMF (5 
mL) under a N2 atmosphere was added anhydrous K2CO3 (83 
mg, 0.60 mmol) and the suspension was stirred at 0-5 oC for 
N
N
H
Me
MeO
150b
N
N
Me
Me
MeO
151b
N
N
Me
Me
F
 156
5 min. Methyl iodide (41 µL, 0.66 mmol) was then added and the reaction mixture 
stirred at r.t. overnight. The solvent was then removed under reduced pressure. Diethyl 
ether (20 mL) was added to the residue and the mixture was washed with water (5 x 20 
mL). The organic layer was dried and concentrated to give a yellow oil. The oil was 
subjected to flash column chromatography (DCM) to afford 151c (0.16 g, 100%) as a 
yellow oil; 1H NMR (500 MHz, CDCl3) δ 2.67 (s, 6H, 2xCH3), 5.31 (s, 2H, CH2),  6.44 
(d, J= 3.0 Hz, 1H, H-3), 6.65 (d, J= 7.5 Hz, 1H, H-3΄), 6.82-6.86 (m, 2H, Ar), 7.09 (dd, 
J= 9.0, 4.5 Hz, 1H, H-7), 7.12-7.13 (m, 2H, Ar), 7.17 (t, J= 7.5 Hz, 1H, H-4΄), 7.24 (dd, 
J= 10.0, 2.5 Hz, 1H, H-6΄); 13C NMR (125 MHz, CDCl3) 45.0 (NCH3), 45.9 (CH2), 
101.2 (d, J= 4.8 Hz, 13C-19F, C3-F), 105.4 (d, J= 22.9 Hz, 13C-19F, C4-F), 109.8 (d, J= 
26.3 Hz, 13C-19F, C6-F), 110.4 (d, J= 9.5 Hz, 13C-19F, C7-F), 119.5, 123.6, 127.7, 128.3 
(all ArC-H), 128.7 (d, J= 10.1 Hz, 13C-19F, C3a-F), 130.1 (ArC-H), 131.8 (C-1΄), 133.0 
(C-7a), 152.0 (C-2΄), 157.8 (d, J= 232.8 Hz, 13C-19F, C5-F); EI-MS m/z 268 ([M]+, 
33%); HREI-MS m/z calcd for [M]+ C17H17N2F: 268.1376, found: 268.1375. 
 
7.2.4 N-benzylation of primary amines 
Synthesis of 1-{[2-N-(4-methoxybenzyl)aminophenyl]methyl}-1H-indole  (152) 
To a solution of 149a (0.13 g, 0.59 mmol) in dry DMF 
(20 mL) was added anhydrous K2CO3 (82 mg, 0.59 
mmol) and the suspension was stirred at 0-5 oC for 5 
min. 4-Methoxybenzyl bromide (0.12 g, 0.59 mmol) in 
DMF (2 mL) was then added and the reaction mixture stirred at r.t. overnight. Solvent 
was then removed under reduced pressure. Diethyl ether (20 mL) was added to the 
residue and the mixture was washed with water (5 x 20 mL). The organic layer was 
dried and concentrated. The crude material was chromatographed on a silica gel column 
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using DCM as eluting solvent to give 152 (0.14 g, 71%) as a yellow solid; mp 105-106 
oC; IR (KBr) νmax: 3425 (NH) cm-1; 1H NMR (CDCl3) δ 3.86 (br s, 1H, NH), 3.88 (s, 
3H, CH3), 4.26 (s, 2H, NHCH2), 5.26 (s, 2H, CH2), 6.63 (d, J= 3.3 Hz, 1H, H-3), 6.77- 
6.83 (m, 2H, Ar), 6.87 (d, J= 8.7 Hz, 2H, Ar), 7.22-7.26 (m, 6H, Ar), 7.32 (t, J= 9.0 Hz, 
1H, Ar), 7.43 (dd, J= 7.5, 1.2 Hz, 1H, H-7), 7.76 (dd, J= 7.5, 1.8 Hz, 1H, H-4); 13C 
NMR (CDCl3) δ 47.4 (NHCH2), 47.7 (CH2), 55.3 (CH3), 102.0 (C-3), 109.3, 111.2, 
113.8, 117.3, 119.6 (all ArC-H), 120.6 (C-1΄), 121.0, 121.7, 127.2, 128.3 (all ArC-H), 
128.7, (C-3a), 129.2 (ArC-H), 129.4 (ArC-H), 130.6 (C-7a), 136.2 (C-1΄΄), 146.0 (C-
2΄), 158.5 (COCH3); CI-MS m/z 343 ([MH]+, 100%); HREI-MS m/z calcd for [M]+ 
C23H22N2O: 342.1732, found: 342.1731.  
Synthesis of 1-[(2-N-benzylaminophenyl)methyl]-1H-indole  (153) 
Method A: To a solution of 149a (0.10 g, 0.45 mmol) in dry 
DMF (20 mL) was added anhydrous K2CO3 (62 mg, 0.45 
mmol) and the suspension was stirred at 0-5 oC for 5 min. 
Benzyl bromide (53 µL, 0.45 mmol) in DMF (2 mL) was 
then added and the reaction mixture stirred at r.t. overnight. Solvent was then removed 
under reduced pressure. Diethyl ether (20 mL) was added to the residue and the mixture 
was washed with water (5 x 20 mL). The organic layer was dried and concentrated. The 
crude material was chromatographed on a silica gel column using DCM as eluting 
solvent to give 153 (0.095 g, 67%) as a yellow solid. 
Method B: To a solution of 149a (0.30 g, 1.35 mmol) in absolute methanol (10 mL) 
with molecular sieves (3Å) was added 5 M HCl-MeOH (90 µL, 0.45 mmol), followed 
by benzaldehyde (0.14 mL, 1.35 mmol) and NaBH3CN (85 mg, 1.35 mmol). The 
reaction mixture was stirred at r.t. for 20 h. The mixture was filtered and the filtrate was 
evaporated to dryness. Water (20 mL) was added and extracted with DCM (20 mL). The 
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aqueous layer was brought to pH > 10 with solid KOH and extracted with DCM (3 x 20 
mL). The organic extracts were combined and washed with brine (20 mL), dried and 
concentrated to give a brown oil. The oil was subjected to flash column chromatography 
by elution with 1:1 DCM/hexane to give compound 153 (0.28 g, 66%) as a yellow solid; 
mp 89-91 oC; IR (KBr) νmax: 3432 (NH) cm-1; 1H NMR (CDCl3) δ 3.93 (br s, 1H, NH), 
4.32 (s, 2H, NHCH2), 5.20 (s, 2H, CH2), 6.65 (dd, J= 3.3, 0.6 Hz, 1H, H-3), 6.76 (d, J= 
8.1 Hz, 1H, H-3΄), 6.83 (td, J= 7.5, 1.2 Hz, 1H, Ar), 7.07- 7.11 (m, with prominent of d, 
J= 3.3 Hz, 2H, H-2 and Ar), 7.18- 7.38 (m, 8H, Ar), 7.44 (dd, J= 7.2, 1.5 Hz, 1H, H-7), 
7.78 (dd, J= 7.5, 0.9 Hz, 1H, H-4); 13C NMR (CDCl3) δ 48.0 (NHCH2), 48.3 (CH2), 
102.5 (C-3), 109.8, 111.7, 120.1 (all ArC-H), 121.0 (C-1΄), 121.5, 122.2, 127.4, 127.6, 
128.9 (all ArC-H), 129.2 (C-3a), 129.7 (ArC-H), 129.8 (ArC-H), 136.6 (C-7a), 139.1 
(C-1΄΄), 146.3 (C-2΄); CI-MS m/z 313 ([MH]+, 100%); HREI-MS m/z calcd for [M]+ 
C22H20N2: 312.1625, found: 312.1621. 
Synthesis of 1-[(2-N-benzylaminophenyl)methyl]-5-methoxy-1H-indole  (154) 
Method A: To a solution of 149b (1.00 g, 4.00 mmol) 
in dry DMF (50 mL) was added anhydrous K2CO3 
(0.58 g, 4.17 mmol) and the suspension was stirred at 
0-5 oC for 5 min. Benzyl bromide (0.50 mL, 4.17 
mmol) in DMF (10 mL) was then added and the reaction mixture stirred at r.t. 
overnight. The solvent was then removed under reduced pressure. Diethyl ether (20 mL) 
was added to the residue and the mixture was washed with water (5 x 20 mL). The 
organic layer was dried and concentrated. The crude material was chromatographed on 
a silica gel column using DCM as eluting solvent to give 154 (0.80 g, 58%) as a yellow 
solid. 
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Method B: To a solution of 149b (1.05 g, 4.17 mmol) in absolute methanol (30 mL) 
with molecular sieves (3Å) was added 5 M HCl-MeOH (0.42 mL, 2.09 mmol), followed 
by benzaldehyde (0.42 mL, 4.17 mmol) and NaBH3CN (0.26 g, 4.17 mmol). The 
reaction mixture was filtered and the filtrate was evaporated to dryness. Water (20 mL) 
was added and extracted with DCM (20 mL). The aqueous layer was brought to pH > 
10 with solid KOH and extracted with DCM (3 x 20 mL). The organic extracts were 
combined and washed with brine (20 mL), dried and concentrated. The crude material 
was chromatographed on a silica gel column using DCM as eluting solvent to give 
compound 154 (0.40 g, 28%) as a yellow solid; mp 108-110 oC; IR (KBr) νmax: 3428 
(NH) cm-1; 1H NMR (CDCl3) δ 3.86 (s, 3H, OCH3), 4.23 (s, 2H, NHCH2), 5.17 (s, 2H, 
CH2), 6.48 (d, J= 3.3 Hz, 1H, H-3), 6.65 (d, J= 8.4 Hz, 1H, H-3΄), 6.73 (t, J= 7.5 Hz, 
1H, Ar), 6.81 (dd, J= 8.7, 2.4 Hz, 1H, H-6), 6.98- 7.02 (m, 2H, H-2 and Ar), 7.07-7.11 
(m, 3H, Ar), 7.18-7.30 (m, 6H, Ar); 13C NMR (CDCl3) δ  48.1 (NCH2), 48.2 (CH2), 
56.1 (CH3), 101.9 (C-3), 103.0 (C-4), 110.4, 111.6, 112.2, 117.7, 120.8 (C-1΄), 127.4, 
128.1, 128.8, 129.6, 129.8, 131.8 (C-7a), 139.0 (C-1΄΄), 146.2 (C-2΄), 154.4 (COCH3); 
CI-MS m/z 343 ([MH]+, 100%); HREI-MS m/z calcd for [M]+ C23H22N2O: 342.1732, 
found: 342.1731. 
Synthesis of 1-[(2-N-benzylaminophenyl)methyl]- 5-fluoro-1H-indole (155) 
 Method A: To a solution of 149c (1.00 g, 4.12 mmol) in dry 
DMF (50 mL) was added anhydrous K2CO3 (0.57 g, 4.12 
mmol) and the suspension was stirred at 0-5 oC for 5 min. 
Benzyl bromide (0.49 mL, 4.12 mmol) in DMF (10 mL) 
was then added and the reaction mixture stirred at r.t. overnight. The solvent then was 
removed under reduced pressure. Diethyl ether (20 mL) was added to the residue and 
the mixture was washed with water (5 x 20 mL). The organic layer was dried and 
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concentrated. The crude material was chromatographed on a silica gel column using 
DCM as eluting solvent to give 155 (0.65 g, 48 %) as a yellow solid. 
Method B: To a solution of 149c (1.04 g, 4.33 mmol) in absolute methanol (30 mL) with 
molecular sieves (3Å) was added 5 M HCl-MeOH (0.43 mL, 2.17 mmol), followed by 
benzaldehyde (0.44 mL, 4.33 mmol) and NaBH3CN (0.27 g, 4.33 mmol). The reaction 
mixture was filtered and the filtrate was evaporated to dryness. Water (20 mL) was 
added and extracted with DCM (20 mL). The aqueous extracts was brought to pH > 10 
with solid KOH and extracted with DCM (3 x 20 mL). The organic layers were 
combined and washed with brine (20 mL), dried and concentrated. The crude material 
was chromatographed on a silica gel column using DCM as eluting solvent to give 
compound 155 (0.30 g, 21%) as colourless needles; mp 189-191 oC; IR (KBr) νmax: 
3430 (NH) cm-1; 1H NMR (CDCl3) δ 4.24 (s, 2H, NHCH2), 5.19 (s, 2H, CH2), 6.50 (d, 
J= 3.3 Hz, 1H, H-3), 6.71 (d, J= 8.1 Hz, 1H, Ar), 6.77 (t, J= 7.5 Hz, 1H, Ar), 6.90 (td, 
J= 9.0, 2.7 Hz, 1H, H-6), 7.00 (dd, J= 7.5, 1.5 Hz, 1H, Ar), 7.05-7.10 (m with 
prominent d, J= 3.3 Hz, 2H, H-2 and Ar), 7.16-7.27 (m, 6H, Ar), 7.30 (dd, J= 9.6, 2.4 
Hz, 1H, H-7); 13C NMR (CDCl3) δ 48.2 (NHCH2), 48.3 (CH2), 102.3 (d, J= 4.9 Hz, 13C-
19F, C3-F), 106.1 (d, J= 23.2 Hz, 13C-19F, C6-F), 110.9 (d, J= 10.3 Hz, 13C-19F, C7-F), 
110.8 (d, J= 27.8 Hz, 13C-19F, C4-F), 117.0 (ArC-H), 118.1 (ArC-H), 120.9 (C-1΄), 
127.5, 128.8, 129.15, 129.23 (all ArC-H), 129.5 (d, J= 16.3 Hz, 13C-19F, C3a-F), 129.8 
(ArC-H), 133.1 (C-7a), 138.6 (C-1΄΄), 146.0 (C-2΄), 158.2 (d, J= 233.1 Hz, 13C-19F, C5-
F); CI-MS m/z 331 ([MH]+, 100%); HREI-MS m/z calcd for C22H19N2F: 330.1532, 
found: 330.1533. 
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Synthesis of 1-{[2-N-(1-phenylethyl)aminophenyl]methyl}-1H-indole  (156) 
To a solution of 149a (0.30 g, 1.42 mmol) in absolute 
methanol (10 mL) with molecular sieves (3Å) was added  5 
M HCl-MeOH (0.10 mL, 0.50 mmol), followed by 
acetophenone (40 µL, 0.34 mmol) and NaBH3CN (10 mg, 
0.14 mmol). The reaction mixture was filtered and the filtrate was evaporated to 
dryness. Water (15 mL) was added and extracted with DCM (15 mL). The aqueous 
layer was brought to pH > 10 with solid KOH and extracted with DCM (3 x 15mL). The 
organic extracts were combined and washed with brine (15 mL), dried and concentrated. 
The crude material was chromatographed on a silica gel column using 1:1 hexane/DCM 
as eluting solvent to give compound 156 (82 mg, 74 %) as an off-white solid; mp 86-88 
oC; IR (KBr) νmax: 3425 (NH) cm-1; 1H NMR (CDCl3) δ 1.11 (d, 3H, J= 6.6 Hz, CH3), 
3.47 (br s, 1H, NH), 4.33 (q, J= 6.6 Hz, 1H, CH), 5.20 (s, 2H, CH2), 6.37 (d, J= 8.1 Hz, 
1H, H-3΄), 6.57 (d, J= 3.3 Hz, 1H, H-3), 6.64 (t, J= 7.5 Hz, 1H, H-5΄), 6.93-6.95 (m, 
2H, H-2΄΄ and H-6΄΄), 7.00- 7.10 (m, 3H, H-2, H-4΄ and H-6΄), 7.11-7.23 (m, 5H, H-5, 
H-6, H-3΄΄, H-4΄΄ and H-5΄΄), 7.42 (d, J= 8.1 Hz, 1H, H-7), 7.66 (d, J= 7.5 Hz, 1H, H-
4); 13C NMR (CDCl3) δ 25.4 (CH3), 48.6 (CH2), 53.2 (CH), 102.7 (C-3), 109.7 (C-7), 
112.6 (C-6), 117.4 (C-4), 120.1 (C-5), 120.8 (C-1΄), 121.6, 122.2, 125.8, 127.1, 127.6, 
128.8 (all ArC-H), 129.1 (C-3a), 129.6 (ArC-H), 130.1 (ArC-H), 136.6 (C-7a), 144.9 
(C-1΄΄), 145.8 (C-2΄); CI-MS m/z 327 ([MH]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C23H23N2: 327.1861, found: 327.1850. 
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7.2.5 Acylation procedure 
Synthesis of N-{2-[1-(3-trifluoroacetyl-1H-indolyl)methyl]phenyl}trifluoro 
acetamide (157) 
  To a stirred solution of 149a (0.2 g, 0.90 mmol) and pyridine 
(0.10 mL, 1.35 mmol) in dry DCM (5 mL) was added a 
solution of trifluoroacetic anhydride (0.19 mL, 1.35 mmol) in 
DCM (5 mL). The reaction mixture was stirred at r.t. for 4 h 
and then water (20 mL) was added. The organic layer was separated, dried and 
concentrated to dryness. The residue was subjected to a short column (silica gel; DCM) 
to give compound 157 (0.24 g, 67%) as a white solid; mp 177-178 oC; 1H NMR 
(CDCl3) δ 5.40 (s, 2H, CH2), 6.96 (d, J= 7.5 Hz, 1H, H-3΄), 7.21-7.43 (m, 6H, Ar), 7.93 
(s, 1H, H-2), 8.04 (br s, 1H, NH), 8.37 (d, J= 7.5 Hz, 1H, H-4); 13C NMR (CDCl3) δ 
48.4 (CH2), 110.5 (C-3), 110.8 (C-7), 117.1 (d, J= 285 Hz, CF3), 123.0 (C-4), 124.5 (C-
5΄), 125.3 (C-6), 126.8 (C-5), 127.2 (C-3a), 128.6 (C-4΄), 129.4 (C-3΄), 129.9 (C-6΄), 
131.3 (C-1΄), 131.5 (C-2΄), 136.9 (C-7a), 137.9 (d, J= 7.5 Hz, 13C-19F, C2-F), 156.4 (d, 
J= 45 Hz, 13C-19F, CO-F), 157.3 (d, J= 52 Hz, 13C-19F, CO-F); CI-MS m/z 414 ([M+H]+, 
100%); HREI-MS m/z calcd for [M]+ C19H12N2O2F6: 414.0803, found: 414.0780. 
Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}trifluoroacetamide (158) 
To a stirred solution of 149a (0.1 g, 0.45 mmol) and pyridine 
(0.05 mL, 0.68 mmol) in dry DCM (5 mL) was added a 
solution of trifluoroacetic anhydride (70 µL, 0.50 mmol) in 
DCM (5 mL). The reaction mixture was stirred at r.t. for 4 h 
and then water (20 mL) was added. The organic layer was separated, dried and 
concentrated to dryness. The residue was subjected to a short column (silica gel; DCM) 
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to give compound 158 (0.13g, 92%) as a white solid; mp 168-170 oC; 1H NMR (CDCl3) 
δ 5.27 (s, 2H, CH2), 6.60 (d, J= 3.0 Hz, 1H, H-3), 7.03 (d, J= 3.0 Hz, 1H, H-2), 7.12-
7.27 (m, 4H, Ar), 7.29 (t, J= 7.5 Hz, 1H, H-5΄), 7.39 (t, J= 7.8 Hz, 1H, H-4΄), 7.60 (d, 
J= 8.1 Hz, 1H, H-3΄), 7.67 (dd, J= 6.6, 2.1 Hz, 1H, H-4); 13C NMR (CDCl3) δ  47.6 
(CH2), 103.0 (C-3), 109.4 (C-7), 115.5 (d, J= 285 Hz, 13C-19F, CF3), 120.1 (C-5), 121.2 
(C-4), 122.2 (C-6), 125.2 (C-3΄), 127.3 (C-2), 127.9 (C-5΄), 128.8 (C-3a), 129.0 (C-4΄), 
129.3 (C-6΄), 130.7 (C-1΄), 132.4 (C-2΄), 136.1 (C-7a), 155.5 (d, J= 37.5 Hz, 13C-19F, 
CO-F); CI-MS m/z 319 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ C17H13N2OF3: 
318.0980, found: 318.0990. 
Synthesis of 1-[(2-N-ethylcarbamoylphenyl)methyl]-1H-indole (159) 
To a stirred suspension of NaH (ca 50% dispersion in 
mineral oil, 23 mg, 0.49 mmol) in dry THF (5 mL) was 
added a solution of 149a (0.10 g, 0.45 mmol) in dry THF 
(10 mL) under a N2 atmosphere which was stirred at r.t. 
for 30 min. Ethyl chloroformate (65 µL, 0.68 mmol) in THF (10 mL) was then added 
and the reaction mixture stirred at r.t. overnight. The solvent was then removed under 
reduced pressure. DCM (15 mL) was added to the residue and the mixture was washed 
with water (3 x 15 mL). The organic extract was dried and concentrated to give a pink 
solid. The solid was passed through a quick column of silica gel eluting with 1:1 
hexane/DCM to give the title compound 159 (130 mg, 98%) as white needles; mp 129-
131 oC; 1H NMR (CDCl3) δ 1.28 (t, J= 7.2 Hz, 3H, CH2CH3), 4.20 (q, J= 7.2 Hz, 2H, 
CH2CH3), 5.29 (s, 2H, CH2), 6.36 (br s, 1H, NH), 6.58 (dd, J= 3.0, 0.9 Hz, 1H, H-3), 
6.92 (d, J= 7.8 Hz, 1H, H-3΄), 7.05 (d, J= 3.0 Hz, 1H, H-2), 7.08 (ddd, J= 7.5, 7.5, 1.2 
Hz, 1H, H-4΄), 7.15 (dd, J= 7.5, 1.2, Hz, 1H, Ar), 7.20 (ddd, J= 7.5, 7.5, 1,2 Hz, 1H, 
Ar), 7.26-7.34 (m, 2H, Ar), 7.58 (d, J= 7.8 Hz, 1H, H-7), 7.67 (dt, J= 7.5, 1.2, 0.6 Hz, 
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1H, H-4); 13C-NMR (CDCl3) δ 15.0 (CH2CH3), 47.4 (CH2), 61.9 (CH2CH3), 102.6 (C-
3), 109.8 (C-7), 120.0 (C-5), 121.3 (C-4), 122.2 (C-6), 124.4, 125.9 (C-4΄), 128.0 (C-2), 
128.8 (C-3΄), 128.9, 129.0, 135.4 (all ArC), 136.5 (C-7a), 154.5 (CO); CI-MS m/z 295 
([M+H]+, 97%); HRCI-MS m/z calcd for [M+H]+ C18H18N2O2: 295.1447, found: 
295.1446.  
Synthesis of 1-[(2-N-tert-butoxycarbonylaminophenyl)methyl]-1H-indole (160) 
To a stirred solution of NaH (ca 50% dispersion in mineral 
oil, 23 mg, 0.49 mmol) in dry THF (5 mL) was added 
amine 149a (0.1 g, 0.45 mmol) in THF (10 mL) and the 
solution was stirred at r.t. for 30 min. (BOC)2O (0.15 g, 
0.68 mmol) in THF (10 mL) was slowly added to the solution. The reaction mixture was 
further stirred at r.t. overnight. The solvent was evaporated to dryness. Diethyl ether (10 
mL) was added and washed with water (3 x 10 mL). The organic layer was dried and 
evaporated to give a crude brown solid. The crude solid was subjected to flash column 
chromatography (silica gel, 1:1 hexane/DCM) to give the Boc compound 160 (0.13 g, 
91%) as orange crystals; mp 139-141 oC; 1H-NMR (CDCl3)  δ 1.47 (s, 9H, CH3), 5.29 
(s, 2H, CH2), 6.20 (br s, 1H, NH), 6.56 (d, J= 3.3 Hz, 1H, H-3), 6.92 (d, J= 7.5 Hz, 1H, 
H-3΄), 7.05-7.09 (m with prominent d, J= 3.3 Hz, 2H, H-2 and Ar), 7.12 (t, J= 7.5 Hz, 
1H, H-5), 7.19 (t, J= 8.1 Hz, 1H, H-6), 7.25-7.32 (m, 2H, H-7 and Ar), 7.56 (d, J= 8.4 
Hz, 1H, H-6΄), 7.65 (d, J= 7.2 Hz, 1H, H-4); 13C NMR (CDCl3) δ 28.6 (CH3), 47.4 
(CH2), 81.0 (C(CH3)3), 102.5 (C-3), 109.7 (C-7), 120.0 (C-5), 121.3 (C-4), 122.1 (C-6), 
124.2 (ArC), 125.5 (C-4΄), 128.0 (C-2), 128.7, 128.8 (all ArC-H), 128.9 (C-3a), 129.8 
(C-1΄), 135.7 (C-2΄), 136.5 (C-7a), 153.5 (CO); CI-MS m/z 323 ([M+H]+, 26%); HREI-
MS m/z calcd for [M]+ C20H22N2O2: 322.1680, found: 322.1697. 
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7.2.6 Preparation of chloroacetamides 
Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}chloroacetamide (161) 
A stirred suspension of amine 149a (0.50 g, 2.2 mmol) and 
anhydrous K2CO3 (0.52 g, 3.74 mmol) in dry DCM (15 mL) 
was cooled to 0-5 oC and chloroacetyl chloride (0.26 mL, 
3.30 mmol) in DCM (10 mL) was added. Stirring was 
continued with cooling for a further 30 min and the reaction then allowed to warm to r.t. 
with stirring overnight. Distilled water (15 mL) was added to the reaction and the 
aqueous layer was extracted with DCM (3 x 20 mL). The combined organic extracts 
were dried and concentrated to yield a brown solid. The solid was subjected to flash 
column chromatography (silica gel, 1:1 DCM/hexane) to give the title compound 161 
(0.55 g, 84%) as colourless, fluffy crystals; mp 123-124 oC (lit.30 120-122 oC); 1H NMR 
(CDCl3) δ 4.03 (s, 2H, CH2Cl), 5.30 (s, 2H, CH2), 6.57 (d, J= 3.3 Hz, 1H, H-3), 7.01 (d, 
J= 3.0 Hz, 1H, H-2), 7.07 (d, J= 7.5 Hz, 1H, Ar), 7.12-7.31 (m, 4H, Ar), 7.37 (t, J= 7.0 
Hz, 1H, H-6), 7.65 (t, J= 7.2 Hz, 2H, H-4 and Ar), 8.00 (s, 1H, NH); 13C NMR (CDCl3) 
δ 42.7 (CH2Cl), 47.3 (CH2), 102.6 (C-3), 109.6 (C-7), 119.9 (ArC-H), 121.2 (C-1΄), 
122.0 (C-3΄), 125.1 (C-2), 127.0 (C-3a), 127.4, 128.8, 128.9, 129.2, 130.4 (all ArC-H), 
134.1 (C-7a), 136.4 (C-2΄), 164.6 (CO); CI-MS m/z 299 ([M+H; 35Cl]+, 100%). 
Synthesis of N-{2-[1-(5-fluoro-1H-indolyl)methyl]phenyl}chloroacetamide (162) 
A stirred suspension of amine 149c (0.15 g, 0.63 mmol) 
and anhydrous K2CO3 (95 mg, 0.69 mmol) in dry DCM 
(15 mL) was cooled to 0-5 oC and chloroacetyl chloride 
(75 µL, 0.94 mmol) in DCM (5 mL) was added. Stirring 
was continued with cooling for a further 30 min and the reaction then allowed to warm 
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to r.t. with stirring overnight. Distilled water (15 mL) was added to the reaction and the 
aqueous layer was extracted with DCM (3 x 20 mL). The combined organic extracts 
were dried and concentrated to yield a brown solid. The solid was subjected to flash 
column chromatography (silica gel, 1:1 DCM/hexane) to give the title compound 162 
(0.17 g, 86%) as colourless solid; mp 145-146 oC (lit.30 142-143 oC); 1H NMR (CDCl3) 
δ 4.06 (s, 2H, CH2Cl), 5.28 (s, 2H, CH2), 6.51 (d, J= 3.0 Hz, 1H, H-3), 9.93 (d, J= 9.3, 
2.4 Hz, 1H, H-6), 7.01-7.04 (m, 2H, Ar), 7.15- 7.25 (m, 2H, H-4 and Ar), 7.29 (dd, J= 
9.6, 2.4 Hz, 1H, H-7), 7.37 (t, J= 7.8, 1.2 Hz, 1H, Ar), 7.61 (d, J= 7.8 Hz, 1H, H-3΄), 
8.00 (br s, 1H, NH); 13C NMR (CDCl3) δ 43.1 (CH2Cl), 48.0 (CH2), 102.7 (d, J= 4.9 
Hz, 13C-19F, C3-F), 106.1 (d, J= 23.3 Hz, 13C-19F, C6-F), 110.4 (C-7), 110.7 (d, J= 15.2 
Hz, 13C-19F, C4-F), 125.4 (ArC-H), 126.0 (d, J= 14.4 Hz, 13C-19F, C3a-F), 127.4, 129.2, 
129.3 (all ArC-H), 130.5 (C-1΄), 133.2 (C-7a), 134.2 (C-2΄), 158.1 (d, J= 234 Hz, 13C-
19F, C5-F), 164.7 (CO); CI-MS m/z 317 ([M+H; 35Cl]+, 100%).    
Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-methylchloroacetamide (163) 
A mixture of 150a  (83 mg, 0.35 mmol) and anhydrous 
K2CO3 (0.18 g, 1.30 mmol) in dry DCM (5 mL) was cooled 
to 0-5 oC and chloroacetyl chloride (70 µL, 0.88 mmol) in 
DCM (3 mL) was added. Stirring was continued with 
cooling for a further 30 min and the reaction then allowed to warm to r.t. with stirring 
overnight. Distilled water (15 mL) was added to the reaction and the aqueous layer was 
extracted with DCM (3 x 20 mL). The combined organic extracts were dried and 
concentrated to yield a yellow solid. The crude soild was subjected to flash column 
chromatography (silica gel, DCM) to give 163 (63 mg, 57%) as a colourless solid; mp 
89-92 oC; IR (KBr) νmax: 2852 (N-CH3), 1658 (C=O), 796 (C-Cl) cm-1; 1H NMR 
(CDCl3) δ 3.24 (s, 3H, CH3), 3.56 (d, J= 12.6 Hz, 1H, CHHCl), 3.66 (d, J= 12.6 Hz, 1H, 
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CHHCl), 5.29 (d, J= 5.7 Hz, 2H, CH2), 6.59 (d, J= 3.3 Hz, 1H, H-3), 6.99 (d, J= 7.5 Hz, 
1H, Ar), 7.06 (d, J= 3.0 Hz, 1H, H-2), 7.11-7.39 (m, 5H, Ar), 7.36 (m, 1H, H-6), 7.67 
(d, J= 7.8 Hz, 1H, H-4); 13C NMR (CDCl3) δ 37.5 (CH3), 41.3 (CH2Cl), 46.7 (CH2), 
102.7 (C-3), 109.6 (C-7), 119.9, 121.2 (C-1΄), 122.0 (C-3΄), 125.1 (C-2), 127.0 (C-3a), 
127.4, 128.8, 128.9, 129.2, 130.4 (all ArC-H), 134.1 (C-7a), 136.4 (C-2΄), 164.6 (CO); 
CI-MS m/z 313 [M+H]+, 100%); HRCI-MS m/z calcd for C18H18N2O35Cl: 313.1108, 
found: 313.1111. 
Synthesis of N-{2-[1-(5-methoxy-1H-indolyl)methyl]phenyl}-N-methylchloro 
acetamide (164) 
Following the procedure for 163, treatment of 150b (0.29 
g, 1.09 mmol) with anhydrous K2CO3 (0.56 g, 4.03 
mmol) and chloroacetyl chloride (0.22 mL, 2.73 mmol) 
gave 164 (0.22 g, 58%), after purification by column 
chromatography (silica gel,  DCM), as a yellow solid; mp 71-73 oC; 1H NMR (CDCl3) δ 
3.21 (s, 3H, CH3), 3.52 (d, J= 12.6 Hz, 1H, CHHCl), 3.62 (d, J= 12.6 Hz, 1H, CHHCl), 
3.83 (s, 3H, OCH3), 5.23 (d, J= 5.1 Hz, 2H, CH2), 6.84 (d, J= 3.6 Hz, 1H, C-3), 6.83 
(dd, J= 9.0, 2.4 Hz, 1H, Ar), 6.87 (d, J= 7.5 Hz, 1H, Ar), 7.02 (d, J= 3.0 Hz, 1H, H-2), 
7.05-7.10 (m with prominent d, J= 2.4 Hz, 2H, Ar), 7.20 (dd, J= 7.5, 1.2 Hz, 1H, Ar), 
7.28- 7.39 (m, 2H, Ar); 13C NMR (CDCl3) δ 37.5 (CH3), 41.2 (CH2Cl), 47.1 (CH2), 56.1 
(OCH3), 102.3 (C-3), 103.0, 110.4, 112.6, 128.9, 129.0 (all ArC-H), 129.3 (C-3a), 
129.7, 129.9, 131.6 (C-1΄), 135.2 (C-7a), 140.6 (C-2΄), 154.4 (COCH3), 166.8 (CO); CI-
MS m/z 343 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C19H20N2O235Cl: 
343.1213, found: 343.1208. 
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Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-(4-methoxybenzyl)chloro 
acetamide  (165) 
To a stirred suspension of NaH (27 mg ca 50% 
dispersion in mineral oil, 0.57 mmol) in dry THF (5 
mL) was added a solution of 152 (0.18 g, 0.52 
mmol) in dry THF (20 mL) under a N2 atmosphere 
with stirring at r.t. for 30 min. Chloroacetyl chloride 
(0.11 mL, 1.42 mmol) in THF (5 mL) was then added and the reaction mixture stirred 
overnight. The solvent was then removed under reduced pressure. DCM (15 mL) was 
added to the residue and the mixture was washed with water (3 x 15 mL). The organic 
layer was dried and concentrated to give a yellow residue. The residue was subjected to 
a flash column of silica gel by eluting with DCM to give 165 (0.20 g, 93%) as a yellow 
solid; mp 82-84 oC; 1H NMR (CDCl3) δ 3.51 (d, J= 12.6 Hz, 1H, CHHCl), 3.62 (d, J= 
12.6 Hz, 1H, CHHCl), 3.75 (s, 3H, OCH3), 4.55 (d, J= 13.8 Hz, 1H, CONCHH), 4.78 
(d, J= 16.8 Hz, 1H, CHH), 4.95 (d, J= 13.8 Hz, 1H, CONCHH), 5.08 (d, J= 16.8 Hz, 
1H, CHH), 6.51 (d, J= 3.3 Hz, 1H, H-3), 6.77-6.80 (m with prominent d, J= 8.7 Hz, 3H, 
H-3΄, H-3΄΄, and H-5΄΄), 6.84-6.88 (m with prominent d, J= 3.0 Hz, 2H, H-2 and H-6΄), 
7.00 (d, J= 8.1 Hz, 1H, Ar), 7.07 (t, J= 7.2 Hz, 1H, H-5), 7.09-7.12 (m with prominent 
d, J= 8.7 Hz, 3H, H-6, H-2΄΄, and H-6΄΄), 7.17-7.24 (m, 2H, Ar), 7.59 (d, J= 7.5 Hz, 1H, 
H-4); 13C NMR (CDCl3) δ 41.8 (CH2Cl), 46.6 (CH2), 53.8 (CONCH2), 55.6 (CH3), 
102.7 (C-3), 109.6, 114.3, 120.8, 121.4, 122.3, 128.2, 128.3 (all ArC-H), 128.8 (C-3a), 
129.3, 129.4, 129.9, 130.1, 131.3 (all ArC-H), 135.9 (C-1΄), 136.4 (C-7a), 138.4 (C-2΄), 
159.7 (COCH3), 166.8 (CO); CI-MS m/z 419 ([M+H]+; 100%), 421 ([M+H]+; 37Cl]+, 
35%); HRCI-MS m/z calcd for C25H24N2O237Cl: 421.1497, found: 421.1498. 
N
N
ClO
OMe
1
2
3
4
5
6
7
1'
2'
3'
4'5'
6'
1''
2'' 3''
4''
5''6''
 169
Synthesis of N-benzyl-N-{2-[1-(1H-indolyl)methyl]phenyl}chloroacetamide (166) 
Following the procedure for 165, NaH (ca 50% 
dispersion in mineral oil, 70 mg, 1.76 mmol) was reacted 
with 153 (0.50 g, 1.60 mmol) and chloroacetyl chloride 
(0.32 mL, 4.00 mmol) to give 166 (0.50 g, 81%), after 
purification by column chromatography (silica gel, DCM), as a yellow solid; mp 148-
149 oC; 1H NMR (CDCl3) δ 3.56 (d, J= 12.9 Hz, 1H, CHHCl, 3.66 (d, J= 13.2 Hz, 1H, 
CHHCl), 4.65 (d, J= 13.8 Hz, 1H, CONCHH), 4.80 (d, J= 16.8 Hz, 1H, CHH), 5.04 (d, 
J= 13.8 Hz, 1H, CONCHH), 5.12 (d, J= 16.8 Hz, 1H, CHH), 6.54 (d, J= 3.0 Hz, 1H, H-
3), 6.78 (m, 1H, Ar), 6.85 (d, J= 3.0 Hz, 1H, H-2), 6.93 (m, 1H, Ar), 7.04 (d, J= 7.8 Hz, 
1H, H-7), 7.13 (td, J= 7.2, 1.5 Hz, 1H, H-5), 7.22 (td, J= 6.9, 0.9 Hz, 1H, H-6), 7.22- 
7.28 (m, 4H, Ar), 7.30-7.36 (m, 3H, Ar), 7.64 (dd, J= 7.5, 0.9 Hz, 1H, H-4). 13C NMR 
(CDCl3) δ 41.3 (CH2Cl), 46.3 (CH2),  53.3 (CONCH2), 102.5 (C-3), 109.3 (C-7), 119.5 
(C-5), 121.2 (C-4), 122.1 (C-6), 127.9 (C-2), 128.3, 128.5 (C-3a), 128.8, 129.0, 129.2, 
129.7, 129.8, 129.9 (all ArC-H), 135.7 (C-1΄), 136.0 (C-7a), 136.2 (C-1΄΄), 138.3 (C-2΄), 
166.5 (CO); CI-MS m/z 388 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ 
C24H21N2O35Cl: 388.1342, found: 388.1334. 
Synthesis of N-benzyl-N-{2-[1-(5-methoxy-1H-indolyl)methyl]phenyl}chloro 
acetamide  (167) 
Following the procedure for 165, NaH (ca 50% 
dispersion in mineral oil, 23 mg, 0.64 mmol) was 
reacted with 154 (0.20 g, 0.58 mmol) and 
chloroacetyl chloride (0.12 mL, 1.45 mmol) to give 
167 (0.14 g, 58%), after purification by column 
chromatography (silica gel, DCM), as a yellow solid; mp 166-169 oC; 1H NMR (CDCl3) 
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δ 3.54 (d, J= 12.9 Hz, 1H, CHHCl), 3.64 (d, J= 12.9 Hz, 1H, CHHCl), 3.83 (s, 3H, 
OCH3), 4.62 (d, J= 13.5 Hz, 1H, CONCHH), 4.78 (d, J= 16.5 Hz, 1H, CHH), 5.04 (d, 
J= 13.8  Hz, 1H, CONCHH), 5.08 (d, J= 16.5 Hz, 1H, CHH), 6.46 (d, J= 2.4 Hz, 1H, H-
3), 6.79- 6.84 (m, 3H, Ar), 6.90-6.93 (m, 2H, Ar), 7.08 (d, J= 2.4 Hz, 1H, H-4), 7.21- 
7.33 (m, 7H, Ar); 13C NMR (CDCl3) δ 41.6 (CH2Cl), 46.8 (CH2), 53.5 (CONCH2), 56.0 
(CH3), 102.2 (C-3), 110.3, 112.6, 128.5, 128.7, 128.9, 129.2 (C-3a), 129.3, 129.5, 129.9, 
130.0, 130.1 (all ArC-H), 131.7 (C-1΄), 136.0 (C-7a), 136.3 (C-1΄΄), 138.6 (C-2΄), 154.5 
(COCH3), 166.7 (CO); CI-MS m/z 419 [(M+H;35Cl]+, 100%); HRCI-MS m/z calcd for 
[M+H]+ C25H24N2O235Cl: 419.1526, found: 419.1506. 
Synthesis of N-benzyl-N-{2-[1-(5-fluoro-1H-indolyl)methyl]phenyl}chloro 
acetamide (168) 
Following the procedure for 165, NaH (ca 50% 
dispersion in mineral oil, 18 mg, 0.46 mmol) was 
reacted with 153 (0.14 g, 0.42 mmol) and chloroacetyl 
chloride (84 µL, 1.05 mmol) to give 168 (0.13 g, 
76%), after purification by column chromatography (silica gel, DCM), as a yellow 
solid; mp 135-136 oC; 1H NMR (CDCl3) δ 3.55 (d, J= 12.6 Hz, 1H, CHHCl), 3.67 (d, 
J= 12.9 Hz, 1H, CHHCl), 4.64 (d, J= 13.8 Hz, 1H, CONCHH), 4.79 (d, J= 16.8 Hz, 1H, 
CHH), 5.02 (d, J= 13.8 Hz, 1H, CONCHH), 5.11 (d, J= 16.5 Hz, 1H, CHH), 6.50 (d, J= 
3.3 Hz, 1H, H-3), 6.79 (ddd, J= 9.3, 8.1, 2.7 Hz, 1H, Ar), 6.90 (d, J= 3.3 Hz, 1H, H-2), 
6.91-6.97 (m, 3H, Ar), 7.22-7.34 (m, 8H, Ar); 13C NMR (CDCl3) δ 41.5 (CH2Cl), 46.8 
(CH2), 53.6 (CONCH2), 102.7 (d, J= 4.6 Hz, 13C-19F, C-3), 106.2 (d, J= 23.0 Hz, 13C-
19F, C-6), 110.2 (d, J= 9.8 Hz, 13C-19F, C-7), 110.7 (d, J= 26 Hz, 13C-19F, C-4), 128.6, 
129.0, 129.2, 129.3, 129.5 (C-3a), 129.7, 129.8, 130.0, 130.2, 133.1 (C-1΄), 135.7 (C-
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7a), 136.2 (C-1΄΄), 138.6 (C-2΄), 158.2 (d, J= 223.6 Hz, 13C-19F, C5-F), 166.9 (CO); CI-
MS m/z 407 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C24H21N2O35ClF: 
407.1326, found: 407.1319. 
Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-(1-phenylethyl)chloro 
acetamide (169) 
A mixture of 156 (87 mg, 0.27 mmol), triethylamine (56 
µL, 0.41 mmol) and DMAP (3.3 mg, 0.03 mmol) in dry 
DCM (10 mL) was stirred at 0 oC. To this solution was 
then added a solution of chloroacetyl chloride (60 µL, 
0.54 mmol) in dry DCM (2 mL) and the mixture was stirred at r.t. for 1 h. The reaction 
mixture was washed with brine (15 mL) and the DCM layer was dried and concentrated. 
The residue was subjected to flash column chromatography (silica gel, 1:1 
hexane/DCM) to give 169 (36 mg, 33%) as a white solid; mp 90-92 oC; 1H NMR 
(CDCl3, rotamer ratio of ca 2:1*, * = minor rotamer) δ 1.58* (d, J= 7.2 Hz, 1H, CH3) 
1.64 (d, J= 7.2 Hz, 2H, CH3), 3.53 (d, J= 13.2 Hz, 1H, CHHCl), 3.63 (d, J= 13.2 Hz, 
1H, CHHCl), 3.73 (d, J= 17.4 Hz, 0.7H, CHH), 4.63 (d, J= 17.4 Hz, 0.7H, CHH), 5.31* 
(d, J= 17.1 Hz, 0.3H, CHH), 5.37* (d, J= 17.1 Hz, 0.3H, CHH), 6.22* (q, J= 7.2 Hz, 
0.3Hz, CH), 6.30 (q, J= 7.2 Hz, 0.7H, CH), 6.40 (d, J= 7.8 Hz, 0.7H, H-3′), 6.50 (d, J= 
3.3 Hz, 0.7H, H-3), 6.51 (d, J= 3.0 Hz, 0.7H, H-2), 6.60* (d, J= 3.3 Hz, 0.3H, H-3), 
6.78 (d, J= 7.8 Hz, 1H, Ar), 7.02-7.04* (m, 0.6H, H-2 and Ar), 7.06-7.16 (m, 3.4H, H-
2΄΄, H-6΄΄ and Ar), 7.22 (td, J= 7.5, 1.5 Hz, 1H, H-4΄ and H-4΄*), 7.27-7.36 (m, 5H, H-
3΄΄, H-5΄΄ and Ar), 7.39-7.43 (m, 1H, H-7 and H-7*), 7.58 (dd, J= 8.1, 2.1 Hz, 0.7H, H-
4), 7.67* (d, J= 7.8 Hz, H-4); 13C NMR (CDCl3) δ 19.4 (CH3), 42.3 (CH2Cl), 46.0 
(CH2), 55.7 (CH),  102.5 (C-3), 109.4, 119.9 (C-5), 121.2 (C-4), 122.1, 128.0 (C-2), 
128.4 (C-3΄), 128.5 (C-3a), 128.6, 128.9, 129.5, 130.2, 131.4, 134.9 (C-1΄), 136.5 (C-
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7a), 138.3 (C-1΄΄), 139.1 (C-N), 166.3 (CO); CI-MS m/z 403 ([M+H]+, 100%), 369 
([MH-Cl]+, 52%); HRCI-MS m/z calcd for [M+H]+ C25H24N2O35Cl: 403.1577, found: 
403.1559. 
Attempted synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-trifluoroacetyl 
chloroacetamide (170) 
Method A: A mixture of 158 (0.10 g, 0.31 mmol) and anhydrous K2CO3 (48 mg, 0.35 
mmol) in dry DCM (20 mL) was cooled to 0-5 oC and chloroacetyl chloride (38 µL, 
0.47 mmol) in DCM (3 mL) was added. Stirring was continued with cooling for a 
further 30 min and the reaction mixture was then allowed to warm to r.t. with stirring 
overnight. Distilled water (20 mL) was added to the reaction mixture and the aqueous 
layer was extracted with DCM (3 x 20 mL). The combined organic extracts were dried 
and concentrated to yield a crude yellow solid (0.12 g). 1H NMR of the crude solid 
showed that mostly starting material was recovered.  
Method B: To a stirred solution of NaH (ca 50% dispersion in mineral oil, 18 mg, 0.38 
mmol) in dry DMF (5 mL) was added amine 158 (0.10 g, 0.31 mmol) in DMF (15 mL) 
and the solution was stirred at r.t. for 30 min. (CF3CO)2O (0.12 mL, 0.85 mmol) in 
DMF (5 mL) was slowly added to the solution. The reaction mixture was then stirred at 
r.t. overnight. The solvent was then evaporated to dryness. Diethyl ether (10 mL) was 
added and washed with water (3 x 10 mL). The organic layer was dried and evaporated 
to give a crude orange solid (0.28 g). 1H NMR of the crude solid showed only starting 
material was recovered. 
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Synthesis of N-{2-[1-(3-trifluoroacetyl-1H-indolyl)methyl]phenyl}chloroacetamide 
(171) 
 To a stirred solution of the chloroacetamide 161 (0.13 g, 0.45 
mmol) and pyridine (0.05 mL, 0.68 mmol) in dry DCM (5 mL) 
was added a solution of trifluoroacetic anhydride (70 µL, 0.50 
mmol) in DCM (5 mL). The reaction mixture was stirred at r.t. 
for 4 h and then water (20 mL) was added. The organic layer 
was separated, dried and concentrated to dryness. The residue was subjected to PTLC 
(silica gel, DCM) to give starting material 161 (70 mg, 51%, higher Rf) and compound 
171 as a white solid (lower Rf) (12 mg, 7%); mp 203-204 oC; 1H NMR (CDCl3) δ 4.16 
(s, 2H, CH2Cl), 5.42 (s, 2H, CH2), 6.97 (d, J= 7.5 Hz, 1H, H-3΄), 7.25-7.43 (m, 6H, Ar), 
7.92 (d, J= 1.8 Hz, 1H, H-2), 8.13 (br s, 1H, NH), 8.41 (d, J= 7.2 Hz, 1H, H-4); 13C 
NMR (CDCl3) δ 43.0 (CH2Cl), 48.7 (CH2), 110.4 (C-3), 110.9 (C-7), 117.2 (d, J= 285 
Hz, 13C-19F, CF3), 123.0 (C-4), 124.4 (C-5΄), 125.1 (C-6), 126.4 (C-5), 127.3 (C-3a), 
128.3 (C-4΄), 128.5 (C-3΄), 129.7 (C-6΄), 130.6 (C-1΄), 133.5 (C-2΄), 137.1 (C-7a), 137.8 
(C-2), 155.2 (d, J= 37.5 Hz, 13C-19F, CO-F), 165.1 (CO); CI-MS m/z 395 ([M+H]+, 
100%); HREI-MS m/z calcd. for [M]+ C19H14N2O235ClF3: 394.0696, found: 394.0689. 
Attempted synthesis of N-ethoxycarbonyl-N-{2-[1-(1H-indolyl)methyl]phenyl} 
chloroacetamide (172) 
A mixture of 159  (0.10 g, 0.34 mmol) and anhydrous K2CO3 (80 mg, 0.58 mmol) in 
dry DCM (20 mL) was cooled to 0-5 oC and chloroacetyl chloride (41 µL, 0.51 mmol) 
in DCM (3 mL) was then added. Stirring was continued with cooling for a further 30 
min and the reaction was then allowed to warm to r.t. with stirring overnight. Distilled 
water (20 mL) was added to the reaction mixture and the aqueous layer was extracted 
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with DCM (3 x 20 mL). The combined organic extracts were dried and concentrated to 
yield a crude yellow solid (0.12 g). 1H NMR of the crude solid showed that only starting 
material was recovered.  
Synthesis of N-ethoxycarbonyl-N-{2-[1-(1H-indolyl)methyl]phenyl}chloro 
acetamide (172) 
To a stirred solution of NaH (ca 50% dispersion in 
mineral oil, 18 mg, 0.38 mmol) in dry DMF (5 mL) was 
added a solution of chloroacetamide 161 (0.10 g, 0.35 
mmol) in DMF (15 mL) and the solution mixture was 
stirred at r.t. for 30 min. Ethyl chloroformate (81 µL, 
0.85 mmol) in DMF (5 mL) was slowly added to the solution. The reaction mixture was 
then stirred at r.t. overnight. The solvent was evaporated to dryness. Diethyl ether (10 
mL) was added and washed with water (3 x 10 mL). The organic layer was dried and 
evaporated to give a crude orange solid (0.13 g). The crude solid was subjected to flash 
column chromatography (silica gel, 70:30 DCM/hexane) to give compound 172 (40 mg, 
32%); mp 45-47 oC; 1H-NMR (CDCl3) δ 1.09 (t, J= 7.2 Hz, 3H, CH2CH3), 3.92 (ddd, 
J= 7.2, 7.2, 6.9 Hz, 1H, CHHCH3), 4.08 (ddd, J= 7.2, 7.2, 6.9 Hz, 1H, CHHCH3), 4.77 
(s, 2H, CH2Cl), 5.12 (d, J= 16.2 Hz, 1H, CHH), 5.21 (d, J= 16.2 Hz, 1H, CHH), 6.54 (d, 
J= 3.0 Hz, 1H, H-3), 6.98 (dd, J= 7.5, 1.8 Hz, 1H, H-3΄), 7.03 (d, J= 3.3 Hz, 1H, H-2), 
7.07 (dd, J= 7.5, 1.8 Hz, 1H, H-6΄),  7.08-7.15 (m, 3H, H-5, H-6, and H-7), 7.30 (td, J= 
7.2, 1.8 Hz, 1H, H-4΄), 7.36 (td, J= 7.5, 1.8 Hz, 1H, H-5΄), 7.64 (dd, J= 6.9, 1.5 Hz, 1H, 
H-4); 13C NMR (CDCl3) δ 14.3 (CH3), 46.3 (CH2), 47.1 (CH2Cl), 64.2 (CH2CH3), 102.3 
(C-3), 109.7 (C-7), 119.9 (C-5), 121.3 (C-4), 122.0 (C-6), 128.5 (C-2), 128.8 (C-3΄), 
128.9 (C-3a), 129.06 (C-6΄), 129.1 (C-5΄), 129.6 (C-4΄), 135.1 (C-1΄), 135.6 (C-7a), 
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136.4 (C-2΄), 153.3 (COO), 168.8 (CO);  CI-MS m/z 371 ([M+H]+, 100%); HREI-MS 
m/z calcd for [M]+ C20H19N2O335Cl: 370.1084, found: 370.1094. 
Attempted synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-tert-butoxycarbonyl 
chloroacetamide (173)  
Method A: To a stirred solution of NaH (ca 50% dispersion in mineral oil, 16 mg, 0.34 
mmol) in dry THF (5 mL) was added the compound 160 (0.10 g, 0.31 mmol) in THF 
(10 mL) and the solution was stirred at r.t. for 30 min. Chloroacetyl chloride (60 µL, 
0.76 mmol) in THF (5 mL) was then slowly added to the solution. The reaction mixture 
was then stirred at r.t. overnight. The solvent was evaporated to dryness and water (20 
mL) was added and the mixture extracted with DCM (3 x 15 mL). The organic layer 
was dried and evaporated to give a crude pale orange solid (0.13 g). The crude solid was 
subjected to flash column chromatography (silica gel, 70:30 DCM/hexane), however, 
only starting material 160 (60 mg) was recovered. 
Method B: A mixture of 160 (80 mg, 0.25 mmol), triethylamine (56 µL, 0.41 mmol) and 
DMAP (3.3 mg, 0.03 mmol) in dry DCM (10 mL) was stirred at 0 oC. To this solution 
was added a solution of chloroacetyl chloride (60 µL, 0.54 mmol) in dry DCM (2 mL) 
and the mixture was stirred at r.t. for 1 h. The reaction mixture was washed with brine 
(15 mL) and the organic layer was dried and concentrated. The residue was subjected to 
flash column chromatography (silica gel, DCM) to give, in the first fraction, the 
chloroacetamide 161 (23 mg, 31%) and, in the second fraction, the starting material 160 
(42 mg, 52%). 
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7.2.7 Preparation of iodoacetamides 
Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}iodoacetamide (174) 
A solution of 161 (73 mg, 0.24 mmol) in acetronitrile (5 mL) 
containing NaI (0.37 g, 2.48 mmol) was heated at reflux for 2 
h. The solution was then cooled and water (10 mL) was added. 
The solution was extracted with ethyl acetate (3 x 20 mL). The 
organic extracts were combined, dried and concentrated. The 
residue was purified by flash column chromatography (silica gel, DCM) to give the title 
compound 174 as a colourless solid (83 mg, 0.21 mmol, 87%); mp 101-103 oC; IR 
(KBr) νmax: 2853 (N-CH3), 1659 (C=O) cm-1; 1H-NMR (CDCl3) δ 3.53 (s, 2H, CH2I), 
5.27 (s, 2H, CH2), 6.58 (d, J= 3.3 Hz, 1H, H-3), 7.03 (br d, J= 3.3 Hz, 2H, H-2 and Ar), 
7.12-7.26 (m, 3H, Ar), 7.29-7.32 (m, 2H, Ar and NH), 7.53 (br.d, J= 7.5 Hz, 2H, H-6 
and Ar), 7.67 (d, J=7.2 Hz, 1H, H-4); 13C-NMR (CDCl3) δ -3.1 (CH2I), 47.5 (CH2), 
102.9 (C-3), 109.8 (C-7), 120.3, 121.5, 122.4, 125.3, 127.1, 127.9, 129.0, 129.2, 131.0, 
134.8, 136.5 (C-N), 166.4 (CO); EI-MS m/z 390 ([M]+, 52%); HREI-MS m/z calcd for 
[M]+  C17H15N2OI: 390.0229, found: 390.0232. 
Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-methyliodoacetamide  (175) 
Following the procedure for 174, treatment of 163 (0.10 g, 0.32 
mmol) with NaI (0.50 g, 3.32 mmol) in refluxing acetonitrile (5 
mL) gave 175 (after purification by column chromatography 
with DCM; 0.12 g, 93%) as a yellow solid; mp 53-54 oC; 1H-
NMR (CDCl3) δ 3.21 (s, 3H, CH3), 3.30 (d, J= 10.2 Hz, 1H, CHHI), 3.45 (d, J= 9.6 Hz, 
1H, CHHI), 5.25 (d, J= 16.5 Hz, 1H, CHH), 5.37 (d, J= 16.5 Hz, 1H, CHH) 6.58 (d, J= 
2.7 Hz, 1H, H-3), 6.96 (d, J= 8.4 Hz, 1H, Ar), 7.09 (d, J= 3.0 Hz, 1H, H-2). 7.11-7.39 
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(m, 6H, Ar), 7.66 (d, J= 7.5 Hz, 1H, H-4); 13C NMR (CDCl3) δ -2.9 (CH2I), 37.7 (CH3), 
47.0 (CH2), 102.7 (C-3), 109.7 (C-7), 120.1, 121.4, 122.3, 128.3, 128.5 (all ArC-H), 
128.6 (C- 3a), 128.9, 129.6, 129.8 (all ArC-H), 134.9 (C-1΄), 136.4 (C-7a), 141.3 (C-2΄), 
168.3 (CO); CI-MS m/z 405 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ 
C18H17N2OI: 404.0386, found: 404.0396. 
Synthesis of N-{2-[1-(5-methoxy-1H-indolyl)methyl]phenyl}-N-methyl 
iodoacetamide  (176) 
Following the procedure for 174, treatment of 164 (0.21g, 
0.63 mmol) with NaI (0.99 g, 6.61 mmol) in refluxing 
acetonitrile (10 mL) gave 176 (after purification by 
column chromatography with DCM; 0.17g, 70%) as a 
yellow solid; mp 75-77 oC; 1H NMR (CDCl3) δ 31.8 (s, 
3H, CH3), 3.27 (d, J= 9.9 Hz, 1H, CHHI), 3.42 (d, J= 10.2 Hz, 1H, CHHI), 3.83 (s, 3H, 
OCH3), 5.26 (d, J= 16.2 Hz, 1H, CHH), 5.37 (d, J= 16.5 Hz, 1H, CHH), 6.48 (d, J= 3.3 
Hz, 1H, H-3), 6.83 (dd, J= 8.7, 2.7 Hz, 1H, Ar), 6.93 (dd, J= 7.2, 2.1 Hz, 1H, Ar), 7.05 
(d, J= 3.0 Hz, 1H, H-2), 7.08-7.11 (m, 2H, Ar), 7.23 (td, J= 8.4, 1.5 Hz, 1H, Ar), 7.35 
(d, J= 8.7 Hz, 1H, Ar), 7.38 (d, J= 9.3 Hz, 1H, H-4); 13C NMR (CDCl3) δ -2.7 (CH2I), 
37.7 (CH3), 47.2 (CH2), 56.1 (OCH3), 102.3 (C-3), 103.0, 110.5, 112.6, 128.5, 128.9, 
129.6, 129.8, 131.7 (C-1΄), 135.0 (C-7a), 141.3 (C-2΄), 154.4 (COCH3), 168.3 (CO); CI-
MS m/z 435 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ C19H19N2O2I: 434.0491, 
found: 434.0476. 
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Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-(4-methoxybenzyl)- 
iodoacetamide (177) 
Following the procedure for 174, treatment of 165 
(0.20g, 0.48 mmol) with NaI (0.76 g, 5.04 mmol) 
in refluxing acetonitrile (10 mL) gave 177 (after 
purification by column chromatography with 
DCM; 0.17g, 70%) as a yellow solid; mp 64-65 oC; 1H NMR (CDCl3) δ 3.20 (d, J= 9.6 
Hz, 1H, CHHI), 3.35 (d, J= 9.9 Hz, 1H, CHHI), 3.72 (s, 3H, OCH3), 4.51 (d, J= 13.8 
Hz, 1H, CONCHH), 4.77 (d, J= 16.8 Hz, 1H, CHH), 4.87 (d, J= 14.1 Hz, 1H, 
CONCHH), 5.10 (d, J= 16.8 Hz, 1H, CHH), 6.47 (dd, J= 3.3, 0.9 Hz, 1H, H-3), 6.70 
(dd, J= 8.1, 2.4 Hz, 1H, H-3΄), 6.76 (dd, J= 9.0, 2.4 Hz, 2H, H-3΄΄ and H-5΄΄), 6.82 (d, 
J= 3.0 Hz, 1H, H-2), 6.95 (dd, J= 9.0, 2.4 Hz, 1H, H-6΄), 6.98 (d, J= 8.4 Hz, 1H, Ar), 
7.04 (td, J= 6.9, 1.2 Hz, 1H, H-5), 7.05-7.12 (m with prominent d, J= 8.7 Hz, 3H, H-6, 
H-2΄΄ and H-6΄΄), 7.14-7.23 (m, 2H, Ar), 7.56 (dd, J= 7.5, 0.9 Hz, 1H, H-4); 13C NMR 
(CDCl3) δ -2.0 (CH2I), 46.8 (CH2), 53.1 (CONCH2), 55.6 (CH3), 102.7 (C-3), 109.7, 
114.3, 120.1, 121.4, 122.2, 128.2, 128.5, 128.7 (C-3a), 129.3, 129.8, 131.2, 135.6 (C-
1΄΄), 136.5 (C-7a), 139.2 (C-2΄), 159.7 (COCH3), 168.0 (CO); CI-MS m/z 511 ([M+H]+, 
13%); HREI-MS m/z calcd for [M]+ C25H23N2O2I: 510.0804, found: 510.0810. 
Synthesis of N-benzyl-N-{2-[1-(1H-indolyl)methyl]phenyl]iodoacetamide (178) 
Following the procedure for 174, treatment of 166 
(0.50 g, 1.29 mmol) with NaI (1.90 g, 12.9 mmol) in 
refluxing acetonitrile (20 mL) gave 178 (after 
purification by column chromatography with DCM; 
0.52 g, 96%) as a yellow solid; mp 101-103 oC; 1H NMR (CDCl3) δ 3.31 (d, J= 9.9 Hz, 
1H, CHHI), 3.46 (d, J= 9.6 Hz, 1H, CHHI), 4.62 (d, J= 13.8 Hz, 1H, CONCHH), 4.85 
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(d, J= 16.8 Hz, 1H, CHH), 5.04 (d, J= 14.1 Hz, 1H, CONCHH), 5.18 (d, J= 16.5 Hz, 
1H, CHH), 6.55 (d, J= 3.3 Hz, 1H, H-3), 6.79 (dd, J= 7.5, 2.7 Hz, 1H, Ar), 6.88 (d, J= 
3.3 Hz, 1H, H-2), 7.03 (d, J= 6.9 Hz, 1H, Ar), 7.06 (d, J= 7.5 Hz, 1H, H-7), 7.11(td, J= 
6.6, 0.9 Hz, 1H, H-5), 7.18 (td, J= 7.5, 1.2 Hz, 1H, H-6), 7.22-7.28 (m, 4H, Ar), 7.30-
7.36 (m, 3H, Ar), (7.64 (dd, J= 7.8, 1.2 Hz, 1H, H-4); 13C NMR (CDCl3) δ -2.2 (CH2I), 
46.8 (CH2), 53.7 (CONCH2), 102.7 (C-3), 109.6, 120.6, 121.4, 122.2, 128.1 (C-2), 
128.4, 128.8 (C-3a), 128.9, 129.2, 129.3, 129.7, 129.8, 129.9, 135.6 (C-1΄), 136.4 (C-
7a), 136.5 (C-1΄΄), 139.3 (C-2΄), 168.1 (CO); EI-MS m/z 480 ([M]+, 100%); HREI-MS 
m/z calcd for [M]+ C24H21N2OI: 480.0690, found: 480.0689. 
Synthesis of N-benzyl-N-{2-[1-(5-methoxy-1H-indolyl)methyl]phenyl}iodo 
acetamide  (179) 
Following the procedure for 174, treatment of 167 (62 
mg, 0.15 mmol) with NaI (0.22 g, 1.50 mmol) in 
refluxing acetonitrile (5 mL) gave 179 (after 
purification by column chromatography with DCM; 
55 mg, 73%) as a yellow solid; mp 59-61 oC; 1H 
NMR (CDCl3) δ 3.28 (d, J= 9.6 Hz, 1H, CHHI), 3.43 (d, J= 9.9 Hz, 1H, CHHI), 3.84 (s, 
3H, OCH3), 4.60 (d, J= 13.8 Hz, 1H, CONCHH), 4.81 (d, J= 16.8 Hz, 1H, CHH), 5.02 
(d, J= 13.8 Hz, 1H, CONCHH), 5.12 (d, J= 16.8 Hz, 1H, CHH), 6.46 (dd, J= 3.3, 0.9 
Hz, 1H, H-3), 6.78-6.81 (m, 2H, Ar), 6.83-6.86 (m, 2H, H-2 and Ar), 6.93 (dd, J= 9.0, 
0.6 Hz, 1H, H-3΄), 7.05 (ddd, J= 9.0, 6.6, 2.4 Hz, 1H, Ar), 7.09 (d, J= 2.4 Hz, 1H, H-4), 
7.27-7.29 (m, 4H, Ar), 7.33-7.36 (m, 2H, Ar); 13C NMR (CDCl3) δ -2.5 (CH2I), 46.9 
(CH2), 53.5 (CONCH2), 56.0 (OCH3), 102.2 (C-3), 102.9, 110.4, 112.5, 128.4, 128.6 
(C-3a), 128.7, 128.9, 129.2, 129.4, 129.7, 129.8, 129.9, 131.8 (C-1΄), 135.7 (C-7a), 
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136.5 (C-1′΄), 139.4 (C-2΄), 154.5 (COCH3), 168.2 (CO); CI-MS m/z 511 ([M+H]+, 
100%); HRCI-MS m/z calcd for [M+H]+ C25H24IN2O2: 511.0883, found: 511.0868. 
Synthesis of N-benzyl-N-{2-[1-(5-fluoro-1H-indolyl)methyl]phenyl}iodoacetamide  
(180) 
Following the procedure for 174, treatment of 168 (74 
mg, 0.18 mmol) with NaI (0.27 g, 1.80 mmol) in 
refluxing acetonitrile (5 mL) gave 180 (after purification 
by column chromatography with DCM; 77 mg, 89%) as 
a yellow solid; mp 53-54 oC; 1H NMR (CDCl3) δ 3.28 
(d, J= 9.9 Hz, 1H, CHHI), 3.42 (d, J= 9.0 Hz, 1H, CHHI), 4.64 (d, J= 13.8 Hz, 1H, 
CONCHH), 4.82 (d, J= 16.8 Hz, 1H, CHH), 4.98 (d, J= 13.8 Hz, 1H, CONCHH), 5.15 
(d, J= 16.8 Hz, 1H, CHH), 6.49 (d, J= 3.3 Hz, 1H, H-3), 6.77 (dd, J= 7.5, 2.7 Hz, 1H, 
Ar), 6.90-6.93 (m with prominent d, J= 3.0 Hz, 3H, H-2 and Ar), 7.05 (dd, J= 8.9, 2.7 
Hz, 1H, Ar), 7.22-7.33 (m, 8H, Ar); 13C NMR (CDCl3) δ -2.6 (CH2I), 47.0 (CH2), 53.6 
(CONCH2), 102.6 (d, J= 5.2 Hz, 13C-19F, C-3), 106.1 (d, J= 22.9 Hz, 13C-19F, C-6), 
110.3 (d, J= 9.8 Hz, 13C-19F, C-7), 110.7 (d, J= 26.3 Hz, 13C-19F, C-4), 128.5, 129.0, 
129.2, 129.6, 129.79, 129.83, 129.88, 129.9, 130.5 (C-3a), 133.1 (C-1΄), 135.4 (C-7a), 
136.5 (C-1΄΄), 139.4 (C-2΄), 158.2 (d, J= 223.7 Hz, 13C-19F, C5-F), 168.2 (CO); CI-MS 
m/z 499 ([M+H]+, 46%); HREI-MS m/z calcd for [M]+ C24H20N2OFI: 498.0604, found: 
498.0600. 
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Synthesis of N-{2-[1-(1H-indolyl)methyl]phenyl}-N-(1-phenylethyl)iodoacetamide  
(181) 
Following the procedure for 174, treatment of 169 (36 
mg, 0.09 mmol) with NaI (0.14 g, 0.95 mmol) in 
refluxing acetonitrile (3 mL) gave 181 (after purification 
by column chromatography with DCM, 37 mg, 82%) as 
a yellow solid; mp 60-61 oC; 1H NMR (CDCl3, isomer 
ratio of ca 2:1*) δ 1.55* (d, J= 7.2 Hz, 1H, CH3), 1.62 (d, J= 6.9 Hz, 2H, CH3), 3.24 (d, 
J= 9.9 Hz, 1H, CHHI), 3.44 (d, J= 9.6 Hz, 1H, CHHI), 3.80 (d, J= 17.1 Hz, 0.7H, 
CHH), 4.69 (d, J= 17.1 Hz, 0.7H, CHH), 5.30* (d, J= 16.8 Hz, 0.3H, CHH), 5.39* (d, 
J= 16.8 Hz, 0.3H, CHH), 6.24-6.29 (m, 1H, CH and CH*), 6.39 (d, J= 7.8 Hz, 0.7H, H-
3΄), 6.45 (dd, J= 3.0, 0.9 Hz, 0.7H, H-3), 6.52-6.54 (m with prominent d, J= 3.3 Hz, 1H, 
H-2 and H-3΄*), 6.60 (d, J= 3.3 Hz, 0.3H, H-3*), 6.78 (d, J= 8.1 Hz, 1H, Ar), 7.03-7.21 
(m, 4H, H-5, H-2΄΄, H-6΄΄and Ar), 7.20-7.21 (m, 1H, H-4΄and Ar), 7.27-7.42 (m, 5H, H-
7, H-3΄΄, H-5΄΄ and Ar), 7.57 (dd, J= 7.5, 1.5 Hz, 0.7H, H-4), 7.69 (d, J= 7.5 Hz, 0.3H, 
H-4*); 13C NMR (CDCl3) δ -1.3 (CH2I), -0.8* (CH2I), 19.1 (CH3), 46.2 (CH2), 55.7 
(CH), 102.5 (C-3), 103.0* (C-3), 109.5, 119.9, 121.2, 122.0, 128.1, 128.2 (C-3a), 128.3, 
128.5, 128.8, 128.89, 128.9, 129.5, 130.1, 135.6 (C-1΄), 136.5 (C-7a), 138.0 (C-1΄΄), 
139.2 (C-2΄), 167.9 (CO); CI-MS m/z 495 ([M+H]+, 100%); HRCI-MS m/z calcd for 
[M+H]+ C25H24N2OI: 495.0933, found: 495.0926. 
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Synthesis of N-ethoxycarbonyl-N-{2-[1-(1H-indolyl)methyl]phenyl}iodoacetamide 
(182) 
Following the procedure for 174, treatment of 169 (32 
mg, 0.091 mmol) with NaI (0.15 g, 0.94 mmol) in 
refluxing acetonitrile (3 mL) gave the title compound 182 
(after purification by column chromatography with DCM; 
27 mg, 66%) as a yellow solid; mp 53-54 oC; 1H NMR (CDCl3) δ 1.18 (t, J= 7.2 Hz, 
3H, CH3), 4.09 (ddd, J= 7.2, 6.9, 6.9 Hz, 1H, CHHCH3), 4.20 (ddd, J= 7.2, 6.9, 6.9 Hz, 
1H, CHHCH3), 4.48 (dd, J= 9.6, 0.6 Hz, 1H, CHHI), 4.63 (dd, J= 9.3, 0.6 Hz, 1H, 
CHHI), 5.18 (d, J= 16.2 Hz, 1H, CHH), 5.25 (d, J= 16.5 Hz, 1H, CHH), 6.56 (d, J= 3.3 
Hz, 1H, H-3), 6.83 (d, J= 7.5 Hz, 1H, H-3′), 7.09 (d, J= 3.0 Hz, 1H, H-2), 7.11-7.17 (m, 
4H, H-5, H-6, H-7, and H-6΄), 7.26 (t, J= 7.2 Hz, 1H, H-4΄), 7.34 (td, J= 7.5, 1.2 Hz, 
1H, H-5΄), 7.65 (dd, J= 6.9, 1.8 Hz, 1H, H-4); 13C NMR (CDCl3) δ 0.9 (CH2I), 14.4 
(CH3), 46.6 (CH2), 64.3 (CH2CH3), 102.2 (C-3), 109.9 (C-7), 119.9 (C-5), 121.2 (C-4), 
122.0 (C-6), 128.2 (C-3΄), 128.4 (C-6΄), 128.7 (C-2), 128.9 (C-4΄), 128.7 (C-3a), 129.5 
(C-5΄), 135.6 (C-1΄), 135.7 (C-7a), 136.5 (C-2΄), 153.1 (COO), 170.3 (CO); CI-MS m/z 
463 ([M+H]+, 15%); HREI-MS m/z calcd for C21H19N2O3I: 462.0440, found: 462.0445. 
Synthesis of N-{2-[1-(5-fluoro-1H-indolyl)methyl]phenyl}-N-methyliodoacetamide  
(183)    
A suspension of NaH (18.2 mg, ca 50% dispersion in mineral 
oil, 0.38 mmol) in dry DMF (5 mL) under a N2 atmosphere 
was cooled to 0-5 oC and a solution of 162 (0.11 g, 0.35 
mmol) in DMF (15 mL) was then added dropwise. The 
mixture was then stirred for 30 min at r.t.. A solution of 
methyl iodide (54 µL, 0.87 mmol) in DMF (2 mL) was added and the reaction mixture 
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was stirred for a further 16 h. at r.t.. The solvent was evaporated, DCM (20 mL) was 
added and the organic layer washed with water (3 x 15 mL), dried and evaporated. The 
crude product was subjected to flash column chromatography (silica gel, DCM) to give 
183 (0.076 g, 66%) as a yellow solid; mp 74-76 oC; 1H NMR (CDCl3) δ 3.17 (s, 3H, 
CH3), 3.29 (d, J= 9.9 Hz, 1H, CHHI), 3.43 (d, J= 10.2 Hz, 1H, CHHI), 5.29 (d, J= 16.5 
Hz, 1H, CHH), 5.39 (d, J= 16.5 Hz, 1H, CHH), 6.53 (dd, J= 3.9, 0.9 Hz, 1H, H-3), 6.91 
(dd, J= 9.3, 2.7 Hz, 1H, H-4), 6.95 (dd, J= 7.8, 2.1 Hz, 1H, H-3′), 7.12 (d, J= 3.3 Hz, 
1H, H-2), 7.15 (dd, J= 7.2, 2.4 Hz, 1H, H-7), 7.29 (ddd, J= 9.6, 7.2, 2.4 Hz, 1H, H-6), 
7.32 (dd, J= 7.8, 1.5 Hz, 1H, H-6′), 7.36-7.44 (m, 2H, Ar); 13C NMR (CDCl3) δ -3.2 
(CH2I), 37.6 (CH3), 47.2 (CH2), 102.7 (d, J= 4.6 Hz, C13-F19, C3-F), 106.2 (d, J= 23.5 
Hz, C13-F19, C6-F), 110.3 (d, J= 9.5 Hz, C13-F19, C7-F), 110.8 (d, J= 26 Hz, C13-F19, C4-
F), 128.7, 129.2 (d, J= 10.4 Hz, C13-F19, C3a-F), 129.6, 129.88, 129.93, 130.0, 133.1 
(C-7a), 134.6 (C-1΄΄), 141.4 (C-2΄), 158.7 (d, J= 225.0 Hz, C13-F19, C5-F), 168.4 (CO); 
CI-MS m/z 423 ([M+H]+, 43%); HRCI-MS m/z calcd for [M+H]+ C18H17N2OFI: 
423.0369, found: 423.0336. 
 
7.2.8 Preparation of bromoacetamides 
Synthesis of N-{2-[1-(5-methoxy-1H-indolyl)methyl]phenyl}-N-methylbromo 
acetamide  (184) 
A mixture of 150b (0.11 g, 0.41 mmol) and anhydrous 
K2CO3 (0.20 g, 1.50 mmol) in dry DCM (5 mL) was 
cooled to 0-5 oC and a solution of bromoacetyl chloride 
(80 µL, 1.03 mmol) in DCM (3 mL) was then added. 
Stirring was continued with cooling for a further 30 min and the reaction mixture then 
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allowed to warm to r.t. with stirring overnight. Distilled water (15 mL) was added to the 
reaction mixture and the aqueous layer was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried and concentrated to yield a yellow solid. The 
soild was subject to flash column chromatography (silica gel, DCM) to give 184 (83 
mg, 54%) as yellow crystals; mp 58-59 oC; 1H NMR (CDCl3) δ 3.21 (s, 3H, CH3), 3.53 
(d, J= 12.6 Hz, 1H, CHHBr), 3.63 (d, J= 12.6 Hz, 1H, CHHBr), 3.84 (s, 3H, OCH3), 
5.25 (d, J= 5.4 Hz, 2H, CH2), 6.49 (dd, J= 3.0, 0.6 Hz, 1H, H-3), 6.83 (dd, J= 9.0, 2.4 
Hz, 1H, Ar), 6.97 (dd, J= 7.8, 2.1 Hz, 1H, Ar), 7.02-7.10 (m, 2H, H-2 and Ar), 7.20-
7.40 (m, 4H, Ar);  13C NMR (CDCl3) δ 37.5 (CH3), 41.2 (CH2Br), 47.1 (CH2), 56.1 
(OCH3), 102.3 (C-3), 103.2, 110.5, 112.6, 128.9, 129.3 (C-3a), 129.7, 129.8, 129.9, 
131.6 (ArC), 135.2 (C-7a), 140.6 (C-2΄), 154.4 (COCH3), 166.8 (CO);  CI-MS m/z 387 
([M+H]+, 13%); HREI-MS m/z calcd for [M]+ C19H19N2O279Br: 386.0630, found: 
386.0624. 
Synthesis of N-benzyl-N-{2-[1-(1H-indolyl)methyl]phenyl}bromoacetamide (185)    
Following the reaction procedure for 184, treatment of 
153 (0.11 g, 0.34 mmol) with NaH (ca 50% dispersion 
in mineral oil, 18 mg, 0.38 mmol) and bromoacetyl 
chloride (0.10 mL, 0.85 ml) in dry DMF (20 mL) gave 
185 (0.10 g, 68%), after purification by column 
chromatography (silica gel, 1:1 hexane/DCM), as a yellow solid; mp 99-101 oC; 1H 
NMR (CDCl3) δ 3.43 (d, J= 1.8 Hz, 2H, CH2Br), 4.62 (d, J= 13.8 Hz, 1H, CONCHH), 
4.34 (d, J= 16.8 Hz, 1H, CHH), 5.06 (d, J= 13.8 Hz, 1H, CONCHH), 5.17 (d, J= 16.8 
Hz, 1H, CHH), 6.55 (dd, J= 3.3, 0.9 Hz, 1H, H-3), 6.81 (m, 1H, Ar), 6.87 (d, J= 3.3 Hz, 
1H, H-2), 6.98 (m, 1H, Ar), 7.07 (dd, J= 6.9, 0.9 Hz, 1H, H-7), 7.12 (ddd, J= 8.4, 7.2, 
1.2 Hz, 1H, H-5), 7.18 (td, J= 8.5, 1.2 Hz, 1H, H-6), 7.23-7.28 (m, 4H, Ar), 7.30- 7.35 
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(m, 3H, Ar), 7.64 (dd, J= 8.0, 1.2 Hz, 1H, H-4); 13C NMR (CDCl3) δ 42.3 (CH2Br), 
46.7 (CH2), 53.6 (CONCH2), 102.7 (C-3), 109.3 (C-7), 120.1, 121.4, 122.3, 128.1, 
128.4, 128.8 (C-3a), 129.0, 129.3, 129.4, 129.9, 130.1, 135.7 (ArC), 136.3 (ArC), 136.4 
(C-2′), 138.9 (C-12a), 166.8 (CO); CI-MS m/z 433 ([M+H]+, 90%); HREI-MS m/z  
calcd for [M]+ C24H21N2O79Br: 432.0837, found: 432.0851. 
 
7.2.9 General procedure for radical cyclisation 
A solution of tributyltin hydride (Bu3SnH) (2.0 eq.) and AIBN (1.0 eq.) in an 
appropriate solvent (40 mM) was added dropwise to a solution of the haloacetamides ( 
1.0 eq.) in boiling solvent (22 mM) over 4 h and the mixture was then heated at reflux 
overnight. After removing the solvent, diethyl ether (20 mL) and saturated potassium 
fluoride solution (20 mL) were added and the mixture was stirred vigorously at r.t. for 
2-3 h. The organic layer was separated, dried and concentrated. The residue was column 
chromatographed on silica gel (hexane-AcOEt (3:1)). 
Attempted cyclisation of 161 
Following the general procedure, 161 (48 mg, 0.16 mmol) in toluene (5 mL) was 
treated with AIBN (26 mg, 0.16 mmol) and Bu3SnH (86 µL, 0.32 mmol). The crude 
material was chromatographed (DCM) to give N-{2-[1-(1H-
indolyl)methyl]phenyl}acetamide 188a (34 mg, 82%) as a 
yellow solid; mp 142-143 °C; 1H NMR (CDCl3) δ 1.87 (s, 3H, 
CH3), 5.28 (s, 2H, CH2), 6.57 (d, J= 3.3 Hz, 1H, H-3), 6.73 (br 
s, 1H, NH), 7.02 (d, J= 3.3 Hz, 1H, H-2), 7.11-7.28 (m, 4H, 
Ar), 7.30-7.35 (m, 2H, H-4΄ and Ar), 7.57 (d, J= 8.1 Hz, 1H, H-3΄), 7.66 (d, J= 8.1 Hz, 
1H, H-4); 13C NMR (CDCl3) δ 24.0 (CH3), 47.9 (CH2), 102.9 (C-3), 109.6 (C-7), 120.2, 
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121.5, 122.3, 125.5, 126.4, 127.8 (all ArCH), 128.9 (C-3a), 129.4 (ArCH), 130.5 (C-1΄), 
135.7 (C-7a), 136.4 (C-2΄), 169.0 (CO); EI-MS m/z 264 ([M]+, 90%); HRCI-MS m/z 
calcd for [M+H]+ C17H17N2O: 265.1341, found: 265.1341. 
Attempted cyclisation of 163 
Following the general procedure, 163 (62 mg, 0.20 mmol) in toluene (5 mL) was 
treated with AIBN (33 mg, 0.20 mmol) and Bu3SnH (0.11 mL, 0.40 mmol). The crude 
material was chromatographed (DCM) to give N-{2-[1-(1H-indolyl)methyl]phenyl}-N-
methylacetamide 188b (46 mg, 83%) as a yellow solid; mp 58-
59 oC; 1H NMR (CDCl3) δ 1.78 (s, 3H, CH3), 3.20 (s, 3H, 
NCH3), 5.26 (s, 2H, CH2-8), 6.58 (d, J= 3.0 Hz, 1H, H-3), 6.90 
(d, J= 7.5 Hz, 1H, Ar), 7.07 (dd, J= 3.0, 0.6 Hz, 1H, H-2), 7.11- 
7.20 (m, 4H, Ar), 7.25 (t, J= 7.5 Hz, 1H, Ar), 7.35 (t, J= 7.5 Hz, 
1H, Ar), 7.66 (dd, J= 7.8, 1.2 Hz, 1H, Ar); 13C NMR (CDCl3) δ 22.2 (CH3), 36.6 
(NCH3), 46.6 (CH2), 102.6, 109.7, 120.1, 121.2, 122.0, 128.2, 128.4, 129.0, 129.4, 
135.0 (ArC), 136.3 (ArC), 140.1 (C-2΄), 171.7 (CO); CI-MS m/z 279 ([M+H]+, 100%); 
HRCI-MS m/z calcd for [M+H]+ C18H19N2O: 279.1497, found: 279.1499. 
Attempted cyclisation of 174 
  Following the general procedure, 174 (0.10 g 0.21 mmol) in toluene (5 mL) was 
treated with AIBN (35 mg, 0.21 mmol) and Bu3SnH (0.11 mL, 0.42 mmol). The crude 
material was chromatographed (DCM) to give 188a (48 mg, 85%). 
Cyclisation of 175 in Toluene 
Following the general procedure, 175 (54 mg, 0.13 mmol) in toluene (5 mL) was 
treated with AIBN (21 mg, 0.13 mmol) and Bu3SnH (70 µL, 0.26 mmol). The crude 
material was column chromatographed (DCM).  
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The first fraction from the column gave 5,14-dihydro-5-methyl-indolo[2,1-
d][1,5]benzodiazocin-6-one 186b (7 mg, 20%) as a yellow solid; mp 211-212 oC (from 
DCM); IR (KBr) νmax: 2852 (N-CH3), 1660 (C=O) cm-1; 1H 
NMR (CDCl3) δ 3.436 (s, 3H, CH3), 3.447 (d, J= 13.8 Hz, 1H, 
CHH-7), 3.67 (d, J= 13.8 Hz, 1H, CHH-7), 4.75 (d, J= 14.1 Hz, 
1H, CHH-14), 5.36 (d, J= 13.8 Hz, 1H, CHH-14), 6.37 (s, 1H, 
H-8), 7.10 (t, J= 7.5 Hz, 1H, H-10), 7.23 (td, J= 8,1 Hz, 1H, 
Ar), 7.38 (d, J= 7.2 Hz, 1H, Ar), 7.46-7.56 (m, 5H, Ar);  13C NMR (CDCl3) δ 36.2 
(CH2-7), 36.7 (NCH3), 45.2 (CH2-14), 103.6 (C-8), 108.7, 119.9, 120.6, 121.7, 125.5, 
128.0 (C-8a), 129.0, 130.6, 131.8 (C-7a), 132.2, 133.0 (C-14a), 136.8 (C-12a), 144.7 
(C-4a), 168.9 (CO); CI-MS m/z 277 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C18H17N2O: 277.1341, found: 277.1341. 
The second fraction gave 5,7a,8,14-tetrahydro-5-methyl-indolo[2,1-d][1,5] 
benzodiazocin-6-one 187b, (22 mg, 60%) as a yellow solid; mp 129-130 oC (from 
DCM);   
1H NMR (CDCl3) δ 2.39-2.50 (m, 2H, CH2-8), 2.60 (dd, J= 
15.9, 9.0 Hz, 1H, CHH-7), 3.29 (dd, J= 15.9, 9.0 Hz, 1H, CHH-
7), 3.38 (s, 3H, CH3), 3.84 (d, J= 14.7 Hz, 1H, CHH-14), 4.08 
(qd, J= 8.1, 1.2 Hz, 1H, H-7a), 4.55 (d, J= 15.0, 1H, CHH-14), 
6.58 (t, J= 7.5 Hz, 1H, H-10), 6.68 (d, J= 7.8 Hz, 1H, H-12), 
6.99 (d, J= 7.2 Hz, 1H, Ar), 7.06 (m, 2H, Ar), 7.22-7.39 (m, 3H, Ar), 7.52 (d, J= 7.2 Hz, 
1H, H-9); 13C NMR (CDCl3) δ 36.8 (CH2-7), 38.0 (CH3), 42.7 (CH2-8), 45.8 (CH2-14), 
62.4 (CH), 105.1 (C-12), 116.9, 124.8, 126.0, 127.6, 127.7 (C-8a), 128.3, 129.2, 131.6, 
135.3 (ArC), 142.4 (ArC), 149.5 (C-4a), 172.1 (CO); CI-MS m/z 279 ([M+H]+, 100%); 
HREI-MS m/z calcd for [M]+ C18H18N2O: 278.1419, found:  278.1413. 
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 The third fraction gave 188b (7 mg, 20%) as a yellow solid. 
Cyclisation of 175 in Toluene on a larger scale 
 Following the general procedure, 175 (0.15 g, 0.36 mmol) in toluene (15 mL) 
was treacted with AIBN (58 mg, 0.36 mmol) and Bu3SnH (1.94 ml, 0.72 mmol). The 
crude material was column chromatographed (DCM) to give 186b (20 mg, 20%), 187b 
(60 mg, 60%) and 188b (20 mg, 20%). 
Cyclisation of 175 in Mesitylene 
  Following the general procedure, 175 (56 mg, 0.14 mmol) in mesitylene (5 mL) 
was treated with AIBN (23 mg, 0.14 mmol) and Bu3SnH (75 µL, 0.28 mmol). The 
crude material was column chromatographed (DCM) to give 186b (17 mg, 44%). 
Cyclisation of 175 using EPHP 
 A solution of 175 (40 mg, 0.10 mmol) and EPHP (0.23 g, 1.3 mmol) in dry 
benzene (5 mL) was heated at reflux for 1 h and a solution of AIBN (9 mg, 0.05 mmol) 
in benzene (10 mL) was added. The reaction mixture was then heated at reflux 
overnight and the solvent was evaporated. DCM (15 mL) was then added and the 
mixture was washed with water (3 x 15 mL). The DCM layer was separated, dried and 
concentrated and the residue was purified by flash column chromatography (silica gel; 
DCM). The first fraction from the column gave 186b (2 mg, 9%) and the second 
fraction gave 188b (9 mg, 33%).  
Cyclisation of 176 using Bu3SnH  
Following the general procedure, 176 (83 mg, 0.19 mmol) in toluene (5 mL) was 
treated with AIBN (31 mg, 0.19 mmol) and Bu3SnH (0.12 mL, 0.38 mmol). The crude 
material was column chromatographed (DCM).  
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The first fraction gave 5,14-dihydro-10-methoxy-5-methyl-indolo[2,1-
d][1,5]benzodiazocin-6-one, 186c (30 mg, 51%) as a yellow 
solid; mp 170-173 oC (DCM); 1H NMR (CDCl3) δ  3.430 
(dd, J= 13.8, 1.2 Hz, 1H, CHH-7), 3.434 (s, 3H, CH3), 3.63 
(d, J= 13.5 Hz, 1H, CHH-7), 3.84 (s, 3H, OCH3), 4.74 (d, 
J= 13.8 Hz, 1H, CHH-14), 5.27 (d, J= 13.8 Hz, 1H, CHH-
14), 6.30 (s, 1H, H-3), 6.90 (dd, J= 9.0, 2.4 Hz, 1H, H-4), 7.01 (d, J= 2.4 Hz, 1H, H-9), 
7.35-7.39 (m, 3H, Ar), 7.45- 7.53 (m, 2H, Ar); 13C NMR (CDCl3) δ 36.1 (CH2-7), 36.5 
(NCH3), 45.3 (CH2-14), 56.1 (OCH3), 102.4 (C-8), 103.2 (C-9), 109.4, 111.7, 125.4, 
128.4 (C-8a), 129.0, 130.6, 131.8 (C-7a), 132.2, 133.1 (C-14a), 133.5 (C-12a), 144.8 
(C-4a), 154.3 (COCH3), 168.9 (CO); CI-MS m/z 307 ([M+H]+, 100%); HRCI-MS m/z 
calcd for [M+H]+ C19H19N2O2: 307.1447, found: 307.1444. 
The second fraction gave N-{2-[1-(5-methoxy-1H-indolyl)methyl]phenyl}-N-
methylacetamide 188c (11 mg, 20%) as a yellow solid; mp 151-153 oC (DCM);  
1H NMR (CDCl3) δ 1.76 (s, 3H, CH3), 3.19 (s, 3H, NCH3), 
3.84 (s, 3H, OCH3), 5.20 (s, 2H, CH2), 6.47 (d, J= 3.0 Hz, 
1H, H-3), 6.80 (dd, J= 8.7, 2.1 Hz, 1H, Ar), 6.87 (d, J= 7.2 
Hz, 1H, Ar), 6.98-7.07 (m with prominent d, J= 3.6 Hz, 
2H, H-2 and Ar), 7.08 (d, J= 2.1 Hz, 1H, H-4), 7.10 (d, J= 7.8 Hz, 1H, Ar), 7.23 (t, J= 
8.7 Hz, 1H, Ar), 7.32 (dd, J= 7.2, 0.9 Hz, 1H, H-7); 13C NMR (CDCl3) δ 22.2 (CH3), 
36.5 (NCH3), 46.8 (CH2), 56.0 (OCH3), 102.0 (C-3), 103.0, 110.3, 112.5, 128.7, 129.1, 
129.16, 129.24, 129.4, 129.7, 131.7 (ArC), 135.1 (ArC), 142.3 (C-2΄), 154.5 (COCH3), 
170.9 (CO); CI-MS m/z 309 ([M+H]+, 87%); HREI-MS m/z calcd for [M]+ C19H20N2O2: 
308.1525, found: 308.1524. 
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Cyclisation of 176 using (TMS)3SiH 
A solution of (TMS)3SiH (92 µL, 0.30 mmol) and AIBN (32 mg, 0.20 mmol) in 
dry toluene (15 mL) was slowly added to a boiling solution of 176 (85 mg, 0.20 mmol) 
in dry toluene (35 mL) under a N2 atmosphere. The solution was heated at reflux 
overnight and the solvent was then evaporated to leave a yellow residue which was 
purified by column chromatography using 2:3 EtOAc/hexane as an eluent. The first 
fraction from the column gave 186c (6 mg, 10%) and the second fraction gave 188c (22 
mg, 36%).  
Cyclisation of 177 
 Following the general procedure, 177 (0.17 g, 0.33 mmol) in toluene (5 mL) was 
treated with AIBN (37 mg, 0.23 mmol) and Bu3SnH (0.12 mL, 0.46 mmol). The crude 
material was column chromatographed (DCM).  
The first fraction gave 5,14-dihydro-5-(4-
methoxybenzyl)indolo[2,1-d][1,5]benzodiazocin-
6-one 186d (16 mg, 13%) as a yellow solid; mp 
213-215 oC (DCM); 1H NMR (CDCl3) δ 3.42 (dd, 
J= 14.1, 1.2 Hz, 1H, CHH-7), 3.68 (d, J= 14.1 Hz, 
1H, CHH-7), 3.76 (s, 3H, OCH3), 4.10 (d, J= 13.8 Hz, 1H, CHH-14), 4.50 (d, J= 13.8 
Hz, 1H, CONCHH), 4.93 (d, J= 13.8 Hz, 1H, CHH-14), 5.52 (d, J= 13.8 Hz, 1H, 
CONCHH), 6.35 (s, 1H, H-8), 6.74 (d, J= 8.7 Hz, 2H, H-3′ and H-5′), 7.06 (t, J= 7.5 
Hz, 1H, H-10), 7.11 (d, J= 8.7 Hz, 2H, H-2′ and H-6′), 7.18 (td, J= 7.2, 0.6 Hz, 1H, H-
11), 7.30-7.40 (m, 4H, Ar), 7.46 (dd, J= 7.2, 1.5 Hz, 1H, Ar), 7.51 (d, J= 7.8 Hz, 1H, H-
9); 13C NMR (CDCl3) δ 36.6 (CH2-7), 44.8 (CH2-14), 52.2 (CONCH2), 55.5 (OCH3), 
103.5 (C-8), 108.7, 114.0, 119.8, 120.5, 121.5, 126.0, 128.0 (ArC), 128.5 (ArC), 129.0, 
130.4, 130.9, 132.8 (ArC), 133.1 (ArC), 137.5 (C-12a), 142.8 (C-1′), 159.3 (COCH3), 
N
N
2 3
4
5
6
7
O
1
8
9
10
11
12 13
14
OMe
1'
2' 3'
4'
5'
6'
 191
168.2 (CO); CI-MS m/z 383 ([M+H]+, 100%); HRES-MS m/z calcd for [M+H]+ 
C25H23N2O2: 383.1763, found: 383.1760. 
The second fraction gave 5,7a,8,14-tetrahydro-5-(4-methoxybenzyl)indolo[2,1-
d][1,5]benzodiazocin-6-one 187d (13 mg, 11%) as a yellow solid; mp 107-109 oC 
(DCM);  
1H NMR (CDCl3) δ 2.39-2.51 (m, 2H, CH2-8), 
2.56 (dd, J= 15.6, 8.4 Hz, 1H, CHH-7), 3.20-3.29 
(m with prominent d, J= 14.1 Hz, 2H, CHH-7 and 
CONCHH), 3.76 (d, J= 1.2 Hz, 3H, OCH3), 4.01 
(q, J= 8.4 Hz, 1H, H-7a),  4.14 (d, J= 15.0 Hz, 1H, 
CONCHH), 4.38 (d, J= 14.1 Hz, 1H, CHH-14), 5.51 (d, J= 13.8 Hz, 1H, CHH-14), 
6.51-6.56 (m with prominent d, J= 6.9 Hz, 2H, Ar), 6.75 (d, J= 7.8 Hz, 2H, H-3′ and H-
5′), 6.95 (d, J= 7.5 Hz, 1H, Ar), 7.04 (t, J= 8.4 Hz, 1H, Ar), 7.07 (d, J= 7.8 Hz, 2H, H-2′ 
and H-6′), 7.22-7.35 (m, 3H, Ar), 7.39 (d, J= 7.5 Hz, 1H, H-9); 13C NMR (CDCl3) δ 
36.7 (CH2-7), 42.6 (CH2-8), 45.6 (CH2-14), 53.1 (CONCH2), 55.5 (OCH3), 62.8 (CH), 
105.0, 113.9, 116.7, 124.7, 126.7, 127.5, 127.7 (ArC), 128.4, 128.9 (ArC), 129.0, 130.7, 
131.3, 136.7 (ArC), 140.4 (ArC), 154.7 (COCH3), 171.5 (CO); CI-MS m/z 385 
([M+H]+, 100%); HRES-MS m/z calcd for [M+H]+ C25H25N2O2: 385.1910, found: 
385.1916.  
The third fraction gave N-{2-[1-(1H-indolyl)methyl]phenyl}-N-(4-methoxy 
benzyl)acetamide 188d (9 mg, 7%) as a yellow 
solid; mp 58-60 oC (DCM); 
1H NMR (CDCl3) δ 1.81 (s, 3H, CH3), 3.79 (s, 3H, 
OCH3), 4.75 (d, J= 15.9 Hz, 2H, CHH and 
CONCHH), 4.84 (d, J= 13.8 Hz, 1H,  CHH), 5.03 
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(d, J= 17.2 Hz, 1H, CONCHH), 6.53 (dd, J= 3.0, 1.5 Hz, 1H, H-3), 6.65 (d, J= 7.8 Hz, 
1H, H-3΄), 6.83 (m with prominent dd, J= 8.7, 2.4 Hz, 3H, H-2, H-3΄΄ and H-5΄΄), 6.95 
(t, J= 8.7 Hz, 1H, H-5′), 7.08-7.17 (m, 3H, H-2΄΄, H-6΄΄ and Ar), 7.20-7.23 (m, 2H, Ar), 
7.42-7.52 (m, 2H, Ar), 7.63 (d, J= 6.9 Hz, 1H, H-4); 13C NMR (CDCl3) δ 22.5 (CH3), 
47.4 (CH2), 52.1 (CONCH2), 55.5 (OCH3), 102.5 (C-3), 109.5, 114.2, 111.9, 121.3, 
122.1, 128.3, 128.5, 129.2, 129.7, 130.9, 131.3, 132.4 (ArC), 135.9 (ArC), 137.6 (C-
1΄΄), 140.3 (C-2΄), 159.6 (COCH3), 168.2 (CO); CI-MS m/z 385 ([M+H]+, 100%); 
HRES-MS m/z calcd for [M+H]+ C25H25N2O2: 385.1910, found: 385.1916. 
Cyclisation of 178 in toluene 
 Following the general procedure, 178 (38 mg, 0.08 mmol) in toluene (5 mL) was 
treated with AIBN (13 mg, 0.08 mmol) and Bu3SnH (43 µL, 0.16 mmol). The crude 
material was column chromatographed (DCM). The first fraction from the column gave 
5-benzyl-5,14-dihydroindolo[2,1-d][1,5]benzodiazocin-6-one 186e (8 mg, 25%) as a 
yellow solid; mp 154-155 oC (DCM); IR (KBr) νmax: 1661 (C=O) cm-1; 
1H NMR (CDCl3) δ 3.45 (dd, J= 13.8, 1.5 Hz, 1H, 
CHH-7), 3.71 (d, J= 13.8 Hz, 1H, CHH-7), 4.13 (d, J= 
14.1 Hz, 1H, CONCHH), 4.62 (d, J= 13.8 Hz, 1H, 
CHH-14), 4.93 (d, J= 13.8 Hz, 1H, CONCHH), 5.53 (d, 
J= 14.1 Hz, 1H, CHH-14), 6.37 (s, 1H, H-8), 7.07 (t, J= 7.8, 1.2 Hz, 1H, H-10), 7.16- 
7.25 (m, 7H, Ar), 7.34 (d, J= 7.8 Hz, 1H, Ar), 7.38-7.42 (m, 2H, Ar), 7.46 (dd, J= 8.1, 
1.8 Hz, 1H, Ar), 7.52 (d, J= 7.8 Hz, 1H, H-9); 13C NMR (CDCl3) δ 36.6 (CH2-7), 44.8 
(CH2-14), 52.8 (CONCH2), 103.6 (C-8), 108.7, 119.8, 120.5, 121.5, 125.9, 128.0 (C-
8a), 128.2, 128.8, 129.0, 129.6, 130.5, 132.1, 132.7 (C-7a), 133.0 (C-14a), 136.3 (C-
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12a), 137.5 (C-1΄), 142.8 (C-4a), 168.4 (CO); CI-MS m/z 353 ([M+H]+, 100%); HREI-
MS m/z calcd for [M]+ C24H20N2O: 352.1576, found: 352.1565. 
The second fraction gave 5-benzyl-5,7a,8,14-
tetrahydroindolo[2,1-d][1,5] benzodiazocin-6-one 187e 
(12 mg, 43%) as a yellow solid; mp 141-144 oC 
(DCM); IR (KBr) νmax: 1647 (C=O) cm-1; 1H NMR 
(CDCl3) δ 2.41- 2.52 (m, 2H, CH2-8), 2.57 (dd, J= 15.9, 
9.3 Hz, 1H, CHH-7), 3.22- 3.30 (m with prominent d, J= 15.3 Hz, 2H, CHH-7 and 
CONCHH), 4.02 (qd, J= 9.0, 1.2 Hz, 1H, H-7a), 4.14 (d, J= 15.0 Hz, 1H, CONCHH),  
4.50 (d, J= 14.1 Hz, 1H, CHH-14), 5.51 (d , J= 14.1 Hz, 1H, CHH-14), 6.51- 6.56 (m, 
2H, Ar), 6.95 (d, J= 6.9 Hz, 1H, Ar), 7.04 (t, J= 7.8 Hz, 1H, Ar), 7.14- 7.19 (m, 2H, Ar), 
7.22-7.27 (m, 5H, Ar), 7.30 (dd, J= 9.0, 1.8 Hz, 1H, Ar), 7.40 (dd, J= 9.0, 2.4 Hz, 1H, 
H-9); 13C NMR (CDCl3) δ 36.6 (CH2-7), 42.5 (CH2-8), 45.5 (CH2-14), 53.7 (CONCH2), 
62.7 (CH-7), 105.0, 116.8, 124.8, 126.7, 127.6, 127.7 (C-8a), 128.0, 128.5, 128.7, 
129.1, 129.4, 131.4 (ArC), 136.7 (ArC), 136.8 (C-1΄), 149.6 (C-4a), 171.1 (CO); CI-MS 
m/z 355 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ C24H22N2O: 354.1732, found: 
354.1718. 
 The third fraction gave N-benzyl-N-{2-[1-(1H-indolyl)methyl]phenyl}acetamide 
188e (3 mg, 10%) as a yellow solid; mp 158-159 oC (DCM); IR (KBr) νmax: 1676 
(C=O), 1358 (CO-CH3) cm-1; 1H NMR (CDCl3) δ 1.83 
(s, 3H, CH3), 4.74 (d, J= 16.8, 1H, CONCHH), 4.80 (d, 
J= 14.1 Hz, 1H, CHH), 4.92 (d, J= 14.1 Hz, 1H, CHH), 
5.04 (d, J= 16.8 Hz, 1H, CONCHH), 6.53 (dd, J= 3.3, 
0.9 Hz, 1H, H-3), 6.65 (d, J= 7.8 Hz, 1H, H-3΄), 6.79 (d, J= 3.3 Hz, 1H, H-2), 6.94- 6.99 
(m, 2H, Ar), 7.11 (td, J= 7.2, 1.2 Hz, 1H, Ar), 7.15-7.16 (m, 2H, H-5 and H-5΄), 7.21 
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(td, J= 8.4, 1.8 Hz, 1H, H-4΄), 7.24- 7.29 (m, 3H, Ar), 7.30- 7.35 (m, 2H, Ar), 7.64 (ddd, 
J= 7.2, 1.8, 0.6 Hz, 1H,  H-4); 13C NMR (CDCl3) δ 22.6 (CH3), 46.4 (CH2), 52.7 
(CONCH2), 102.5 (C-3), 109.6, 120.0, 121.3, 122.1, 128.4, 128.5, 128.8 (C-3a), 128.9, 
129.2, 129.7, 129.8, 135.9 (C-1΄), 136.5 (C-7a), 137.2 (C-1΄΄), 140.3 (C-2΄), 170.6 
(CO);  CI-MS m/z 355 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ C24H22N2O: 
354.1732, found:  354.1732. 
Cyclisation of 178 on a larger scale 
Compound 178 (0.30 g, 0.68 mmol) in toluene (45 mL) was treated with AIBN 
(0.12 g, 0.72 mmol) and Bu3SnH (0.39 mL, 1.44 mmol). The crude material was 
column chromatographed (DCM) to give 186e (26 mg, 12%), 187e (42.8 mg, 19%) and 
188e (70 mg, 32%). A further product from the chromatographic separation was 
compound 189 (10 mg, 4%), obtained as a yellow solid; mp 76-77 oC; IR (KBr) νmax: 
1650 (C=O) cm-1; 
1H NMR (CDCl3) δ 1.23 (s, 3H ,CH3), 1.49 (s, 3H, 
CH3), 2.21 (d, J= 12.3 Hz, 1H, CHH-7), 2.58 (dd, J= 
12.3, 10.5 Hz, 1H, CHH-7), 3.01 (d, J= 3.3 Hz, 1H,  H-
8), 3.43 (d, J= 15.6 Hz, 1H, CHH-14), 3.96 (dd, J= 10.5, 
3.6 Hz, 1H, H-7a), 4.24 (d, J= 15.6 Hz, 1H, CHH-14), 
4.56 (d, J= 13.5 Hz, 1H, CONCHH), 5.44 (d, J= 13.5 Hz, 1H, CONCHH), 6.58 (t, J= 
7.2 Hz, 1H, H-10), 6.65 (d, J= 8.1 Hz, 1H, H-12), 7.12-7.20 (m, 3H, H-2, H-11 and Ar), 
7.22-7.29 (m, 5H, Ar), 7.30-7.34 (m, 2H, H-9 and Ar), 7.47 (d, J= 7.5 Hz, 1H, H-1); 13C 
NMR (CDCl3) δ 21.9 (CH3), 24.5 (CH3), 36.7 (CCN), 44.2 (CH2-7), 44.3 (CH2-14), 
53.6 (CONCH2), 56.1 (C-8), 63.5 (C-7a), 106.8 (C-7), 116.8 (C-5), 124.7 (CN), 125.4 
(C-8a), 126.2 (C-4), 126.6, 128.0, 128.1, 128.7 (all ArCH), 129.2 (C-11), 129.37, 129.4 
(all ArCH), 132.0 (C-1), 135.3 (C-14a), 136.6 (C-1΄), 140.7 (C-4a), 149.1 (C-12a), 
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171.1 (CO); CI-MS m/z 422 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ 
C28H27N3O: 421.2154, found: 421.2160.           
Cyclisation of 178 in xylene 
 Following the general procedure, 178 (52 mg, 0.11 mmol) in xylene (5 mL) was 
treated with AIBN (18 mg, 0.11 mmol) and Bu3SnH (59 µL, 0.22 mmol). The crude 
material was column chromatographed (DCM) to give 186e (22 mg, 57%). 
Cyclisation of 178 in mesitylene 
 Following the general procedure, 178 (51 mg, 0.11 mmol) in mesitylene (5 mL) 
was treated with AIBN (18 mg, 0.11 mmol) and Bu3SnH (59 µL, 0.22 mmol). The 
crude material was column chromatographed (DCM) to give 186e (27 mg, 70%). 
Cyclisation of 178 in tert-butylbenzene 
 Following the general procedure, 178 (55mg, 0.12 mmol) in tert-butylbenzene 
(5 mL) was treated with AIBN (20 mg, 0.11 mmol) and Bu3SnH (65 µL, 0.22 mmol). 
The crude material was column chromatographed (DCM) to give 186e (19 mg, 46%) 
and 187e (4 mg, 9%). 
Cyclisation of 178 in toluene using (TMS)3SiH 
A solution of (TMS)3SiH (74 µL, 0.30 mmol) and AIBN (20 mg, 0.12 mmol) in 
dry toluene (25 mL) was slowly added to a boiling solution of 178 (55 mg, 0.12 mmol) 
in dry toluene (5 mL) under a N2 atmosphere. The solution was heated at reflux 
overnight and the solvent was then evaporated to leave a yellow residue which was 
purified by PTLC (DCM). The higher Rf band gave 186e (13 mg, 31%) and the lower Rf 
band gave 188e (23 mg, 54%).  
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Cyclisation of 178 in xylenes using (TMS)3SiH 
A solution of (TMS)3SiH (67 µL, 0.22 mmol) and AIBN (18 mg, 0.11 mmol) in 
dry xylenes (25 mL) was slowly added to a boiling solution of 178 (53 mg, 0.11 mmol) 
in dry xylenes (5 mL) under a N2 atmosphere. The solution was heated at reflux 
overnight and the solvent was then evaporated to leave a yellow residue which was 
purified by PTLC (DCM). The first band (higher Rf ) gave 186e (3 mg, 9%) and the 
second band (lower Rf ) gave 188e (17 mg, 43%).  
Cyclisation of 179 
Following the general procedure, 179 (55 mg, 0.11 
mmol) in mesitylene (5 mL) was treated with AIBN 
(18 mg, 0.11 mmol) and Bu3SnH (59 µL, 0.22 
mmol). The crude material was column 
chromatographed (0 to 100% DCM-hexane) to give 5-benzyl-5,14-dihydro-10-
methoxyindolo[2,1-d][1,5]benzodiazocin-6-one 186f (12 mg, 29%) as a yellow solid; 
mp 113-114 oC (DCM); 1H NMR (CDCl3) δ 3.42 (dd, J= 15, 1.2 Hz, 1H, CHH-7), 3.68 
(d, J= 13.8 Hz, 1H, CHH-7), 3.82 (s, 3H, OCH3), 4.12 (s, J= 13.8 Hz, 1H, CONCHH), 
4.62 (d, J= 13.8 Hz, 1H, CHH-14), 4.85 (d, J= 14.0 Hz, 1H, CONCHH), 5.51 (d, J= 
13.8 Hz, 1H, CHH-14), 6.28 (s, 1H, H-8), 6.84 (dd, J= 9.0, 2.4 Hz, 1H, H-4), 6.99 (d, 
J= 2.4 Hz, 1H, H-9), 7.21-7.25 (m, 6H, Ar), 7.31-7.50 (m, 4H, Ar); 13C NMR (CDCl3) δ 
36.4 (CH2-7), 44.9 (CH2-14), 52.7 (CONCH2), 56.1 (OCH3), 102.4 (C-8), 109.4, 111.6, 
125.9, 128.2, 128.3 (C-8a), 128.8, 129.7, 129.6, 130.0, 130.5, 132.1, 132.7 (C-7a), 
132.9 (C-14a), 133.5 (C-12a), 136.4 (C-1′), 142.9 (C-4a), 154.3 (COCH3), 168.4 (CO); 
CI-MS m/z 383 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C25H23N2O2: 
383.1760, found: 383.1766. 
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Cyclisation of 180 
Following the general procedure, 180 (77 mg, 0.16 
mmol) in mesitylene (7 mL) was treated with AIBN 
(25 mg, 0.16 mmol) and Bu3SnH (77 µL, 0.31 mmol). 
The crude material was column chromatographed (0 to 
100% DCM-hexane). The first fraction gave 5-benzyl-10-fluoro-5,14-
dihydroindolo[2,1-d][1,5]benzodiazocin-6-one 186g (14 mg, 23%) as a yellow solid; 
mp 115-116 oC (DCM); 1H NMR (CDCl3) δ 3.43 (dd, J= 13.8, 1.2 Hz, 1H, CHH-7), 
3.69 (d, J= 13.8 Hz, 1H, CHH-7), 4.13 (d, J= 14.1 Hz, 1H, CHH-14), 4.63 (d, J= 14.1 
Hz, 1H, CONCHH), 4.86 (d, J= 13.8 Hz, 1H, CHH-14), 5.52 (d, J= 14.1 Hz, 1H, 
CONCHH), 6.31 (s, 1H, H-8), 6.90 (dd, J= 9.0, 2.7 Hz, 1H, Ar), 6.94 (dd, J= 9.0, 2.4 
Hz, 1H, H-9), 7.16 (dd, J= 9.6, 2.4 Hz, 1H, H-12), 7.19-7.27 (m, 5H, Ar), 7.31-7.40 (m, 
3H, Ar), 7.47 (dd, J= 6.6, 2.1 Hz, 1H, H-1); 13C NMR (CDCl3) δ 36.4 (CH2-7), 45.0 
(CH2-14), 52.6 (CONCH2), 105.5 (d, J= 4.6 Hz, C13-F19, C8-F), 105.3 (d, J= 23.5 Hz, 
C13-F19, C11-F), 109.3 (d, J= 9.8 Hz, C13-F19, C12-F), 109.7 (d, J= 26.3 Hz, C13-F19, 
C9-F),  126.0, 128.2, 129.2, 129.6, 130.1, 130.7, 132.1, 132.4 (ArC), 134.1 (ArC), 134.6 
(ArC), 136.3 (C-1′), 142.8 (C-4a), 158.7 (d, J= 238.6 Hz, C13-F19, C10-F), 168.2 (CO); 
CI-MS m/z 371 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C24H20N2O2F: 
371.1560, found: 371.1552. 
The second fraction gave N-benzyl-N-{2-[1-(5-fluoro-
1H-indolyl)methyl]- phenyl}acetamide 188g (9 mg, 
15 %) as a yellow solid; mp 63-64 oC (DCM); 1H 
NMR (CDCl3) δ 1.80 (d, 3H, CH3), 4.70 (d, J = 16.8 
Hz, 1H, CONCHH), 4.84 (d, J= 5.1 Hz, 1H, CH2-8), 
5.00 (d, J= 16.8 Hz, 1H, CONCHH), 6.48 (dd, J= 2.7, 0.6 Hz, 1H, H-3), 6.63 (dd, J= 
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7.5, 1.2 Hz, 1H, H-12), 6.79 (m with prominent d, J= 3.3 Hz, 2H, H-2 and H-4), 6.88 
(td, J= 9.0, 2.4 Hz, 1H, H-6), 6.97 (dd, J= 7.8, 1.5 Hz, 1H, H-9), 7.20 (td, J= 7.5, 1.5 
Hz, 1H, Ar), 7.23-7.28 (m, 5H, Ar), 7.29-7.34 (m, 3H, Ar); 13C NMR (CDCl3) δ 22.2 
(CH3), 46.4 (CH2-8), 52.5 (CH2-1′), 102.1 (d, J= 4.9 Hz, C13-F19, C3-F), 105.8 (d, J= 
11.6 Hz, C13-F19, C7-F), 109.9 (d, J= 9.8 Hz, C13-F19, C6-F), 110.3 (d, J= 26.3 Hz, C13-
F19, C4-F), 127.9, 128.2, 128.7, 128.9, 129.0, 129.2, 129.5, 129.67, 129.71, 135.4 (C-
7a), 136.9 (C-8a), 140.1 (C-4a), 157.9 (d, J= 233.1 Hz, C13-F19, C5-F), 170.3 (CO); CI-
MS m/z 373 [M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C24H22N2O2F: 373.1716, 
found: 373.1704. 
Cyclisation of 181 
 Following the general procedure, 181 (37 mg, 0.07 mmol) in toluene (5 mL) was 
treated with AIBN (12 mg, 0.07 mmol) and Bu3SnH (40 µL, 0.15 mmol). The crude 
material was column chromatographed (DCM). The first fraction gave 5,14-dihydro-5-
(1-phenylethyl)indolo[2,1-d][1,5]benzodiazocin-6-one 186h (6 mg, 22%) as a yellow 
solid; mp 157-159 oC (DCM);  
1H NMR (CDCl3, rotamer ratio 52:48*) δ 1.56 (d, J= 
7.2 Hz, 1.6H, CHCH3), 1.78* (d, J= 7.5 Hz, 1.4 Hz, 
CHCH3), 3.33* (d, J= 13.8 Hz, 0.5 H, CHH-7), 3.38 
(d, J= 12.3 Hz, 0.5 H, CHH-7), 3.66* (d, J= 13.5 Hz, 
0.5 H, CHH-7), 3.72 (d, J= 14.1 Hz, 0.5 H, CHH-7), 
3.73* (d, J= 13.8 Hz, 0.5H, CHH-14), 4.64* (d, J= 13.8 Hz, 0.5 H, CHH-14), 4.88 (d, 
J= 13.8 Hz, 0.5 H, CHH-14), 5.37 (d, J= 13.5 Hz, 0.5 H, CHH-14), 6.32* (br s, 0.5H, 
CHCH3), 6.32* (s, 0.5 Hz, H-8), 6.35 (s, 0.5 Hz, H-8), 6.38 (br s, 0.5H, CHCH3), 6.54 
(d, J= 8.1 Hz, 0.5H, H-4), 7.02-7.56 (m, 12.5H, Ar); 13C NMR (CDCl3) δ 16.4 (CH3), 
19.0* (CH3), 36.9 (CH2-7), 44.3* (CH2-14), 45.2 (CH2-14), 52.8* (CH), 53.9 (CH), 
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103.2* (C-8), 103.3 (C-8), 108.4 (C-15), 119.4*, 119.6, 120.2*, 120.3. 121.1*, 121.3, 
127.0* (C-4), 127.7, 128.0, 128.1, 128.2, 128.5, 129.0, 129.4, 130.8 (C-3a), 131.7*, 
131.8, 132.8 (C-7a), 133.0* (C-14a), 133.2* (C-7a), 134.2, (C-14a), 137.3* (C-12a), 
138.9 (C-12a), 139.5 (C-1΄), 140.3* (C-1΄), 141.6 (C-4a), 145.5* (C-4a), 164.4 (CO), 
168.4* (CO); CI-MS m/z 367 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C25H23N2O: 367.1810, found: 367.1796. 
Further fractions then gave a mixture of 187h and 188h (7 mg, 26%) in a ratio of 
ca 1:1 (determined by 1H NMR spectroscopy). 
Cyclisation of 182 
Following the general procedure, 182 (23 mg, 0.06 mmol) in toluene (5 mL) was 
treated with AIBN (10 mg, 0.06 mmol) and Bu3SnH (32 µL, 0.12 mmol). The crude 
material was column chromatographed (DCM). The first fraction gave the amine 149a 
(4 mg, 34%), the second fraction gave N-ethoxycarbonyl-N-{2-[1-(1H-indolyl)methyl]- 
phenyl}acetamide 188i (7 mg, 37%) as a yellow solid; mp 82-83 oC (DCM); 1H NMR 
(CDCl3) δ 1.10 (td, J= 6.9, 0.6 Hz, 3H, CH2CH3), 2.64 
(s, 3H, CH3),  3.97 (ddd, J= 7.2, 7.2, 6.9 Hz, 1H, 
CHHCH3), 4.06 (ddd, J= 7.2, 7.2, 6.9 Hz, 1H, 
CHHCH3), 5.10 (d, J= 16.2 Hz, 1H, CHH), 5.18 (d, J= 
16.2 Hz, 1H, CHH), 6.54 (d, J= 3.0 Hz, 1H, H-3), 6.88 (dd, J= 7.5, 1.5 Hz, 1H, H-3΄), 
7.05 (d, J= 3.0 Hz, 1H, H-2), 7.08-7.15 (m, 4H, Ar), 7.25 (td, J= 7.8, 1.5 Hz, 1H, H-4΄), 
7.32 (dd, J= 7.5, 1.5 Hz, 1H, Ar), 7.63 (dd, J= 6.3, 2.1 Hz, 1H, H-4); 13C NMR (CDCl3) 
δ 14.4 (CH2CH3), 26.9 (CH3), 47.0 (CH2), 63.6 (CH2CH3), 102.1 (C-3), 109.9 (C-7), 
119.8 (C-5), 121.2 (C-4), 122.0 (C-6), 128.3 (C-2), 128.6 (C-3΄), 128.86 (C-6΄), 128.9 
(C-3a), 129.0 (C-5΄), 129.2 (C-4΄), 135.1 (C-1΄), 136.3 (C-7a), 136.5 (C-2΄), 153.7 
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(COO), 172.8 (CO); EI-MS m/z 336 ([M]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C20H21N2O3: 337.1552, found: 337.1552. 
Cyclisation of 183 
 Following the general procedure, 183 (60 mg, 0.14 mmol) in toluene (5 mL) was 
treated with AIBN (23 mg, 0.14 mmol) and Bu3SnH (75 µL, 0.28 mmol). The crude 
material was column chromatographed (DCM).  
The first fraction gave 10-fluoro-5,14-dihydo-5-methyl-indolo[2,1-d][1,5] 
benzodiazocin-6-one 186j (15 mg, 35%) as a yellow solid; mp 200-202 oC (DCM); 
 1H NMR (CDCl3) δ 3.436 (s, 3H, CH3), 3.439 (d, J= 13.8 Hz, 
1H, CHH-7), 3.65 (d, J= 14.1 Hz, 1H, CHH-7), 4.76 (d, J= 
13.8 Hz, 1H, CHH-14), 5.29 (d, J= 13.8 Hz, 1H, CHH-14), 
6.33 (s, 1H, H-8), 6.97 (td, J= 9.0, 2.7 Hz, 1H, H-11), 7.18 (dd, 
J= 9.3, 2.4 Hz, 1H, H-9), 7.35-7.40 (m, 3H, Ar), 7.48 (dd, J= 
7.5, 1.8 Hz, 1H, Ar), 7.51 (d, J= 7.2 Hz, 1H, Ar); 13C NMR (CDCl3) δ 36.2 (CH2-7), 
36.7 (NCH3), 45.5 (CH2-14), 103.5 (d, J= 4.3 Hz, C13-F19, C8-F), 105.4 (d, J= 23.2 Hz, 
C13-F19, C11-F), 109.3 (d, J= 9.5 Hz, C13-F19, C12-F), 109.9 (d, J= 49.0 Hz, C13-F19, 
C9-F), 125.5, 128.2 (d, J= 10.1 Hz, C13-F19, C8a-F), 129.0, 130.7, 131.4 (C-7a), 132.1, 
134.3 (C-14a), 134.6 (C-12a), 144.6 (C-4a), 158.0 (d, J= 232.7 Hz, C13-F19, C10-F), 
168.6 (CO); CI-MS m/z 295 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ 
C18H15N2OF: 294.1168, found: 294.1159. 
The second fraction gave N-{2-[1-(5-fluoro-1H-
indolyl)methyl]phenyl}-N-methylacetamide 188j (7 mg, 
17%) as a yellow solid; mp 70-72 oC (DCM);  
1H NMR (CDCl3) δ 1.74 (s, 3H, CH3), 3.17 (s, 3H, NCH3), 
5.23 (s, 2H, CH2-8), 6.52 (dd, J= 3.3, 0.9 Hz, 1H, H-3), 6.89-6.95 (m, 2H, Ar), 7.06 (dd, 
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J= 9.3, 4.5 Hz, 1H, H-4), 7.09 (d, J= 3.0 Hz, 1H, H-2), 7.18 (dd, J= 7.8, 1.5 Hz, 1H, 
Ar), 7.25-7.30 (m, 2H, Ar), 7.36 (dd, J= 7.5, 1.5 Hz, 1H, Ar); 13C NMR (CDCl3) δ 22.3 
(CH3), 36.7 (NCH3), 47.1 (CH2), 102.5 (d, J= 4.6 Hz, C13-F19, C3-F), 106.2 (d, J= 23.2 
Hz, C13-F19 , C6-F), 110.2 (d, J= 9.7 Hz, C13-F19, C7-F), 110.7 (d, J= 26.5 Hz, C13-F19, 
C4-F), 128.8, 128.9, 129.1, 129.2, 129.5 (d, J= 4.5 Hz, C13-F19, C3a-F), 129.9, 130.0, 
133.0 (C-1΄), 134.6 (C-7a), 142.4 (C-2΄), 157.6 (d, J= 232.2 Hz, C13-F19, C5-F), 170.7 
(CO); CI-MS m/z 297 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ C18H17N2OF: 
296.1325, found: 296.1320. 
Cyclisation of 184 
Following the general procedure, 184 (45 mg, 0.12 mmol) in toluene (5 mL) was 
treated with AIBN (20 mg, 0.12 mmol) and Bu3SnH (64 µL, 0.24 mmol). The crude 
material was column chromatographed (DCM). The first fraction gave 186c (9 mg, 
24%) and the second fraction gave 188c (12 mg, 33%).  
Cyclisation of 185 
Following the general procedure, 185 (44 mg, 0.10 mmol) in toluene (5 mL) was 
treated with AIBN (16 mg, 0.10 mmol) and Bu3SnH (53 µL, 0.20 mmol). The crude 
material was column chromatographed (DCM) to give 186e (19 mg, 54%) and in the 
second fraction, a mixture of 187e and 188e (7 mg, 20%) in a ratio of ca 2:1 
(determined by 1H NMR spectroscopy).  
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7.2.10 Dehydrogenation of 187b 
5,14-dihydro-5-methyl-indolo[2,1-d][1,5]benzodiazocin-6-one 
To a solution of 187b (98 mg, 0.35 mmol) in dry toluene (5 mL) was added 10% 
Pd/C (20 mg). The reaction mixture was then heated at reflux for 8 h. The mixture was 
then cooled, filtered through Celite and the filtrate evaporated to dryness. The crude 
yellow solid residue was column chromatographed (DCM) to yield 186b (48 mg, 50%) 
and the starting material 187b (40 mg, 40%).  
 
7.2.11 Debenzylation 
Debenzylation of 186e 
Method A: Sodium metal (ca 30 mg) was added in dry THF under a N2 
atmosphere and then the mixture was cooled using liquid N2 bath. Liquid ammonia 
(condensed at –70 oC, ca 7 mL) and a solution of 186e (30 mg, 0.09 mmol) in dry THF 
(2 mL) was added. The frozen mixture was warmed to –60 oC and the reaction was 
stirred for 30 min.  Solid ammonium chloride was added until the colour dissipated at 
which point the reaction was allowed to warm to r.t.. The residue was dissolved in ethyl 
acetate (30 mL), extracted with water (20 mL), dried and concentrated to give a yellow 
residue. The residue was purified using preparative thin layer chromatography (silica 
gel, 1% MeOH/DCM) to give two major bands.  
 The first band (higher Rf) gave 2-(1H-indol-2yl)-N-o-
tolylacetamide 190 (3.3 mg, 14%) as a yellow solid; mp 
131-133 oC; 1H NMR (CDCl3) δ 1.98 (s, 3H, CH3), 3.91 (s, 2H, CH2), 6.48 (s, 1H, H-3), 
7.05-7.21 (m, 5H, Ar), 7.34 (dd, J= 7.5, 0.9 Hz, 1H, H-7), 7.36 (br s, 1H, indole NH), 
7.59 (d, J= 7.8 Hz, 1H, Ar), 7.78 (d, J= 8.1 Hz, 1H, H-6΄), 8.82 (br s, 1H, NH); 13C 
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NMR (CDCl3) δ 17.5 (CH3), 37.6 (CH2), 102.6 (C-3), 111.3 (C-7), 120.3 (C-5), 120.5 
(C-4), 122.4 (C-6), 123.0 (C-6΄), 125.8 (C-4΄), 127.0 (ArC-H), 128.5 (C-3a), 129.4 (C-
2΄), 130.8 (ArC-H), 131.8 (C-2), 135.3 (C-1΄), 136.9 (C-7a), 168.3 (CO); CI-MS m/z 
265 [M+H]+, 100%); HREI-MS m/z calcd for [M]+ C17H16N2O: 264.1262, found: 
264.1260. 
The second band (lower Rf) gave 5,14-dihydroindolo[2,1-
d][1,5]benzodiazocin-6(7H)-one 29a (6.8 mg, 29%) as an off- 
white solid; mp  269-271 oC (lit.30 268-270 oC); ); IR (KBr) νmax:  
3415 (NH), 1655 (C=O) cm-1; 1H NMR (CDCl3) δ 3.58 (s, 2H, 
CH2-7), 5.18 (s, 2H, CH2-14), 6.40 (s, 1H, H-8), 7.12 (td, J= 7.2, 0.9 Hz, 1H, Ar), 7.24- 
7.30 (m, 2H, Ar), 7.36-7.41 (m, 1H, Ar), 7.44 (dd, J= 7.5, 1.8 Hz, 1H, Ar), 7.48-7.58 
(m, 3H, Ar), 7.73 (br s, 1H, NH); 13C NMR (CDCl3) δ 35.2 (CH2-14), 45.5 (CH2-7), 
103.8 (C-8), 108.9, 120.1, 120.7, 121.8, 125.7, 128.1 (C-8a), 128.97, 129.02 (ArC), 
130.4, 132.6, 138.3 (ArC), 144.0 (ArC), 170.7 (CO); CI-MS m/z 263 ([M+H]+, 100%); 
HREI-MS m/z calcd for [M]+ C17H14N2O: 262.1106, found: 262.1104. 
Method B: This method followed the above procedure, apart from the reaction 
mixture being stirred for 8 min. Solid ammonium chloride was added until the colour 
dissipated at which point the reaction was allowed to warm to r.t.. The residue was 
dissolved in ethyl acetate (30 mL), extracted with water (20 mL), dried and 
concentrated to give a yellow residue. The residue was purified using preparative thin 
layer chromatography (silica gel, 1% MeOH/DCM) to give the product 29a (7.8 mg, 
35%). 
N
N
O
H
 204
7.2.12 Anionic inducted thermal cyclisation 
Attempted cyclisation using AgBF4, AgPF6 
To a solution of 161 (20 mg, 0.067 mmol) or 163 (21 mg, 0.066 mmol) in dry 
CH3CN (15 mL) was added AgBF4 (3 mg) or AgPF6 (3 mg) and the suspension was 
heated at reflux under a N2 atmosphere overnight. The suspension was filtered through 
silica gel and the solvent was evaporated to dryness to give a purple solid (37 mg). TLC 
and 1H NMR analysis showed only starting material was obtained. 
Attempted cyclisation using AgBF4 in DME 
A solution of 178 (90 mg, 0.19 mmol) in dry DME (10 mL) was added AgBF4 
(93 mg, 0.48 mmol) and the reaction mixture was stirred at reflux for 4 h under an Ar 
atmosphere. The DME was evaporated in vacuo. The resultant residue was dissolved in 
EtOAc (50 mL), washed with a 1% aq. TFA solution (3 x 50 mL), then water (3 x 50 
mL), dried and concentrated. The resulting oil was subjected to preparative layer 
chromatography (silica gel, DCM). Only starting material was obtained. 
Attempted cyclisation using AgOTf 
To a solution of 161 (72 mg, 0.24 mmol) in acetone (2.4 mL) was added NaI 
(0.37 mmol, 2.48 mmol). The resulting solution was heated at reflux for 2 h. The 
solution was then cooled to r.t.. EtOAc (15 mL) was added and washed with water (10 
mL), dried and concentrated. The residue was immediately dissolved in THF (2.5 mL) 
and AgOTf (0.11 g, 0.44 mmol) was added. The reaction mixture was allowed to stir for 
30 min, then it was poured into EtOAc (20 mL) and washed with satd. NaHCO3 (3 x 15 
mL). The organic layer was separated, dried and concentrated to give a yellow residue. 
1H NMR spectroscopic analysis showed only starting material was recovered.   
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Attempted cyclisation using Pd  
A mixture of 178 (50 mg, 0.12 mmol), Pd(Ph3)4 (7 mg, 0.006 mmol), and KOAc 
(12 mg, 0.12 mmol) in dry DMF (5mL) was heated at reflux under a N2 atmosphere for 
10 h. The reaction mixture was cooled to r.t. and passed through a short column of silica 
gel. The filtrate was evaporated to dryness. 1H NMR spectroscopic analysis showed 
only starting material was recovered. 
Attempted cyclisation using In powder 
To a solution of 176 (70 mg, 0.16 mmol) in MeOH (0.2 mL) was added water 
(0.8 mL) dropwise over 5 min at r.t. and then indium powder (60 mg, 0.52 mmol) was 
added. After being stirred at r.t. for 2 days, the reaction mixture was diluted with water 
(15 mL) and then extracted with DCM (20 mL). The organic phase was separated, dried 
and concentrated. The residue was purified using preparative layer chromatography to 
give 2 major bands. The higher Rf band gave starting material 176 (6 mg, 9%) and the 
second band gave the simple reduced compound 188c (1.3 mg, 3%). 
Preparation of Zn-Ag couple 
Silver acetate (35 mg) in acetic acid (1.25 ml) was heated until boiling. Zinc 
dust (0.5 g) was then added carefully. A vigorous exothermic reaction followed, stirring 
was continued for 2 min. and then the mixture was cooled on ice. The suspension was 
filtered using a sintered funnel and washed with water, methanol and diethyl ether, with 
filtration between washes. The Zn-Ag couple was dried and stored in a desiccator at r.t.. 
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Attempted cyclisation using Zn-Ag couple 
A mixture of 178 (0.10 g, 0.21 mmol), Zn-Ag couple (41 mg, 0.63 mmol) in dry 
THF (15 ml) was heated at 80 oC in sealed tube under an Ar atmosphere for 5 h with 
periodic ultrasonication. The reaction mixture was then filtered through celite and 
washed with cold THF. The filtrate was evaporated, concentrated and the residue 
subjected to preparative thin layer chromatography 
(silica gel; 10% EtOAc in pet. spirit) to give two major 
bands. The higher Rf band gave N-benzyl-N-{2-[1-(3-
iodo-1H-indolyl)methyl]phenyl}acetamide 203 (48 mg, 
48%) as a yellow solid; mp 153-154 oC; 1H NMR 
(CDCl3) δ 1.83 (s, 3H, CH3), 4.69 (d, J= 17.1 Hz, 1H, CONCHH), 4.69 (d, J= 13.8 Hz, 
1H, CHH), 4.92 (d, J= 13.5 Hz, 1H, CHH), 5.01 (d, J= 16.8 Hz, 1H, CONCHH), 6.66 
(d, J= 7.5 Hz, 1H, H-3΄), 6.75 (s, 1H, H-2), 6.94 (m, 1H, H-7), 7.01 (dd, J= 7.8, 1.5 Hz, 
1H, H-6΄), 7.17-7.33 (m, 9H, Ar), 7.44 (m, 1H, H-4); 13C NMR (CDCl3) δ  22.5 (CH3), 
46.3 (CONCH2), 52.9 (CH2), 56.8 (C-3), 109.7 (C-7), 120.9 (C-4), 121.7 (C-6), 123.3 
(C-5), 128.3 (C-4΄), 128.4 (C-5΄), 129.0 (C-2΄ and C-6΄), 129.3, 129.5, 129.7 (all ArC-
H), 130.0 (C-3΄ and C-5΄), 130.7 (C-3a), 132.1 (C-6΄), 135.4 (C-1), 136.7 (C-7a), 137.1 
(C-2΄), 140.4 (C-1΄΄), 170.4 (CO); EI-MS m/z 480 ([M]+, 85%); HREI-MS m/z calcd for 
[M]+ C24H21N2OI: 480.0699, found: 480.0701. 
 The second band (lower Rf) gave N-benzyl-N-{2-[(2,3-dioxoindolin-1-
yl)methyl]phenyl}acetamide 204 (21 mg, 35%) as a bright yellow solid; mp 75-77 oC; 
IR (KBr) νmax:  1743 (C=O), 1651 (C=O) and 1612 (C=O) cm-1; 1H 
NMR (CDCl3) δ 1.94 (s, 3H, CH3), 4.26 (d, J= 16.8 Hz, 1H, CHH), 
4.83 (d, J= 17.1 Hz, 1H, CHH), 4.96 (d, J= 2.4 Hz, 2H, CONCH2), 
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6.15 (d, J= 7.8 Hz, 1H, H-7), 7.01 (d, J= 6.9, 2.1 Hz, 1H, H-3΄), 7.09-7.14 (m , 2H, Ar), 
7.29-7.32 (m, 7H, Ar), 7.44 (td, J= 8.1, 1.5 Hz, 1H, H-5), 7.63 (dd, J= 7.2, 0.9 Hz, 1H, 
H-4); 13C NMR (CDCl3) δ 22.7 (CH3), 40.3 (CH2), 52.8 (CONCH2), 110.6 (C-7), 117.9 
(C-3a), 124.3 (C-5), 125.8 (C-4), 127.1, 128.2 (all ArCH), 128.9 (C-2΄΄ and C-6΄΄), 
129.2, 129.5 (all ArCH), 129.9 (C-3΄΄ and C-5΄΄), 130.1 (C-3΄), 132.6 (C-1΄), 137.3 (C-
2΄), 138.6 (C-5), 140.8 (C-1΄΄), 150.8 (C-7a), 158.4 (C-2), 170.8 (CO), 183.6 (C-3); EI-
MS m/z 384 ([M]+, 29%); HRCI-MS m/z calcd for [M+H]+ C24H21N2O3: 385.1552, 
found: 385.1615. 
 
7.3 Experimental for Chapter 3 
7.3.1 N-acylation of indoles 
Synthesis of  5-methoxy-N-phenyl-1H-indole-1-carboxamide (219) 
To a stirred suspension of sodium hydride (60% dispersion 
in mineral oil, 45 mg, 1.12 mmol) in dry DMF (10 mL) at 
0-5 oC was added a solution of 5-methoxyindole (0.15 g, 
1.02 mmol) in dry DMF (20 mL) under a N2 atmosphere and the solution was then 
stirred at r.t. for 2 h. An excess DMF (20 mL) was added and the mixture was cooled to 
-60 °C. Phenyl isocyanate (0.11 mL, 1.02 mmol) in DMF (20 mL) was slowly added 
and the reaction mixture was stirred at r.t. overnight. Solvent was evaporated and DCM 
(30 mL) was added and then washed with water several times. The DCM phase was 
dried and concentrated to give a yellow solid. The solid was subjected to flash column 
chromatography (10% EtOAc/pet. spirit) to give 219 (0.33 g, 95%) as white needles; 
mp 122-123 oC; 1H NMR (CDCl3) δ 3.88 (s, 3H, OCH3), 6.59 (d, J= 3.0 Hz, 1H, H-3), 
6.97 (dd, J= 9.3, 2.4 Hz, 1H, H-6), 7.08 (d, J= 2.4 Hz, 1H,  H-4), 7.18 (dd, J= 7.2, 6.9 
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Hz, 1H, H-4´), 7.32 (br s, 1H, NH), 7.40 (t, J= 7.5 Hz, 2H, H-3´ and H-5´), 7.52-7.54 
(m, 3H, H-2, H-2´ and H-6´), 8.02 (d, J= 8.7 Hz, 1H, H-7); 13C NMR (CDCl3) δ 55.9 
(OCH3), 103.9 (C-4), 107.9 (C-3), 113.8 (C-6), 115.1 (C-7), 120.6 (C-2΄ and C-6΄), 
124.7 (C-2), 125.0 (C-4΄), 129.5 (C-3΄ and C-5΄), 130.2 (C-3a), 131.4 (C-7a), 137.3 (C-
1΄), 149.7 (COCH3), 156.1 (CO); CI-MS m/z 267 ([M+H]+, 100%); HRCI-MS m/z calcd 
for [M+H]+ C16H15N2O2: 267.1134, found: 267.1124.    
Synthesis of N-(2-bromophenyl)-1H-indole-1-carboxamide (220a) 
To a stirred suspension of sodium hydride (60% dispersion in 
mineral oil, 0.12 g, 2.8 mmol) in dry DMF (10 mL) at 0-5 oC was 
added a solution of 1H-indole (0.30 g, 2.56 mmol) in dry DMF 
(40 mL) under a N2 atmosphere and the solution was then stirred 
at r.t. for 2 h. An excess DMF (20 mL) was added and the mixture was cooled to -60 oC. 
2-Bromophenyl isocyanate (0.40 mL, 3.28 mmol) in DMF (20 mL) was slowly added 
and the reaction mixture was stirred at r.t. overnight. Solvent was evaporated and DCM 
(30 mL) was added and then washed with water several times. The DCM phase was 
dried and concentrated to give a yellow solid. The solid was subjected to flash column 
chromatography (10% EtOAc/pet. spirit) to give 220a (0.35 g, 43%) as white needles; 
mp 120-121 oC; IR (KBr) νmax: 3258 (NH), 1676 (C=O) cm-1; 1H NMR (CDCl3) δ 6.73 
(dd, J= 3.3, 0.9 Hz, 1H, H-3), 7.05 (td, J= 7.2, 1.5 Hz, 1H, H-4΄), 7.29 (dd, J= 8.1, 0.9 
Hz, 1H, H-4), 7.36 (m, 2H, H-6 and H-5΄), 7.60 (m, 3H, H-2, H-5 and H-3΄), 8.00 (br s, 
1H, NH), 8.25 (d, J= 8.1 Hz, 1H, H-7), 8.36 (dd, J= 8.7, 1.5 Hz, 1H, H-6΄); 13C NMR 
(CDCl3) δ 108.6 (C-3), 113.9 (C-2΄), 114.5 (C-7), 121.7 (C-6΄), 121.8 (ArC-H), 123.1 
(C-4), 124.1 (ArC-H), 125.0 (ArC-H), 125.6 (C-4΄), 128.9 (ArC-H), 130.7 (C-3a), 132.6 
(ArC-H), 135.4 (C-7a), 135.5 (C-1΄), 149.2 (CO); CI-MS m/z 315 ([M+H; 79Br]+, 
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100%), 317 ([M+H; 81Br]+, 99%); HRCI-MS m/z calcd for [M+H]+ C15H12N2O79Br: 
315.0133, found: 315.0091.  
Synthesis of N-(2-bromophenyl)-5-methoxy-1H-indole-1-carboxamide (220b) 
To a stirred suspension of sodium hydride (60% dispersion 
in mineral oil, 0.18 g, 4.49 mmol) in dry DMF (10 mL) at 
0-5 oC was added a solution of 5-methoxy-1H-indole (0.60 
g, 4.08 mmol) in dry DMF (40 mL) under a N2 
atmosphere and the reaction mixture was then stirred at r.t. for 2 h. An excess DMF (20 
mL) was then added and the mixture was cooled to -60 oC. 2-Bromophenyl isocyanate 
(0.64 mL, 5.22 mmol) in DMF (20 mL) was slowly added and the reaction mixture was 
stirred at r.t. overnight. Solvent was evaporated and DCM (30 mL) was added and then 
washed with water several times. The DCM phase was dried and concentrated to give a 
yellow solid. The solid was subjected to flash column chromatography (10% 
EtOAc/pet. spirit) to give 220b (0.80 g, 56%) as white needles; mp 117-118 oC; 1H 
NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 6.67 (dd, J= 3.6, 0.9 Hz, 1H, H-3), 7.02 (dd, J= 
9.0, 2.4 Hz, 1H, H-6), 7.04 (td, J= 7.8, 2.4 Hz, 1H, H-4΄), 7.10 (d, J= 3.0 Hz, 1H, H-4), 
7.40 (td, J= 8.7, 1.5 Hz, 1H, H-5΄), 7.58 (d, J= 3.9 Hz, 1H, H-2), 7.60 (dd, J= 8.4, 1.2 
Hz, 1H, H-3΄), 7.95 (br s, 1H, NH), 8.14 (d, J= 9.0 Hz, 1H, H-7), 8.35 (dd, J= 8.1, 1.5 
Hz, 1H, H-6΄); 13C NMR (CDCl3) δ 55.7 (OCH3), 103.8 (C-4), 108.2 (C-3), 113.6 (C-
2΄), 113.7 (C-6), 115.1 (C-7), 121.5 (C-6΄), 124.3 (C-2), 125.3 (C-4΄), 128.7 (C-5΄), 
130.3 (C-3a), 131.3 (C-7a), 132.4 (C-3΄), 135.3 (C-1΄), 148.7 (COCH3), 156.0 (CO); CI-
MS m/z 345 ([M+H; 79Br]+, 100%), 347 ([M+H; 81Br]+, 99%); HRCI-MS m/z calcd for 
[M+H]+ C16H14N2O281Br: 347.0218, found: 347.0204.  
 
 
N
N
H
O
1'
2'
3'
4'
5'
6'
1
2
3
45
6
7
Br
MeO
 210
Synthesis of N-(2-bromophenyl)-5-fluoro-1H-indole-1-carboxamide (220c) 
To a stirred suspension of sodium hydride (60% dispersion in 
mineral oil, 0.39 g, 8.14 mmol) in dry DMF (10 mL) at 0-5 
oC was added a solution of 5-fluoro-1H-indole (1.0 g, 7.40 
mmol) in dry DMF (20 mL) under a N2 atmosphere and the 
reaction mixture was then stirred at r.t. for 2 h. An excess DMF (20 mL) was added and 
the mixture was cooled to -60 oC. 2-Bromophenyl isocyanate (1.20 mL, 9.62 mmol) in 
DMF (40 mL) was slowly added and the reaction mixture was stirred at r.t. overnight. 
Solvent was evaporated and DCM (30 mL) was added and then washed with water 
several times. The DCM phase was dried and concentrated to give a yellow solid. The 
solid was subjected to flash column chromatography (10% EtOAc/pet. spirit) to give 
220c (1.3 g, 53%) as white needles; mp 108-110 oC; 1H NMR (CDCl3) δ 6.70 (d, J= 3.6 
Hz, 1H, H-3), 7.06 (t, J= 8.4 Hz, 1H, H-4΄), 7.14 (td, J= 9.0, 2.7 Hz, 1H, H-6), 7.29 (dd, 
J= 9.0, 2.4 Hz, 1H, H-4), 7.41 (t, J= 7.8 Hz, 1H, H-5΄), 7.63 (m, 2H, H-2 and H-3΄), 
7.93 (br s, 1H, NH), 8.23 (dd, J= 9.0, 4.5 Hz, 1H, H-7), 8.34 (d, J= 8.1 Hz, 1H, H-6΄); 
13C NMR (CDCl3) δ 106.9 (d, J= 23.8 Hz, 13C-19F, C4-F), 108.5 (d, J= 3.9 Hz, 13C-19F, 
C3-F), 113.0 (d, J= 25.2 Hz, 13C-19F, C6-F), 114.0 (C-2΄), 115.8 (d, J= 9.2 Hz, 13C-19F, 
C7-F), 121.8 (C-6΄), 125.1 (C-2), 125.7 (C-4΄), 128.9 (C-5΄), 131.3 (C-3a), 132.1 (C-
7a), 132.6 (C-3΄), 135.3 (C-1΄), 148.9 (CO), 159.5 (d, J= 238.0 Hz, 13C-19F, C5-F); CI-
MS m/z 333 ([M+H; 79Br]+, 100%), 335 ([M+H; 81Br]+, 95%); HRCI-MS m/z calcd for 
[M+H]+ C15H11N2O281BrF: 335.0018, found: 335.0006.  
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7.3.2 N-alkylation procedure 
Synthesis of 5-methoxy-N-methyl-N-phenyl-1H-indole-1-carboxamide (221) 
Method A: A suspension of 219 (79 mg, 0.30 mmol) and 
KOH (66 mg, 1.20 mmol) in dry DMSO (4 mL) was 
stirred at 0-5 oC for 30 min. Methyl iodide (38 µL, 0.60 
mmol) was then added and the reaction mixture was stirred 
at r.t. for 16 h. Water (15 mL) was added and the mixture was extracted with DCM (3 x 
15 mL). The combined organic extracts were washed with water (15 mL), dried and 
evaporated. The residue was subjected to flash column chromatography (silica gel, 
DCM) to give 221 (36 mg, 43%) as a colourless oil. 
Method B: To a stirred suspension of sodium hydride (60% dispersion in mineral oil, 33 
mg, 0.83 mmol) in dry THF (10 mL) at 0-5 oC was added a solution of 219 (0.20 g, 0.75 
mmol) in dry THF (40 mL) under a N2 atmosphere. A solution was stirred at r.t. for 2 h, 
and a solution of methyl iodide (0.17 mL, 1.88 mmol) in THF (10 mL) was added and 
then the reaction mixture was stirred at r.t. overnight. THF was evaporated and water 
(15 mL) was added and the mixture extracted with DCM (3 x 20 mL). The combined 
DCM extracts were dried and concentrated to give a yellow residue. The residue was 
subjected to flash column chromatography (10% EtOAc/pet. spirit) to give the title 
compound 221 (0.16 g, 76%) as a colourless oil; 1H NMR (CDCl3) δ 3.51 (s, 3H, 
NCH3), 3.82 (s, 3H, OCH3), 6.19 (d, J= 3.6 Hz, 1H, H-3), 6.75 (d, J= 3.6 Hz, 1H, H-2), 
6.93 (dd, J= 6.6, 2.4 Hz, 1H, H-6), 6.94 (s, 1H, H-4), 7.05 (dd, J= 7.8, 1.2 Hz, 2H, C-3΄ 
and C-5΄), 7.16 (t, J= 6.9 Hz, 1H, H-4΄), 7.27 (t, J= 7.2 Hz, 2H, H-2΄ and H-6΄), 7.97 
(dd, J= 6.9, 2.7 Hz, 1H, H-7); 13C NMR (CDCl3) δ 39.8 (CH3), 55.9 (OCH3), 103.1 (C-
4), 106.1 (C-3), 113.2 (C-6), 115.7 (C-7), 125.1 (C-3΄ and C-5΄), 126.5 (C-4΄), 127.4 
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(C-2), 130.0 (C-2΄ and C-6΄), 130.2 (C-3a), 131.1 (C-7a), 145.0 (C-1΄), 154.0 (CO), 
155.9 (COCH3); CI-MS m/z 281 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C17H17N2O2: 281.1290, found: 281.1285.    
Synthesis of N-(2-bromophenyl)-N-methyl-1H-indole-1-carboxamide (222a) 
To a stirred suspension of sodium hydride (60% dispersion in 
mineral oil, 13 mg, 0.33 mmol) in dry THF (5 mL) at 0-5 oC 
was added a solution of 220a (94 mg, 0.30 mmol) in THF (20 
mL) under a N2 atmosphere. The solution was stirred at r.t. for 
2 h, and a solution of methyl iodide (38 µL, 0.60 mmol) in THF (3 mL) was added and 
then the reaction mixture was stirred at r.t. overnight. THF was evaporated and water 
(15 mL) was added and the mixture extracted with DCM (3 x 20 mL). The combined 
DCM extracts were dried and concentrated to give a yellow residue. The residue was 
subjected to flash column chromatography (10% EtOAc/pet. spirit) to give 222a (73 
mg, 76%) as a white solid; mp 136-137 oC; IR (KBr) νmax: 1688 (C=O) cm-1; 1H NMR 
(CDCl3) δ 3.42 (s, 3H, CH3), 6.25 (dd, J= 3.3, 0.9 Hz, 1H, H-3), 6.79 (d, J= 3.9 Hz, 1H, 
H-2), 7.08-7.13 (m, 2H, H-5 and H-5΄), 7.15-7.25 (m, 2H, H-3΄ and H-4΄), 7.32 (td, J= 
7.8, 1.2 Hz, 1H, H-6), 7.46 (dd, J= 7.8, 0.6 Hz, 1H, H-4), 7.61 (dd, J= 7.8, 1.8 Hz, 1H, 
H-6΄), 8.11 (dd, J= 7.2, 0.6 Hz, 1H, H-7); 13C NMR (CDCl3) δ 39.0 (CH3), 106.5 (C-3), 
114.9 (C-7), 120.8 (C-4), 122.3 (C-2΄), 122.5 (C-5), 124.1 (C-6), 125.9 (C-2), 129.1 (C-
3΄), 129.3 (C-4΄), 129.36 (C-5΄), 129.4 (C-3a), 134.4 (C-6΄), 136.6 (C-7a), 143.6 (C-1΄), 
154.1 (CO); CI-MS m/z 329 ([M+H; 79Br]+, 100%), 331 ([M+H; 81Br]+, 97%); HRCI-
MS m/z calcd for [M+H]+ C16H14N2O79Br: 329.0289, found: 329.0283.  
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Synthesis of N-(2-bromophenyl)-5-methoxy-N-methyl-1H-indole-1-carboxamide 
(222b) 
To a stirred suspension of sodium hydride (60% dispersion 
in mineral oil, 34 mg, 0.70 mmol) in dry THF (10 mL) at 
0-5 oC was added a solution of 220b (0.22 g, 0.64 mmol) 
in THF (40 mL) under a N2 atmosphere. The solution was 
stirred at r.t. for 2 h and a solution of methyl iodide (0.10 mL, 1.60 mmol) in THF (10 
mL) was added and then the reaction mixture was stirred at r.t. overnight. THF was 
evaporated and water (15 mL) was added and the mixture extracted with DCM (3 x 20 
mL). The combined DCM extracts were dried and concentrated to give a yellow 
residue. The residue was subjected to flash column chromatography (10% EtOAc/pet. 
spirit) to give 222b (0.20, 88%) as a white solid; mp 130-132 oC; IR (KBr) νmax: 1685 
(C=O) cm-1; 1H NMR (CDCl3) δ 3.39 (s, 3H, NCH3), 3.80 (s, 3H, OCH3), 6.18 (dd, J= 
3.6, 0.6 Hz, 1H, H-3), 6.74 (d, J= 3.6 Hz, 1H, H-2), 6.92 (s, 1H, H-4), 6.93 (dd, J= 8.4, 
2.4 Hz, 1H, H-6), 7.07-7.12 (m, 2H, H-4΄ and H-5΄), 7.19 (dd, J= 6.9, 1.2 Hz, 1H, H-
3΄), 7.60 (dd, J= 7.8, 1.8 Hz, 1H, H-6΄), 8.00 (dd, J= 8.7, 0.6 Hz, 1H, H-7); 13C NMR 
(CDCl3) δ 39.0 (CH3), 55.9 (OCH3), 103.1 (C-4), 106.4 (C-3), 113.3 (C-6), 115.7 (C-7), 
122.3 (C-2΄), 126.5 (C-2), 129.1, 129.2 (C-4΄ or C-5΄), 129.4 (C-3΄), 130.1 (C-3a), 
131.4 (C-7a), 134.4 (C-6΄), 143.7 (C-1΄), 154.1 (COCH3), 155.9 (CO); CI-MS m/z 359 
([M+H; 79Br]+, 100%), 361 ([M+H; 81Br]+, 95%); HRCI-MS m/z calcd for [M+H]+ 
C17H16N2O279Br: 359.0395, found: 359.0391. 
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Synthesis of N-(2-bromophenyl)-5-fluoro-N-methyl-1H-indole-1-carboxamide 
(222c) 
To a stirred suspension of sodium hydride (60% dispersion in 
mineral oil, 40 mg, 0.83 mmol) in dry THF (10 mL) at 0-5 oC 
was added a solution of 220c (0.25 g, 0.75 mmol) in THF (40 
mL) under a N2 atmosphere. The solution was stirred at r.t. 
for 2 h and a solution of methyl iodide (0.12 mL, 1.88 mmol) in THF (10 mL) was 
added and the reaction mixture was stirred at r.t. overnight. THF was evaporated and 
water (15 mL) was added and the mixture extracted with DCM (3 x 20 mL). The 
combined DCM extracts were dried and concentrated to give a yellow residue. The 
residue was subjected to flash column chromatography (10% EtOAc/pet. spirit) to give 
222c (0.18 g, 69%) as a white solid; mp 133-134 oC; IR (KBr) νmax: 1689 (C=O) cm-1; 
1H NMR (CDCl3) δ 3.42 (s, 3H, CH3), 6.22 (dd, J= 3.6, 0.6 Hz, 1H, H-3), 6.83 (d, J= 
3.3 Hz, 1H, H-2), 7.04 (td, J= 9.0, 2.7 Hz, 1H, H-6), 7.09-7.16 (m, 3H, Ar), 7.24 (td, J= 
6.9, 1.5 Hz, 1H, H-5΄), 7.61 (dt, J= 7.5, 0.6 Hz, 1H, H-6΄), 8.06 (dd, J= 8.7, 4.2 Hz, 1H, 
H-7); 13C NMR (CDCl3) δ 39.1 (CH3), 106.1 (d, J= 23.6 Hz, 13C-19F, C6-F), 106.3 (d, 
J= 3.9 Hz, 13C-19F, C3-F), 112.4 (d, J= 25.2 Hz, 13C-19F, C4-F), 115.9 (d, J= 9.2 Hz, 
13C-19F, C7-F), 122.4 (C-2΄), 127.5 (C-2), 129.1, 129.4, 129.45 (all ArC-H), 130.1 (d, 
J= 10.3 Hz, 13C-19F, C3a-F), 133.0 (C-7a), 134.5 (C-6΄), 143.4 (C-1΄), 155.8 (d, J= 
286.3 Hz, 13C-19F, C5-F), 160.9 (CO); CI-MS m/z 347 ([M+H; 79Br]+, 100%), 349 
([M+H; 81Br]+, 95%); HRCI-MS m/z calcd for [M+H]+ C16H13N2O279BrF: 347.0195, 
found: 347.0194. 
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Synthesis of N-benzyl-N-(2-bromophenyl)-1H-indole-1-carboxamide (223a) 
 To a suspension of sodium hydride (ca 50% dispersion in 
mineral oil, 88 mg, 1.80 mmol) in dry DMF (10 mL) at 0 oC 
was added a solution of 220a (0.44 g, 1.40 mmol) in DMF (30 
mL) followed by addition of tert-butylammonium iodide (7 
mg). After 30 min, a solution of  benzyl bromide (0.26 mL, 2.10 mmol) in DMF (20 
mL) was added and the reaction mixture was stirred for 16 h at r.t.. DMF was then 
evaporated, DCM (20 mL) was added to the residue and the mixture washed with water 
several times. The DCM phase was dried, concentrated and subjected to flash column 
chormatography (silica gel, 10% EtOAc/pet. spirit) to give 223a (0.35 g, 62%) as a 
white solid; mp 109-111 oC; 1H NMR (CDCl3) δ 4.63 (br s, 1H, CHH), 5.38 (br s, 1H, 
CHH), 6.21 (d, J= 3.9 Hz, 1H, H-3), 6.74 (m, 1H, H-3΄), 6.80 (d, J= 3.6 Hz, 1H, H-2), 
7.00-7.04 (m, 2H, H-4΄ and H-5΄), 7.14 (td, J= 7.5, 0.6 Hz, 1H, H-5), 7.20-7.27 (m, 3H, 
H-6, H-3΄΄ and H-5΄΄), 7.30-7.34 (m, 3H, H-2΄΄, H-4΄΄ and H-6΄΄), 7.42 (dd, J= 7.5, 0.3 
Hz, 1H, H-4), 7.53 (m, 1H, H-6΄), 8.11 (d, J= 8.4 Hz, 1H, H-7); 13C NMR (CDCl3) δ 
54.3 (CH2), 106.5 (C-3), 115.1 (C-7), 120.9 (C-4), 122.6 (C-5), 123.0 (C-2΄), 124.1 (C-
6), 125.9 (C-2), 128.1 (C-4΄΄), 128.7 (C-3΄΄ and C-5΄΄), 128.9, 129.3 (C-4΄ and C-5΄), 
129.4 (C-3a), 129.7 (C-2΄΄ and C-6΄΄), 130.7 (C-3΄), 134.4 (C-6΄), 136.5 (C-7a), 136.8 
(C-1΄΄), 141.4 (C-1΄), 153.9 (CO); EI-MS m/z 404 ([M; 79Br]+, 49%), 406 ([M; 81Br]+, 
52%); HREI-MS m/z calcd for [M]+ C22H17N2OBr: 404.0524, found: 404.0525. 
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Synthesis of N-benzyl-N-(2-bromophenyl)-5-methoxy-1H-indole-1-carboxamide 
(233b) 
To a suspension of NaH (ca 50% dispersion in mineral oil, 
44 mg, 0.91 mmol) in dry DMF (5 mL) at 0 oC was added 
a solution of 220b (0.24 g, 0.70 mmol) in DMF (25 mL) 
followed by addition of tert-butylammonium iodide (3.5 
mg). After 30 min, a solution of benzyl bromide (0.13 mL, 1.05 mmol) in DMF (10 mL) 
was added and the reaction mixture was stirred for 16 h at r.t.. DMF was then 
evaporated, DCM (20 mL) was added to the residue and the mixture washed with water 
several times. The DCM phase was dried and concentrated to give a brown oil. The oil 
was subjected to column chromatography (silica gel, 10% EtOAc/pet. spirit) to give 
233b (0.25 g, 81%) as a white solid; mp 117-118 oC; 1H NMR (500 MHz, CDCl3) δ 
3.79 (s, 3H, CH3), 4.66 (br s, 1H, CHH), 5.34 (br s, 1H, CHH), 6.08 (dd, J= 3.5 Hz, 1H, 
H-3), 6.69-6.71 (m, 2H, H-2 and Ar), 6.82 (s, 1H, H-4), 6.83 (dd, J= 9.0, 2.5 Hz, 1H, H-
6), 6.95-6.98 (m, 2H, H-5΄ and Ar), 7.17-7.19 (m, 3H, H-3΄΄, H-5΄΄ and Ar), 7.24 (dd, 
J= 6.5, 2.5 Hz, 2H, H-2΄΄ and H-6΄΄), 7.46 (dd, J= 6.5, 2.5 Hz, 1H, H-6΄), 7.94 (d, J= 9.0 
Hz, 1H, H-7); 13C NMR (125 MHz, CDCl3) δ 54.0 (CH2), 55.6 (CH3), 102.8 (C-4), 
106.1 (C-3), 113.0 (C-6), 115.6 (C-7), 122.6 (C-2΄), 126.1 (C-2), 127.7 (ArC-H), 128.3 
(C-3΄΄ and C-5΄΄), 128.4, 128.8, 129.3 (all ArC-H), 129.8 (C-3a), 130.3 (C-2΄΄ and C-
6΄΄), 131.3 (C-7a), 134.0 (C-6΄), 136.2 (C-1΄΄), 141.3 (C-1΄), 153.5 (CO), 155.6 
(COCH3); CI-MS m/z 335 ([M+H; 79Br]+, 100%), 337 ([M+H; 81Br]+, 95%); HRCI-MS 
m/z calcd for [M+H]+ C23H20N2O281Br: 437.0688, found: 437.0669. 
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Synthesis of N-benzyl-N-(2-bromophenyl)-5-fluoro-1H-indole-1-carboxamide 
(223c) 
To a suspension of NaH (ca 50% dispersion in mineral oil, 44 
mg, 0.91 mmol) in dry DMF (5 mL) at 0 oC was added on a 
solution of 220c (0.23 g, 0.70 mmol) in DMF (25 mL), 
followed by addition of tert-butylammonium iodide (3.5 mg). 
After 30 min, a solution of benzyl bromide (0.13 mL, 1.05 
mmol) in DMF (10 mL) was added and the reaction mixture was stirred for 16 h at r.t.. 
DMF was evaporated, DCM (20 mL) was added to the residue and the mixture washed 
with water several times. The DCM phase was dried and concentrated to give a brown 
oil, which was subjected to column chromatography (silica gel, 10% EtOAc/pet. spirit) 
to give 223c (0.27 g, 91%) as a white solid; mp 116-118 oC; 1H NMR (CDCl3) δ 4.64 
(br s, 1H, CHH), 5.36 (br s, 1H, CHH), 6.14 (d, J= 3.6 Hz, 1H, H-3), 6.77 (m, 1H, H-
3΄), 6.80 (d, J= 3.6 Hz, 1H, H-2), 6.94-7.06 (m, 4H, Ar), 7.20-7.25 (m, 3H, H-3΄΄, H-5΄΄ 
and Ar), 7.29-7.32 (m, 2H, H-2΄΄ and H-6΄΄), 7.50 (m, 1H, H-6΄), 8.05 (d, J= 9.0, 4.5 
Hz, 1H, H-7); 13C NMR (CDCl3) δ 54.4 (CH2), 106.11 (d, J= 20.0 Hz, 13C-19F, C6-F), 
106.3 (C-3), 112.1 (d, J= 25.2 Hz, 13C-19F, C4-F), 116.1 (d, J= 9.2 Hz, 13C-19F, C7-F), 
113.0 (C-2΄), 127.4 (C-2), 128.2 (ArC-H), 128.7 (C-3΄΄ and C-5΄΄), 129.0 (ArC-H), 
129.4 (ArC-H), 129.7 (C-2΄΄ and C-6΄΄), 130.1 (d, J= 9.8 Hz, 13C-19F, C3a-F), 130.6 
(ArC-H), 133.2 (C-7a), 134.4 (C-6΄), 136.4 (C-1΄΄), 154.0 (C-1΄), 159.9 (d, J= 285.0, 
13C-19F, C5-F), 171.8 (CO); CI-MS m/z 423 ([M+H; 79Br]+, 100%), 425 ([M+H; 81Br]+, 
95%); HREI-MS m/z calcd for [M]+ C22H16N2O81BrF: 424.0410, found: 424.0415. 
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7.3.3 Palladium cyclisation procedure 
Attempted synthesis of 10-methoxyindolo[1,2-c]quinazolin-6(5H)-one (224b) 
A mixture of 219 (80 mg, 0.30 mmol) and palladium 
acetate (73 mg, 0.30 mmol) in glacial acetic acid (12 mL) 
was heated at 110 oC for 8 h. The reaction mixture was 
then cooled and the solvent evaporated under reduced 
pressure. The crude reaction mixture was purified by column chromatography using 
10% ethyl acetate in pet. spirit as eluant. However, 1H NMR spectroscopic analysis 
showed that none of the cyclised product was obtained. 
Attempted synthesis of indolo[1,2-c]quinazolin-6(5H)-one (224a) 
 A mixture of 220a (94 mg, 0.30 mmol), palladium acetate (7 mg, 
0.03 mmol), triphenylphosphine (16 mg, 0.06 mmol), tert-
butylammonium bromide (98 mg, 0.30 mmol) and K2CO3 (84 mg, 
0.60 mmol) in dry DMF (25 mL) was heated at 120 oC under an Ar atmosphere for 3 h. 
After cooling, the DMF was evaporated and DCM (20 mL) was added and washed with 
water several times. The DCM layer was washed with brine, dried and evaporated to 
give a yellow solid. The solid was subjected to flash column chromatography (silica gel, 
9:1 pet. spirit/EtOAc) to give several fractions, however, 1H NMR spectroscopic 
analysis showed that none of them contained the title compound. 
Synthesis of 5-methylindolo[1,2-c]quinazolin-6(5H)-one (225a) 
A mixture of 222a (50 mg, 0.15 mmol), palladium acetate (12 
mg, 0.05 mmol), triphenylphosphine (8 mg, 0.03 mmol), tert-
butylammonium bromide (49 mg, 0.15 mmol) and K2CO3 (42 
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mg, 0.30 mmol) in dry DMF (13 mL) was heated at 120 oC under an Ar atmosphere for 
3 h. After cooling, DMF was evaporated, and then DCM (15 mL) was added and 
washed with water several times. The DCM layer was washed with brine, dried, 
evaporated and subjected to flash column chromatography (silica gel, 9:1 pet. 
spirit/EtOAc) to give compound 225a (31 mg, 87%) as white needles; mp 181-183 oC; 
IR (KBr) νmax: 1677 (C=O) cm-1; 1H NMR (CDCl3) δ  3.71 (s, 3H, CH3), 7.03 (d, J= 0.6 
Hz, 1H, H-12), 7.22 (td, J= 8.1, 0.9 Hz, 1H, H-3), 7.24 (td, J= 7.5, 0.9 Hz, 1H, H-10), 
7.35-7.46 (m, 3H, H-2, H-9, H-10), 7.68 (ddd, J= 6.0, 2.1, 0.9 Hz, 1H, H-1), 7.92 (dd, 
J= 8.1, 1.8 Hz, 1H, H-4), 8.69 (ddd, J= 5.7, 2.7, 0.9 Hz, 1H, H-8); 13C NMR (CDCl3) δ 
30.4 (CH3), 98.3 (C-12), 114.5 (C-8), 115.6 (C-12b), 116.5 (C-11), 120.3 (C-9), 123.3, 
123.7, 123.9 (all ArC-H), 124.0 (C-1), 129.4 (C-3), 130.1 (C-12a), 133.3 (C-11a), 134.6 
(C-4a), 135.8 (C-7a), 148.2 (CO); CI-MS m/z 249 ([M+H]+, 100%); HRCI-MS m/z 
calcd for [M+H]+ C16H13N2O: 249.1028, found: 249.1021. 
Synthesis of 10-methoxy-5-methylindolo[1,2-c]quinazolin-6(5H)-one (225b) 
Method A: A mixture of 222b (37 mg, 0.13 mmol) and 
palladium acetate (29 mg, 0.13 mmol) in glacial acetic acid 
(6 mL) was heated at 110 oC for 48 h. The reaction mixture 
was then cooled and the solvent evaporated under reduced 
pressure. The crude reaction mixture was purified by column chromatography (silica 
gel, DCM) to give 2 fractions. The first fraction gave the title compound 225b (7.3 mg, 
20%) as a white solid and the second fraction gave the starting material (3.3 mg, 9%). 
Method B:  A solution of 222b (40 mg, 0.18 mmol) and palladium acetate (41 mg, 0.18 
mmol) in propanoic acid (6 mL) was heated at reflux at 110 oC for 48 h. The reaction 
mixture was then cooled and the solvent evaporated under reduced pressure. The crude 
reaction residue was purified by column chromatography (silica gel, DCM), however 
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only starting material (21.5 mg, 33%) could be separated pure. The higher Rf which 
contained 2 spots could not be separated (preparative thin layer chromatography, 40% 
DCM/hexane developed 10 times).  
Method C: A mixture of 222b (0.15 g, 0.42 mmol), palladium acetate (40 mg, 0.18 
mmol), triphenylphosphine (22 mg, 0.08 mmol), tert-butylammonium bromide (0.14 g, 
0.42 mmol) and K2CO3 (0.12 g, 0.84 mmol) in dry DMF (35mL) was heated at 120 oC 
under an Ar atmosphere for 6 h. After cooling, the DMF was evaporated, and then 
DCM (15 mL) was added and washed with water several times. The DCM layer was 
washed with brine, dried, evaporated and subjected to flash column chromatography 
(silica gel, 9:1 pet. spirit/EtOAc) to give the title compound 225b (65 mg, 55%); mp 
146-147 oC; 1H NMR (CDCl3) δ 3.73 (s, 3H, NCH3), 3.90 (s, 3H, OCH3),  6.99 (s, 1H, 
H-12), 7.00 (dd, J= 9.0, 2.7 Hz, 1H, H-9), 7.12 (d, J= 2.7 Hz, 1H, H-11), 7.22-7.28 (m, 
2H, H-1 and H-3), 7.44 (td, J= 7.5, 1.5 Hz, 1H, H-2), 7.94 (dd, J= 7.8, 1.5 Hz, 1H, H-4), 
8.57 (d, J= 9.3 Hz, 1H, H-8); 13C NMR (CDCl3) δ 30.4 (CH3), 55.8 (OCH3), 98.1 (C-
12), 102.2 (C-8), 113.0 (C-11), 114.5 (C-9), 115.5 (C-12b), 117.3, 123.3, 123.9 (all 
ArC-H), 129.4 (C-12a), 131.0 (C-11a), 133.9 (C-4a), 135.8 (C-7a), 148.2 (CO), 156.8 
(COCH3); CI-MS m/z 279 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C17H15N2O2: 279.1134, found: 279.1122. 
Synthesis of 10-fluoro-5-methylindolo[1,2-c]quinazolin-6(5H)-one (225c) 
A mixture of 222c (0.10 g, 0.29 mmol), palladium acetate 
(24 mg, 0.10 mmol), triphenylphosphine (16 mg, 0.06 
mmol), tert-butylammonium bromide (49 mg, 0.15 mmol), 
and K2CO3 (42 mg, 0.30 mmol) in dry DMF (20mL) was 
heated at 120 oC under an Ar atmosphere for 6 h. After cooling, DMF was evaporated, 
and then DCM (15 mL) was added and washed with water several times. The DCM 
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layer was washed with brine, dried, evaporated and subjected to flash column 
chromatography (silica gel, 9:1 pet. spirit/EtOAc) to give the title compound 225c (59 
mg, 76%) as off-white needles; mp 188-189 oC; 1H NMR (CDCl3) δ 3.66 (s, 3H, CH3), 
6.89 (s, 1H, H-12), 7.05 (td, J= 9.0, 2.7 Hz, 1H, H-9), 7.16 (d, J= 8.7 Hz, 1H, H-1), 
7.19-7.25 (m, 2H, H-2 and H-11), 7.41 (ddd, J= 8.1, 7.5, 1.2 Hz, 1H, H-3), 7.84 (dd, J= 
7.8, 1.2 Hz, 1H, H-4), 8.57 (dd, J= 9.0, 5.1 Hz, 1H, H-8); 13C NMR (CDCl3) δ 30.4 
(CH3), 97.8 (d, J= 4.3 Hz, 13C-19F, C12-F), 105.3 (d, J= 23.8 Hz, 13C-19F, C11-F), 111.6 
(d, J= 25.2 Hz, 13C-19F, C9-F), 114.5 (C-4), 115.0 (C-12b), 117.5 (d, J= 9.4 Hz, 13C-19F, 
C8-F), 123.7 (C-2), 124.0 (C-3), 129.7 (C-1), 130.8 (C-11a), 131.0 (C-12a), 134.7 (C-
4a), 135.8 (C-7a), 147.8 (CO), 160.0 (d, J= 238.5 Hz, 13C-19F, C10-F); CI-MS m/z 267 
([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C17H12N2OF: 267.0934, found: 
267.0926. 
Synthesis of 5-benzylindolo[1,2-c]quinazolin-6(5H)-one (226a) 
A mixture of 223a (0.30 g, 0.74 mmol), palladium acetate 
(66 mg, 0.30 mmol), triphenylphosphine (52 mg, 0.20 
mmol), tert-butylammonium bromide (0.31 g, 0.95 mmol), 
and K2CO3 (0.27 g, 1.92 mmol) in dry DMF (60mL) was 
heated at 120 oC under an Ar atmosphere for 6 h. After 
cooling, DMF was evaporated, and then DCM (25 mL) was added and washed with 
water several times. The DCM layer was washed with brine, dried, evaporated and 
subjected to flash column chromatography (silica gel, 9:1 pet. spirit/EtOAC) to give 
226a (0.16g, 66%) as white needles; mp 141-143 oC; IR (KBr) νmax 1685 (C=O) cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.54 (s, 2H, CH2), 7.12-7.16 (m, 2H, H-12 and H-9), 
7.22 (td, J= 7.5 Hz, 1H, H-10), 7.26-7.34 (m, 6H, Ar), 7.39-7.41 (m, 2H, Ar), 7.72 (dd, 
J= 7.5, 2.1 Hz, 1H, H-11), 7.98 (d, J= 7.5 Hz, 1H, H-4), 8.74 (dd, J= 8.0, 1.5 Hz, 1H, 
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H-8); 13C NMR (125 MHz, CDCl3) δ 47.0 (CH2), 98.6 (C-12), 115.5 (C-9), 115.9 (C-
12b), 116.7 (C-8), 120.3 (C-11), 123.5, 123.9, 124.10 (all ArC-H), 124.12 (C-4), 126.7 
(C-2΄ and C-6΄), 127.7 (ArC-H), 129.1 (C-3΄ and C-5΄), 129.4 (ArC-H), 130.2 (C-11a), 
133.4 (C-12a), 134.7 (C-4a), 135.2 (C-7a), 136.5 (C-1΄), 148.6 (CO); EI-MS m/z  324 
([M]+, 50%); HREI-MS m/z calcd for [M]+ C22H16N2O: 324.1263, found: 324.1261.   
Synthesis of 5-benzyl-10-methoxyindolo[1,2-c]quinazolin-6(5H)-one (226b) 
 A mixture of 223b (0.25 g, 0.57 mmol), palladium acetate 
(52 mg, 0.23 mmol), triphenylphosphine (39 mg, 0.15 
mmol), tert-butylammonium bromide (0.24 g, 0.73 mmol) 
and K2CO3 (0.20 g, 1.48 mmol) in dry DMF (60mL) was 
heated at 120 oC under an Ar atmosphere for 6 h. After 
cooling, the DMF was evaporated, and then DCM (25 mL) was added and washed with 
water several times. The DCM layer was washed with brine, dried, evaporated and 
subjected to flash column chromatography (silica gel, 9:1 pet. spirit/EtOAc) to give the 
title compound 226b (0.18 g, 89%) as white needles; mp 214-215 oC; 1H NMR (CDCl3) 
δ 3.91 (s, 3H, CH3), 5.52 (s, 2H, CH2), 7.02 (dd, J= 9.0, 2.7 Hz, 1H, H-9), 7.03 (s, 1H, 
H-12), 7.14 (s, 1H, H-11), 7.15 (t, J= 9.3 Hz, 1H, H-3), 7.02-7.33 (m, 7H, Ar), 7.94 (dd, 
J= 7.8, 1.2 Hz, 1H, H-4), 8.61 (d, J= 9.0 Hz, 1H, H-8); 13C NMR (CDCl3) δ 47.0 (CH2), 
55.9 (CH3), 98.3 (C-12), 102.3 (C-8), 113.1 (C-11), 115.5 (C-9), 115.7 (C-12b), 117.4, 
123.4, 124.0 (all ArC-H), 126.7 (C-2΄ and C-6΄), 127.7 (ArC-H), 129.1 (C-3΄and C-5΄), 
129.3 (ArC-H), 129.5 (C-11a), 131.2 (C-12a), 134.0 (C-4a), 135.1 (C-7a), 136.5 (C-1΄), 
148.0 (CO), 157.0 (COCH3); CI-MS m/z 355 ([M+H]+, 100%); HREI-MS m/z calcd for 
[M]+ C23H18N2O2: 354.1368, found: 354.1386. 
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Synthesis of 5-benzyl-10-fluoroindolo[1,2-c]quinazolin-6(5H)-one (226c) 
A mixture of 223c (0.27 g, 0.64 mmol), palladium acetate (58 
mg, 0.26 mmol), triphenylphosphine (45 mg, 0.0917 mmol), 
tert-butylammonium bromide (0.26 g, 0.82 mmol) and K2CO3 
(0.22 g, 1.66 mmol) in dry DMF (60mL) was heated at 120 oC 
under an Ar atmosphere for 6 h. After cooling, the DMF was 
evaporated, and then DCM (25 mL) was added and washed with water several times. 
The DCM layer was washed with brine, dried, evaporated and subjected to flash column 
chromatography (silica gel, 9:1 pet. spirit/EtOAc) to give the title compound 226c (0.15 
g, 69%) as off-white needles; mp 185-186 oC; 1H NMR (CDCl3) δ 5.45 (s, 2H, CH2), 
6.97 (s, 1H, H-12), 7.03 (td, J= 9.0, 2.4 Hz, 1H, H-9), 7.07 (d, J= 8.1 Hz, 1H, H-1), 7.15 
(t, J= 8.1 Hz, 1H, H-3), 7.18-7.28 (m, 7H, Ar), 7.87 (d, J= 7.5 Hz, 1H, H-4), 8.59 (dd, 
J= 9.0, 5.1 Hz, 1H, H-8); 13C NMR (CDCl3), δ 47.1 (CH2), 98.2 (d, J= 4.6 Hz, 13C-19F, 
C12-F), 105.5 (d, J= 23.8 Hz, 13C-19F, C11-F), 111.8 (d, J= 25.2 Hz, 13C-19F, C9-F), 
115.4 (C-12b), 115.6 (C-4), 117.8 (d, J= 9.4 Hz, 13C-19F, C8-F), 123.6 (ArC-H), 124.2 
(ArC-H), 126.7 (C-2΄ and C-6΄), 127.8 (ArC-H), 129.2 (C-3΄ and C-5΄), 129.8 (ArC-H), 
131.1 (C-11a), 131.2 (C-12a), 134.9 (C-4a), 135.2 (C-7a), 136.3 (C-1΄), 148.4 (CO), 
160.2 (d, J= 238.5 Hz, 13C-19F, C10-F); CI-MS m/z 343 ([M+H]+, 100%); HRCI-MS 
m/z calcd for [M+H]+ C22H16N2OF: 343.1247, found: 343.1249. 
Synthesis of 2-(N-benzylaminophenyl)-1H-indole (227a)  
Method A: A stirred suspension of 212a (0.57g, 2.74 
mmol) and K2CO3 (0.38 g, 2.74 mmol) in dry THF (25 
ml) was cooled to 0-5 oC and a solution of benzyl 
bromide (0.36 mL, 3.01 mmol) in THF (5 mL) was 
added dropwise. Stirring was continued with cooling and the reaction mixture was then 
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stirred at r.t. overnight. Water (30 mL) was added to the reaction and the mixture 
extracted with DCM (3 x 20 mL). The organic layers were combined, dried and 
evaporated to yield a yellow solid. The solid was subjected to flash column 
chromatography (silica gel, 1:1 hexane/DCM) to give 227a (0.37 g, 45%) as a yellow 
solid (however the colour turned to blue after contact with air); 1H NMR (CDCl3) δ 4.30 
(s, 2H, CH2), 5.03 (br s, 1H, NH), 6.65-6.68 (m, 2H, H-3 and H-3΄), 6.75 (t, J= 7.2 Hz, 
1H, H-5΄), 7.06-7.31 (m, 10H, Ar), 7.58 (d, J= 7.8 Hz, 1H, H-4), 8.17 (br s, 1H, indole 
NH); 13C NMR (CDCl3) δ 48.6 (CH2), 102.0 (C-3), 111.1 (C-7), 111.9 (C-3΄), 117.7 (C-
5΄), 118.9 (C-1΄), 120.4 (C-4), 120.7 (C-6), 122.4 (C-5), 127.4 (C-2΄΄ and C-6΄΄), 127.5 
(C-4΄΄), 129.0 (C-3΄΄ and C-5΄΄), 129.2 (C-3a), 129.6 (C-6΄), 129.7 (C-4΄), 135.8 (C-2), 
136.4 (C-7a), 139.4 (C-1΄΄), 145.9 (C-2΄); CI-MS m/z 299 ([M+H]+, 100%); HRCI-MS 
m/z calcd for [M+H]+ C21H19N2: 299.1548, found: 299.1543. 
 
7.3.4 Hydrolysis and chloroacetylation 
Synthesis of N-[2-(1H-indol-2-yl)phenyl]-N-methylchloroacetamide (228a) 
Compound 225a (26 mg, 0.10 mmol) was heated at reflux in  
25% NaOH (6 mL) and EtOH (10 mL) for 24 h. The EtOH 
was evaporated and water (15 mL) was added and extracted 
with DCM (3x 15 mL). The organic layer was separated, 
dried and concentrated to give a blue solid. The solid was dried on a high vacuum pump 
for 2-3 h and then K2CO3 (50 mg, 0.43 mmol) and dry THF (10 mL) were added. The 
reaction mixture was stirred at 0-5 oC under a N2 atmosphere for 30 min and a solution 
of chloroacetyl chloride (23 µL, 0.30 mmol) in THF (3 mL) was then added and the 
mixture stirred overnight at r.t.. The THF was evaporated to dryness and DCM (15 mL) 
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was then added. The reaction mixture was washed with water (3 x 10 mL) and the DCM 
layer was separated, dried and concentrated. The residue was subjected to PTLC (silica 
gel, 10% EtOAc/pet. spirit) to give the title compound 228a (21 mg, 70%) as a yellow 
solid; mp 84-86 oC; IR (KBr) νmax: 3310 (NH), 1655 (C=O), 747 (C-Cl) cm-1; 1H NMR 
(CDCl3) δ 3.16 (s, 3H, CH3), 3.81 (d, J= 12.6 Hz, 1H, CHHCl), 3.87 (d, J= 14.1 Hz, 1H, 
CHHCl), 6.56 (s, 1H, H-3), 7.08 (t, J= 7.8 Hz, 1H, H-5), 7.18-7.59 (m, 2H, Ar), 7.30-
7.39 (m, 2H, Ar), 7.45 (t, J= 7.8 Hz, 1H, H-5΄), 7.58 (d, J= 7.8 Hz, 1H, H-4), 7.69 (d, J= 
8.1 Hz, 1H, H-6΄), 8.37 (br s, 1H, NH); 13C NMR (CDCl3) δ  37.2 (CH3), 41.9 (CH2Cl), 
103.6 (C-3), 111.3 (C-7), 120.8 (C-5), 121.3 (C-4), 123.5 (C-6), 129.0 (C-3a), 129.35, 
129.4, 129.65, 129.7 (all ArC-H), 132.0 (C-1΄), 133.5 (C-2), 135.0 (C-7a), 140.0 (C-2΄), 
167.3 (CO); CI-MS m/z 299 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ 
C17H16N2O35Cl: 299.0951, found: 299.0945. 
Synthesis of N-[2-(5-methoxy-1H-indol-2-yl)phenyl]-N-methylchloroacetamide 
(228b) 
Compound 225b (35 mg, 0.14 mmol) was heated at 
reflux in 25% NaOH (10 mL) and EtOH (25 mL) for 
48 h. The EtOH was then evaporated and water (20 
mL) was added and extracted with DCM (3x 20 mL). 
The organic layer was separated, dried, and concentrated to give a blue solid. The solid 
was dried on a high vacuum pump for 2-3 h and then K2CO3 (0.10 g, 0.74 mmol) and 
dry THF (10 mL) were added. The reaction mixture was stirred at 0-5 oC under a N2 
atmosphere for 30 min and a solution of chloroacetyl chloride (42 µL, 0.53 mmol) in 
THF (3 mL) was then added and the mixture stirred overnight at r.t.. The THF was 
evaporated to dryness and DCM (20 mL) was then added. The reaction mixture was 
washed with water (3 x 15 mL) and the DCM layer was separated, dried and 
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concentrated. The residue was subjected to PTLC (silica gel, 10% EtOAc/pet. spirit) to 
give the title compound 228b (29 mg, 64%) as a yellow solid; mp 88-89 oC; IR (KBr) 
νmax: 3314 (NH), 1653 (C=O), 763 (C-Cl) cm-1; 1H NMR (CDCl3) δ 3.23 (s, 3H, 
NCH3), 3.86 (s, 3H, OCH3), 3.89 (d, J= 5.1 Hz, 2H, CH2Cl), 6.40 (d, J= 1.2 Hz, 1H, H-
3), 6.90 (dd, J= 8.7, 2.4 Hz, 1H, H-6), 7.08 (d, J= 2.1 Hz, 1H, H-4), 7.30 (d, J= 8.7 Hz, 
2H, H-7 and H-3΄), 7.41 (td, J= 8.1, 0.9 Hz, 1H, H-4΄), 7.49 (t, J= 7.8 Hz, 1H, H-5΄), 
7.73 (d, J= 7.8 Hz, 1H, H-6΄), 8.32 (br s, 1H, NH); 13C NMR (CDCl3), δ 37.3 (CH3), 
41.9 (CH2Cl), 55.8 (OCH3), 102.2 (C-3), 103.2 (C-4), 112.3 (C-6), 113.9 (C-7), 128.4 
(C-3΄), 129.1 (C-3a), 129.4, 129.7, 129.8 (all ArC-H), 130.7 (C-1΄), 132.0 (C-2), 135.0 
(C-7a), 139.0 (C-2΄), 155.0 (COCH3), 167.0 (CO); CI-MS m/z 329 ([M+H; 35Cl]+, 
32%); HRCI-MS m/z calcd for [M+H]+ C18H18N2O237Cl: 331.1027, found: 331.1032. 
Synthesis of N-[2-(5-fluoro-1H-indol-2-yl)phenyl]-N-methylchloroacetamide (228c) 
Compound 225c (50 mg, 0.19 mmol) was heated at reflux 
in 25% NaOH (10 mL) and EtOH (25 mL) for 24 h. The 
EtOH was then evaporated and water (20 mL) was added 
and extracted with DCM (3 x 20 mL). The organic layer was separated, dried and 
concentrated to give a blue solid. The solid was dried on a high vacuum pump for 2-3 h 
and then K2CO3 (0.10 g, 0.74 mmol) and dry THF (10 mL) were added. The reaction 
mixture was stirred at 0-5 oC under a N2 atmosphere for 30 min and a solution of 
chloroacetyl chloride (42 µL, 0.53 mmol) in THF (5 mL) was then added and the 
mixture stirred overnight at r.t.. The THF was evaporated to dryness and DCM (20 mL) 
was then added. The reaction mixture was washed with water (3 x 15 mL) and the DCM 
layer was separated, dried and concentrated. The residue was subjected to PTLC (silica 
gel, 10% EtOAc/pet. spirit) to give the title compound 228c (46 mg, 79%) as a yellow 
solid; mp 175-176 oC; IR (KBr) νmax: 3315 (NH), 1654 (C=O), 764 (C-Cl) cm-1; 1H 
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NMR (CDCl3) δ 3.21 (s, 3H, NCH3), 3.84 (d, J= 12.9 Hz, 1H, CHHCl), 3.91 (d, J= 12.9 
Hz, 1H, CHHCl), 6.64 (d, J= 2.1 Hz, 1H, H-3), 6.95 (td, J= 9.3, 2.4 Hz, 1H, H-6), 7.23-
7.35 (m, 4H, Ar), 7.40-7.51 (m, 2H, Ar), 7.76 (dd, J= 7.5, 1.5 Hz, 1H, H-6΄); 13C NMR 
(CDCl3) δ 37.3 (CH3), 41.9 (CH2Cl), 103.3 (d, J= 4.6 Hz, 13C-19F, C3-F), 105.9 (d, J= 
23.5 Hz, 13C-19F, C4-F), 111.9 (d, J= 26.3 Hz, 13C-19F, C6-F), 112.2 (d, J= 9.5 Hz, 13C-
19F, C7-F), 129.2 (d, J= 10.4 Hz, 13C-19F, C3a-F), 129.5 (C-6΄), 129.6, 129.7, 129.8 (all 
ArC-H), 130.2 (C-1΄), 133.7 (C-2), 135.0 (C-7a), 139.2 (C-2΄), 158.4 (d, J= 234.2 Hz, 
13C-19F, C5-F), 167.2 (CO); CI-MS m/z 317 ([M+H]+, 100%); HREI-MS m/z calcd for 
[M]+ C17H14N2O35ClF: 316.0779, found: 316.0778. 
Synthesis of N-benzyl-N-[2-(1H-indol-2-yl)phenyl]chloroacetamide (229a) 
Method A; A suspension of 227a (0.20 g, 0.67 mmol) 
and K2CO3 (0.33 g, 2.4 mmol) in dry THF (25 mL) 
was cooled to 0-5 oC and a solution of chloroacetyl 
chloride (0.13 mL, 1.68 mmol) in THF (10 mL) was 
then added dropwise and the reaction mixture stirred at r.t. overnight. The solvent was 
then evaporated under reduced pressure. Water (15 mL) was added and the mixture 
extracted with DCM (2 x 15 mL). The combined organic extracts were dried and 
concentrated to give a yellow residue. The residue was subjected to flash column 
chromatography (silica gel, 1: 1 hexane/DCM) to give the chloroacetamide 229a (0.20 
g, 79%) as a yellow solid. 
Method B; Compound 225a (0.14g, 0.10 mmol) was heated at reflux in 25% NaOH (27 
mL) and EtOH (40 mL) for 24 h. The EtOH was then evaporated and water (40 mL) 
was added and extracted with DCM (3 x 30 mL). The organic layer was separated, dried 
and concentrated to give a blue solid. The solid was dried on a high vacuum pump for 
2-3 h and then K2CO3 (0.23 g, 1.7 mmol) and dry THF (20 mL) were added. The 
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reaction mixture was stirred at 0-5 oC under a N2 atmosphere for 30 min and a solution 
of chloroacetyl chloride (96 µL, 1.20 mmol) in THF (10 mL) was then added and the 
mixture stirred overnight at r.t.. The THF was evaporated to dryness and DCM (20 mL) 
was then added. The reaction mixture was washed with water (3 x 25 mL) and the DCM 
layer was separated, dried and concentrated. The residue was subjected to PTLC (silica 
gel, 10% EtOAc/pet. spirit) to give the title compound 229a (0.20g, 79%) as a yellow 
solid; mp 139-141 oC; IR (KBr) νmax: 3311 (NH), 1638 (C=O), 745 (C-Cl) cm-1;  1H-
NMR (CDCl3) δ 3.74 (d, J= 13.5 Hz, 1H, CHHCl), 3.87 (d, J= 13.2 Hz, 1H, CHHCl), 
4.58 (d, J= 14.1 Hz, 1H, CHH), 5.17 (d, J= 13.8 Hz, 1H, CHH), 6.69 (d, J= 2.4 Hz, 1H, 
H-3), 7.03 (dd, J= 8.1, 1.2 Hz, 1H, H-3΄), 7.12 (m, 2H, Ar), 7.19 (m, 2H, Ar), 7.25 (m, 
2H, Ar), 7.31 (m, 3H, Ar), 7.46 (td, J= 7.8, 1.5 Hz, 1H, H-5΄), 7.61 (dd, J= 7.5, 0.9 Hz, 
1H, H-4), 7.71 (dd, J= 7.8, 1.2 Hz, 1H, H-6΄), 7.86 (br s, 1H, NH); 13C NMR (CDCl3) δ 
42.4 (CH2Cl), 53.7 (CH2), 103.6 (C-3), 111.4 (C-7), 120.6 (C-4), 121.1 (C-6), 123.3 (C-
5), 128.5 (C-3΄), 128.6 (C-3a), 129.0 (C-2΄΄ and C-6΄΄), 129.1 (ArC-H), 129.6 (C-3΄΄ 
and C-5΄΄), 129.9 (ArC-H), 130.1 (ArC-H), 131.0 (C-1΄), 133.6 (C-2), 136.2 (C-7a), 
136.8 (C-2΄), 137.2 (C-1΄΄), 166.8 (CO); CI-MS m/z 375 ([M+H]+, 11%); HRCI-MS m/z 
calcd for [M+H]+ C23H20N2O35Cl: 375.1264; found: 375.1267. 
Synthesis of N-benzyl-N-[2-(5-methoxy-1H-indol-2-yl)phenyl]chloroacetamide 
(229b) 
Compound 226b (0.12 g, 0.22 mmol) was heated 
at reflux in 25% NaOH (30 mL) and EtOH (40 
mL) for 48 h. The EtOH was then evaporated and 
water (20 mL) was added and extracted with DCM 
(3 x 20 mL). The organic layer was separated, dried and concentrated to give a blue 
solid. The solid was dried on a high vacuum pump for 2-3 h and then K2CO3 (0.11 g, 
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0.79 mmol) and dry THF (15 mL) were added. The reaction mixture was stirred at 0-5 
oC under a N2 atmosphere for 30 min and a solution of chloroacetyl chloride (71 µL, 
0.55 mmol) in THF (5 mL) was then added and the mixture stirred overnight at r.t.. The 
THF was evaporated to dryness and DCM (20 mL) was then added. The reaction 
mixture was washed with water (3 x 15 mL) and the DCM layer was separated, dried 
and concentrated. The residue was subjected to PTLC (silica gel, 10% EtOAc/pet.  
spirit) to give the title compound 229b (97 mg, 71%) as a yellow solid; mp 109-111 oC; 
IR (KBr) νmax: 3297 (NH), 1655 (C=O), 736 (C-Cl) cm-1; 1H NMR (CDCl3) δ 3.75 (d, 
J= 13.5 Hz, 1H, CHHCl), 3.84 (s, 3H, CH3), 3.88 (d, J= 13.8 Hz, 1H, CHHCl), 4.44 (d, 
J= 13.8 Hz, 1H, CHH), 5.26 (d, J= 14.1 Hz, 1H, CHH), 6.61 (dd, J= 2.1, 0.9 Hz, 1H, H-
3), 6.85 (dd, J= 9.0, 2.4 Hz, 1H, H-6), 6.97 (dd, J= 8.1, 1.5 Hz, 1H, H-3΄), 7.06 (d, J= 
2.4 Hz, 1H, H-4), 7.13 (d, J= 8.7 Hz, 1H, H-7), 7.21-7.32 (m, 6H, Ar), 7.42 (td, J= 7.5, 
1.2 Hz, 1H, H-5΄), 7.73 (dd, J= 7.8, 1.3 Hz, 1H, H-6΄), 8.17 (br s, 1H, NH); 13C NMR 
(CDCl3) δ 42.5 (CH2Cl), 53.4 (CH2), 56.0 (OCH3), 102.2 (C-3), 103.2 (C-4), 112.3 (C-
6), 114.0 (C-7), 128.5 (ArC-H), 128.9 (ArC-H), 129.0 (C-2΄΄ and C-6΄΄), 129.2 (C-3a), 
129.6 (ArC-H), 129.8 (ArC-H), 129.9 (C-3΄΄ and C-5΄΄), 130.7 (C-6΄), 130.9 (C-1΄), 
132.2 (C-2), 134.1 (C-7a), 136.3 (C-2΄), 137.0 (C-1΄΄), 154.7 (COCH3), 167.0 (CO); CI-
MS m/z 405 ([M+H; 35Cl]+, 100%); HREI-MS m/z calcd for [M]+ C24H21N2O237Cl: 
406.1262; found: 406.1208. 
Synthesis of N-benzyl-N-[2-(5-fluoro-1H-indol-2-yl)phenyl]chloroacetamide (229c) 
Compound 226c (0.13 g, 0.38 mmol) was heated at 
reflux in 25% NaOH (30 mL) and EtOH (40 mL) for 
24 h. The EtOH was then evaporated and water (20 
mL) was added and extracted with DCM (3 x 20 
mL). The organic layer was separated, dried and concentrated to give a blue solid. The 
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solid was dried on a high vacuum pump for 2-3 h and then K2CO3 (0.19 g, 1.37 mmol) 
and dry THF (30 mL) were added. The reaction mixture was stirred at 0-5 oC under a N2 
atmosphere for 30 min and a solution of chloroacetyl chloride (76 µL, 0.53 mmol) in 
THF (15 mL) was then added and the mixture stirred overnight at r.t.. The THF was 
evaporated to dryness and DCM (20 mL) was then added. The reaction mixture was 
washed with water (3 x 15 mL) and the DCM layer was separated, dried and 
concentrated. The residue was subjected to preparative layer chromatography (silica gel, 
10% EtOAc/pet. spirit) to give the title compound 229c (90 mg, 82%) as a yellow solid; 
mp 202-203 oC; 1H NMR (CDCl3) δ 3.70 (d, J= 13.2 Hz, 1H, CHHCl), 3.82 (d, J= 13.2 
Hz, 1H, CHHCl), 4.64 (d, J= 14.1 Hz, 1H, CHH), 5.07 (d, J= 13.8 Hz, 1H, CHH), 6.60 
(d, J= 1.8 Hz, 1H, H-3), 6.91 (td, J= 9.0, 2.4 Hz, 1H, H-6), 7.04-7.08 (m, 2H, H-4 and 
Ar), 7.19-7.31 (m, 6H, Ar), 7.34 (td, J= 7.8, 1.8 Hz, 1H, H-4΄), 7.44 (td, J= 7.2, 0.9 Hz, 
1H, H-5΄), 7.68 (dd, J= 7.8, 1.5 Hz, 1H, H-6΄), 7.77 (br s, 1H, NH);  13C NMR (CDCl3) 
δ 42.3 (CH2Cl), 53.8 (CH2), 103.6 (d, J= 4.8 Hz, 13C-19F, C3-F), 105.7 (d, J= 23.5 Hz, 
13C-19F, C4-F), 111.8 (d, J= 26.3 Hz, 13C-19F, C6-F), 112.2 (d, J= 9.8 Hz, 13C-19F, C7-
F), 128.7 (ArC-H), 129.2 (C-2΄΄ and C-6΄΄), 129.5 (ArC-H), 129.7 (ArC-H), 130.1 (C-
3΄΄ and C-5΄΄), 130.1 (ArC-H), 130.6 (ArC-H), 130.8 (C-1΄), 133.4 (C-2), 135.4 (C-7a), 
136.1 (C-2΄), 137.3 (C-1΄΄), 159.2 (d, J= 240.0 Hz, 13C-19F, C5-F), 166.9 (CO); CI-MS 
m/z 393 ([M+H]+, 100%); HREI-MS m/z calcd for [M]+ C23H18N2OClF: 392.1092, 
found: 392.1091. 
Synthesis of N-benzyl-N-[2-(1H-indol-2-yl)phenyl]trichloroacetamide (230) 
Compound 226a (0.14 g, 0.47 mmol) was heated at reflux 
in 25% NaOH (30 mL) and EtOH (40 mL) for 24 h. The 
EtOH was then evaporated and water (20 mL) was added N
H
N
O
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and extracted with DCM (3 x 20 mL). The organic layer was separated, dried and 
concentrated to give a blue solid (1H NMR spectroscopic analysis showed that no 
starting material remained). The solid was dried on a high vacuum pump for 2-3 h and 
then K2CO3 (0.23 g, 1.70 mmol) and dry THF (45 mL) were added. The reaction 
mixture was stirred at 0-5 oC under a N2 atmosphere for 30 min and a solution of 
trichloroacetyl chloride (0.13 mL, 1.20 mmol) in THF (20 mL) was then added and the 
mixture stirred overnight at r.t.. The THF was evaporated to dryness and DCM (20 mL) 
was then added. The reaction mixture was washed with water (3 x 15 mL) and the DCM 
layer was separated, dried and concentrated. The residue was subjected to PTLC (silica 
gel, 10% EtOAc/pet. spirit) to give, in the first fraction, compound 226a (26 mg, 17%), 
and in the second fraction, the title compound 230 (44 mg, 21%) as a yellow solid; mp 
99-101 oC; 1H HMR (acetone-d6) δ 3.95 (br s, 1H, CHH), 5.70 (br s, 1H, CHH), 7.05-
7.10 (m, 2H, H-3 and H-5΄), 7.15-7.26 (m, 9H, Ar), 7.47-7.50 (m, 2H, H-4 and Ar), 7.66 
(d, J= 8.1 Hz, 1H, H-6΄), 7.91 (br s, 1H, NH); 13C NMR (Acetone-d6) δ 56.6 (CH2), 
103.0 (CCl3), 111.6 (C-4), 120.1 (C-3), 120.9 (C-6΄), 122.8 (C-4΄), 127.4, 128.1, 128.5, 
129.3 (all ArC-H), 130.9 (C-3a), 132.1 (C-5΄), 134.9 (C-1΄), 137.0 (C-2΄), 137.4 (C-2), 
145.9 (C-7a), 148.1 (C-1΄΄), 160.9 (CO); ES-MS m/z 442 ([M]+, 100%); HREI-MS m/z 
calcd for [M]+ C23H17N2OCl3: 442.0406, found: 442.0405. 
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7.3.5 Preparation of iodoacetamides 
Synthesis of N-benzyl-N-[2-(1H-indol-2-yl)phenyl]iodoacetamide (231a) 
To a solution of chloroacetamide 229a (0.20 g, 0.53 
mmol) in acetonitrile (20 mL) was added NaI (0.78 g, 
5.30 mmol), and the mixture was stirred at r.t. for 15 h. 
The solvent was evaporated to dryness in vacuo. The 
residue was dissolved in DCM (25 mL), and the mixture was washed with water (3 x 15 
mL), dried and concentrated. The solid obtained was chromatographed through a short 
column (silica gel, DCM) to give 231a (0.23 g, 92%) as a yellow solid; mp 168-169 oC; 
IR (KBr) νmax: 3312 (NH), 1637 (C=O) cm-1;  1H NMR (CDCl3)  δ 3.49 (d, J= 9.9 Hz, 
1H, CHHI), 3.59 (d, J= 10.2 Hz, 1H, CHHI), 4.54 (d, J= 13.8 Hz, 1H, CHH), 5.17 (d, 
J= 13.8 Hz, 1H, CHH), 6.69 (dd, J= 2.1, 0.6 Hz, 1H, H-3), 7.12 (m, 2H, Ar), 7.20 (m, 
2H, Ar), 7.25 (m, 2H, Ar), 7.32 (m, 4H, Ar), 7.44 (td, J= 8.7, 1.2 Hz, 1H, H-5΄), 7.61 (d, 
J= 7.8 Hz, 1H, H-4), 7.70 (dd, J= 7.8, 1.2 Hz, 1H, H-6΄), 7.94 (br s, 1H, NH); 13C NMR 
(CDCl3) δ -1.9 (CH2I), 53.3 (CH2), 103.3 (C-3), 111.1 (C-7), 120.3 (C-4), 120.8 (C-6), 
122.9 (C-5), 128.2 (C-3΄), 128.4 (C-3a), 128.7 (ArC-H), 128.8 (C-2΄΄ and C-6΄΄), 129.2 
(ArC-H), 129.6 (C-3΄΄ and C-5΄΄), 129.7 (ArC-H), 130.1 (ArC-H), 130.5 (C-1΄), 133.4 
(C-2), 136.2 (C-7a), 136.6 (C-2΄), 137.8 (C-1΄΄), 168.1 (CO); CI-MS m/z 467 ([M+H]+, 
15%); HRCI-MS m/z calcd for [M+H]+ C23H20N2OI: 467.0620, found 467.0612. 
Synthesis of N-benzyl-N-[2-(5-methoxy-1H-indol-2-yl)phenyl]iodoacetamide (231b) 
To a solution of chloroacetamide 229b (97 mg, 
0.24 mmol) in acetonitrile (20 mL) was added NaI 
(0.36 g, 2.40 mmol), and the mixture was stirred at N
H 1
2
3
4
5
6
7
1' 2'
3'
4'5'
6'
1''
2''
3'' 4''
5''
6''
N
OI
MeO
N
H 1
2
3
4
5
6
7
1' 2'
3'
4'5'
6'
1''
2''
3'' 4''
5''
6''
N
OI
 233
r.t. for 16 h. The solvent was evaporated to dryness in vacuo. The residue was dissolved 
in DCM (15 mL), and the mixture was washed with water (3 x 10 mL), dried and 
concentrated. The solid obtained was passed through a short column chromatography 
(silica gel, DCM) to give 231b (65 mg, 55%) as a yellow solid; mp 138-139 oC; IR 
(KBr) νmax: 3311 (NH), 1637 (C=O) cm-1; 1H NMR (CDCl3) δ 3.50 (d, J= 9.9 Hz, 1H, 
CHHI), 3.56 (d, J= 10.2 Hz, 1H, CHHI), 3.84 (s, 3H, OCH3), 4.44 (d, J= 13.8 Hz, 1H, 
CHH), 5.24 (d, J= 13.8 Hz, 1H, CHH), 6.62 (d, J= 2.4 Hz, 1H, H-3), 6.84 (dd, J= 9.0, 
2.4 Hz, 1H, H-6), 7.03-7.13 (m, 3H, Ar), 7.24-7.32 (m, 6H, Ar), 7.42 (t, J= 7.5 Hz, 1H, 
H-5΄), 7.71 (dd, J= 7.8, 1.5 Hz, 1H, H-6΄), 8.05 (br s, 1H, NH); 13C NMR (CDCl3) δ -
1.5 (CH2I), 53.5 (CH2), 56.0 (OCH3), 102.3 (C-3), 103.3 (C-4), 112.3 (C-6), 113.9 (C-
7), 128.4 (ArC-H), 128.8 (ArC-H), 129.0 (C-2΄΄ and C-6΄΄), 129.2 (C-3a), 129.5 (ArC-
H), 129.7 (ArC-H), 129.8 (C-3΄΄ and C-5΄΄), 130.4 (ArC-H), 130.8 (C-1΄), 132.2 (C-2), 
134.3 (C-7a), 136.5 (C-2΄), 138.0 (C-1΄΄), 154.7 (COCH3), 168.5 (CO); CI-MS m/z 497 
([M+H]+, 14%); HREI-MS m/z calcd for [M]+ C24H21N2O2I: 496.0648; found: 
496.0643. 
Synthesis of N-benzyl-N-[2-(5-fluoro-1H-indol-2-yl)phenyl]iodoacetamide (231c) 
To a solution of chloroacetamide 229c (90 mg, 0.31 
mmol) in acetonitrile (10 mL) was added NaI (0.46 g, 
3.10 mmol), and the mixture was stirred at r.t. for 16 
h. The solvent was evaporated to dryness in vacuo. 
The residue was dissolved in DCM (15 mL) and washed with water (3 x 10 mL). The 
organic extract was dried, concentrated and chromatographed through a short column 
(silica gel, DCM) to give the title compound 231c (0.10 g, 68%) as a yellow solid; mp 
172-173 °C; IR (KBr) νmax: 3297 (NH), 1636 (C=O) cm-1; 1H NMR (CDCl3) δ 3.48 (d, 
J= 10.2 Hz, 1H, CHHI), 3.53 (d, J= 10.2 Hz, 1H, CHHI), 4.62 (d, J= 14.1 Hz, 1H, 
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CHH), 5.11 (d, J= 14.1 Hz, 1H, CHH), 6.63 (d, J= 2.1 Hz, 1H, H-3), 6.92 (td, J= 9.3, 
2.7 Hz, 1H, H-6), 7.09 (dd, J= 8.7, 4.5 Hz, 1H, H-7), 7.16 (dd, J= 7.8, 1.2 Hz, 1H, H-
3΄), 7.21-7.33 (m, 6H, Ar), 7.36 (td, J= 7.5, 1.5 Hz, 1H, H-4΄), 7.46 (td, J= 7.8, 1.5 Hz, 
1H, H-5΄), 7.70 (dd, J= 7.8, 1.5 Hz, 1H, H-6΄), 7.91 (br s, 1H, NH); 13C NMR (CDCl3) δ 
-1.8 (CH2I), 53.8 (CH2),  103.6 (d, J= 5.2 Hz, 13C-19F, C3-F), 105.7 (d, J= 23.5 Hz, 13C-
19F, C4-F), 111.7 (d, J= 26.6 Hz, 13C-19F, C6-F), 112.1 (d, J= 9.7 Hz, 13C-19F, C7-F), 
128.6 (ArC-H), 129.0 (d, J= 10.5 Hz, 13C-19F, C3a-F), 129.1 (C-2΄΄ and C-6΄΄), 129.4 
(ArC-H), 129.5 (ArC-H), 129.6 (C-3΄΄ and C-5΄΄), 130.2 (ArC-H), 130.3 (ArC-H), 
130.6 (C-1΄), 133.4 (C-2), 135.5 (C-7a), 136.3 (C-2΄), 138.1 (C-1΄΄), 158.4 (d, J= 221.1 
Hz, 13C-19F, C5-F), 168.4 (CO); CI-MS m/z 485 ([M+H]+, 25%); HREI-MS m/z calcd 
for [M]+ C23H18N2OFI: 484.0448, found: 484.0497. 
 
7.3.6 Radical cyclisation 
Cyclisation of 231a in toluene 
To a boiling solution of 231a (60 mg, 0.13 mmol) in 
toluene (9 mL) under a N2 atmosphere was added 
dropwise a solution of tri-n-butyltin hydride (70 µL, 
0.26 mmol) and AIBN (21 mg, 0.13 mmol) in toluene 
(33 mL) over 2 h, and the reaction mixture was heated at reflux for 16 h. After 
evaporating the solvent, diethyl ether (20 mL) and satd. KF (20 mL) were added to the 
residue, and the mixture was stirred vigorously at r.t. for 2 h. The organic extract was 
separated, dried and concentrated. The residue was chromatographed on silica gel 
(hexane/AcOEt, 70:30) to give compound 96a (11 mg, 25%) as yellow needles, mp 
214-216 oC; IR (KBr) νmax: 3270 (NH), 1646 (C=O) cm-1; 1H NMR (500 MHz, DMSO-
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d6 ) δ 3.37 (d, J= 13.5 Hz, 1H, CHH-7), 3.73 (d, J= 14.0 Hz, 1H, CHH-7), 4.88 (d, J= 
16.0 Hz, 1H, CHH), 5.08 (d, J= 16.0 Hz, 1H, CHH), 6.76 (d, J= 7.0 Hz, 2H, H-2΄ and 
H-6΄), 7.00 (m, 3H, H-3΄, H-4΄ and H-5΄), 7.11 (t, J= 8.0 Hz, 1H, H-9), 7.16 (t, J= 7.5 
Hz, 1H, H-10), 7.21 (td, J= 8.0, 1.5 Hz, 1H, H-2), 7.27 (t, J= 7.5 Hz, 1H, H-3), 7.47 (m, 
2H, H-4 and H-11), 7.72 (d, J= 7.5 Hz, 1H, H-8), 7.75 (dd, J= 8.0, 1.5 Hz, 1H, H-1), 
11.62 (s, 1H, NH); 13C NMR (125 MHz, DMSO-d6) δ 35.3 (CH2-7), 53.2 (CH2), 110.1 
(C-7a), 112.7 (C-11), 118.7 (C-8), 121.2 (C-10), 122.5 (C-9), 125.0 (C-4), 125.3 (C-7b), 
126.7 (C-2), 126.8 (C-2΄ and C-6΄), 127.5 (C-3), 128.2 (C-1), 128.9 (C-3΄ and C-5΄), 
130.2 (C-12b), 133.4 (C-12a), 137.0 (C-11a), 138.2 (C-4a), 138.5 (C-1΄), 169.4 (CO); 
CI-MS m/z 339 ([M+H]+, 100%); HRCI-MS m/z calcd for [M+H]+ C23H19N2O: 
339.1497, found: 339.1498. 
Cyclisation of 231a in de-gassed toluene 
To a boiling solution of 231a (70 mg, 0.15 mmol) in boiling de-gassed toluene 
(11 mL) under an Ar atmosphere was added dropwise a solution of tri-n-butyltin 
hydride (80 µL, 0.30 mmol) and AIBN (24 mg, 0.15 mmol) in de-gassed toluene (38 
mL) over 2 h, and the reaction mixture was heated at reflux for 16 h. After evaporating 
the solvent, diethyl ether (30 mL) and satd. KF (30 mL) were added to the residue, and 
the mixture was stirred vigorously at r.t. for 2 h. The organic extract was separated, 
dried and concentrated. The residue was chromatographed on silica gel (hexane/AcOEt, 
70:30).  
The first fraction gave spiro[(1,2,3,4 tetrahydroquinolin-2-
one)-4,2΄-(2,3-dihydro-1H-indole)] 232 (6.4 mg, 13%) 
and the second fraction gave 96a (4 mg, 8%).   
232 was obtained as a yellow solid; mp 61-62 oC; IR 
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(KBr) νmax: 3350 (NH), 1654 (C=O) cm-1; 1H (CDCl3) δ 2.89 (d, J= 15.3 Hz, 1H, CHH-
7), 3.03 (d, J= 15.9 Hz, 1H, CHH-3΄), 3.09 (d, J= 15.6 Hz, 1H, CHH-3), 3.31 (d, J= 
15.6 Hz, 1H, CHH-3΄), 3.95 (br s, 1H, NH), 5.13 (d, J= 16.2 Hz, 1H, CHH), 5.33 (d, J= 
16.2 Hz, 1H, CHH),  6.70 (d, J= 8.1 Hz, 1H, H-7΄), 6.74 (t, J= 7.2 Hz, 1H, H-5΄), 6.95 
(d, J= 8.1 Hz, 1H, H-8), 7.00 (t, J= 7.8 Hz, 1H, H-6), 7.04-7.11 (m, 2H, H-4΄ and H-6΄), 
7.16 (td, J= 7.5, 1.2 Hz, 1H, H-7), 7.22-7.26 (m, 3H, H-2΄, H-4΄ and H-6΄), 7.30-7.36 
(m, 2H, H-3΄ and H-5΄), 7.54 (dd, J= 7.5, 0.1 Hz, 1H, H-5); 13C NMR (CDCl3) δ 42.4 
(CH2-3), 44.8 (CH2), 46.3 (CH2-3΄), 63.7 (C-4), 109.3 (C-7΄), 116.3 (C-5΄), 119.5 (C-8), 
123.9 (C-6), 124.7 (C-7), 125.5 (C-5), 126.1 (C-3΄a), 126.8 (C-2΄ and C-6΄), 127.5, 
128.1, 128.8 (all ArC-H), 129.0 (C-3΄ and C-5΄), 133.5 (C-4a), 137.0 (C-8a), 138.2 (C-
1΄), 149.4 (C-7a), 168.9 (CO); EI-MS m/z 340 ([M]+, 100%); HRCI-MS m/z calcd for 
[M+H]+ C23H21N2O: 341.1654, found: 341.1638.  
Cyclisation of 231a in toluene on a larger scale 
To a boiling solution of 231a (0.17 g, 0.36 mmol) in toluene (25 mL) under a N2 
atmosphere was added dropwise a solution of tri-n-butyltin hydride (0.20 mL, 0.73 
mmol) and AIBN (59 mg, 0.36 mmol) in toluene (92 mL) over 4 h, and the reaction 
mixture was heated at reflux for 16 h. After evaporating the solvent, diethyl ether (50 
mL) and satd. KF (50 mL) were added to the residue and the mixture was stirred 
vigorously at r.t. for 6 h. The organic extract was separated, dried and concentrated. The 
residue was chromatographed on silica gel (hexane/AcOEt, 70:30) to give the spiro 232 
(12 mg, 10%) and some unidentified compounds. 
Cyclization of 231a in mesitylene  
To a boiling solution of 231a (60 mg, 0.13 mmol) in mesitylene (9 mL) was 
added dropwise a solution of tri-n-butyltin hydride (70 µL, 0.26 mmol) and AIBN (21 
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mg, 0.13 mmol) in mesitylene (30 mL) over 2 h, and the reaction mixture was heated at 
reflux for 16 h. After evaporating the solvent, diethyl ether (30 mL) and satd. KF (30 
mL) were added to the residue, and the mixture was stirred vigorously at r.t. for 2 h. The 
organic extract was separated, dried and concentrated. The residue was 
chromatographed on silica gel (hexane/AcOEt, 70:30) to give compound 96a (23 mg, 
52%). 
Cyclisation of 231b 
To a boiling solution of 231b (55 mg, 0.11 mmol) in mesitylene (20 mL) was 
added dropwise a solution of tri-n-butyltin hydride (59 µL, 0.22 mmol) and AIBN (18 
mg, 0.11 mmol) in mesitylene (60 mL) over 2 h, and the reaction mixture was heated at 
reflux for 16 h. After evaporating the solvent, diethyl ether (30 mL) and satd. KF (30 
mL) were added to the residue, and the mixture was stirred vigorously at r.t. for 2 h. The 
organic extract was separated, dried, and concentrated. The residue was 
chromatographed on silica gel (AcOEt/pet. spirit, 9:1). 
The first fraction gave 5-benzyl-11-methoxy-5H-indolo[1,2-d][1,4]benzodiazepin-
6(7H)-one 233 (12 mg,  30%) as a yellow solid; mp 
153-154 oC; IR (KBr) νmax: 1670 (C=O) cm-1; 1H 
NMR (500 MHz, CDCl3) δ 3.88 (s, 3H, OCH3), 4.56 
(d, J= 13.0 Hz, 1H, CHH), 4.97 (d, J= 15.0 Hz, 1H, 
CHH), 5.01 (d, J= 16.0 Hz, 1H, CHH-7), 5.10 (d, J= 14.5 Hz, 1H, CHH-7), 6.69 (s, 1H, 
H-13), 6.95 (dd, J= 9.0, 2.5 Hz, 1H, H-10), 7.00 (d, J= 7.5 Hz, 1H, H-4), 7.14 (d, J= 2.5 
Hz, 1H, H-12), 7.16-7.20 (m, 3H, H-3, H-2΄ and H-6΄), 7.27 (td, J= 8.5, 1.5 Hz, 1H, H-
2), 7.31-7.34 (m, 3H, H-3΄, H-4΄ and H-5΄), 7.43 (d, J= 8.5 Hz, 1H, H-9), 7.65 (dd, J= 
7.5, 1.5 Hz, 1H, H-1), 13C NMR (125 MHz, CDCl3) δ 47.7 (CH2), 52.6 (CH2-7), 55.9 
(OCH3), 99.5 (C-13), 102.3 (C-12), 110.0 (C-9), 112.8 (C-10), 123.4 (C-4΄), 126.4 (C-
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2), 126.8 (C-2΄ and C-6΄), 127.1 (C-4), 127.2 (C-13b), 128.5 (C-3΄ and C-5΄), 128.7 (C-
13a), 129.0 (C-3), 130.4 (C-1), 131.7 (C-12a), 136.8 (C-1΄), 137.5 (C-8a), 139.2 (C-4a), 
154.6 (COCH3), 167.2 (CO); EI-MS m/z 368 ([H]+, 100%); HREI-MS m/z calcd for 
[M]+ C24H20N2O2: 368.1525, found: 368.1529. 
 The second fraction gave 5-benzyl-7,12-dihydro-9-methoxy-indolo[3,2-
d][1]benzazepin-6(5H)-one 96b (10 mg, 25%) as an off-white solid; mp 213-215 oC; IR 
(KBr) νmax: 3300 (NH), 1647 (C=O) cm-1; 1H 
NMR (500 MHz, DMSO-d6) δ 3.54 (br s, 2H, 
CH2-7), 3.08 (s, 3H, CH3), 5.08 (br s, 2H, CH2), 
6.83 (dd, J= 8.5, 2.5 Hz, 1H, H-10), 6.90 (d, J= 6.5 Hz, 2H, H-2΄ and H-6΄), 7.10-7.15 
(m, 3H, H-3΄, H-4΄ and H-5΄), 7.21 (d, J= 2.5 Hz, 1H, H-8), 7.29 (t, J= 7.0 Hz, 1H, H-
2), 7.32-7.36 (m, 2H, H-11 and H-3), 7.55 (d, J= 8.5 Hz, 1H, H-4), 7.65 (dd, J= 7.5, 1.5 
Hz, 1H, H-1), 11.57 (s, 1H, NH); 13C NMR (125 MHz, DMSO-d6) δ  31.7 (CH2-7), 52.1 
(CH2), 55.4 (OCH3), 99.7 (C-8), 109.7 (C-7a), 112.4 (C-11), 112.8 (C-10), 124.2 (C-4), 
125.1 (C-2), 126.3 (C-2΄ and C-6΄), 126.3 (C-7b), 126.4 (C-12b), 126.6 (C-4΄), 127.2 
(C-1), 127.8 (C-3), 128.2 (C-3΄ and C-5΄), 132.6 (C-11a), 133.0 (C-12a), 137.9 (C-1΄), 
138.9 (C-4a), 153.6 (COCH3), 170.3 (CO); CI-MS m/z 369 ([M+H]+, 100%); HREI-MS 
m/z calcd for [M]+ C24H20N2O2: 368.1525, found: 368.1531. 
5-benzyl-9-fluoro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one (96c) 
To a boiling solution of 231c (50 mg, 0.10 mmol) in 
mesitylene (20 mL) was added dropwise a solution of 
tri-n-butyltin hydride (54 µL, 0.20 mmol) and AIBN 
(16 mg, 0.10 mmol) in mesitylene (60 mL) over 2 h, and the reaction mixture was 
heated at reflux for 16 h. After evaporating the solvent, diethyl ether (30 mL) and satd. 
KF (30 mL) were added to the residue, and the mixture was stirred vigorously at r.t. for 
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2 h. The organic extract was separated, dried and concentrated. The residue was 
chromatographed on silica gel (AcOEt/pet. spirit, 9:1) to give off white needles of 96c 
(16 mg, 45%); mp 247-248 oC; 1H NMR (CDCl3) δ 3.50 (d, J= 13.5 Hz, 1H, CHH-7), 
3.91 (d, J= 13.8 Hz, 1H, CHH-7), 5.05 (d, J= 15.6 Hz, 1H, CHH), 5.14 (d, J= 15.4 Hz, 
1H, CHH), 6.95 (td, J= 8.7, 2.4 Hz, 1H, H-10), 7.03-7.05 (m, 2H, H-2΄ and H-6΄), 7.15-
7.17 (m, 2H, H-3΄ and H-5΄), 7.23-7.27 (m, 2H, H-11 and Ar), 7.30-7.39 (m, 2H, H-2 
and Ar), 7.43-7.51 (m, 2H, H-8 and Ar), 7.83 (d, J= 7.2 Hz, 1H, H-1), 10.09 (s, 1H, 
NH); 13C NMR (CDCl3) δ 35.6 (CH2-7), 54.6 (CH2), 103.9 (d, J= 24.1 Hz, 13C-19F, C8-
F), 110.5 (d, J= 25.8 Hz, 13C-19F, C10-F), 111.1 (C-7a), 112.7 (d, J= 9.8 Hz, 13C-19F, 
C11-F), 124.4 (ArC-H), 125.7 (d, J= 10.0 Hz, 13C-19F, C7b-F), 126.4 (ArC-H), 126.5 
(ArC-H), 126.8 (C-2΄ and C-6΄), 127.2 (C-4΄), 128.0 (C-1), 128.7 (C-3΄ and C-5΄), 129.1 
(C-12b), 129.8 (C-12a), 133.2 (C-11a), 137.6 (C-1΄), 138.8 (C-4a), 159.0 (d, J= 230.6 
Hz, 13C-19F, C9-F), 169.4 (CO); CI-MS m/z 357 ([M+H]+, 100%); HREI-MS m/z calcd 
for [M]+ C23H17N2OF: 356.1325, found: 356.1381. 
Cyclisation of trichloroacetamide 230 
To a boiling solution of trichloroacetamide 230 (40 mg, 0.09 mmol) in 
mesitylene (20 mL) was added dropwise a solution of tri-n-butyltin hydride (48 µL, 
0.18 mmol) and AIBN (14 mg, 0.09 mmol) in mesitylene (60 mL) over 2 h, and the 
reaction mixture was heated at reflux for 16 h. After evaporating the solvent, diethyl 
ether (30 mL) and satd. KF (30 mL) were added to the residue, and the mixture was 
stirred vigorously at r.t. for 2 h. The organic extract was separated, dried and 
concentrated. The residue was chromatographed on silica gel (AcOEt/pet. spirit, 9:1) to 
give two major fractions. 
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The first fraction gave spiro[(1-benzyl-2,3-dihydro-1H-indole)-3,2΄-(3΄-
hydroxy-2΄,3΄-dihydro-1H-indole)] 235 (3.1 mg, 11%) and the second fraction gave 
226a (3.2 mg, 11%). 
235 obtained as a yellow solid; mp 137-138 oC; 1H NMR 
(500 MHz, CD3CN) δ 3.60 (d, J= 16.5 Hz, 1H, CHH-2), 
3.93 (d, J= 16.5 Hz, 1H, CHH-2), 4.18 (br s, 1H, OH), 
5.01 (br d, J= 17.0 Hz, 2H, CHH and NH), 5.52 (d, J= 
16.5 Hz, 1H, CHH), 6.48 (s, 1H, H-3΄), 6.83 (d, J= 8.0 Hz, 1H, H-7), 7.05-7.10 (m, 2H, 
H-5΄ and H-6΄), 7.17-7.20 (m, 2H, H-5 and H-6), 7.25-7.28 (m, 4H, H-4, H-2΄, H-4΄ and 
H-6΄), 7.43 (d, J= 7.5 Hz, 3H, H-4, H-3΄ and H-5΄), 8.45 (d, J= 8.5 Hz, 1H, H-7΄); 13C 
NMR (125 MHz, CD3CN) δ 32.9 (CH2-2), 41.2 (CH2), 65.9 (C-2΄), 71.6 (C-3΄), 108.6 
(C-7), 109.6 (C-7), 115.9 (C-3a), 116.2, 117.1, 118.3 (all ArCH), 120.9 (C-3΄ and C-5΄), 
121.1 (ArCH), 121.9 (C-4), 122.0 (C-3a), 122.3 (C-4΄), 122.7 (C-2΄ and C-6΄), 123.8 
(ArCH), 131.7 (C-1΄), 132.5 (C-7a), 137.5 (C-7΄a); CI-MS m/z 329 ([M+H]+, 15%); 
HRCI-MS m/z calcd for [M+H]+ C22H21N2O: 329.1654, found: 329.1643. 
  
7.3.7 Debenzylation 
7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one (96) 
 Sodium metal (ca 30 mg) was added to dry THF (2 mL) 
under a N2 atmosphere and then the mixture was frozen using 
a liquid N2 bath. Liquid ammonia (condensed at –70 oC, ca 7 
mL) and a solution of 96a (26 mg, 0.08 mmol) in dry THF (2 
mL) were added. The frozen mixture was warmed to –60 oC and the mixture was stirred 
for at r.t. for 10 min.  Solid ammonium chloride was then added until the colour 
dissipated at which point the reaction was allowed to warm to r.t.. The residue was 
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dissolved in ethyl acetate (30 mL), extracted with water (3 x 20 mL), dried and 
concentrated to give a yellow residue. The residue was purified using PTLC (silica gel, 
1% MeOH/DCM) to give the title compound 96 (8 mg, 40%) as a yellow solid; mp 
>272 oC (lit.77 >315 oC); 1H NMR (DMSO-d6) δ 3.54 (s, 2H, CH2), 7.11 (ddd, J= 7.2, 
6.9, 1.5 Hz, 1H, H-9), 7.16 (ddd, J= 7.5, 6.9, 1.5 Hz, 1H, H-10), 7.23-7.29 (m, 3H, H-2, 
H-3 and H-4), 7.44 (dd, J= 7.2, 1.5 Hz, 1H, H-11), 7.80 (d, J= 6.9 Hz, 1H, H-8), 7.85 
(m, 1H, H-1), 10.08 (s, 1H, NH), 11.62 (br s, 1H, indole NH); 13C NMR (CDCl3) δ 35.7 
(CH2), 109.7 (C-7a), 112.5 (C-11), 118.7 (C-8), 120.7 (C-9), 122.1 (C-10), 123.3 (ArC-
H), 124.8 (ArC-H), 125.9 (C-12b), 126.3 (ArC-H), 126.9 (C-7b), 128.2 (C-1), 132.2 (C-
12a), 134.8 (C-4a), 136.9 (C-11a), 170.3 (CO); EI-MS m/z 248 ([M]+, 100%), HRCI-
MS m/z calcd for [M+H]+ C16H13N2O: 249.1028, found: 249.1032. 
 
7.4 Experimental for Chapter 4 
7.4.1 Synthesis of N-substituted 5-methoxyindole-2,3-dione  
Synthesis of 5-methoxy-1-methylindole-2,3-dione (243a) 
A suspension of 5-methoxyindole-2,3-dione (0.50 g, 2.82 mmol) 
and anhydrous K2CO3 (0.56 g, 4.05 mmol) in dry DMF (30 mL) 
was stirred at 0-5 oC for 30 min. Methyl iodide (0.19 mL, 3.10 
mmol) was then added and the reaction mixture was heated at 80 oC for 10 h. DMF was 
evaporated and DCM (30 mL) was added and then washed with water (25 mL) several 
times. The organic extract was separated, dried and evaporated to give a red residue. 
The residue was subjected to flash column chromatography (silica gel, DCM) to give 
the 5-methoxy-1-methylindole-2,3-dione 243a (0.36 g, 67%) as red crystals; mp 170-
172 oC (lit.206 173-174 °C); 1H NMR (CDCl3) δ 3.21 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 
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6.80 (d, J= 7.8, 0.9 Hz, 1H, H-7), 7.12-7.16 (m, 2H, H-4 and H-6); 13C NMR (CDCl3) δ 
26.5 (CH3), 56.2 (OCH3), 109.8 (C-4), 111.1 (C-6), 118.0 (C-3a), 124.8 (C-7), 145.6 
(C-7a), 156.9 (COCH3), 158.5 (C-2), 184.0 (C-3); EI-MS m/z 191 ([M]+, 100%); HREI-
MS m/z calc. for [M]+ C10H9NO3: 191.0582, found: 191.0583. 
Synthesis of 1-allyl-5-methoxyindole-2,3-dione (243b) 
A suspension of 5-methoxyindole-2,3-dione (0.52 g, 2.94 mmol) 
and anhydrous K2CO3 (0.56 g, 4.05 mmol) in dry DMF (30 mL) 
was stirred at 0-5 oC for 30 min. Allyl bromide (0.27 mL, 3.12 
mmol) was then added and the reaction mixture was heated at 80 
oC for 10 h. DMF was evaporated and DCM (30 mL) was added and washed with water 
(25 mL) several times. The organic extract was separated, dried and evaporated to give 
a red residue. The residue was subjected to flash column chromatography (silica gel, 
DCM) to give the 1-allyl-5-methoxyindole-2,3-dione 243b (0.63 g, 99%) as red 
crystals; mp 81-82 oC; 1H NMR (500 MHz, CDCl3) δ 3.80 (s, 3H, OCH3), 4.34 (d, J= 
5.5 Hz, 2H, CH2), 5.29 (d, J= 11.5 Hz, 1H, CHaHb), 5.32 (d, J= 11.0 Hz, 1H, CHaHb), 
5.84 (m, 1H, CHc), 6.82 (d, J= 8.0 Hz, 1H, H-7), 7.12 (dd, J= 8.0, 2.5 Hz, 1H, H-6), 
7.15 (d, J= 2.5 Hz, 1H, H-4); 13C NMR (125 MHz, CDCl3) δ 42.7 (CH2), 56.2 (CH3), 
109.7 (C-4), 112.2 (CHaHb), 118.2 (C-3a), 118.8 (C-6), 124.9 (C-7), 130.8 (CHc), 145.0 
(C-7a), 156.7 (C-5), 158.2 (C-2), 183.8 (C-3); EI-MS m/z  217 ([M]+, 47%); HREI-MS 
m/z calcd for [M]+ C12H11NO3: 217.0739, found: 217.0739.  
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7.4.2 Condensation between isatins and tryptamine 
Preparation of spiro[(3H-indol-2-one)-3,1΄-(1΄,2΄,3΄,4΄-tetrahydro-9H-pyrido[3,4-
b]indole)] (250a) 
A mixture of isatin (0.74 g, 5.0 mmol) and tryptamine 
(0.80 g, 5.0 mmol) in EtOH (25 mL) in the presence of 
glacial acetic acid (0.10 mL) was stirred at r.t. for 24 h. 
The solid formed was suction filtered, washed with cold 
water and air dried to give the title compound 250a (1.3 g, 89%) as a yellow solid; mp 
157-158 oC; 1H NMR (CDCl3) δ 2.00 (br s, 1H, NH-2΄), 2.88 (s, 2H, CH2-4΄), 3.23 (m, 
1H, CHH-3΄), 3.58 (m, 1H, CHH-3΄), 6.58 (d, J= 7.5 Hz, 1H, H-7), 6.90-6.94 (m, 2H, 
H-5 and H-8΄), 6.99-7.10 (m, 4H, H-4, H-6, H-6΄ and H-7΄), 7.51 (d, J= 7.2 Hz, 1H, H-
5΄), 8.21 (br s, 1H, NH-9΄), 9.04 (br s, 1H, NH-1); 13C NMR (CDCl3) δ 22.2 (CH2-4΄), 
40.1 (CH2-3΄), 62.3 (C-1΄), 111.1 (C-7), 111.4 (C-8΄), 112.3 (C-4a΄), 118.6 (C-5΄), 119.6 
(C-6΄), 122.6 (C-7΄), 123.3 (C-5), 125.0 (C-4), 127.2 (C-9a΄), 129.9 (C-6), 130.0 (C-
4b΄), 132.3 (C-3a), 136.5 (C-8a΄), 141.0 (C-7a), 179.6 (CO); CI-MS m/z 290 ([M+H]+, 
100%); HREI-MS m/z calcd. for [M]+ C18H15N3O: 289.1215, found: 289.1217.    
Preparation of spiro[(N-methyl-3H-indol-2-one)-3,1΄-(1΄,2΄,3΄,4΄-tetrahydro-9H-
pyrido[3,4-b]indole)] (250b) 
A mixture of 1-methylisatin (0.16 g, 0.93 mmol) and 
tryptamine (0.16 g, 1.00 mmol) in EtOH (5 mL) in the 
presence of glacial acetic acid (0.02 mL) was stirred at r.t. 
for 24 h. The solid formed was suction filtered, washed 
with cold water and air dried to give the title compound 250b (0.15 g, 54%) as a yellow 
solid; mp 239-241 oC; 1H NMR (CDCl3) δ 2.04 (br s, 1H, NH-2΄), 2.93 (t, J= 5.4 Hz, 
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2H, CH2-4΄), 3.20 (s, 3H, CH3), 3.30 (m, 1H, CHH-3΄), 3.79 (m, 1H, CHH-3΄), 6.84-
6.89 (m, 2H, H-7 and H-8΄), 7.01 (t, J= 7.5 Hz, 1H, H-5), 6.07-7.17 (m, 3H, H-4, H-5΄ 
and H-7΄), 7.32 (t, J= 7.8 Hz, 1H, H-6΄), 7.55 (t, J= 7.5 Hz, 1H, H-6), 7.76 (br s, 1H, 
NH); 13C NHR (CDCl3) δ  22.3 (CH2-4΄), 26.8 (CH3), 40.2 (CH2-3΄), 61.7 (C-1΄), 109.0 
(C-7), 110.2 (C-8΄), 111.3 (C-5΄), 112.6 (C-4a΄), 118.7 (C-6΄), 119.7 (C-7΄), 123.5 (C-
5), 124.9 (C-4), 127.3 (C-9a΄), 130.1 (C-6), 131.7 (C-4b΄), 136.4 (C-8a΄), 138.7 (C-3a), 
143.8 (C-7a), 176.9 (CO); EI-MS m/z 303 ([M]+, 28%); HRCI-MS m/z calcd for 
[M+H]+ C19H18N3O: 304.1450, found: 304.1456.   
Preparation of spiro[(5-methoxy-N-methyl-3H-indol-2-one)-3,1΄-(1΄,2΄,3΄,4΄-
tetrahydro-9H-pyrido[3,4-b]indole)] (250c) 
A mixture of 243a (0.36 g, 1.88 mmol) and tryptamine 
(0.30 g, 1.88 mmol) in EtOH (25 mL) in the presence of 
glacial acetic acid (0.10 mL) was stirred at r.t. for 24 h. 
The solid formed was suction filtered, washed with cold 
water and air dried to give the title compound 250c (0.35 g, 56%) as a yellow solid; mp 
255-256 oC; 1H NMR (DMSO-d6) δ 2.76 (m, 2H, CH2-4΄), 3.14 (s, 3H, CH3), 3.16 (m, 
1H, CHH-3΄), 3.32 (br s, 1H, NH), 3.60 (m, 1H, CHH-3΄), 3.65 (s, 3H, OCH3), 6.75 (d, 
J= 2.1 Hz, 1H, H-4), 6.94 (td, J= 8.4, 2.4 Hz, 1H, H-6), 6.96-7.04 (m, 3H, Ar), 7.15 (d, 
J= 8.1 Hz, 1H, H-8΄), 7.45 (d, J= 7.5 Hz, 1H, H-5΄), 10.37 (br s, 1H, indole NH); 13C 
NMR (DMSO-d6) δ 22.6 (C-4΄), 26.9 (CH3), 39.6 (C-3΄), 56.2 (OCH3), 61.9 (C-1΄), 
109.9 (C-7), 111.0 (C-4a΄), 111.8 (C-8΄), 111.9 (C-4), 114.5 (C-6), 118.5 (C-5΄), 119.1 
(C-6΄), 121.9 (C-7΄), 127.2 (C-4b΄), 132.2 (C-9a΄), 133.8 (C-8a΄), 136.7 (C-7a), 137.9 
(C-3a), 156.2 (COCH3), 176.8 (CO); EI-MS m/z 333 ([M]+, 69%); HREI-MS m/z calcd. 
for [M]+ C20H19N3O2: 333.1477, found: 333.1472.  
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Attempted preparation of spiro[(N-allyl-5-methoxy-3H-indol-2-one)-3,1΄-
(1΄,2΄,3΄,4΄-tetrahydro-9H-pyrido[3,4-b]indole)] (250d) 
A mixture of 243b (0.43 g, 1.98 mmol) and tryptamine (0.34 g, 2.12 mmol) in EtOH 
(25 mL) in the presence of glacial acetic acid (0.10 mL) was stirred at r.t. for 48 h. The 
solid formed was suction filtered, washed with cold water and air dried to give a red 
solid. The solid was subjected to flash column chromatography (silica gel, 9:1 pet. 
spirit/hexane) to give three fractions. However, 1H NMR spectroscopic analysis of the 
fractions were still mixtures.  
 
7.4.3 Partly reduced amide 
Attempted preparation of spiro[(2,3-dihydro-2-hydroxy-1H-indole)-3,1΄-
(1΄,2΄,3΄,4΄-tetrahydro-9H-pyrido[3,4-b]indole)] (269a) 
A mixture of 250a (69 mg, 0.24 mmol) and Red-Al® (ca 
50%, 0.20 mL, 0.24 mmol) in dry toluene (4 mL) was 
stirred under a N2 atmosphere at r.t. for 6 h. A solution of 
5% NaOH (8 mL) was then added and toluene was separated. The aqueous layer was 
extracted with EtOAc (3 x 10 mL). The combined organic extracts were washed with 
brine (20 mL), dried and concentrated to give only starting material (50 mg). 
Preparation of spiro[(2,3-dihydro-2-hydroxy-1-methyl-1H-indole)-3,1΄-(1΄,2΄,3΄,4΄-
tetrahydro-9H-pyrido[3,4-b]indole)] (269b) 
A mixture of the spiro compound 250b (0.15 g, 0.49 
mmol) and Red-Al® (0.15 mL, 0.50 mmol) in dry toluene 
(4 mL) was stirred under a N2 atmosphere at r.t. for 5 h 
(TLC showed no starting material was present after this N
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time). A solution of 5% NaOH (8 mL) was added and the toluene was separated. The 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic extracts 
were washed with brine (20 mL), dried and concentrated to give an unstable 
oxyindoline, whose colour changed on a silica column and a PTLC, and in CDCl3 (0.13 
g). It was thus used without further purification. 1H NMR (CDCl3) δ 2.86 (m, 2H, CH2-
4΄), 2.92 (s, 3H, CH3), 3.13 (m, 1H, CHH-3΄), 3.40 (m, 1H, CHH-3΄), 4.96 (s, 1H, CH), 
6.60 (d, J= 8.1 Hz, 1H, H-7), 6.69 (d, J= 7.2 Hz, 1H, H-5), 6.98 (d, J= 7.2 Hz, 1H, H-4), 
7.10-7.23 (m, 4H, Ar), 7.51 (dd, J= 6.9, 1.5 Hz, 1H, H-5΄), 7.72 (br s, 1H, NH); EI-MS 
m/z 305 ([M]+, 60%). 
Preparation of spiro[(2,3-dihydro-2-hydroxy-5-methoxy-1-methyl-1H-indole)-3,1΄-
(1΄,2΄,3΄,4΄-tetrahydro-9H-pyrido[3,4-b]indole)] (269c) 
A mixture of the spiro compound 250c (0.16 g, 0.49 
mmol) and Red-Al® (0.15 mL, 0.50 mmol) in dry 
toluene (4 mL) was stirred under a N2 atmosphere at 
r.t. for 5 h (TLC showed no starting material was 
present after this time). A solution of 5% NaOH (8 mL) was added and the toluene was 
separated. The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were washed with brine (20 mL), dried and concentrated to give an 
unstable oxyindoline, whose colour changed on a silica column and on PTLC, and in 
CDCl3 (85 mg). It was thus used without further purification. 1H NMR (CDCl3) δ 2.86 
(m, 2H, CH2-4΄), 2.89 (s, 3H, CH3), 3.08 (m, 1H, CHH-3΄), 3.37 (m, 1H, CHH-3΄), 3.61 
(s, 3H, OCH3), 4.88 (s, 1H, CH), 6.54 (d, J= 8.4 Hz, 1H, H-7), 6.59 (d, J= 2.7 Hz, 1H, 
H-4), 6.80 (dd, J= 8.7, 2.7 Hz, 1H, H-6), 7.10-7.19 (m, 2H, H-6΄ and H-7΄), 7.22 (d, J= 
6.9 Hz, 1H, H-8΄), 7.53 (d, J= 7.2 Hz, 1H, H-5΄), 7.73 (br s, 1H, NH). 
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7.4.4 Rearrangement 
Preparation of the azepino bisindole and its trifluoroacetate salt (270) 
Note: The numbering used for 270 in the figure is the same as that used for iheyamine A 
and is not systematic. 
The hydroxyindoline 269b (0.13 g) in 5M HCl (20 mL) was 
warmed to 90 oC for 30 min and then basified with 25% 
KOH until the pH was >12. The black precipitate formed 
was filtered through a sintered glass funnel. The solid was 
subjected to flash column chromatography (silica gel, 1% DCM/MeOH) to give the title 
compound 270 (21 mg, 17% over 2 steps from 250b) as a green solid; mp 193-195 oC; 
UV (EtOH): λmax=  236 (ε 115,022), 249 (ε 105,022), 308 (ε 157,152), 328 (ε 173,497), 
445 (ε 37,085) nm; 1H NMR (CDCl3) δ 4.14 (s, 3H, CH3), 7.41 (td, J= 8.1, 1.2 Hz, 1H, 
H-6), 7.61 (m with dd prominent, J= 8.7, 1.2 Hz, 2H, H-14 and H-15), 7.72 (dd, J= 6.9, 
1.2 Hz, 1H, H-13), 7.80 (td, J= 8.1, 1.2 Hz, 1H, H-7), 8.13 (d, J= 8.1 Hz, 1H, H-5), 8.27 
(d, J= 7.8 Hz, 1H, H-8), 8.39 (d, J= 5.7 Hz, 1H, H-2), 8.97 (d, J= 6.3 Hz, 1H, H-1), 9.60 
(d, J= 8.1 Hz, 1H, H-16); 13C NMR (CDCl3) δ 28.7 (CH3), 109.4 (C-15), 112.2 (C-18), 
119.2 (C-5), 120.1 (C-2), 121.6 (C-6), 121.7 (C-8), 122.3 (C-14), 125.8 (C-3), 127.2 (C-
16), 128.7 (C-13), 130.2 (C-17), 132.6 (C-7), 139.8 (C-11), 145.5 (C-1), 147.0 (C-4), 
147.4 (C-12), 158.0 (C-10), 160.0 (C-9); EI-MS m/z 283 ([M]+, 100%); HRCI-MS m/z 
calcd for ([M+H]+ C19H14N3: 284.1188, found: 284.1178. 
The trifluoroacetate salt of 270 was prepared by reaction of 270 (20 mg, 0.071 mmol) 
with trifluoroacetic acid (8 µL, 0.11 mmol) in DCM (3 mL). After stirring at r.t. for 3 h, 
DCM and excess trifluoroacetic acid was evaporated to dryness and the residue was 
analysed by 1H NMR spectroscopy. 1H NMR (CDCl3, isomer ratio 2:1*) δ 3.93* (s, 1H, 
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CH3), 4.01 (s, 2H, CH3), 6.86-7.02 (m, 4.5H, Ar), 7.20* (d, J= 7.8 Hz, 0.5H, Ar), 7.30-
7.37 (m, 3H, Ar), 7.46 (t, J= 7.8 Hz, 1H, Ar), 7.55 (d, J= 8.0 Hz, 1H, Ar), 7.58-7.65 (m, 
1.5 H, Ar), 7.93 (d, J= 8.1 Hz, 1H, Ar), 8.00* (d, J= 8.1 Hz, 0.5 H, Ar), 8.08* (d, J= 7.8 
Hz, 0.5H, Ar), 8.21 (d, J= 5.7 Hz, 1H, H-2), 8.62 (d, J= 7.5 Hz, 1H, Ar), 8.94 (d, J= 5.4 
Hz, 1H, H-1), 9.30 (d, J= 8.1 Hz, 1H, Ar), 10.28* (s, 0.5H, NH), 11.40* (s, 0.5H, NH).   
Preparation of the azepino bisindole (271) 
Note: The numbering used for 271 in the figure is the same as that used for iheyamine A 
and is not systematic. 
The hydroxyindoline 269c (85 mg) in 5M HCl (15 mL) 
was warmed to 90 oC for 30 min and then basified with 
25% KOH until the pH was >12. The black precipitate 
formed was filtered through a sintered glass funnel. The 
solid was subjected to flash column chromatography (silica gel, 1% DCM/MeOH) to 
give the title compound 271 (8 mg, 10% over 2 steps from 269c) as a purple solid, mp 
147-148  oC; UV (EtOH): λmax= 250 (ε 16,475), 338 (ε 39,642), 370 (sh; ε 15,000), 490 
(ε 7,667) nm; 1H NMR (CDCl3) δ 4.04 (s, 3H, CH3), 5.00 (s, 3H, OCH3), 7.37 (dd, J= 
8.7, 2.4 Hz, 1H, H-14), 7.52 (br dd, J= 7.5, 6.6 Hz, 1H, H-6), 7.58 (d, J= 8.7 Hz, 1H, H-
13), 7.80 (br dd, J= 8.1, 7.5 Hz, 1H, H-7), 7.98 (d, J= 2.4 Hz, 1H, H-16), 8.14 (d, J= 8.4 
Hz, 1H, H-8), 8.35 (d, J= 7.5 Hz, 1H, H-5), 8.50 (d, J= 6.0 Hz, 1H, H-2), 8.96 (d, J= 5.4 
Hz, 1H, H-1); 13C NMR (CDCl3) δ 30.0 (CH3), 56.3 (OCH3), 102.4 (C-16), 111.4 (C-
14), 119.5 (C-5), 120.2 (C-2), 121.1 (C-6), 122.1 (C-8), 122.8 (C-13), 126.8 (C-4), 
127.2 (C-17), 129.0 (C-3), 131.0 (C-10), 131.1 (C-12), 131.2 (C-7), 136.6 (C-18), 140.6 
(C-1), 143.1 (C-9), 151.0 (C-11), 156.5 (C-15); EI-MS m/z 313 ([M]+, 51%); HREI-MS 
m/z calcd for ([M]+ C20H15N3O: 313.1215, found: 313.1210 
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7.4.5 N-demethylation 
Attempted N-demethylation of 270 using 2,2,2-trichloroethylchloroformate 
A mixture of compound 270 (21 mg, 0.074 mmol), 2,2,2-trichloroethyl chloroformate 
(11 µL, 0.084 mmol) and anhydrous K2CO3 (10.2 mg, 0.074 mmol) in dry benzene (5 
mL) under an Ar atmosphere was heated at reflux for 4 days. Methanol (15 mL) was 
then added and the reaction mixture was evaporated to dryness. The residue was 
dissolved in DCM (10 mL) and washed with water (3 x 10 mL). The organic extract 
was separated, dried and concentrated. The 1H NMR spectroscopic analysis of the 
residue showed only starting material was obtained.    
Attempted N-demethylation of 271 using thiophenol and BF3.Et2O 
A mixture of compound 271 (21 mg, 0.067 mmol) and BF3.Et2O (12 µL, 0.10 mmol) in 
dry THF (3 mL) was stirred under a N2 atmosphere for 10 min. An excess of thiophenol 
(0.5 mL) in dry THF (3 mL) was then added and the reaction mixture was heated at 
reflux for 3 days. Satd. aqueous KMnO4 solution (30 mL) and DCM (25 mL) were 
added to the reaction mixture. The organic extract was separated, washed sequentially 
with water (20 mL) and brine (20 mL), then dried and concentrated. The residue was 
subjected to PTLC (silica gel, DCM) to give three major product bands, which could 
not be identified. However, no starting material 271 or demethylated product, 
iheyamine A, was observed on the basis of 1H NMR and MS analysis. 
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Appendix 
1.1 Antibacterial testing methodology206 
The Mueller-Hinton Broth (MHB) Medium culture media was prepared with 
final concentration of 1 µg/mL MgCl2 and 2 µg/mL CaCl2 and was pre-warmed for 2-3 
hours at 37 °C before use. Mueller-Hinton Agar (MHA) Medium culture media was 
prepared with final concentration of 1.5% Agar (Meck Agar 1.01614). S. aureus was 
streaked onto MHA and the plate was incubated overnight at 37 °C. From this plate, 10 
cryovial were prepared by looping several colonies into 0.5 mL of 20% glycerol 
solution and were immediately stored at -140 °C. A cryovial was removed from -140 °C 
storage and thawed at room temperature. The MHA plate was streaked with a loopful of 
bacterial suspension and incubated overnight at 37 °C to create a parent plate (P1). The 
P1 was stored at -4 °C. A daughter plate (D1) was incubated overnight at 37 °C and its 
loop of colony was used to inoculate at 125 mL flask containing 20 mL of MHB, 25 
µg/mL CaCl2.2H2O and 12.5 µg/mL MgCl2.6H2O.  The flask was shaken at 260 
round/minute (rpm) for 18 hours at 37 °C on an orbital incubator shaker. The parent 
plates 1 and 2 were each used twice to generate two daughter plates (D1 and D2) before 
being discarded. 
The standardized inocula for assays were prepared as 1/10 dilution of seed 
cultures by adding 250 µL of the cultures to 2,250 µL of MHB in a disposable cuvette 
and the required dilution factor was calculated by diving the observed OD650. Sufficient 
volumes of the final inoculum cultures were prepared in pre-warmed MHB (37 °C) by 
diluting the standardized cultures to the required final concentration (108 dilution).   
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1.2 Assay procedure for 96-well microtitre plates 
To each well of the 96-well microtitre plate was added 50 µL of liquid medium 
and 50 µL of peptoid test solution which was prepared by dissolving in 2.5% DMSO 
was added in triplicate to the top of the microtitre plate. A vancomycin control set 
(triplicate) and a compound negative control set (triplicate) were also set up on each 
plate. The inoculated culture medium was incubated at 37 °C for 30 minute shaking at 
130 rpm and using the multichannel pipette and multistepper pipette, the adding, 
transferring and mixing of the inoculum were performed in the wells of the plates. The 
plates were incubated at 37 °C for 18 hours shaking at 100 rpm in an environment with 
90% relative humidity and the results were recorded as the highest dilution of test 
compound that prevented bacterial growth (MIC). The MIC was also determined for 
DMSO (2.5%) as a control measure. 
1.3 Antimalarial assay method  
Samples were made up in DMSO solution. Using the Microdilution Radioisotope 
Technique, the sample (25 µL, in the culture medium) was placed in triplicate in a 96-
well plate. Red blood cells (200 µL) infected with Plasmodium falciparum with a cell 
suspension (1.5%) of parasitemia (0.5-1%) were added to the wells. The range of the 
final concentrations of the samples varied from 1 x 10-5 to 1 x 10-8 g/mL with 0.1% of 
the organic solvent. The plates were cultured under standard conditions for 24 hours and 
the 3H-hyphoxanthine (25 µL, 0.5 mCi) was added. The culture was incubated for 18-20 
hours. The parasite’s DNA was then harvested from the culture onto glass fibre filters. 
A radiation counter determined the amount of 3H-hyphoxanthine. The inhibitory 
concentration of the sample was determined from its dose-response curves or by 
calculation. 
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The Trager and Jensen method207 was used to culture Plasmodium falciparum K1 
strain. The parasites were maintained in human red blood cells in a culture medium. 
RPM1 1640 was supplemented with 25 mM HEPES, 0.2% sodium bicarbonate, and 8% 
human serum, at 37 °C in a CO2 incubator. 
 
